<mediawiki xmlns="http://www.mediawiki.org/xml/export-0.10/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.mediawiki.org/xml/export-0.10/ http://www.mediawiki.org/xml/export-0.10.xsd" version="0.10" xml:lang="en">
  <siteinfo>
    <sitename>Wikipedia</sitename>
    <dbname>enwiki</dbname>
    <base>https://en.wikipedia.org/wiki/Main_Page</base>
    <generator>MediaWiki 1.33.0-wmf.6</generator>
    <case>first-letter</case>
    <namespaces>
      <namespace key="-2" case="first-letter">Media</namespace>
      <namespace key="-1" case="first-letter">Special</namespace>
      <namespace key="0" case="first-letter" />
      <namespace key="1" case="first-letter">Talk</namespace>
      <namespace key="2" case="first-letter">User</namespace>
      <namespace key="3" case="first-letter">User talk</namespace>
      <namespace key="4" case="first-letter">Wikipedia</namespace>
      <namespace key="5" case="first-letter">Wikipedia talk</namespace>
      <namespace key="6" case="first-letter">File</namespace>
      <namespace key="7" case="first-letter">File talk</namespace>
      <namespace key="8" case="first-letter">MediaWiki</namespace>
      <namespace key="9" case="first-letter">MediaWiki talk</namespace>
      <namespace key="10" case="first-letter">Template</namespace>
      <namespace key="11" case="first-letter">Template talk</namespace>
      <namespace key="12" case="first-letter">Help</namespace>
      <namespace key="13" case="first-letter">Help talk</namespace>
      <namespace key="14" case="first-letter">Category</namespace>
      <namespace key="15" case="first-letter">Category talk</namespace>
      <namespace key="100" case="first-letter">Portal</namespace>
      <namespace key="101" case="first-letter">Portal talk</namespace>
      <namespace key="108" case="first-letter">Book</namespace>
      <namespace key="109" case="first-letter">Book talk</namespace>
      <namespace key="118" case="first-letter">Draft</namespace>
      <namespace key="119" case="first-letter">Draft talk</namespace>
      <namespace key="710" case="first-letter">TimedText</namespace>
      <namespace key="711" case="first-letter">TimedText talk</namespace>
      <namespace key="828" case="first-letter">Module</namespace>
      <namespace key="829" case="first-letter">Module talk</namespace>
      <namespace key="2300" case="first-letter">Gadget</namespace>
      <namespace key="2301" case="first-letter">Gadget talk</namespace>
      <namespace key="2302" case="case-sensitive">Gadget definition</namespace>
      <namespace key="2303" case="case-sensitive">Gadget definition talk</namespace>
    </namespaces>
  </siteinfo>
  <page>
    <title>Anderson orthogonality theorem</title>
    <ns>0</ns>
    <id>12342942</id>
    <revision>
      <id>809963348</id>
      <parentid>809369623</parentid>
      <timestamp>2017-11-12T16:32:59Z</timestamp>
      <contributor>
        <ip>217.118.78.115</ip>
      </contributor>
      <model>wikitext</model>
      <format>text/x-wiki</format>
      <text xml:space="preserve" bytes="822">The '''Anderson orthogonality theorem''' is a theorem in [[physics]] by the physicist [[P. W. Anderson]].

It relates to the introduction of a [[magnetic impurity]] in a metal. When a magnetic impurity is introduced into a metal, the [[conduction electron]]s will tend to [[Electric field screening|screen]] the potential &lt;math&gt;V(r)&lt;/math&gt; that the impurity creates. The N-electron [[ground state]] for the system when &lt;math&gt;V(r) = 0&lt;/math&gt;, which corresponds to the absence of the impurity and &lt;math&gt;V(r) \neq 0&lt;/math&gt;, which corresponds to the introduction of the impurity are [[orthogonal]] in the thermodynamic limit &lt;math&gt;N \to \infty &lt;/math&gt;.

==References==
* P.W. Anderson, ''Phys. Rev. Lett.'', 18, (1967) 1049
* P.W. Anderson, ''Phys. Rev.'', 164, (1967) 352

[[Category:Condensed matter physics]]


{{CMP-stub}}</text>
      <sha1>5tz1nzabzbi15a5krz5rxaes4bkezk5</sha1>
    </revision>
  </page>
  <page>
    <title>Asimut Glacier</title>
    <ns>0</ns>
    <id>28913873</id>
    <revision>
      <id>840691751</id>
      <parentid>822800518</parentid>
      <timestamp>2018-05-11T14:40:03Z</timestamp>
      <contributor>
        <username>Giammarco Ferrari</username>
        <id>27823968</id>
      </contributor>
      <minor/>
      <comment>Giammarco Ferrari moved page [[Asimutbreen Glacier]] to [[Asimut Glacier]]: Breen in norwegian means "Glacier"</comment>
      <model>wikitext</model>
      <format>text/x-wiki</format>
      <text xml:space="preserve" bytes="1735">{{Infobox glacier 
| child         = 
| name          = Asimutbreen Glacier 
| other_name    =  
| photo         = Antarctica, Norway territorial claim (Queen Maud Land, 2015).svg
| photo_alt     = 
| photo_caption =  Location of Queen Maud Land in Antarctica
| map           = Antarctica
| map_width     = 
| map_alt       = 
| map_caption   = Location of Asimutbreen Glacier in [[Antarctica]]
| mark = Blue_pog.svg
| type          =  steep tributary
| location      = [[Queen Maud Land]]
| coordinates   = {{coord|71|23|S|13|42|E|region:AQ|format=dms|display=inline}}
| coords_ref    = 
| area          = 
| length        = 
| width         = 
| thickness     = unknown
| elevation_max =
| elevation_min = 
| terminus      = [[Vangengeym Glacier]]
| status        = unknown
| embedded      = 
}}

'''Asimutbreen Glacier''' ({{Coord|71|23|S|13|42|E|source:GNIS|display=inline,title}}) is a small, steep tributary [[glacier]] to [[Vangengeym Glacier]], descending southeast and then northeast between [[Solhogdene Heights]] and [[Skuggekammen Ridge]], in the eastern [[Gruber Mountains]] of the [[Wohlthat Mountains]], [[Queen Maud Land]]. It was discovered and plotted from air photos by the [[Third German Antarctic Expedition]], 1938–39, replotted from air photos and from surveys by the [[Sixth Norwegian Antarctic Expedition]], 1956–60, and named Asimutbreen (the azimuth glacier).

==See also==
* [[List of glaciers in the Antarctic]]
* [[Glaciology]]

==References==
* {{usgs-gazetteer|id=652}}

{{Portalbar|Antarctica|Geography}}
{{Glaciers in the Antarctic}}
{{Glaciers of Queen Maud Land}}

[[Category:Glaciers of Queen Maud Land]]
[[Category:Princess Astrid Coast]]


{{PrincessAstridCoast-geo-stub}}
{{Glaciology-stub}}</text>
      <sha1>styq5kzr1q7ch8rtni8vttr1iqvgzy0</sha1>
    </revision>
  </page>
  <page>
    <title>Balish Glacier</title>
    <ns>0</ns>
    <id>28914043</id>
    <revision>
      <id>826536442</id>
      <parentid>823499283</parentid>
      <timestamp>2018-02-19T18:16:02Z</timestamp>
      <contributor>
        <username>Chesipiero</username>
        <id>13272187</id>
      </contributor>
      <comment>{{Glaciers}}</comment>
      <model>wikitext</model>
      <format>text/x-wiki</format>
      <text xml:space="preserve" bytes="1891">{{Infobox glacier 
| child         = 
| name          = Balish Glacier
| other_name    = 
| photo         =  Heritage-Range-location-map.png
| photo_width   = 
| photo_alt     = 
| photo_caption = Location of Heritage Range in Western Antarctica
| map           = Antarctica
| map_width     = 
| map_alt       = 
| map_caption   = Location of Balish Glacier in [[Antarctica]]
| mark = Blue_pog.svg
| type          = 
| location      = [[Heritage Range]]
| coordinates   = {{coord|79|25|S|84|30|W|region:AQ|format=dms|display=inline}}
| coords_ref    = 
| area          = 
| length        = {{convert|18|nmi|0|abbr=on}}
| width         = 
| thickness     = unknownn
| elevation_max =
| elevation_min = 
| terminus      = [[Splettstoesser Glacier]]
| status        = unknown
| embedded      = 
}}

'''Balish Glacier''' ({{Coord|79|25|S|84|30|W|source:GNIS|display=inline,title}}) is a [[glacier]], {{convert|18|nmi|km}} long, flowing north from the [[Soholt Peaks]] to enter [[Splettstoesser Glacier]] just northeast of [[Springer Peak]], in the [[Heritage Range]], [[Ellsworth Mountains]]. It was mapped by the [[United States Geological Survey]] from surveys and from [[U.S. Navy]] air photos, 1961–66, and was named by the [[Advisory Committee on Antarctic Names]] for Commander [[Daniel Balish]], [[Executive Officer]] of U.S. Navy Squadron [[VX-6]] during [[Operation Deep Freeze]] 1965, and [[Commanding Officer]] in 1967.&lt;ref name=gnis/&gt;

==See also==
* [[List of glaciers in the Antarctic]]
* [[Glaciology]]

== References ==
{{Reflist|refs=
&lt;ref name=gnis&gt;{{cite gnis | type = antarid | id = 907| name = Balish Glacier | accessdate = 2011-05-18}}&lt;/ref&gt;
}}

{{usgs-gazetteer|id=907}}

{{Portalbar|Antarctica|Geography}}
{{Glaciers}}
{{Glaciers in the Antarctic}}
{{Glaciers of Ellsworth Land}}

[[Category:Glaciers of Ellsworth Land]]


{{EllsworthLand-geo-stub}}
{{Glaciology-stub}}</text>
      <sha1>drg1t45096fhev6gal6j8s27jt4sazq</sha1>
    </revision>
  </page>
  <page>
    <title>Bat SARS-like coronavirus WIV1</title>
    <ns>0</ns>
    <id>40943939</id>
    <revision>
      <id>829674851</id>
      <parentid>823309840</parentid>
      <timestamp>2018-03-10T02:12:35Z</timestamp>
      <contributor>
        <username>Tom.Reding</username>
        <id>9784415</id>
      </contributor>
      <minor/>
      <comment>Fix {{Taxonbar}} [[Template:Taxonbar/doc#Position|position]]; [[WP:GenFixes]] on, using [[Project:AWB|AWB]]</comment>
      <model>wikitext</model>
      <format>text/x-wiki</format>
      <text xml:space="preserve" bytes="1922">{{Italic title}}
{{Taxobox
| color              = violet
| image              = 
| name               = ''Bat SL-CoV-WIV1''
| virus_group        = iv
| ordo               = ''[[Nidovirales]]''
| familia            = ''[[Coronaviridae]]''
| subfamilia         = ''[[Coronavirinae]]''
| genus              =
*''[[Alphacoronavirus]]''
*''[[Betacoronavirus]]''
*''[[Deltacoronavirus]]''
*''[[Gammacoronavirus]]''
| type_species      = ''Coronavirus''
| subdivision_ranks = Species
| subdivision       =
''[[Bat SL-CoV-WIV1]]'' 
}}
'''Bat SARS-like coronavirus WIV1,''' ('''Bat SL-CoV-WIV1''') also sometimes called '''SARS-like coronavirus WIV1''', is a newly identified [[Coronavirus|CoV]] isolated from [[Chinese rufous horseshoe bat]]s. The discovery confirms that bats are the natural reservoir of the SARS virus. Phylogenetic analysis shows the possibility of direct transmission of SARS from bats to humans without the intermediary Chinese civets, as previously believed. It is a single-stranded, enveloped, positive-sense RNA betacoronavirus.&lt;ref&gt;{{ cite journal |author= Xing-Yi Ge |author2= Jia-Lu Li |author3= Xing-Lou Yang |display-authors= etal |title=Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor |journal=Nature |volume=503 |issue=7477 |pages=535–8 |date=2013 |pmid=24172901 |pmc=5389864 |doi=10.1038/nature12711}}&lt;/ref&gt;&lt;ref&gt;{{cite web|last=Naik |first=Gautam |url=https://www.wsj.com/news/articles/SB10001424052702304073204579167613127982886 |title=Study: Bat-to-Human Leap Likely for SARS-Like Virus - WSJ.com |publisher=Online.wsj.com |date= |accessdate=2013-10-31}}&lt;/ref&gt;

== See also ==
*[[Severe acute respiratory syndrome (SARS)]]

== References ==
{{Reflist}}

{{Zoonotic viral diseases|state=expanded}}
{{Taxonbar|from=Q16000326}}

[[Category:Animal virology]]
[[Category:Coronaviridae]]
[[Category:Zoonoses]]
[[Category:Bat-borne viruses]]


{{virus-stub}}</text>
      <sha1>bkztsqanlh56kh1pi2jj7qnv4ox5v6n</sha1>
    </revision>
  </page>
  <page>
    <title>Bay de Verde Formation</title>
    <ns>0</ns>
    <id>54097327</id>
    <revision>
      <id>781918352</id>
      <parentid>781439181</parentid>
      <timestamp>2017-05-24T00:00:05Z</timestamp>
      <contributor>
        <username>Graeme Bartlett</username>
        <id>38427</id>
      </contributor>
      <comment>added [[Category:Ediacaran Newfoundland and Labrador]] using [[WP:HC|HotCat]]</comment>
      <model>wikitext</model>
      <format>text/x-wiki</format>
      <text xml:space="preserve" bytes="805">{{Infobox rockunit
| image          =
| caption        = 
| type           = [[Formation (stratigraphy)|Formation]]
| period         = Ediacaran
| age            = 
| prilithology   =
| otherlithology =
| namedfor       =
| namedby        =
| region         = {{Flag|Newfoundland}}
| country        = {{Flag|Canada}}
| coordinates    =
| unitof         = [[Signal Hill Group]]
| subunits       = 
| underlies      = 
| overlies       = 
| thickness      =
| extent         =
| area           =
| map            = Bay de Verde Formation map.svg
| map_caption    = Occurrence of the Bay de Verde Formation in southeastern Newfoundland
}}
The '''Bay de Verde Formation''' is a [[formation (geology)|formation]] cropping out in Newfoundland.

{{Geology-stub}}

[[Category:Ediacaran Newfoundland and Labrador]]</text>
      <sha1>dp8k28h9bpf5ke3qrui6hr1szii078y</sha1>
    </revision>
  </page>
  <page>
    <title>Bethesda Statement on Open Access Publishing</title>
    <ns>0</ns>
    <id>35019188</id>
    <revision>
      <id>793785177</id>
      <parentid>710891880</parentid>
      <timestamp>2017-08-03T22:59:48Z</timestamp>
      <contributor>
        <username>BD2412</username>
        <id>196446</id>
      </contributor>
      <minor/>
      <comment>/* The statement */clean up spacing around commas, replaced: ,s → , s using [[Project:AWB|AWB]]</comment>
      <model>wikitext</model>
      <format>text/x-wiki</format>
      <text xml:space="preserve" bytes="2804">The '''Bethesda Statement on Open Access Publishing''' is a 2003 statement which defines the concept of [[open access]] and then supports that concept.

==The statement==
On 11 April 2003, the [[Howard Hughes Medical Institute]] held a meeting for 24 people to discuss better access to scholarly literature.&lt;ref name="crawford"&gt;{{cite book|last=Crawford|first=Walt|title=Open access : what you need to know now|publisher=American Library Association|location=Chicago|isbn=9780838911068|pages=11–15}}&lt;/ref&gt; The group made a definition of an [[open access journal]] as one which grants a "free, irrevocable, worldwide, perpetual right of access to, and a license to copy, use, distribute, transmit, and display the work publicly and to make and distribute derivative works, in any digital medium for any responsible purpose, subject to proper attribution of authorship" and from which every article is "deposited immediately upon initial publication in at least one online repository".&lt;ref&gt;[http://www.earlham.edu/~peters/fos/bethesda.htm Statement on Open Access Publishing], by [[Patrick O. Brown]], [[Diane Cabell]], [[Aravinda Chakravarti]], [[Barbara Cohen]], [[Tony Delamothe]], [[Michael Eisen]], [[Les Grivell]], [[Jean-Claude Guédon]], [[R. Scott Hawley]], [[Richard K. Johnson]], [[Marc W. Kirschner]], [[David Lipman]], [[Arnold P. Lutzker]], [[Elizabeth Marincola]], [[Richard J. Roberts]], [[Gerald M. Rubin]], [[Robert Schloegl]], [[Vivian Siegel]], [[Anthony D. So]], [[Peter Suber]], [[Harold E. Varmus]], [[Jan Velterop]], [[Mark Walport]], and [[Linda Watson]]. 20 June 2003&lt;/ref&gt;

==Significance==
Along with the [[Budapest Open Access Initiative]] (BOAI) and the [[Berlin Declaration on Open Access to Knowledge in the Sciences and Humanities]], the Bethesda Statement established "open access" as the term to describe initiatives to make information more widely and easily available.&lt;ref name="crawford"/&gt;

The Bethesda Statement builds on the BOAI by saying how users will enact open access.&lt;ref name="bailey"&gt;{{cite web |url= http://www.digital-scholarship.org/cwb/WhatIsOA.htm |title=What Is Open Access? |first=Charles W. |last=Bailey Jr. |work=digital-scholarship.org |year=2006 |accessdate=9 March 2012}}&lt;/ref&gt; Specifically, open access practitioners will put content online with a license granting rights for reuse including the right to make derivative works.&lt;ref name="bailey"/&gt; The BOAI does not mention derivative works.&lt;ref name="bailey"/&gt;

==References==
{{reflist}}

==External links==
{{Wikisource|Bethesda Statement on Open Access Publishing}}
*[http://legacy.earlham.edu/~peters/fos/bethesda.htm The Bethesda Statement on Open Access Publishing]

{{Open access navbox}}

[[Category:Academic publishing]]
[[Category:Open access (publishing)]]
[[Category:2003 works]]</text>
      <sha1>la7pcwo0wn0ib3hx7anowwsiwg2ggs3</sha1>
    </revision>
  </page>
  <page>
    <title>Bongard problem</title>
    <ns>0</ns>
    <id>1191936</id>
    <revision>
      <id>787686288</id>
      <parentid>754787067</parentid>
      <timestamp>2017-06-26T22:17:55Z</timestamp>
      <contributor>
        <username>Bellerophon5685</username>
        <id>1258165</id>
      </contributor>
      <comment>/* External links */</comment>
      <model>wikitext</model>
      <format>text/x-wiki</format>
      <text xml:space="preserve" bytes="4457">[[File:Bongard_problem_convex_polygons.svg|thumb|300px|An example Bongard problem, the common factor of the left set being convex shapes (the right set are instead all concave).]]
A '''Bongard problem''' is a kind of puzzle invented by the Russian [[computer scientist]] [[Mikhail Moiseevich Bongard]] (Михаил Моисеевич Бонгард, 1924–1971), probably in the mid-1960s. They were published in his 1967 book on [[pattern recognition]]. Bongard, in the introduction of the book (which deals with a number of topics including [[perceptron]]s) credits the ideas in it to a group including [[M. N. Vaintsvaig]], [[V. V. Maksimov]], and [[M. S. Smirnov]].

==Overview==
The idea of a Bongard problem is to present two sets of relatively simple diagrams, say ''A'' and ''B''. All the diagrams from set ''A'' have a common factor or attribute, which is lacking in all the diagrams of set ''B''. The problem is to find, or to formulate, convincingly, the common factor. The problems were popularised by their occurrence in the 1979 book ''[[Gödel, Escher, Bach]]'' by [[Douglas Hofstadter]], himself a composer of Bongard problems. Bongard problems are also at the heart of the game [[Zendo (game)|Zendo]].

Many computational architectures have been devised to solve Bongard problems, the most extensive of which being [[Phaeaco]], by [[Harry Foundalis]],&lt;ref&gt;{{cite web|url=http://www.foundalis.com/res/diss_research.html|accessdate=24 October 2013|author=Harry Foundalis|title=The Bongard Problems}}&lt;/ref&gt; who left the field in 2008 due to ethical concerns regarding machines that can pass as human.&lt;ref&gt;{{cite web|url=http://www.foundalis.com/soc/why_no_more_Bongard.html|accessdate=24 October 2013|title=Why I stopped working on the Bongard Problems|author=Harry Foundalis}}&lt;/ref&gt;

==Scientific works on Bongard problems==

* Bongard, M. M. (1970). Pattern Recognition. Rochelle Park, N.J.: Hayden Book Co., Spartan Books.  (Original publication: Проблема Узнавания, Nauka Press, Moscow, 1967)
* Maksimov, V. V. (1975). Система, обучающаяся классификации геометрических изображений (A system capable of learning to classify geometric images; as translated from the Russian by Marina Eskina), in Моделирование Обучения и Поведения (Modeling of Learning and Behavior, in Russian), M.S. Smirnov, V.V. Maksimov (eds.), Nauka, Moskva.
* Hofstadter, D. R. (1979). Gödel, Escher, Bach: an Eternal Golden Braid. New York: Basic Books.
* Montalvo, F. S. (1985). Diagram Understanding: the Intersection of Computer Vision and Graphics. M.I.T. Artificial Intelligence Laboratory, A. I. Memo 873, November 1985.
* Saito, K., and Nakano, R. (1993) A Concept Learning Algorithm with Adaptive Search. Proceedings of Machine Intelligence 14 Workshop. Oxford University Press. See pp.&amp;nbsp;347–363.
* Hofstadter, D. R. and the Fluid Analogies Research Group (1995). [[Fluid Concepts and Creative Analogies|Fluid Concepts and Creative Analogies: Computer Models of the Fundamental Mechanisms of Thought]]. New York: Basic Books.
* Hofstadter, D. R. (1995). On Seeing A’s and Seeing As. Stanford Humanities Review 4/2 pp.&amp;nbsp;109–121.
* Hofstadter, D. R. (1997). Le Ton beau de Marot. New York: Basic Books.
* Linhares, A. (2000). [http://app.ebape.fgv.br/comum/arq/Linhares2.pdf A glimpse at the metaphysics of Bongard problems]. [[Artificial Intelligence (journal)|Artificial Intelligence]], Volume 121, Issue 1-2, pp.&amp;nbsp;251–270.
* Foundalis, H. (2006). Phaeaco: A Cognitive Architecture Inspired by Bongard’s Problems. Doctoral dissertation, Indiana University, Center for Research on Concepts and Cognition (CRCC), Bloomington, Indiana.
* Anastasiade, J., and Szalwinski, C. (2010). Building Computer-Based Tutors to Help Learners Solve Ill-Structured Problems. In [http://aace.org/conf/edmedia Proceedings of the World Conference on Educational Multimedia, Hypermedia and Telecommunications 2010]. Toronto, Ontario, Canada: Association for the Advancement of Computing in Education. pp.&amp;nbsp;3726–3732.

==References==
&lt;references/&gt;
==External links==
{{Wikibooks|Puzzles|Bongard problems}}
*[http://www.foundalis.com/res/bps/bpidx.htm Index of Bongard problems]

[[Category:Puzzles]]
[[Category:Machine learning]]
[[Category:Cognitive science]]
[[Category:Cognitive psychology]]
[[Category:Computer-related introductions in 1967]]</text>
      <sha1>ormvysx9bwfhhch3z3kliwgg4i8a2mt</sha1>
    </revision>
  </page>
  <page>
    <title>Brain Electrical Oscillation Signature Profiling</title>
    <ns>0</ns>
    <id>53466077</id>
    <revision>
      <id>843000132</id>
      <parentid>839385026</parentid>
      <timestamp>2018-05-26T04:51:30Z</timestamp>
      <contributor>
        <ip>117.229.104.157</ip>
      </contributor>
      <comment>/* Procedure */</comment>
      <model>wikitext</model>
      <format>text/x-wiki</format>
      <text xml:space="preserve" bytes="7653">{{Redirect|BEOS|other uses|Beos (disambiguation){{!}}Beos}}
{{Forensic science|social|image=PET-image.jpg}}
{{Psychology sidebar}}

'''Brain Electrical Oscillation Signature Profiling''' (BEOSP or '''BEOS''') is a technique by which a suspect's participation in a [[crime]] is detected by eliciting [[electrophysiological]] impulses.&lt;ref&gt;{{Cite journal|last=Rissman|first=Jesse|last2=Greely|first2=Henry T.|last3=Wagner|first3=Anthony D.|date=2010-05-25|year=|title=Detecting individual memories through the neural decoding of memory states and past experience|pmc=2906873|journal=Proceedings of the National Academy of Sciences of the United States of America|volume=107|issue=21|pages=9849–9854|doi=10.1073/pnas.1001028107|issn=0027-8424|pmid=20457911|via=}}&lt;/ref&gt;

It is a non-invasive, scientific technique with a great degree of sensitivity and a [[Neuropsychological|neuro-psychological]] method of interrogation which is sometimes also referred to as ‘[[brain fingerprinting]]’.

== History ==
The methodology was developed by Champadi Raman Mukundan (C. R. Mukundan), a [[Neuroscientist]], former Professor &amp; Head of [[Clinical psychology|Clinical Psychology]] at the [[National Institute of Mental Health and Neurosciences]] ([[Bangalore, India]]),&lt;ref&gt;{{Cite web|url=https://kclpure.kcl.ac.uk/portal/files/48486571/Rose_The_Mind_Transparent_No_Endnote_FINAL_for_publication_in_Body_Society.pdf|title=The Mind Transparent? Reading the human brain.|last=|first=|date=|website=King's College London|archive-url=|archive-date=|dead-url=|access-date=}}&lt;/ref&gt; while he worked as a Research Consultant to TIFAC-DFS Project on ‘Normative Data for Brain Electrical Activation Profiling’.&lt;ref&gt;{{Cite web|url=http://www.axxonet.com/pdfs/BEOS_Profile_of_Experiential_Knowledge.pdf|title=Brain Electrical Oscillations Signature Profile Brain Electrical Oscillations Signature Profile of Experiential Knowledge|last=|first=|date=|website=Axxonet - A Research Center recognised by the Department of Scientific and Industrial Research, India.|archive-url=|archive-date=|dead-url=|access-date=}}&lt;/ref&gt;

His works are based on research that was also formerly pursued by other scientists at American universities including J. Peter Rosenfeld, [[Lawrence Farwell]] &amp; Emanuel Donchin.&lt;ref&gt;{{Cite news|url=https://www.nytimes.com/2008/09/15/world/asia/15iht-15brainscan.16148673.html|title=India's use of brain scans in courts dismays critics|last=Giridharadas|first=Anand|date=2008-09-15|work=The New York Times|access-date=2017-03-12|issn=0362-4331}}&lt;/ref&gt;

== Principle ==
The human brain receives millions of arrays of signals in different modalities, all through the waking periods. These signals are classified and stored in terms of their relationship perceived as function of experience and available knowledge base of an individual, as well as new relationship produced through sequential processing. The process of encoding is primarily when the individual is directly participating in an activity or experiencing it.&lt;ref&gt;{{Cite web|url=https://cubist.cs.washington.edu/Security/2008/11/19/security-review-brain-electrical-oscillation-signature-profiling-in-criminal-trials/|title=UW Computer Security Research and Course Blog » Security Review: Brain Electrical Oscillation Signature Profiling in Criminal Trials|website=cubist.cs.washington.edu|access-date=2017-03-12}}&lt;/ref&gt;

It is considered secondary, when the information is obtained from a secondary source viz. books, conversations, [[hearsay]] etc. in which there is no primary experiential component and the brain deals mainly with conceptual aspects.&lt;ref&gt;{{Cite web|url=https://dfsl.maharashtra.gov.in/1121/Psychology|title=Directorate of Forensic Science Laboratories|last=|first=|date=|website=Government of Maharashtra|archive-url=|archive-date=|dead-url=|access-date=}}&lt;/ref&gt;

Primary encoding is deep seated and has specific source memory in terms of time and space of occurrence of experience, as individual himself/herself has shared or participated in the experience/act/event at certain time in his/her life at a certain place.

It is found that when the brain of an individual is activated by a piece of information of an event in which he/she has taken part, the brain of the individual will respond differently from that of a person who has received the same information from secondary sources (non-experiential).&lt;ref&gt;{{Cite web|url=http://forensic-centre.com/2013/07/26/brainwave-signature-profiling/|title=Brainwave Signature Profiling|last=Ashcroft|first=Keith|date=2013-07-26|website=Centre for Forensic Neuroscience|language=en-US|access-date=2017-03-12}}&lt;/ref&gt;

BEOSP is based on this principle, thereby intending to demonstrate that the suspect who have primary encoded information of those who have participated in the suspected events&lt;ref&gt;{{Cite news|url=http://timesofindia.indiatimes.com/city/mumbai/This-brain-test-maps-the-truth/articleshow/3257032.cms|title=This brain test maps the truth - Times of India|work=The Times of India|access-date=2017-03-12}}&lt;/ref&gt; will show responses indicating firsthand (personally acquired) knowledge of the event.

== Procedure ==
# Pretest interview with the suspecT IN BEOS

# The suspect is acquainted with BEOSP test procedure
# Informed consent is obtained
Ideally, no questions are to be asked while conducting the test; rather, the subject is simply provided with the probable events/scenarios in the aftermath of which, the results are analyzed to verify if the brain produces any experiential knowledge, which is essentially the recognition of events disclosed. This way, all fundamental rights are protected, as neither there are no questions that are being asked or any answers reciprocated.

== Applications ==
[[University of Pennsylvania]] conducted a research along with the [[Brigham &amp; Women's Hospital]] ([[Boston Massachusetts|Boston, Massachusetts]]), Children's Hospital Boston &amp; the University Hospital of Freiburg, [[Germany]] which determined that [[Gamma oscillations|Gamma Oscillations]] in the brain could help distinguish [[false memories]] from the real ones. Their analysis concluded that in the retrieval of truthful memories, as compared to false, human brain creates an extremely distinct pattern of gamma oscillations, indicating a recognition of context based information associated with a prior experience.&lt;ref&gt;{{Cite journal|last=Sederberg|first=Per B.|last2=Schulze-Bonhage|first2=Andreas|last3=Madsen|first3=Joseph R.|last4=Bromfield|first4=Edward B.|last5=Litt|first5=Brian|last6=Brandt|first6=Armin|last7=Kahana|first7=Michael J.|date=2007-11-01|year=|title=Gamma Oscillations Distinguish True From False Memories|url=https://dx.doi.org/10.1111/j.1467-9280.2007.02003.x|journal=Psychological Science|language=en|volume=18|issue=11|pages=927–932|doi=10.1111/j.1467-9280.2007.02003.x|issn=0956-7976|pmc=|pmid=17958703|via=}}&lt;/ref&gt;

== Criticism ==
* [https://www.nytimes.com/2008/09/15/world/asia/15brainscan.html India’s Novel Use of Brain Scans in Courts Is Debated] as featured on [[The New York Times]]
* [https://www.wired.com/2008/10/indias-judges-o/ India’s Judges Overrule Scientists on ‘Guilty Brain’ Tech] as discussed over [[Wired (magazine)]]

== See also ==
* [[Polygraph]]
* [[Criminal profiling]]

== External links ==
{{reflist|30em}}

{{Pseudoscience|state=expanded}}

{{DEFAULTSORT:Brain Electrical Oscillation Signature Profiling}}
[[Category:Forensic psychology]]
[[Category:Pseudoscience]]
[[Category:Physiological instruments]]
[[Category:Forensic equipment]]
[[Category:Neurophysiology]]
[[Category:Scientific controversies]]
[[Category:Lie detection]]</text>
      <sha1>nu4aq8nj8raeo7gwyzjglciq01vvap0</sha1>
    </revision>
  </page>
  <page>
    <title>Centre de Sociologie de l'Innovation</title>
    <ns>0</ns>
    <id>4150226</id>
    <revision>
      <id>631796158</id>
      <parentid>620851503</parentid>
      <timestamp>2014-10-30T20:11:55Z</timestamp>
      <contributor>
        <username>Rhododendrites</username>
        <id>5661201</id>
      </contributor>
      <comment>latour navbox -- it's a new navbox and I'm open to the argument that he's not sufficiently connected to this article (i.e. feel free to remove if you know better)</comment>
      <model>wikitext</model>
      <format>text/x-wiki</format>
      <text xml:space="preserve" bytes="985">The '''Centre de Sociologie de l'Innovation''' ('''CSI'''; "Center for the Sociology of Innovation") is a research center at the [[Mines Paristech]], [[France]].

The CSI was created in 1967 and is known for its members' contributions to the field of [[science and technology studies]] and to [[actor–network theory]].{{Ref|Dosse-History}} Prominent past and current members include academics such as [[Bruno Latour]] and [[Michel Callon]].

==References==
* {{note|Dosse-History}} {{cite book|title=Empire of Meaning: The Humanization of the Social Sciences|last=Dosse|first=François|
isbn=978-0-8166-2964-0|publisher=University of Minnesota Press}}

==External links==
* [http://www.csi.ensmp.fr/ Centre de Sociologie de l'Innovation]

{{Bruno Latour}}
{{coord missing|France}}

[[Category:Science and technology studies]]
[[Category:ParisTech]]
[[Category:Actor-network theory]]
[[Category:Educational institutions established in 1967]]
[[Category:1967 establishments in France]]</text>
      <sha1>2wng4h8idc5zwa1mcvi40xl925sx7dr</sha1>
    </revision>
  </page>
  <page>
    <title>Chen Quan</title>
    <ns>0</ns>
    <id>2290139</id>
    <revision>
      <id>868356495</id>
      <parentid>858616251</parentid>
      <timestamp>2018-11-11T17:47:16Z</timestamp>
      <contributor>
        <username>Mys 721tx</username>
        <id>10394083</id>
      </contributor>
      <comment>removed [[Category:Chinese astronauts]]; added [[Category:People's Liberation Army Astronaut Corps]] using [[WP:HC|HotCat]]</comment>
      <model>wikitext</model>
      <format>text/x-wiki</format>
      <text xml:space="preserve" bytes="2112">{{Use dmy dates|date=July 2013}}
{{chinese-name|[[Chen (surname)|Chen]]}}
{{update|date=November 2010}}
{{Infobox astronaut
| name = Chen Quan
| honorific_suffix = 
| image = Chen Quan 2010 Somalia stamp.jpg
| image_size = 250px
| alt =
| caption = 
| type = [[China National Space Administration|CNSA]] Astronaut
| native_name = 陈全
| native_name_lang = zh
| nationality = [[China]]
| status = 
| birth_name = 
| birth_date = December 1963
| birth_place = 
| death_date = 
| death_place = 
| resting_place = 
| resting_place_coords = 
| other_names = 
| occupation = 
| current_occupation = [[Astronaut]]
| previous_occupation = 
| alma_mater = 
| rank = 
| space_time = 
| selection = 
| evas = 
| eva_time =    &lt;!-- h m s --&gt;
| missions =    &lt;!-- or: |mission= --&gt;
| insignia = 
| retirement =  &lt;!-- {{end date|YYYY|MM|DD}} --&gt;
| awards = 
| memorials = 
| website =     &lt;!-- {{URL|example.com}} --&gt;
| module = 
| child =
}}

'''Chen Quan''' ({{zh|s=陈全|t=陳全|p=Chén Quán}}) is a Chinese pilot selected as part of the [[Shenzhou spacecraft|Shenzhou program]].

Chen was born in [[Suining]], [[Sichuan]], [[People's Republic of China|China]].

He joined the [[People's Liberation Army Air Force]] and became a fighter interceptor pilot and later as a [[regiment]] commander in the PLAAF.

==Career as an astronaut==
Chen was selected to be an astronaut in 1998 and served as commander of the backup crew for [[Shenzhou 7]] which flew in September 2008.

==See also==
*[[List of Chinese astronauts]]

==References==
{{Commons category|Chen Quan}}
*[https://web.archive.org/web/20050416050825/http://astronautix.com/astros/chenquan.htm Chen Quan] at the [[Encyclopedia Astronautica]]. Accessed 23 July 2005.
*[http://www.spacefacts.de/bios/international/english/chen_quan.htm Spacefacts biography of Chen Quan]

{{DEFAULTSORT:Chen, Quan}}
[[Category:Living people]]
[[Category:People's Liberation Army Astronaut Corps]]
[[Category:People from Suining]]
[[Category:Shenzhou program]]
[[Category:People's Liberation Army Air Force personnel]]
[[Category:1963 births]]


{{china-bio-stub}}
{{space-stub}}</text>
      <sha1>s32u4y3qomo0q98agebltm03g84kxtj</sha1>
    </revision>
  </page>
  <page>
    <title>Citation analysis</title>
    <ns>0</ns>
    <id>1235972</id>
    <revision>
      <id>864173511</id>
      <parentid>854113267</parentid>
      <timestamp>2018-10-15T15:41:32Z</timestamp>
      <contributor>
        <username>Wbm1058</username>
        <id>14383484</id>
      </contributor>
      <minor/>
      <comment>Spelling correction; redirect bypass from [[Journal of the American Society of Information Science and Technology]] to [[Journal of the Association for Information Science and Technology]] using [[:en:Wikipedia:Tools/Navigation_popups|popups]]</comment>
      <model>wikitext</model>
      <format>text/x-wiki</format>
      <text xml:space="preserve" bytes="20925">'''Citation analysis''' is the examination of the frequency, patterns, and graphs of [[citation]]s in documents. It uses the pattern of citations, links from one document to another document, to reveal properties of the documents.  A typical aim would be to identify the most important documents in a collection.  A classic example is that of the citations between academic [[article (publishing)|article]]s and books.&lt;ref&gt;{{cite book | last = Rubin | first = Richard | title = Foundations of library and information science |edition=3rd | publisher = Neal-Schuman Publishers | location = New York | year = 2010 | isbn = 978-1-55570-690-6 | url = https://books.google.com/books?id=Pk1TSAAACAAJ}}&lt;/ref&gt;&lt;ref&gt;[http://www.garfield.library.upenn.edu/ci/title.pdf Garfield, E. ''Citation Indexing - Its Theory and Application in Science, Technology and Humanities'' Philadelphia:ISI Press, 1983.]&lt;/ref&gt; The [[Judgment (law)|judgements]] produced by judges of law to support their decisions refer back to judgements made in earlier cases so [[#Citation analysis for legal documents|citation analysis in a legal context]] is important. Another example is provided by patents which contain [[prior art]], citation of earlier patents relevant to the current claim.

Documents can be associated with many other features in addition to citations, such as authors, publishers, journals as well as their actual texts.  The general analysis of collections of documents is known as [[bibliometrics]] and citation analysis is a key part of that field. For example, [[bibliographic coupling|bibliographic coupling and co-citation]] are association measures based on citation analysis (shared citations or shared references). The citations in a collection of documents can also be represented in forms such as a [[citation graph]], as pointed out by [[Derek J. de Solla Price]] in his 1965 article "Networks of Scientific Papers".&lt;ref name="Price65"&gt;{{cite journal | author=Derek J. de Solla Price | title=Networks of Scientific Papers | journal=[[Science (journal)|Science]] | date=July 30, 1965 | volume=149 | issue=3683| pages=510&amp;ndash;515 | url=http://garfield.library.upenn.edu/papers/pricenetworks1965.pdf | pmid=14325149 | doi=10.1126/science.149.3683.510|format=PDF| bibcode=1965Sci...149..510D }}&lt;/ref&gt;  This means that citation analysis draws on aspects of [[social network analysis]] and [[network science]].

An early example of automated citation indexing was [[CiteSeer]], which was used for citations between academic papers, while [[Google Scholar]] is an example of a modern system which includes more than just academic books and articles reflecting a wider range of information sources. Today, automated [[citation index]]ing&lt;ref&gt;{{Citation | title = CiteSeer: an automatic citation indexing system.  | doi = 10.1145/276675.276685 | year = 1998 | journal = Digital libraries 98 : the Third ACM Conference on Digital Libraries, June 23–26, 1998, Pittsburgh, PA | pages = 89–98 | url = http://doi.acm.org/10.1145/276675.276685 | isbn = 0-89791-965-3 | last1 =  Giles	 | first1 =  C. Lee  | last2 =  Bollacker    | first2 =  Kurt D. | last3 =  Lawrence	 | first3 =  Steve  | publisher = Association for Computing Machinery  | location = New York | accessdate = July 7, 2011	}}&lt;/ref&gt; has changed the nature of citation analysis research, allowing millions of citations to be analyzed for [[Big data analytics|large-scale patterns]] and [[knowledge discovery]]. Citation analysis tools can be used to compute various impact measures for scholars based on data from [[citation indices]].&lt;ref&gt;Examples include  subscription-based tools based on proprietary data, such as [[Web of Science]] and [[Scopus]], and free tools based on open data, such as [http://scholarometer.indiana.edu Scholarometer] by [[Filippo Menczer]] and his team.&lt;/ref&gt;&lt;ref&gt;{{cite journal|last=Kaur|first=Jasleen|author2=Diep Thi Hoang |author3=Xiaoling Sun |author4=Lino Possamai |author5=Mohsen JafariAsbagh |author6=Snehal Patil |author7=Filippo Menczer |title=Scholarometer: A Social Framework for Analyzing Impact across Disciplines|journal=PLoS ONE|date=2012|volume=7|issue=9|page=e43235|doi=10.1371/journal.pone.0043235|url=http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0043235 |pmid=22984414 |pmc=3440403|bibcode=2012PLoSO...743235K}}&lt;/ref&gt;&lt;ref&gt;{{citation |last=Hoang |first=D. |author2=Kaur, J. |author3=Menczer, F. |year=2010 |title=Crowdsourcing Scholarly Data |journal=Proceedings of the WebSci10: Extending the Frontiers of Society On-Line, April 26-27th, 2010, Raleigh, NC: US |url=http://journal.webscience.org/321/ |access-date=2015-08-09 |archive-url=https://web.archive.org/web/20150417002430/http://journal.webscience.org/321/ |archive-date=2015-04-17 |dead-url=yes |df= }}&lt;/ref&gt; These have various applications, from the identification of expert referees to review papers and grant proposals, to providing transparent data in support of academic merit review, [[tenure]], and promotion decisions. This competition for limited resources may lead to ethical questionable behavior to increase citations.&lt;ref&gt;{{cite journal|doi=10.1007/s11948-007-9042-5|first=M.S. van|last=Anderson|first2=E.A. van|last2=Ronning|first3=R.|last3=de Vries|first4=B.C.|last4=Martison|title=The perverse effects of competition on scientists’ work and relationship |journal=Science and Engineering Ethics |issue=13|volume=4|pages=437–461|year=2007}}&lt;/ref&gt;&lt;ref&gt;{{cite journal|doi=10.1007/s11948-015-9638-0|pmid=25742806|pmc=4750571|first=M. van|last=Wesel |title=Evaluation by Citation: Trends in Publication Behavior, Evaluation Criteria, and the Strive for High Impact Publications|journal=Science and Engineering Ethics|issue=1|volume=22|pages=199–225|year=2016 }}&lt;/ref&gt;

A great deal of criticism has been made of the practice of naively using citation analyses to compare the impact of different scholarly articles without taking into account other factors which may affect citation patterns.&lt;ref&gt;{{cite journal | last1 = Bornmann | first1 = L. | last2 = Daniel | first2 = H. D. | year = 2008 | title = What do citation counts measure? A review of studies on citing behavior | url = | journal = Journal of Documentation | volume = 64 | issue = 1| pages = 45–80 | doi=10.1108/00220410810844150}}&lt;/ref&gt; Among these criticisms, a recurrent one focuses on “field-dependent factors”, which refers to the fact that citation practices vary from one area of science to another, and even between fields of research within a discipline.&lt;ref&gt;Anauati, Maria Victoria and Galiani, Sebastian and Gálvez, Ramiro H., Quantifying the Life Cycle of Scholarly Articles Across Fields of Economic Research (November 11, 2014). Available at SSRN: http://ssrn.com/abstract=2523078&lt;/ref&gt;

==Overview==
{{cleanup merge|Citation index|date=August 2015}}
While citation indexes were originally designed for [[information retrieval]], they are increasingly used for [[bibliometrics]] and other studies involving research evaluation. Citation data is also the basis of the popular [[journal impact factor]].

There is a large body of literature on citation analysis, sometimes called [[scientometrics]], a term invented by [[Vasily Nalimov]], or more specifically [[bibliometrics]]. The field blossomed with the advent of the [[Science Citation Index]], which now covers source literature from 1900 on. The leading journals of the field are ''[[Scientometrics]],'' ''Informetrics,'' and the ''[[Journal of the Association for Information Science and Technology]]''. [[American Society for Information Science and Technology|ASIST]] also hosts an [[electronic mailing list]] called SIGMETRICS at  ASIST.&lt;ref&gt;{{cite web | title=The American Society for Information Science &amp; Technology | work=The Information Society for the Information Age | url=http://www.asis.org| accessdate=2006-05-21}}&lt;/ref&gt; This method is undergoing a resurgence based on the wide dissemination of the Web of Science and Scopus subscription databases in many universities, and the universally available free citation tools such as  [[CiteBase]],  [[CiteSeerX]], [[Google Scholar]], and the former [[Windows Live Academic]] (now available with extra features as [[Microsoft Academic]]). Methods of citation analysis research include qualitative, quantitative and computational approaches. The main foci of such scientometric studies have included productivity comparisons, institutional research rankings, journal rankings &lt;ref&gt;Lowry, Paul Benjamin; Moody, Gregory D.; Gaskin, James; Galletta, Dennis F.; Humpherys, Sean; Barlow, Jordan B.; and Wilson, David W.  (2013). "[http://papers.ssrn.com/sol3/papers.cfm?abstract_id=2186798  Evaluating journal quality and the Association for Information Systems (AIS) Senior Scholars’ journal basket via bibliometric measures: Do expert journal assessments add value?]," MIS Quarterly (MISQ), vol. 37(4), 993–1012. Also, see YouTube video narrative of this paper at: https://www.youtube.com/watch?v=LZQIDkA-ke0&amp;feature=youtu.be.&lt;/ref&gt; establishing faculty productivity and tenure standards,&lt;ref&gt;Dean, Douglas L; Lowry, Paul Benjamin; and Humpherys, Sean (2011). "[http://papers.ssrn.com/sol3/papers.cfm?abstract_id=1562263  Profiling the research productivity of tenured information systems faculty at U.S. institutions]," MIS Quarterly (MISQ), vol. 35(1), pp. 1–15 ({{ISSN|0276-7783}}).&lt;/ref&gt; assessing the influence of top scholarly articles,&lt;ref&gt;Karuga, Gilbert G.; Lowry, Paul Benjamin; and Richardson, Vernon J. (2007). "[http://papers.ssrn.com/sol3/papers.cfm?abstract_id=976891 Assessing the impact of premier information systems research over time," Communications of the Association for Information Systems, vol. 19(7), pp. 115–131 (http://aisel.aisnet.org/cais/vol19/iss1/7) ]&lt;/ref&gt; tracing the development trajectory of a science or technology field,&lt;ref&gt;{{Cite journal|last=Liu|first=John S.|last2=Lu|first2=Louis Y.Y.|date=2012-03-01|title=An integrated approach for main path analysis: Development of the Hirsch index as an example|url=http://onlinelibrary.wiley.com/doi/10.1002/asi.21692/abstract|journal=Journal of the American Society for Information Science and Technology|language=en|volume=63|issue=3|pages=528–542|doi=10.1002/asi.21692|issn=1532-2890}}&lt;/ref&gt; and developing profiles of top authors and institutions in terms of research performance.&lt;ref&gt;Lowry, Paul Benjamin; Karuga, Gilbert G.; and Richardson, Vernon J. (2007). "[http://papers.ssrn.com/sol3/papers.cfm?abstract_id=1021603 Assessing leading institutions, faculty, and articles in premier information systems research journals," Communications of the Association for Information Systems, vol. 20(16), pp. 142–203 (http://aisel.aisnet.org/cais/vol20/iss1/16). ]&lt;/ref&gt;

[[Legal citation]] analysis is a citation analysis technique for analyzing [[legal documents]] to facilitate the understanding of the inter-related regulatory compliance documents by the exploration the citations that connect provisions to other provisions within the same document or between different documents. Legal citation analysis uses a [[citation graph]] extracted from a regulatory document, which could supplement [[E-discovery]] - a process that leverages on technological innovations in [[big data analytics]].&lt;ref&gt;{{cite web|url=http://ieeexplore.ieee.org/search/wrapper.jsp?arnumber=5070630&amp;tag=1 |accessdate=November 29, 2009 }}{{dead link|date=May 2016|bot=medic}}{{cbignore|bot=medic}}&lt;/ref&gt;&lt;ref&gt;Mohammad Hamdaqa and A. Hamou-Lhadj, "Citation Analysis: An Approach for Facilitating the Understanding and the Analysis of Regulatory Compliance Documents",  In Proc. of the 6th International Conference on Information Technology, Las Vegas, USA&lt;/ref&gt;&lt;ref name=BD-HB-R-01&gt;{{cite web |title=E-Discovery Special Report: The Rising Tide of Nonlinear Review |url=http://hudsonlegalblog.com/e-discovery/e-discovery-special-report-rising-tide-nonlinear-review.html |publisher=[[Hudson Global]] |accessdate=1 July 2012 |deadurl=yes |archiveurl=https://web.archive.org/web/20120703221100/http://hudsonlegalblog.com/e-discovery/e-discovery-special-report-rising-tide-nonlinear-review.html |archivedate=3 July 2012 |df= }} by Cat Casey and Alejandra Perez&lt;/ref&gt;&lt;ref name=BD-HB-R-02&gt;{{cite web|title=What Technology-Assisted Electronic Discovery Teaches Us About The Role Of Humans In Technology - Re-Humanizing Technology-Assisted Review|url=https://www.forbes.com/sites/benkerschberg/2012/01/09/what-technology-assisted-electronic-discovery-teaches-us-about-the-role-of-humans-in-technology/|publisher=[[Forbes]]|accessdate=1 July 2012}}&lt;/ref&gt;

==History==
In a 1965 paper, [[Derek J. de Solla Price]] described the inherent linking characteristic of the SCI as "Networks of Scientific Papers".&lt;ref name="Price65" /&gt; The links between citing and cited papers became dynamic when the SCI began to be published online. The [[Social Sciences Citation Index]] became one of the first databases to be mounted on the [[Dialog (online database)|Dialog]] system&lt;ref&gt;{{cite web | title=Dialog, A Thomson Business | work="Dialog invented online information services" | url=http://www.dialog.com| accessdate=2006-05-21}}&lt;/ref&gt; in 1972. With the advent of the [[CD-ROM]] edition, linking became even easier and enabled the use of [[bibliographic coupling]] for finding related records. In 1973, Henry Small published his classic work on [[Co-Citation analysis]] which became a [[self-organizing]] classification system that led to [[document clustering]] experiments and eventually an "Atlas of Science" later called "Research Reviews".

The inherent topological and graphical nature of the worldwide citation network which is an inherent property of the [[scientific literature]] was described by [[Ralph Garner]] ([[Drexel University]]) in 1965.&lt;ref&gt;http://www.garfield.library.upenn.edu/rgarner.pdf&lt;/ref&gt;

The use of citation counts to rank journals was a technique used in the early part of the nineteenth century but the systematic ongoing measurement of these counts for scientific journals was initiated by Eugene Garfield at the Institute for Scientific Information who also pioneered the use of these counts  to rank authors and [[academic paper|papers]].  In a landmark paper of 1965 he and [[Irving Sher]] showed the correlation between citation frequency and eminence in demonstrating that [[Nobel Prize]] winners published five times the average number of papers while their work was cited 30 to 50 times the average. In a long series of essays on the Nobel and other prizes Garfield reported this phenomenon.  The usual summary measure is known as [[impact factor]], the number of citations to a journal for the previous two years, divided by the number of articles published in those years. It is widely used, both for appropriate and inappropriate purposes—in particular, the use of this measure alone for  ranking authors and papers is therefore [[Impact factor#|quite controversial.]]

In an early study in 1964 of the use of Citation Analysis in writing the history of [[DNA]], Garfield and Sher demonstrated the potential for generating [[historiograph]]s, [[topological map]]s of the most important steps in the history of scientific topics. This work was later automated by E. Garfield, [[A. I. Pudovkin]] of the [[Institute of Marine Biology (Vladivostok)|Institute of Marine Biology]], [[Russian Academy of Sciences]] and [[V. S. Istomin]] of [[Center for Teaching, Learning, and Technology]], [[Washington State University]] and led to the creation of the [[Histcite|HistCite]] &lt;ref&gt;{{cite web |author1=Eugene Garfield |author2=A. I. Pudovkin |author3=V. S. Istomin | year=2002 | title=Algorithmic Citation-Linked Historiography—Mapping the Literature of Science | work=Presented the ASIS&amp;T 2002: Information, Connections and Community. 65th Annual Meeting of ASIST in Philadelphia, PA. November 18–21, 2002  | url=http://www.garfield.library.upenn.edu/papers/asis2002/asis2002presentation.html | accessdate=2006-05-21}}&lt;/ref&gt; software around 2002.

Automatic citation indexing was introduced in 1998 by [[Lee Giles]], [[Steve Lawrence]] and [[Kurt Bollacker]] &lt;ref&gt;C.L. Giles, K. Bollacker, S. Lawrence, "CiteSeer: An Automatic Citation Indexing System," DL'98 Digital Libraries, 3rd ACM Conference on Digital Libraries, pp. 89-98, 1998.&lt;/ref&gt; and enabled automatic algorithmic extraction and grouping of citations for any digital academic and scientific document. Where previous citation extraction was a manual process, citation measures could now scale up and be computed for any scholarly and scientific field and document venue, not just those selected by organizations such as ISI. This led to the creation of new systems for public and automated citation indexing, the first being [[CiteSeer]] (now [[CiteSeerX]], soon followed by Cora, which focused primarily on the field of [[computer science]] and [[information science]]. These were later followed by large scale academic domain citation systems such as the Google Scholar and Microsoft Academic. Such autonomous citation indexing is not yet perfect in citation extraction or citation clustering with an error rate estimated by some at 10% though a careful statistical sampling has yet to be done. This has resulted in such authors as [[Ann Arbor, Michigan|Ann Arbor]], [[Milton Keynes]], and [[Walton Hall, Milton Keynes|Walton Hall]] being credited with extensive academic output.&lt;ref name="pmid18354457"&gt;{{cite journal |author=Postellon DC |title=Hall and Keynes join Arbor in the citation indexes |journal=[[Nature (journal)|Nature]] |volume=452 |issue=7185 |page=282 |date=March 2008 |pmid=18354457 |doi=10.1038/452282b|bibcode=2008Natur.452..282P }}&lt;/ref&gt;  SCI claims to create automatic citation indexing through purely programmatic methods. Even the older records have a similar magnitude of error.

==Citation analysis for legal documents==
{{see also|Legal citation#Legal citation analysis}}
Citation analysis for legal documents is an approach to facilitate the understanding and analysis of inter-related [[regulatory compliance]] documents by exploration of the citations that connect [[wikt:provision|provisions]] to other provisions within the same document or between different documents. Citation analysis uses a [[citation graph]] extracted from a regulatory document, which could supplement [[E-discovery]] - a process that leverages on technological innovations in [[big data analytics]].&lt;ref name="BD-HB-R-01"/&gt;&lt;ref name="BD-HB-R-02"/&gt;&lt;ref&gt;{{Cite book
|publisher=IEEE |url=http://ieeexplore.ieee.org/xpl/articleDetails.jsp?arnumber=5070630|doi = 10.1109/ITNG.2009.161|isbn = 978-1-4244-3770-2|pages = 278–283|last = Hamdaqa|first = M.|author2=A Hamou-Lhadj  |title = Citation Analysis: An Approach for Facilitating the Understanding and the Analysis of Regulatory Compliance Documents|booktitle =2009 Sixth International Conference on Information Technology: New Generations|location = Las Vegas, NV|date=2009}}&lt;/ref&gt;

==Controversies==
'''E-publishing'''. Due to the unprecedented growth of [[web resource|electronic resource]] (e-resource) availability, one of the questions currently being explored is, "how often are e-resources being cited in my field?"&lt;ref&gt;Zhao, Lisa. "How Librarian Used E-Resources--An Analysis of Citations in CCQ." [[Cataloging &amp; Classification Quarterly]] 42(1) (2006): 117-131.&lt;/ref&gt; For instance, there are claims that on-line access to [[computer science]] [[Scientific literature|literature]] leads to higher citation rates,&lt;ref&gt;Lawrence, Steve. ''Free online availability substantially increases a paper's impact.'' Nature volume 411 (number 6837) (2001): 521. Also online at http://citeseer.ist.psu.edu/online-nature01/&lt;/ref&gt; however, [[humanities]] articles may suffer if not in print.

'''Self-citations'''. It has been criticized that authors game the system by accumulating citations by citing themselves excessively.&lt;ref name="10.1007/s11192-017-2330-1"&gt;{{cite journal |author=Gálvez RH |title=Assessing author self-citation as a mechanism of relevant knowledge diffusion |journal=Scientometrics |volume=111 |issue=3 |pages=1801 |date=March 2017 |doi=10.1007/s11192-017-2330-1}}&lt;/ref&gt; For instance, it has been found that men tend to cite themselves more often than women.&lt;ref&gt;{{Cite web|url=http://www.nature.com/news/men-cite-themselves-more-than-women-do-1.20176|title=Men cite themselves more than women do|last=Singh Chawla|first=Dalmeet|date=5 July 2016|website=Nature|publisher=Nature|access-date=7 July 2016}}&lt;/ref&gt;

==See also==
*[[Citation graph]]
*[[Citation impact]]
*[[Citation index]]
*[[Google economy]]
*[[h-index]]
*[[Journal ranking]]
* [[San Francisco Declaration on Research Assessment]], 2012-
*[[Bibliographic coupling]]
*[[Co-citation]]
*[[Co-citation Proximity Analysis]]
*[[Main path analysis]]

==Notes==
{{reflist}}

[[Category:Bibliometrics]]
[[Category:Analysis]]
[[Category:Citation metrics]]</text>
      <sha1>n1vf57qm4m56uxags35qwkgbiqwryze</sha1>
    </revision>
  </page>
  <page>
    <title>Clark's Tree</title>
    <ns>0</ns>
    <id>52918756</id>
    <revision>
      <id>857974854</id>
      <parentid>815171932</parentid>
      <timestamp>2018-09-04T07:14:08Z</timestamp>
      <contributor>
        <username>GeoEvan</username>
        <id>84276</id>
      </contributor>
      <comment>Correction. As per cited sources (and implied by title), it was Clark, not Lewis, who carved his name into the tree</comment>
      <model>wikitext</model>
      <format>text/x-wiki</format>
      <text xml:space="preserve" bytes="4259">{{Infobox artwork
| title = Clark's Tree
| other_language_1 = 
| other_title_1 = 
| other_language_2 = 
| other_title_2 = 
| image = 
| image_upright = 
| alt = 
| caption = 
| artist = Stanley Wanlass
| catalogue = 
| year = 2003
| medium = [[Lost-wax casting|Lost-wax]] cast bronze
| movement =
| subject = [[Lewis and Clark Expedition]] 1805 arrival at the Pacific Ocean
| height_metric =      &lt;!-- (i.e. in metric units) --&gt;
| width_metric = 
| length_metric = 
| diameter_metric = 
| height_imperial =    &lt;!-- (i.e. in imperial units) --&gt;
| width_imperial = 
| length_imperial = 
| diameter_imperial = 
| dimensions = 
| dimensions_ref = 
| metric_unit = cm     &lt;!-- Note: this parameter must either use the value given or not be included --&gt;
| imperial_unit = in   &lt;!-- Note: this parameter must either use the value given or not be included --&gt;
| designation = 
| condition = 
| city = [[Long Beach, Washington|Long Beach]], [[Washington (state)|Washington]]
| museum = 
| accession = 
| coordinates = {{Coord|46.37118|N|124.06182|W|type:landmark|display=inline,title}}
| owner = 
}}
'''''Clark's Tree''''' is a bronze memorial sculpture in [[Long Beach, Washington ]] commemorating [[Lewis and Clark]]'s journey across North America. It sits on a dune above the Pacific Ocean beach at [[Breakers station|Breakers]] near where Clark carved a message on a living tree to establish United States precedence of discovery and occupation in what was then the [[Oregon Country]]. The memorial was created by Stanley Wanlass, a sculptor educated at [[Brigham Young University]].&lt;ref&gt;{{citation|title=Sculpting an LDS Tradition|author=Richard G. Oman|work=lds.org|publisher=The Church of Jesus Christ of Latter-Day Saints|url=https://www.lds.org/ensign/1990/10/sculpting-an-lds-tradition?lang=eng}}&lt;/ref&gt; The sculpture marks the westernmost and northernmost point of Lewis and Clark's journey on the Pacific coast.&lt;ref name=Stratton2014&gt;{{citation|title=Famed bronze sculptor offers memorial for those lost at sea|author=Edward Stratton|newspaper=The Daily Astorian|location=Astoria, Oregon|date=April 10, 2014 |url=http://www.dailyastorian.com/20140410/famed-bronzesculptor-offers-memorial-for-those-lost-at-sea}}&lt;/ref&gt;&lt;ref&gt;{{Historylink|title=Captain William Clark of the Lewis and Clark Expedition visits the future site of Long Beach on November 19, 1805|author=Jennifer Ott |date=May 8, 2011 |article=9814}}&lt;/ref&gt; 

The sculpture was built in Clarkston, then barged down the Columbia River in 2003 with stops for public viewing in Richland, Hood River, Portland and Vancouver,&lt;ref&gt;{{citation|title=Lewis &amp; Clark Bicentennial: Bronze tree honoring Lewis &amp; Clark to dock here|newspaper=The Columbian|location=Vancouver, Washington|date=October 2, 2003 | author=DEAN BAKER|via=[[HighBeam]] {{subscription required}}|url=https://www.highbeam.com/doc/1P2-23246293.html}}&lt;/ref&gt; then into the Pacific Ocean to reach Long Beach. In the process the sculpture was nearly lost at sea, according to Wanlass.&lt;ref name=Stratton2014/&gt;

Another marker with the same name was constructed in 1932 at 3rd and Pacific in Long Beach's downtown area.{{sfn | Saindon | 2003 | p=530}}

==References==
{{reflist|30em}}
*{{citation|title=William Clark, Master Graffitist |publisher=Washington State Chapter, LCTHF |work=Worthy of Notice |date=January 2004 |author=Tom Laidlaw|volume= 5|issue=1 |p=7|url=http://www.wa-lcthf.org/newsletters/pdf/2004_01_news.pdf}}
===Sources===
* {{cite book | last=Saindon | first=R.A. | title=Explorations Into the World of Lewis and Clark V-2 of 3 | publisher=Lewis and Clark Trail Heritage Foundation | issue=v. 2 | year=2003 | isbn=978-1-58218-764-8 | url=https://books.google.com/books?id=TygK-g-UguQC&amp;pg=PA530 | ref=harv | accessdate=2017-03-26}}

==External links==
*[http://www.oregonhikers.org/field_guide/Clark%27s_Tree Clark's Tree] at Oregon Hikers
*[http://www.lewis-clark.org/article/1455 Arrival at the Pacific Ocean], Discovering Lewis &amp; Clark

[[Category:2003 sculptures]]
[[Category:History of Pacific County, Washington]]
[[Category:Individual trees in Washington (state)]]
[[Category:Lewis and Clark Expedition]]
[[Category:Outdoor sculptures in Washington (state)]]
[[Category:Tourist attractions in Pacific County, Washington]]</text>
      <sha1>80lchjza1ldlh4qti89v6hnhadytnkk</sha1>
    </revision>
  </page>
  <page>
    <title>Colorpuncture</title>
    <ns>0</ns>
    <id>24320602</id>
    <revision>
      <id>859170897</id>
      <parentid>859168578</parentid>
      <timestamp>2018-09-12T06:24:47Z</timestamp>
      <contributor>
        <username>Sgerbic</username>
        <id>12235651</id>
      </contributor>
      <comment>/* Reception */ corrected spelling of name and hyperlinked to her</comment>
      <model>wikitext</model>
      <format>text/x-wiki</format>
      <text xml:space="preserve" bytes="7918">{{Infobox alternative medicine
| name =Colorpuncture
| image=
| claims = Applying colored light to meridian points on the body, derived from [[acupuncture]], has beneficial health effects.
| topics = [[Acupressure]], [[Acupuncture]], [[Biophotonics]], [[Iridology]], [[Kirlian photography]]
| orig_year = 1970s
| orig_prop = Peter Mandel
| later_prop =
| see_also = [[Chromotherapy]]
}}
'''Colorpuncture''', or '''color light acupuncture''', is a [[pseudoscientific]]&lt;ref name=Quackwatch/&gt; [[alternative medicine]] practice based on "mystical or supernatural" beliefs&lt;ref name=Skeptical/&gt; which asserts that colored lights can be used to stimulate [[acupuncture point]]s to promote healing and better health. It is a form of [[chromotherapy]] or color therapy.&lt;ref&gt;{{cite journal |pmid=10513100 |year=1999 |author1=Cocilovo |first1=A |title=Colored light therapy: Overview of its history, theory, recent developments and clinical applications combined with acupuncture |journal=American journal of acupuncture |volume=27 |issue=1–2 |pages=71–83 }}&lt;/ref&gt;  There is no known [[anatomical]] or [[histological]] basis for the existence of acupuncture points or meridians.&lt;ref name="Mann_drunkard"&gt;{{cite book |last = Mann | first = F | authorlink = Felix Mann |title=Reinventing acupuncture: a new concept of ancient medicine |publisher=Butterworth-Heinemann |location=Oxford |year=2000 |pages= [https://books.google.com/books?id=ErALnM5c8I4C&amp;pg=PA14 14] |isbn=0-7506-4857-0 |oclc= |doi= |accessdate=}}&lt;/ref&gt; Scientific support for the efficacy of colorpuncture is lacking.&lt;ref name=Reddy/&gt;&lt;ref&gt;{{cite journal |doi=10.1016/S2005-2901(09)60031-5 |pmid=20633463 |title=Effect of Colorpuncture on Spontaneous Photon Emission in a Subject Suffering from Multiple Sclerosis |journal=Journal of Acupuncture and Meridian Studies |volume=1 |issue=2 |pages=114–20 |year=2008 |last1=Bajpai |first1=RP |last2=Drexel |first2=M }}&lt;/ref&gt;

== Background ==

Colorpuncture was developed in the 1980s by German [[naturopath]] and acupuncturist Peter Mandel, who named it ''esogetic colorpuncture''. "Esogetic" is a term coined by Mandel to refer to the "merger of esoteric wisdom of life with the energetic principles of life's processes".&lt;ref name="ec"&gt;{{cite web|url=http://www.acupuncturetoday.com/mpacms/at/article.php?id=27983|title=Esogetic Colorpuncture: A Complete Aculight Therapy System for Body, Mind and Spirit|last=Croke|first=Manohar|date=June 2002|work=Acupuncture Today|accessdate=2009-09-15}}&lt;/ref&gt;

Mandel cited [[Fritz-Albert Popp]], who claimed that the body's cells communicate with each other through a steady stream of [[photon]]s. This is not a scientifically recognized method of cell [[Cell signaling|communication]]. Using [[Kirlian photography]], Mandel concluded that the [[acupuncture]] meridians absorb and disseminate colored light within the body.

Colorpuncture is based on the idea that illness and pain occur when an individual has strayed off his or her "life path". For example, a treatment might be intended to release an emotional blockage to heal a nervous system condition, allowing patients to devote themselves to their individual spiritual purpose.&lt;ref&gt;{{cite book|title=Light Years Ahead: The Illustrated Guide to Full Spectrum and Colored Light in Mindbody Healing|editor=Brian Breiling|publisher=Celestial Arts|date=May 1996|pages=233–257|article=Colorpuncture and Esogetic Healing: The Use of Colored Light in Acupuncture|author1=Akhila Dass  |author2=Manohar Croke |lastauthoramp=yes |isbn=0-89087-762-9}}&lt;/ref&gt;  Mandel's model is a [[holographic]] representation of how [[Vitalism|vital energy]] is produced in the body.{{Clarify|date=January 2010}}  Three of the six factors (called ''molecules'') represent the [[Energy (esotericism)|subtle energies]]: the ''[[chakra]]s'', the ''formative field'', and the ''converter model''.  The other three factors describe the physical reality: the ''body systems'', the ''coordination system'', and the ''transmitter relays''.&lt;ref name="Dale 2009 359"&gt;{{cite book|last=Dale|first=Cyndi|title=The Subtle Body: An Encyclopedia of Your Energetic Anatomy|publisher=Sounds True, Boulder Colorado|year=2009|page=359|isbn=978-1-59179-671-8}}&lt;/ref&gt;

== Treatment ==
Colorpuncture employs seven basic colors.  In general, the warm colors - red, orange, and yellow - are believed to add energy, while the cool colors - green, blue, and violet - decrease energy.  Mandel also claims that warm and cool colors, when used together, balance [[yin and yang]] energy flows.&lt;ref name="Dale 2009 359"/&gt;&lt;ref&gt;{{cite book|last=Dale|first=Cyndi|title=The Subtle Body: An Encyclopedia of Your Energetic Anatomy|publisher=Sounds True, Boulder Colorado|year=2009|pages=358–359|isbn=978-1-59179-671-8}}&lt;/ref&gt;

A small handheld instrument resembling a torch ([[flashlight]]) with a colored quartz rod is used. The tip is placed directly onto acupoints or held a short distance above. Unlike acupuncture, the skin is not broken. Colorpuncture sessions last 10 to 90 minutes.&lt;ref name="wcc"&gt;{{cite news|url=http://www.taipeitimes.com/News/feat/archives/2005/09/18/2003272235|title=Working a colorful cure|last=Phipps|first=Gavin|date=Gavin Phipps|work=The Taipei Times|accessdate=2009-09-15}}&lt;/ref&gt;  Colorpuncturists claim to diagnose through the use of [[Kirlian photography]].&lt;ref&gt;{{cite web|url=http://www.quackwatch.org/01QuackeryRelatedTopics/dictionary/mdc.html|title=Unnaturalistic Methods|last=Raso|first=Jack|year=1997|work=Dictionary of Metaphysical Healthcare|accessdate=2009-09-15}}&lt;/ref&gt;&lt;ref&gt;{{cite book|last=Carroll|first=Robert Todd|authorlink = Robert Todd Carroll|title=The skeptic's dictionary: a collection of strange beliefs, amusing deceptions, and dangerous delusions|publisher=John Wiley and Sons|year=2003|pages=[https://books.google.com/books?id=6FPqDFx40vYC&amp;pg=PA190#v=onepage&amp;q&amp;f=false 190]|isbn=0-471-27242-6}}&lt;/ref&gt;

== Reception ==
Jack Raso writing in the ''[[Skeptical Inquirer]]'' included colorpuncture in a list of "mystical or supernaturalistic" therapies.&lt;ref name=Skeptical&gt;{{cite web|url=http://www.csicop.org/si/show/mystical_medical_alternativism/|title=Mystical Medical Alternativism|last=Raso|first=Jack|date=Volume 19.5, September / October 1995|work=Skeptical Inquirer|publisher=The Committee for Skeptical Inquiry|accessdate=2009-09-15}}&lt;/ref&gt; Doctor [[Harriet Hall]] points out there is no supporting research for colorpuncture and explains how color can be used for diagnosis rather than treatment.&lt;ref&gt;{{cite web |last1=Hall |first1=Harriet |authorlink = Harriet Hall|title=Colorpuncture |url=https://www.csicop.org/specialarticles/show/colorpuncture |website=Skeptical Inquirer |publisher=The Committee for Skeptical Inquiry |accessdate=12 September 2018}}&lt;/ref&gt; A review of research studies conducted in Europe to evaluate the efficacy of colorpuncture concluded that the approach lacked a research base to be considered anything but a pilot or preliminary research stage.&lt;ref name=Reddy&gt;{{cite book|title=The abnormal menstrual cycle |editor1=Margaret Rees |editor2=Sally Hope |editor3=Veronica Ravnikar |publisher=Taylor and Francis|year=2005|pages=176|chapter=12, Alternative Medicines, by K.Reddy|url=https://books.google.com/books?id=AFGq2OtnfAIC&amp;pg=PA176|accessdate=2009-09-15|isbn=978-1-84214-212-7}}&lt;/ref&gt; [[Quackwatch]] lists it as a questionable treatment, and research on colorpuncture has failed to demonstrate a consistent effect.&lt;ref name=Quackwatch&gt;{{cite web | url = http://www.quackwatch.org/01QuackeryRelatedTopics/treatmentindex.html | publisher = [[Quackwatch]] | title = Index of Questionable Treatments | date = 2010-01-15 | accessdate = 2010-03-19 }}&lt;/ref&gt;

==See also==
* [[Chromotherapy]]
* [[Pseudoscience]]
* [[List of topics characterized as pseudoscience]]

== References ==
{{reflist|2}}
{{color topics}}

[[Category:Acupuncture]]
[[Category:Pseudoscience]]
[[Category:Light therapy]]</text>
      <sha1>kd6vb0norkbwvapoqx50up92hdzbypq</sha1>
    </revision>
  </page>
  <page>
    <title>Conservative force</title>
    <ns>0</ns>
    <id>44158</id>
    <revision>
      <id>871465353</id>
      <parentid>871352962</parentid>
      <timestamp>2018-12-01T07:16:07Z</timestamp>
      <contributor>
        <username>Materialscientist</username>
        <id>7852030</id>
      </contributor>
      <comment>Reverted 1 [[WP:AGF|good faith]] edit by [[Special:Contributions/106.76.206.193|106.76.206.193]] using [[WP:STiki|STiki]]</comment>
      <model>wikitext</model>
      <format>text/x-wiki</format>
      <text xml:space="preserve" bytes="10165">{{Classical mechanics}}
A '''conservative force''' is a force with the property that the total [[Work (physics)|work]] done in moving a particle between two points is independent of the taken path.&lt;ref&gt;[http://hyperphysics.phy-astr.gsu.edu/hbase/pegrav.html#cfor HyperPhysics - Conservative force]&lt;/ref&gt;  Equivalently, if a particle travels in a closed loop, the net work done (the sum of the force acting along the path multiplied by the displacement) by a conservative force is zero.&lt;ref name=Hand&gt;{{cite book |title=Analytical Mechanics |author =Louis N. Hand, Janet D. Finch |page=41 |isbn=0-521-57572-9 |publisher=Cambridge University Press |year=1998 }}&lt;/ref&gt;

A conservative force is dependent only on the position of the object.  If a force is conservative, it is possible to assign a numerical value for the [[Scalar potential|potential]] at any point. When an object moves from one location to another, the force changes the [[potential energy]] of the object by an amount that does not depend on the path taken. If the force is not conservative, then defining a scalar potential is not possible, because taking different paths would lead to conflicting potential differences between the start and end points.

[[Gravitation|Gravitational force ]] is an example of a conservative force, while [[frictional force]] is an example of a non-conservative force.

Other examples of conservative forces are: force in elastic spring, electrostatic force between two electric charges, and magnetic force between two magnetic poles. The last two forces are called central forces as they act along the line joining the centres of two charged/magnetized bodies. Thus, all central forces are conservative forces.

==Informal definition==
Informally, a conservative force can be thought of as a force that ''conserves'' [[mechanical energy]]. Suppose a particle starts at point A, and there is a force ''F'' acting on it. Then the particle is moved around by other forces, and eventually ends up at A again. Though the particle may still be moving, at that instant when it passes point A again, it has traveled a closed path. If the net work done by ''F'' at this point is 0, then ''F'' passes the closed path test. Any force that passes the closed path test for all possible closed paths is classified as a conservative force.

The [[gravitational force]], [[Hooke's law|spring force]], [[magnetic force]] (according to some definitions, see below) and [[electric force]] (at least in a time-independent magnetic field, see [[Faraday's law of induction]] for details) are examples of conservative forces, while [[friction]] and [[air drag]] are classical examples of non-conservative forces.

For non-conservative forces, the mechanical energy that is lost (not conserved) has to go somewhere else, by [[conservation of energy]]. Usually the energy is turned into [[heat]], for example the heat generated by friction. In addition to heat, friction also often produces some [[sound]] energy. The water drag on a moving boat converts the boat's mechanical energy into not only heat and sound energy, but also wave energy at the edges of its [[wake]]. These and other energy losses are irreversible because of the [[second law of thermodynamics]].

==Path independence==
[[Image:Conservative Force Gravity Example.svg|right|150px]]
A direct consequence of the closed path test is that the work done by a conservative force on a particle moving between any two points does not depend on the path taken by the particle.

This is illustrated in the figure to the right: The work done by the gravitational force on an object depends only on its change in height because the [[gravitational force]] is conservative. The work done by a conservative force is equal to the negative of change in potential energy during that process. For a proof, imagine two paths 1 and 2, both going from point A to point B. The variation of energy for the particle, taking path 1 from A to B and then path 2 backwards from B to A, is 0; thus, the work is the same in path 1 and 2, i.e., the work is independent of the path followed, as long as it goes from A to B.

For example, if a child slides up a frictionless slide, the work done by the gravitational force on the child from the down of the slide to the up will be the same no matter what the shape of the slide; it can be straight or it can be a spiral or conical.  The amount of work done only depends on the vertical displacement of the child.

==Mathematical description==
A [[force field (physics)|force field]] ''F'', defined everywhere in space (or within a [[simply-connected]] volume of space), is called a ''conservative force'' or ''[[conservative vector field]]'' if it meets any of these three ''equivalent'' conditions:

{{ordered list
| The [[Curl (mathematics)|curl]] of ''F'' is the zero vector:
:&lt;math&gt;\nabla \times \vec{F} = \vec{0}. \,&lt;/math&gt;
| There is zero net [[work (physics)|work]] (''W'') done by the force when moving a particle through a trajectory that starts and ends in the same place:
:&lt;math&gt;W \equiv \oint_C \vec{F} \cdot \mathrm{d}\vec r = 0.\,&lt;/math&gt;
| The force can be written as the negative [[gradient]] of a [[potential energy|potential]], &lt;math&gt;\Phi&lt;/math&gt;:
:&lt;math&gt;\vec{F} = -\nabla \Phi. \,&lt;/math&gt;
}}

{| class="toccolours collapsible collapsed" width="80%" style="text-align:left"
! Proof that these three conditions are equivalent when ''F'' is a [[force field (physics)|force field]]
|-
| {{Main|Conservative vector field}}
{{glossary}}
{{term|1 implies 2}}{{defn|
Let ''C'' be any simple closed path (i.e., a path that starts and ends at the same point and has no self-intersections), and consider a surface ''S'' of which ''C'' is the boundary. Then [[Stokes' theorem]] says that
:&lt;math&gt; \int_S \left(\nabla \times \vec{F}\right) \cdot \mathrm{d}\vec{a} = \oint_C \vec{F} \cdot \mathrm{d}\vec{r} &lt;/math&gt;
If the curl of '''F''' is zero the left hand side is zero - therefore statement 2 is true.
}}
{{term|2 implies 3}}{{defn|
Assume that statement 2 holds. Let ''c'' be a simple curve from the origin to a point &lt;math&gt;x&lt;/math&gt; and define a function
:&lt;math&gt;\Phi(x) = -\int_c \vec{F} \cdot \mathrm{d}\vec{r}.&lt;/math&gt;
The fact that this function is well-defined (independent of the choice of ''c'') follows from statement 2. Anyway, from the [[fundamental theorem of calculus]], it follows that 
:&lt;math&gt;\vec{F} = -\nabla \Phi.&lt;/math&gt;
So statement 2 implies statement 3 ([[Gradient theorem#Converse of the gradient theorem|see full proof]]).
}}
{{term|3 implies 1}}{{defn|
Finally, assume that the third statement is true. A well-known vector calculus identity states that the curl of the gradient of any function is 0. (See [[Vector calculus identities#Curl of the gradient|proof]].) Therefore, if the third statement is true, then the first statement must be true as well.

This shows that statement 1 implies 2, 2 implies 3, and 3 implies 1. Therefore, all three are equivalent, [[Q.E.D.]].

(The equivalence of 1 and 3 is also known as (one aspect of) [[Helmholtz decomposition|Helmholtz's theorem]].)
}}
{{glossary end}}
|}

The term ''conservative force'' comes from the fact that when a conservative force exists, it conserves mechanical energy. The most familiar conservative forces are [[gravity]], the [[electric force]] (in a time-independent magnetic field, see [[Faraday's law of induction|Faraday's law]]), and [[Hooke's law|spring force]].

Many forces (particularly those that depend on velocity) are not [[force field (physics)|force ''fields'']]. In these cases, the above three conditions are not mathematically equivalent. For example, the [[magnetic force]] satisfies condition 2 (since the work done by a magnetic field on a charged particle is always zero), but does not satisfy condition 3, and condition 1 is not even defined (the force is not a vector field, so one cannot evaluate its curl). Accordingly, some authors classify the magnetic force as conservative,&lt;ref name="srivastava1997mechanics"&gt;For example, {{Cite book|title=Mechanics|author=P. K. Srivastava|url=https://books.google.at/books?id=yCw_Hq53ipsC|year=2004|publisher=New Age International Pub. (P) Limited|access-date=2018-11-20|ISBN=9788122411126|page=94}}: "In general, a force which depends explicitly upon the velocity of the particle is not conservative. However, the magnetic force (q'''v'''×'''B''') can be included among conservative forces in the sense that it acts perpendicular to velocity and hence work done is always zero". [https://books.google.com/books?id=yCw_Hq53ipsC Web link]&lt;/ref&gt; while others do not.&lt;ref&gt;For example, ''The Magnetic Universe: Geophysical and Astrophysical Dynamo Theory'', Rüdiger and Hollerbach, page 178, [https://books.google.com/books?id=IRJO9gvkJo8C Web link]&lt;/ref&gt; The magnetic force is an unusual case; most velocity-dependent forces, such as [[friction]], do not satisfy any of the three conditions, and therefore are unambiguously nonconservative.

==Non-conservative forces==
Non-conservative forces can arise in classical physics due to neglected [[degrees of freedom (physics and chemistry)|degrees of freedom]] or from time-dependent potentials.&lt;ref&gt;Friedhelm Kuypers. Klassische Mechanik. WILEY-VCH 2005. Page 9.&lt;/ref&gt;  For instance, friction may be treated without resorting to the use of nonconservative forces by considering the motion of individual molecules; however that means every molecule's motion must be considered rather than handling it through statistical methods.  For macroscopic systems the nonconservative approximation is far easier to deal with than millions of degrees of freedom. Examples of nonconservative forces are [[friction]] and non-elastic material [[stress (mechanics)|stress]].

However, [[general relativity]] is non-conservative, as seen in the [[Tests of general relativity#Perihelion precession of Mercury|anomalous precession]] of Mercury's orbit{{citation needed|date=April 2017}}.  However, general relativity can be shown to conserve a [[stress–energy–momentum pseudotensor]].

==See also==
* [[Conservative vector field]]

==References==
{{Reflist}}

{{DEFAULTSORT:Conservative Force}}
[[Category:Force]]</text>
      <sha1>4r98jvhy2p94b7r8e1gtyoivomrqrk1</sha1>
    </revision>
  </page>
  <page>
    <title>Current (fluid)</title>
    <ns>0</ns>
    <id>24483792</id>
    <revision>
      <id>616697794</id>
      <parentid>576163022</parentid>
      <timestamp>2014-07-12T20:49:38Z</timestamp>
      <contributor>
        <username>Invertzoo</username>
        <id>4863204</id>
      </contributor>
      <comment>add two more</comment>
      <model>wikitext</model>
      <format>text/x-wiki</format>
      <text xml:space="preserve" bytes="467">A '''current''' in a [[fluid]] is the magnitude and direction of flow within that fluid. An [[air current]] presents the same properties specifically for a [[gas]]eous medium.

Types of fluid currents include

* [[Boundary current]]
* [[Current (stream)]], a current in a river or stream
* [[Longshore current]]
* [[Ocean current]]
* [[Rip current]]
* [[Rip tide]]
* [[Subsurface currents]]
* [[Turbidity current]]

{{Fluiddynamics-stub}}

[[Category:Fluid dynamics]]</text>
      <sha1>3udpmj4zdovkbqoeu23a6o7odr8xipr</sha1>
    </revision>
  </page>
  <page>
    <title>Cyprinid herpesvirus 3</title>
    <ns>0</ns>
    <id>19107240</id>
    <revision>
      <id>862375360</id>
      <parentid>855225715</parentid>
      <timestamp>2018-10-04T00:02:45Z</timestamp>
      <contributor>
        <ip>2601:681:5280:2BA6:5D1C:133E:BE78:D4AF</ip>
      </contributor>
      <comment>Fix spelling of Cyprinus carpio</comment>
      <model>wikitext</model>
      <format>text/x-wiki</format>
      <text xml:space="preserve" bytes="4348">{{Taxobox
| image              =
| virus_group        = i
| ordo               = ''[[Herpesvirales]]''
| familia            = ''[[Alloherpesviridae]]''
| genus              = ''[[Cyprinivirus]]''
| species  = '''''Cyprinid herpesvirus 3'''''
| synonyms        = CyHV-3&lt;br /&gt;Koi herpes virus&lt;br /&gt;KHV
}}

'''''Cyprinid herpesvirus 3''''' (also '''CyHV-3''', '''koi herpes virus''' or '''KHV''') is a species of virus causing a [[viral disease]] that is very contagious to the [[common carp]] ''Cyprinus carpio''. It is most commonly found in ornamental [[koi]], which are often used in outdoor ponds or as feeder stock. The first case of KHV was reported in 1998, but not confirmed until later in 1999.

KHV is a DNA-based virus. After discovery, it was identified as a strain of [[herpesvirus]]. Like other strains, KHV stays with the infected fish for the duration of their lives, making the recovered and exposed fish potential carriers of the virus. Koi fish infected with KHV may die within the first 24–48 hours of exposure. The virus is found in 33 countries.&lt;ref&gt;{{cite news|url=http://www.canberratimes.com.au/environment/animals/millions-of-lake-burley-griffin-carp-face-swift-death-from-cyprinid-herpesvirus-release-20160606-gpcs3e.html|title=Millions of Lake Burley Griffin carp face swift death from cyprinid herpesvirus release|date=13 June 2016|first=John|last=Thistleton|newspaper=The Canberra Times|publisher=Fairfax Media|archiveurl=https://web.archive.org/web/20160613040446/http://www.canberratimes.com.au/environment/animals/millions-of-lake-burley-griffin-carp-face-swift-death-from-cyprinid-herpesvirus-release-20160606-gpcs3e.html|archivedate=13 June 2016}}&lt;/ref&gt;

KHV is listed as a nonexotic disease of the [[European Union|EU]], so is watched closely by the [[European Community Reference Laboratory for Fish Diseases]].

Symptoms of KHV include:
* Gill [[mottling]]
* Red and white patches appearing on gills
* Bleeding gills
* Sunken eyes
* Pale patches
* [[Blisters]]

Changes in the specimen's behaviour may also indicate the presence of KHV. Behavioural symptoms may include disorientation, hyperactivity and potentially isolation, in which the specimen detaches themselves from the shoal.&lt;ref&gt;{{Cite web|url = http://www.fishingbaitworld.co.uk/blog/what-is-koi-herpesvirus/|title = What is Koi Herpesvirus? - Fishing Bait World Blog|website = Fishing Bait World Blog|language = en-GB|access-date = 2017-07-14}}&lt;/ref&gt;

In 2016 the Australian Government announced plans to release the virus into the [[Murray-Darling basin]] in an attempt to control carp populations in the water system.&lt;ref&gt;{{cite news|url=https://www.rt.com/news/341556-australia-carps-herpes-virus/|title= Australia to spend over $11mn to eradicate carps by releasing herpes virus into rivers|first=David W.|last=Cerny|date=1 May 2016|archiveurl=https://web.archive.org/web/20160602132347/https://www.rt.com/news/341556-australia-carps-herpes-virus/|archivedate=2 June 2016}}&lt;/ref&gt;&lt;ref&gt;{{cite news|url=http://www.abc.net.au/news/2016-05-01/herpes-to-eradicate-carp-in-murray-river-pyne-says/7373736|title=Herpes virus to be used in fight against carp in Murray River, Christopher Pyne says|first1=Nick|last1=Kilvert|first2=Kerrin|last2=Thomas|publisher=Australian Broadcasting Corporation|website=ABC News|archiveurl=https://web.archive.org/web/20160505164116/http://www.abc.net.au/news/2016-05-01/herpes-to-eradicate-carp-in-murray-river-pyne-says/7373736|archivedate=5 May 2016|date=1 May 2016}}&lt;/ref&gt;

==References==
{{Reflist}}

==External links==
* [http://www.invadingspecies.com/Invaders.cfm?A=Page&amp;PID=42 Invading Species.com]{{dead link|date=August 2017 |bot=InternetArchiveBot |fix-attempted=yes }} Ontario Ministry of Natural Resources and the Ontario Federation of Anglers and Hunters
* [http://edis.ifas.ufl.edu/pdffiles/vm/vm11300.pdf Koi Herpes Virus (KHV) Disease. Institute of Food and Agricultural Sciences Fact Sheet VM-149, University of Florida.]
* [http://www.nationalfishpharm.com/KHV.html K.H.V. Koi Herpes Virus. National Fish Pharmaceuticals]
* [http://arquivo.pt/wayback/20141127111700/http://www.crl-fish.eu/ European Community Reference Laboratory for Fish Diseases]

{{Fish disease topics}}
{{Taxonbar|from=Q386469}}

[[Category:Carp]]
[[Category:Fish viral diseases]]
[[Category:Alloherpesviridae]]


{{virus-stub}}</text>
      <sha1>olvqlzdnbe025ohpp53wjqrgo05j8dl</sha1>
    </revision>
  </page>
  <page>
    <title>Dead-beat control</title>
    <ns>0</ns>
    <id>5409095</id>
    <revision>
      <id>784051127</id>
      <parentid>762580412</parentid>
      <timestamp>2017-06-06T05:39:31Z</timestamp>
      <contributor>
        <username>Magic links bot</username>
        <id>30707369</id>
      </contributor>
      <minor/>
      <comment>Replace [[Help:Magic links|magic links]] with templates per [[Special:Permalink/772743896#Future of magic links|local RfC]] and [[:mw:Requests for comment/Future of magic links|MediaWiki RfC]]</comment>
      <model>wikitext</model>
      <format>text/x-wiki</format>
      <text xml:space="preserve" bytes="2146">In discrete-time [[control theory]], the '''dead-beat control''' problem consists of finding what input signal must be applied to a system in order to bring the output to the steady state in the smallest number of time steps.

For an ''N''th-order linear system it can be shown that this minimum number of steps will be at most ''N'' (depending on the initial condition), provided that the system  is null controllable (that it can be brought to state zero by ''some'' input).  The solution is to apply [[feedback]] such that all poles of the closed-loop transfer function are at the origin of the ''z''-plane.  (For more information about transfer functions and the ''z''-plane see [[z-transform]]).  Therefore the linear case is easy to solve.  By extension, a closed loop transfer function which has all poles of the transfer function at the origin is sometimes called a dead beat transfer function.

For nonlinear systems, dead beat control is an open research problem.  (See Nesic reference below).

Dead beat controllers are often used in [[process control]] due to their good dynamic properties. They are a classical [[feedback controller]] where the control gains are set using a table based on the plant system order and normalized natural frequency.

The deadbeat response has the following characteristics:
# Zero steady-state error
# Minimum rise time
# Minimum settling time
# Less than 2% overshoot/undershoot
# Very high control signal output

== References ==
*Kailath, Thomas: ''Linear Systems'', Prentice Hall, 1980,  {{ISBN|9780135369616}}
*[http://www.inma.ucl.ac.be/~bastin/paper46.pdf] Nesic et al.:''Output dead beat control for a class of planar polynomial systems''
*[[Kevin Warwick|Warwick, Kevin]]: ''Adaptive dead beat control of stochastic systems'', International Journal of Control, 44(3), 651-663, 1986.
*{{cite book
  | last = Dorf
  | first = Richard C.
  | authorlink =
  |author2=Bishop, Robert H.
  | title = Modern Control Systems
  | publisher = Pearson Prentice Hall
  | date = 2005
  | location = Upper Saddle River, NJ 07458
  | pages = 617–619
  }}

[[Category:Control theory]]


{{mathanalysis-stub}}</text>
      <sha1>sylcnaiqqfdq8slsgl04n4vblvhtw89</sha1>
    </revision>
  </page>
  <page>
    <title>Detunatele</title>
    <ns>0</ns>
    <id>47231050</id>
    <revision>
      <id>753867570</id>
      <parentid>750295956</parentid>
      <timestamp>2016-12-09T17:17:17Z</timestamp>
      <contributor>
        <username>Cydebot</username>
        <id>1215485</id>
      </contributor>
      <minor/>
      <comment>Robot - Speedily moving category Visitor attractions in Alba County to [[:Category:Tourist attractions in Alba County]] per [[WP:CFDS|CFDS]].</comment>
      <model>wikitext</model>
      <format>text/x-wiki</format>
      <text xml:space="preserve" bytes="1156">[[File:Basalt columns in Romania.jpg|thumb|Detunata goala]]
'''Detunatele''' is a site of [[columnar jointing]] in [[Transylvania]], [[Alba County]], [[Romania]].  ''Detunatele'' means lightning strike. The columns are hexagonal shaped basalt and 1,258 meters tall on two peaks: Detunata Goala and Detunata Flocoasa (Barren Detunata and Shaggy Detunata). They are located in the [[Metaliferi Mountains]] and are a tourist attraction. They are 1.5&amp;nbsp;km apart. They formations are shaped like humps and there are stories and legends associated with them.&lt;ref&gt;[http://www.romaniajournal.ro/detunatele-a-unique-natural-reservation-of-basalt-columns/ ‘Detunatele’ – a unique natural reservation of basalt columns] by Ramona Ciortescu March 6, 2015 Romania Journal&lt;/ref&gt;

==References==
{{reflist}}

==External links==
*[http://cityoftheweek.net/2015/02/24/the-detunata/ The Detunata] Write up of a hike up Detunata Flocoasa including photos

{{coord missing|Romania}}

[[Category:Columnar basalts]]
[[Category:Geology of Romania]]
[[Category:Geography of Alba County]]
[[Category:Tourist attractions in Alba County]]

{{geology-stub}}
{{Alba-geo-stub}}</text>
      <sha1>4fr7vmu0z7gudz8t4t8fjyyxdtwn6o4</sha1>
    </revision>
  </page>
  <page>
    <title>Force field (fiction)</title>
    <ns>0</ns>
    <id>286106</id>
    <revision>
      <id>861753272</id>
      <parentid>858337172</parentid>
      <timestamp>2018-09-29T19:25:19Z</timestamp>
      <contributor>
        <username>Smeagol 17</username>
        <id>7183365</id>
      </contributor>
      <model>wikitext</model>
      <format>text/x-wiki</format>
      <text xml:space="preserve" bytes="9215">In [[speculative fiction]], a '''force field''', sometimes known as an '''energy shield''', '''force shield''', '''defence shield''' or '''deflector shield''', is a barrier made of energy, [[plasma (physics)|plasma]], or particles. It protects a person, area, or object from attacks or intrusions. This [[fictional technology]] is created as a [[field (physics)|field]] of energy without mass that acts as a wall, so that objects affected by the particular force relating to the field are unable to pass through the field and reach the other side. This concept has become a staple of many science-fiction works, so much that authors frequently do not even bother to explain or justify them to their readers treating them almost as established fact and attributing whatever capabilities the plot requires.

There is ongoing scientific research into real force fields, primarily to [[radiation protection|protect against radiation]].

==History==
The concept of a force field goes back at least as far as the 1920s, in the works of [[Edward Elmer Smith|E.E. 'Doc' Smith]] and others; in [[William Hope Hodgson]]'s ''[[The Night Land]]'' (1912)  the Last Redoubt, the remnants of an humanity shelter is generated by something very like a force field.

In [[Isaac Asimov]]'s [[Foundation series|''Foundation'']] universe, personal shields have been developed by scientists specializing in the miniaturization of planet-based shields. As they are primarily used by Foundation Traders, most other inhabitants of the [[Galactic Empire (Asimov)|Galactic Empire]] do not know about this technology.  In an unrelated short story ''[[Breeds There a Man...?]]'' by Asimov, scientists are working on a force field ("energy so channelled as to create a wall of matter-less inertia"), capable of protecting the population in case of a nuclear war. The force field demonstrated in the end is a solid hemisphere, apparently completely opaque and reflective from both sides.

The concept of force fields as a defensive measure from enemy attack or as a form of attack can be regularly found in modern [[video games]] as well as in movies, such as in ''[[The War of the Worlds (1953 film)|The War of the Worlds]]'' (1953, George Pál) and ''[[Independence Day (1996 film)|Independence Day]]''.

The ability to create a force field has been a common [[superpower (ability)|superpower]] in [[comic book]]s and associated media. While only a few characters have the explicit ability to create force fields (for example, the [[Invisible Woman]] of the [[Fantastic Four]] and [[Violet Parr]] from ''[[The Incredibles]]''), it has been emulated via other powers, such as [[Green Lantern]]'s energy constructs, [[Jean Grey]]'s telekinesis, and [[Magneto (comics)|Magneto]]'s manipulation of electromagnetic fields. Apart from this, its importance is also highlighted in [[Dr. Michio Kaku]]'s books (such as ''[[Physics of the Impossible]]'').

==Fictional uses==
Science fiction and fantasy avenues suggest a number of potential uses of force fields&lt;ref&gt;, for instance, as:[http://virginia.cc.vt.edu/files/books/235/ComputationalDynamicsbuk157p.pdf]{{dead link|date=March 2017|bot=medic}}{{cbignore|bot=medic}}&lt;/ref&gt;

* A barrier allowing workers to function in areas exposed to the [[vacuum]] of space. The atmosphere inside would be habitable by humans, while at the same time allowing permissible objects to pass through the barrier
* A walkable surface between two points without the necessity of building a bridge.
* An emergency quarantine area to service those afflicted by harmful biological or chemical agents
* A fire extinguisher where oxygen is exhausted by the use of a space confined by a force field thereby starving the fire
* As a shield to protect against damage from natural forces or an enemy attack
* A temporary habitable space in an area otherwise unsuitable for sustaining life
* As a security apparatus used to confine or contain a captive

The capabilities and functionality of force fields vary; in some works of fiction (such as in the ''[[Star Trek]]'' universe), energy shields can nullify or mitigate the effects of both energy and particle (e.g., [[phaser (fictional weapon)|phasers]]) and conventional weapons, as well as supernatural forces. In many fictional scenarios, the [[shields (Star Trek)|shields]] function primarily as a defensive measure against weapons fired from other spacecraft. Force fields in these stories also generally prevent [[transporter (Star Trek)|transporting]]. There are generally two kinds of force fields postulated: one in which energy is projected as a flat plane from emitters around the edges of a spacecraft and another where energy surrounds a ship like a bubble.

==Scientific research==
A [[University of Washington]] group in [[Seattle]] has been experimenting with using a bubble of charged [[plasma (physics)|plasma]], contained by a fine mesh of superconducting wire, to surround a spacecraft.&lt;ref&gt;{{cite web|url=https://www.newscientist.com/article/dn9567 |title=Plasma bubble could protect astronauts on Mars trip - space - 17 July 2006 |publisher=New Scientist |date=2006-07-17 |accessdate=2014-04-12}}&lt;/ref&gt; This would protect the spacecraft from interstellar radiation and some particles without needing physical [[armor|shielding]].

Likewise, [[Rutherford Appleton Laboratory]] is attempting to design an actual test satellite, which would orbit Earth with a charged plasma field around it.&lt;ref&gt;{{cite web|url=https://www.newscientist.com/article/dn11623 |title='Deflector' shields could protect future astronauts - space - 18 April 2007 |publisher=New Scientist |date=2007-04-18 |accessdate=2014-04-12}}&lt;/ref&gt;&lt;ref&gt;{{cite web|last=Rincon |first=Paul |url=http://news.bbc.co.uk/2/hi/science/nature/6567709.stm |title=Science/Nature &amp;#124; Space shield to block radiation |publisher=BBC News |date=2007-04-18 |accessdate=2014-04-12}}&lt;/ref&gt;&lt;ref&gt;{{cite web|url=http://www.esdjournal.com/articles/final/final.htm |title=The ESD &amp; Electrostatics Magazine |publisher=ESD Journal |date= |accessdate=2014-04-12}}&lt;/ref&gt;&lt;ref&gt;{{cite web|url=http://amasci.com/weird/unusual/e-wall.html |title=David Swenson's electrostatic "invisible wall" (1996) |publisher=Amasci.com |date= |accessdate=2014-04-12}}&lt;/ref&gt;

In 2008, ''[[Cosmos Magazine]]'' reported on research into creating an artificial replica of Earth’s [[magnetic field]] around a spacecraft to protect astronauts from dangerous [[cosmic rays]].&lt;ref&gt;{{cite web |url=http://www.cosmosmagazine.com/news/star-trek-style-starship-shields-could-become-reality/ |title=Star Trek-style shields could become reality |publisher=Cosmos Magazine |date=2008-11-05 |accessdate=2014-04-12 |deadurl=yes |archiveurl=https://web.archive.org/web/20131105175408/http://www.cosmosmagazine.com/news/star-trek-style-starship-shields-could-become-reality/ |archivedate=2013-11-05 |df= }}&lt;/ref&gt; British and Portuguese scientists used a mathematical simulation to prove that it would be possible to create a "[[Magnetic sail#Mini-magnetospheric plasma propulsion (M2P2)|mini-magnetosphere]]" bubble several hundred meters wide, possibly generated by a small unmanned vessel that could accompany a future manned mission to Mars.

In 2015, [[Boeing]] was granted a [[patent]] on a force field designed to protect against [[shock wave]]s generated by explosions. It is not intended to protect against projectiles, radiation, or energy weapons such as lasers. The field purportedly works by creating a field of (ionised) superheated air-plasma which disrupts, or at least attenuates, the shock wave. As of March 2016, no working models are known to have been demonstrated.&lt;ref&gt;{{cite web |url=http://abcnews.go.com/Technology/boeing-patents-star-wars-style-force-field-technology/story?id=29839654 |title=Boeing Patents 'Star Wars'-Style Force Field Technology |author=Alyssa Newcomb |date=March 23, 2015 |publisher=ABC News |accessdate=March 23, 2015}}&lt;/ref&gt;

==See also==
*[[Li's field]]
*[[Magic circle]]
*[[Plasma window]]

==Notes==
{{Reflist}}

==Further reading==
* {{Cite conference |last=Andrews |first=Dana G. |date=2004-07-13 |title=Things to do While Coasting Through Interstellar Space |conference=40th AIAA/ASME/SAE/ASEE Joint Propulsion Conference and Exhibit |conferenceurl=https://web.archive.org/web/20100305173854/http://www.aiaa.org/agenda.cfm?lumeetingid=946 |series=Future Flight II |location=[[Fort Lauderdale, Florida]] |id=AIAA 2004-3706 |url=http://pdf.aiaa.org/preview/CDReadyMJPC2004_946/PV2004_3706.pdf |format=PDF |accessdate=2008-12-13 |deadurl=yes |archiveurl=https://web.archive.org/web/20130420044528/http://pdf.aiaa.org/preview/CDReadyMJPC2004_946/PV2004_3706.pdf |archivedate=2013-04-20 |df= }}
* {{Cite journal|last=Martin |first=A.R. |year=1978 |title=Bombardment by Interstellar Material and Its Effects on the Vehicle, Project Daedalus Final Report |journal=[[Journal of the British Interplanetary Society]] |pages=S116–S121}}

{{Emerging technologies}}

{{DEFAULTSORT:Force Field}}
[[Category:Physics in fiction]]
[[Category:Fictional superhuman features or abilities]]
[[Category:Science fiction themes]]
[[Category:Fictional armour]]
[[Category:Fictional technology]]
[[Category:Space technology]]</text>
      <sha1>mvmqhozyxaemtg2dvfdthxg80g9pk8d</sha1>
    </revision>
  </page>
  <page>
    <title>Gaze heuristic</title>
    <ns>0</ns>
    <id>4281425</id>
    <revision>
      <id>846586080</id>
      <parentid>846585835</parentid>
      <timestamp>2018-06-19T17:43:18Z</timestamp>
      <contributor>
        <ip>73.96.119.135</ip>
      </contributor>
      <comment>/* Example */Changed 'fielder' back to 'catcher.'</comment>
      <model>wikitext</model>
      <format>text/x-wiki</format>
      <text xml:space="preserve" bytes="2700">The '''gaze heuristic''' is a [[heuristic]] used in directing correct motion to achieve a goal using one main variable.&lt;ref&gt; Shaffer et al., 2004, Psychological Science; McLeod et al., 2003, Nature &lt;/ref&gt; An example of the gaze heuristic is catching a ball. The gaze heuristic is one example of psychologist [[Gerd Gigerenzer|Gerd Gigerenzer's]] one good reason heuristic, where humans and animals are able to process large amounts of information quickly and react, regardless of whether the information is consciously processed.&lt;ref&gt;{{Cite journal | last1 = Gigerenzer | first1 = Gerd| last2 = Brighton | first2 = Henry| doi = 10.1111/j.1756-8765.2008.01006.x | title = Homo Heuristicus: Why Biased Minds Make Better Inferences | journal = Topics in Cognitive Science | volume = 1 | pages = 107–143| year = 2009 | pmid =  25164802| pmc = }}&lt;/ref&gt;

The gaze heuristic is a critical element in animal behavior, being used in [[predation]] heavily.&lt;ref&gt;Shaffer et al., 2004, Psychological Science; McLeod et al., 2003, Nature &lt;/ref&gt; At the most basic level, the gaze heuristic ignores all casual relevant variables to make quick [[gut reaction]]s. 

==Example==


A catcher using the gaze heuristic observes the initial angle of the ball and runs towards it in such a way as to keep this angle constant.  [[Experiment|Experimental studies]] have shown that if people ignore the fact they were solving a system of [[differential equation]]s to catch the ball, and simply follow the gaze heuristic they will consistently arrive in the exact spot the ball is predicted to hit the ground.&lt;ref&gt; [http://djmarsay.wordpress.com/bibliography/rationality-and-uncertainty/more-rationality/gigerenzers-homo-heuristicus/ Gigerenzer's Heuristics] Word Press. Retrieved 27 March 2014 &lt;/ref&gt; The gaze heuristic does not require knowledge of any of the variables required by the optimizing approach, nor does it require the catcher to integrate information, yet it allows the catcher to successfully catch the ball.&lt;ref&gt; [http://library.mpib-berlin.mpg.de/ft/wb/WB_Fast_2006.pdf Fast and frugal heuristics in sports] Bennis and Pachur. Retrieved 27 March 2014 &lt;/ref&gt; The gaze heuristic may therefore be described at [[ecological rationality|ecologically rational]] at least in the simple case of catching a ball in the air. A criticism is that application of the gaze heuristic is limited by simple situations far from real complexity of environment.&lt;ref&gt;[https://papers.ssrn.com/sol3/papers.cfm?abstract_id=2484001 Poddiakov, A. (2013). Catching a Flying Ball – is that Really that Easy? A Contribution to the Critique of G. Gigerenzer's Approach. SSRN.]&lt;/ref&gt;

==References==
{{reflist}}

[[Category:Heuristics]]</text>
      <sha1>ezwkc094zk9c0zg5czvj90399xipphk</sha1>
    </revision>
  </page>
  <page>
    <title>Henry Hurd Swinnerton</title>
    <ns>0</ns>
    <id>16182302</id>
    <revision>
      <id>778509664</id>
      <parentid>773217388</parentid>
      <timestamp>2017-05-03T15:35:35Z</timestamp>
      <contributor>
        <username>GreenC bot</username>
        <id>27823944</id>
      </contributor>
      <minor/>
      <comment>Rescued 1 archive link; remove 1 link. [[User:Green Cardamom/WaybackMedic_2.1|Wayback Medic 2.1]]</comment>
      <model>wikitext</model>
      <format>text/x-wiki</format>
      <text xml:space="preserve" bytes="3391">'''Henry Hurd Swinnerton''' (1875–1966) was a British [[geologist]] (Not to be confused with American geologist A.C. Swinnerton). He was professor of geology at [[University College Nottingham]] from 1910 to 1946.

Swinnerton was educated at the [[Royal College of Science]], and earned a doctorate in zoology (D.Sc) from the [[University of London]] in July 1902.&lt;ref&gt;{{Cite newspaper The Times |articlename=University intelligence |day_of_week=Friday |date=25 July 1902 |page_number=5 |issue=36829| }}&lt;/ref&gt;

In the 1930s Swinnerton was a member of the Fenland Research Committee, contributing valuable knowledge of the geomorphology of the [[Lincolnshire]] coast.&lt;ref&gt;{{cite web|url=http://www.arch.cam.ac.uk/~pjs1011/grahame-clark+fenland-research-committee.pdf |archive-url=https://web.archive.org/web/20110514232036/http://www.arch.cam.ac.uk/~pjs1011/grahame-clark+fenland-research-committee.pdf |dead-url=yes |archive-date=2011-05-14 |title=Grahame Clark, the Fenland Research Committee and prehistory at Cambridge |author=Smith P.J. |year=1994 |publisher=University of Cambridge |accessdate=2008-03-08 }}&lt;/ref&gt; In 1942 he was awarded the [[Murchison Medal]] of the [[Geological Society of London]].

==Selected bibliography==
*Swinnerton H.H. (1910) ''Nottinghamshire'', [[Cambridge County Geographies]].
*Swinnerton H.H. (1912) The palmistry of the rocks.  ''Rep Trans Notts Nat Soc''; 60: 65-68.
*Swinnerton H.H.; [[Arthur Elijah Trueman|Trueman, A.E.]] (1917).  The Morphology and Development of the Ammonite Septum. ''Quarterly Journal of the Geological Society'', London 73, 26–58
*Swinnerton H.H. (1923) ''Outlines of Palaeontology''. Third edition. London, Edward Arnold, 1958.
*Swinnerton H.H. (1935)  The Rocks Below the Red Chalk of Lincolnshire, and Their Cephalopod Faunas.  ''Quarterly Journal of the Geological Society'', London 91, 1–46.
*Swinnerton H.H. (1937). A monograph of British Lower Cretaceous belemnites. Part 2. Monograph of the Palaeontological Society, 90 (for 1936): xvii-xxxii + 17-30.
*Swinnerton H.H. (1938). Presidential Address. The Problem of the Lincoln Gap. ''Transactions of the Lincolnshire Naturalists' Union'' 9, 145-153.
*Swinnerton H.H. (1941). Further observations on the Lower Cretaceous rocks of Lincolnshire. ''Proceedings of the Geologists’ Association'' 52, 198-207.
*Swinnerton H.H. (1943)  Belemnites from East Greenland. ''Ann. Mag. Nat. Hist. Ser. II'' 10 (66), 406–410.
*Swinnerton H.H. (1936–1955) A Monograph of British Cretaceous Belemnites.  Lower Cretaceous.  ''Palaeontographical Society'', London 1-5, 1–86.
*Swinnerton H.H. &amp; Kent P.E. (1949) ''The Geology of Lincolnshire'' (Lincolnshire Natural History Brochure No. 1.) Lincoln, Lincolnshire Naturalists' Union 1949 (2nd Ed, 1981).
*Swinnerton H.H. (1958) ''The Earth Beneath Us'' Harmondsworth: Pelican .
*Swinnerton H.H. (1960) ''Fossils'' (New Naturalist Series). London: Collins.

==References==
&lt;references/&gt;

==External links==
* [http://www.nottshistory.org.uk/swinnerton1910/preface.htm Swinnerton (1910) ''Nottinghamshire'', Cambridge County Geographies]

{{GLS Presidents}}

{{Authority control}}
{{DEFAULTSORT:Swinnerton, Henry Hurd}}
[[Category:1875 births]]
[[Category:1966 deaths]]
[[Category:Academics of the University of Nottingham]]
[[Category:New Naturalist writers]]

{{paleontologist-stub}}
{{UK-geologist-stub}}
{{UK-scientist-stub}}</text>
      <sha1>2k8x3nfiprf5roaeeqamv0qe7rnafdh</sha1>
    </revision>
  </page>
  <page>
    <title>Hidden Markov model</title>
    <ns>0</ns>
    <id>98770</id>
    <revision>
      <id>870958228</id>
      <parentid>870567183</parentid>
      <timestamp>2018-11-28T01:30:40Z</timestamp>
      <contributor>
        <username>Citation bot</username>
        <id>7903804</id>
      </contributor>
      <minor/>
      <comment>Alter: pages, journal, title, template type, isbn. Add: pmid, hdl, doi, bibcode, pages, issue, class, eprint, citeseerx. Removed parameters. Formatted [[WP:ENDASH|dashes]]. You can [[WP:UCB|use this bot]] yourself. [[WP:DBUG|Report bugs here]]. | [[WP:UCB|User-activated]]; [[Category:Bioinformatics]].</comment>
      <model>wikitext</model>
      <format>text/x-wiki</format>
      <text xml:space="preserve" bytes="66145">{{good article}}
{{machine learning bar}}

'''Hidden Markov Model''' ('''HMM''') is a [[Statistical model|statistical]] [[Markov model]] in which the system being modeled is assumed to be a [[Markov process]] with unobserved (i.e. ''hidden'') states.

The hidden Markov model can be represented as the simplest [[dynamic Bayesian network]]. The mathematics behind the HMM were developed by [[Leonard E. Baum|L. E. Baum]] and coworkers.
&lt;ref&gt;{{cite journal |last=Baum |first=L. E. |author2=Petrie, T. |title=Statistical Inference for Probabilistic Functions of Finite State Markov Chains |journal=The Annals of Mathematical Statistics |year=1966 |volume=37 |issue=6 |pages=1554–1563 |url=http://projecteuclid.org/DPubS/Repository/1.0/Disseminate?handle=euclid.aoms/1177699147&amp;view=body&amp;content-type=pdf_1 |accessdate=28 November 2011 |doi=10.1214/aoms/1177699147}}&lt;/ref&gt;&lt;ref&gt;{{Cite journal |last1=Baum |first1=L. E. |last2=Eagon |first2=J. A. |doi=10.1090/S0002-9904-1967-11751-8 |title=An inequality with applications to statistical estimation for probabilistic functions of Markov processes and to a model for ecology |journal=[[Bulletin of the American Mathematical Society]] |volume=73 |issue=3 |pages=360 |year=1967 |zbl=0157.11101 |pmid= |url=http://projecteuclid.org/euclid.bams/1183528841 |pmc=}}&lt;/ref&gt;&lt;ref&gt;{{cite journal |last=Baum |first=L. E. |author2=Sell, G. R. |title=Growth transformations for functions on manifolds |journal=Pacific Journal of Mathematics |year=1968 |volume=27 |issue=2 |pages=211–227 |url=https://www.scribd.com/doc/6369908/Growth-Functions-for-Transformations-on-Manifolds |accessdate=28 November 2011 |doi=10.2140/pjm.1968.27.211}}&lt;/ref&gt;&lt;ref&gt;{{Cite journal |last1=Baum |first1=L. E. |authorlink1=Leonard E. Baum |last2=Petrie |first2=T. |last3=Soules |first3=G. |last4=Weiss |first4=N. |title=A Maximization Technique Occurring in the Statistical Analysis of Probabilistic Functions of Markov Chains |doi=10.1214/aoms/1177697196 |journal=[[The Annals of Mathematical Statistics]] |volume=41 |pages=164–171 |year=1970 |jstor=2239727 |zbl=0188.49603 |mr=287613 |url=http://projecteuclid.org/euclid.aoms/1177697196 |pmid= |pmc=}}&lt;/ref&gt;&lt;ref&gt;{{cite journal |last=Baum |first=L.E. |title=An Inequality and Associated Maximization Technique in Statistical Estimation of Probabilistic Functions of a Markov Process |journal=Inequalities |year=1972 |volume=3 |pages=1–8}}&lt;/ref&gt; HMM is closely related to earlier work on the optimal nonlinear [[filtering problem (stochastic processes)|filtering problem]] by [[Ruslan L. Stratonovich]],&lt;ref name=Stratonovich1960&gt;{{cite journal |author=Stratonovich, R.L. |year=1960 |title=Conditional Markov Processes |journal=Theory of Probability and its Applications |volume=5 |issue=2 |pages=156–178 |doi=10.1137/1105015}}&lt;/ref&gt; who was the first to describe the [[Forward–backward algorithm|forward-backward procedure]].

In simpler [[Markov model]]s (like a [[Markov chain]]), the state is directly visible to the observer, and therefore the state transition probabilities are the only parameters, while in the hidden Markov model, the state is not directly visible, but the output (in the form of data or "token" in the following), dependent on the state, is visible. Each state has a probability distribution over the possible output tokens.  Therefore, the sequence of tokens generated by an HMM gives some information about the sequence of states; this is also known as pattern theory, a topic of [[grammar induction]].

The adjective ''hidden'' refers to the state sequence through which the model passes, not to the parameters of the model; the model is still referred to as a hidden Markov model even if these parameters are known exactly.

Hidden Markov models are especially known for their application in [[reinforcement learning]] and [[time|temporal]] [[pattern recognition]] such as [[speech recognition|speech]], [[handwriting recognition|handwriting]], [[gesture recognition]],&lt;ref&gt;Thad Starner, Alex Pentland. [http://www.cc.gatech.edu/~thad/p/031_10_SL/real-time-asl-recognition-from%20video-using-hmm-ISCV95.pdf Real-Time American Sign Language Visual Recognition From Video Using Hidden Markov Models]. Master's Thesis, MIT, Feb 1995, Program in Media Arts&lt;/ref&gt; [[part-of-speech tagging]], musical score following,&lt;ref&gt;B. Pardo and W. Birmingham. [http://www.cs.northwestern.edu/~pardo/publications/pardo-birmingham-aaai-05.pdf Modeling Form for On-line Following of Musical Performances]. AAAI-05 Proc., July 2005.&lt;/ref&gt; [[partial discharge]]s&lt;ref&gt;Satish L, Gururaj BI (April 2003). "[http://ieeexplore.ieee.org/xpl/freeabs_all.jsp?arnumber=212242 Use of hidden Markov models for partial discharge pattern classification]". ''IEEE Transactions on Dielectrics and Electrical Insulation''.&lt;/ref&gt; and [[bioinformatics]].&lt;ref&gt;{{cite journal|last1=Li|first1=N|last2=Stephens|first2=M|title=Modeling linkage disequilibrium and identifying recombination hotspots using single-nucleotide polymorphism data.|journal=Genetics|date=December 2003|volume=165|issue=4|pages=2213–33|pmid=14704198|pmc=1462870}}&lt;/ref&gt;

A hidden Markov model can be considered a generalization of a [[mixture model]] where the hidden variables (or [[latent variables]]), which control the mixture component to be selected for each observation, are related through a Markov process rather than independent of each other. Recently, hidden Markov models have been generalized to pairwise Markov models and triplet Markov models which allow consideration of more complex [[data structure]]s&lt;ref name="TMMEV"&gt;{{cite journal |url=http://www.sciencedirect.com/science/article/pii/S0888613X06000375 |doi=10.1016/j.ijar.2006.05.001 |volume=45 |title=Multisensor triplet Markov chains and theory of evidence |year=2007 |journal=International Journal of Approximate Reasoning |pages=1–16 |last1=Pieczynski |first1=Wojciech}}&lt;/ref&gt;&lt;ref name="JASP"&gt;[http://asp.eurasipjournals.com/content/pdf/1687-6180-2012-134.pdf Boudaren et al.], M. Y. Boudaren, E. Monfrini, W. Pieczynski, and A. Aissani, Dempster-Shafer fusion of multisensor signals in nonstationary Markovian context, EURASIP Journal on Advances in Signal Processing, No. 134, 2012.&lt;/ref&gt; and the modeling of nonstationary data.&lt;ref name="TSP"&gt;[http://ieeexplore.ieee.org/xpl/articleDetails.jsp?tp=&amp;arnumber=1468502&amp;contentType=Journals+%26+Magazines&amp;searchField%3DSearch_All%26queryText%3Dlanchantin+pieczynski Lanchantin et al.], P. Lanchantin and W. Pieczynski, Unsupervised restoration of hidden non stationary Markov chain using evidential priors, IEEE Transactions on Signal Processing, Vol. 53, No. 8, pp. 3091-3098, 2005.&lt;/ref&gt;&lt;ref name="SPL"&gt;[http://ieeexplore.ieee.org/xpl/articleDetails.jsp?tp=&amp;arnumber=6244854&amp;contentType=Journals+%26+Magazines&amp;searchField%3DSearch_All%26queryText%3Dboudaren Boudaren et al.], M. Y. Boudaren, E. Monfrini, and W. Pieczynski, Unsupervised segmentation of random discrete data hidden with switching noise distributions, IEEE Signal Processing Letters, Vol. 19, No. 10, pp. 619-622, October 2012.&lt;/ref&gt;

== Description in terms of urns ==

[[File:HiddenMarkovModel.svg|right|thumb|300px|
Figure 1. Probabilistic parameters of a hidden Markov model (example)&lt;br /&gt;
''X'' — states&lt;br /&gt;
''y'' — possible observations&lt;br /&gt;
''a'' — state transition probabilities&lt;br /&gt;
''b'' — output probabilities]]
In its discrete form, a hidden Markov process can be visualized as a generalization of the [[Urn problem]] with replacement (where each item from the urn is returned to the original urn before the next step).&lt;ref&gt;{{cite journal |author=[[Lawrence Rabiner|Lawrence R. Rabiner]] |title=A tutorial on Hidden Markov Models and selected applications in speech recognition |journal=Proceedings of the IEEE |volume=77 |issue=2 |pages=257–286 |date=February 1989 |url=http://www.ece.ucsb.edu/Faculty/Rabiner/ece259/Reprints/tutorial%20on%20hmm%20and%20applications.pdf |doi=10.1109/5.18626|citeseerx=10.1.1.381.3454 }} [http://www.cs.cornell.edu/courses/cs481/2004fa/rabiner.pdf]&lt;/ref&gt; Consider this example: in a room that is not visible to an observer there is a genie. The room contains urns X1, X2, X3, … each of which contains a known mix of balls, each ball labeled y1, y2, y3, … .  The genie chooses an urn in that room and randomly draws a ball from that urn.  It then puts the ball onto a conveyor belt, where the observer can observe the sequence of the balls but not the sequence of urns from which they were drawn. The genie has some procedure to choose urns; the choice of the urn for the ''n''-th ball depends only upon a random number and the choice of the urn for the (''n''&amp;nbsp;−&amp;nbsp;1)-th ball.  The choice of urn does not directly depend on the urns chosen before this single previous urn; therefore, this is called a [[Markov process]]. It can be described by the upper part of Figure 1.

The Markov process itself cannot be observed, only the sequence of labeled balls, thus this arrangement is called a "hidden Markov process". This is illustrated by the lower part of the diagram shown in Figure 1, where one can see that balls y1, y2, y3, y4 can be drawn at each state. Even if the observer knows the composition of the urns and has just observed a sequence of three balls, ''e.g.'' y1, y2 and y3 on the conveyor belt, the observer still cannot be ''sure'' which urn (''i.e.'', at which state) the genie has drawn the third ball from. However, the observer can work out other information, such as the likelihood that the third ball came from each of the urns.

== Structural architecture ==
The diagram below shows the general architecture of an instantiated HMM. Each oval shape represents a random variable that can adopt any of a number of values. The random variable ''x''(''t'') is the hidden state at time {{mvar|t}} (with the model from the above diagram, ''x''(''t'')&amp;nbsp;∈&amp;nbsp;{&amp;nbsp;''x''&lt;sub&gt;1&lt;/sub&gt;,&amp;nbsp;''x''&lt;sub&gt;2&lt;/sub&gt;,&amp;nbsp;''x''&lt;sub&gt;3&lt;/sub&gt;&amp;nbsp;}). The random variable ''y''(''t'') is the observation at time {{mvar|t}} (with ''y''(''t'')&amp;nbsp;∈&amp;nbsp;{&amp;nbsp;''y''&lt;sub&gt;1&lt;/sub&gt;,&amp;nbsp;''y''&lt;sub&gt;2&lt;/sub&gt;,&amp;nbsp;''y''&lt;sub&gt;3&lt;/sub&gt;,&amp;nbsp;''y''&lt;sub&gt;4&lt;/sub&gt;&amp;nbsp;}). The arrows in the diagram (often called a [[Trellis (graph)|trellis diagram]]) denote conditional dependencies.

From the diagram, it is clear that the [[conditional probability distribution]] of the hidden variable ''x''(''t'') at time {{mvar|t}}, given the values of the hidden variable {{mvar|x}} at all times, depends ''only'' on the value of the hidden variable ''x''(''t''&amp;nbsp;−&amp;nbsp;1); the values at time ''t''&amp;nbsp;−&amp;nbsp;2 and before have no influence. This is called the [[Markov property]]. Similarly, the value of the observed variable ''y''(''t'') only depends on the value of the hidden variable ''x''(''t'') (both at time {{mvar|t}}).

In the standard type of hidden Markov model considered here, the state space of the hidden variables is discrete, while the observations themselves can either be discrete (typically generated from a [[categorical distribution]]) or continuous (typically from a [[Gaussian distribution]]).  The parameters of a hidden Markov model are of two types, ''transition probabilities'' and ''emission probabilities'' (also known as ''output probabilities'').  The transition probabilities control the way the hidden state at time {{mvar|t}} is chosen given the hidden state at time &lt;math&gt;t-1&lt;/math&gt;.

The hidden state space is assumed to consist of one of {{mvar|N}} possible values, modeled as a categorical distribution. (See the section below on extensions for other possibilities.) This means that for each of the {{mvar|N}} possible states that a hidden variable at time {{mvar|t}} can be in, there is a transition probability from this state to each of the {{mvar|N}} possible states of the hidden variable at time &lt;math&gt;t+1&lt;/math&gt;, for a total of &lt;math&gt;N^2&lt;/math&gt; transition probabilities. Note that the set of transition probabilities for transitions from any given state must sum to 1. Thus, the &lt;math&gt;N \times N&lt;/math&gt; matrix of transition probabilities is a [[Stochastic matrix|Markov matrix]]. Because any one transition probability can be determined once the others are known, there are a total of &lt;math&gt;N(N-1)&lt;/math&gt; transition parameters.

In addition, for each of the {{mvar|N}} possible states, there is a set of emission probabilities governing the distribution of the observed variable at a particular time given the state of the hidden variable at that time.  The size of this set depends on the nature of the observed variable.  For example, if the observed variable is discrete with {{mvar|M}} possible values, governed by a [[categorical distribution]], there will be &lt;math&gt;M-1&lt;/math&gt; separate parameters, for a total of &lt;math&gt;N(M-1)&lt;/math&gt; emission parameters over all hidden states.  On the other hand, if the observed variable is an {{mvar|M}}-dimensional vector distributed according to an arbitrary [[multivariate Gaussian distribution]], there will be {{mvar|M}} parameters controlling the [[mean]]s and &lt;math&gt;\frac {M(M+1)} 2&lt;/math&gt; parameters controlling the [[covariance matrix]], for a total of &lt;math&gt;N \left(M + \frac{M(M+1)}{2}\right) = \frac {NM(M+3)} 2 = O(NM^2)&lt;/math&gt; emission parameters. (In such a case, unless the value of {{mvar|M}} is small, it may be more practical to restrict the nature of the covariances between individual elements of the observation vector, e.g. by assuming that the elements are independent of each other, or less restrictively, are independent of all but a fixed number of adjacent elements.)

[[File:hmm temporal bayesian net.svg|500px|center|Temporal evolution of a hidden Markov model]]

== Inference ==
[[File:HMMsequence.svg|thumb|400px|The state transition and output probabilities of an HMM are indicated by the line opacity in the upper part of the diagram. Given that we have observed the output sequence in the lower part of the diagram, we may be interested in the most likely sequence of states that could have produced it. Based on the arrows that are present in the diagram, the following state sequences are candidates:&lt;br /&gt;
5 3 2 5 3 2&lt;br /&gt;
4 3 2 5 3 2&lt;br /&gt;
3 1 2 5 3 2&lt;br /&gt;
We can find the most likely sequence by evaluating the joint probability of both the state sequence and the observations for each case (simply by multiplying the probability values, which here correspond to the opacities of the arrows involved). In general, this type of problem (i.e. finding the most likely explanation for an observation sequence) can be solved efficiently using the [[Viterbi algorithm]].]]

Several [[inference]] problems are associated with hidden Markov models, as outlined below.

=== Probability of an observed sequence ===
The task is to compute in a best way, given the parameters of the model, the probability of a particular output sequence.  This requires summation over all possible state sequences:

The probability of observing a sequence
: &lt;math&gt;Y=y(0), y(1),\dots,y(L-1)\,&lt;/math&gt;
of length ''L'' is given by
:&lt;math&gt;P(Y)=\sum_{X}P(Y\mid X)P(X),\,&lt;/math&gt;
where the sum runs over all possible hidden-node sequences
: &lt;math&gt;X=x(0), x(1), \dots, x(L-1).\,&lt;/math&gt;

Applying the principle of [[dynamic programming]], this problem, too, can be handled efficiently using the [[forward algorithm]].

=== Probability of the latent variables ===
A number of related tasks ask about the probability of one or more of the latent variables, given the model's parameters and a sequence of observations &lt;math&gt;y(1),\dots,y(t).&lt;/math&gt;

==== Filtering ====
The task is to compute, given the model's parameters and a sequence of observations, the distribution over hidden states of the last latent variable at the end of the sequence, i.e. to compute &lt;math&gt;P(x(t)\ |\ y(1),\dots,y(t))&lt;/math&gt;.  This task is normally used when the sequence of latent variables is thought of as the underlying states that a process moves through at a sequence of points of time, with corresponding observations at each point in time.  Then, it is natural to ask about the state of the process at the end.

This problem can be handled efficiently using the [[forward algorithm]].

==== Smoothing ====
This is similar to filtering but asks about the distribution of a latent variable somewhere in the middle of a sequence, i.e. to compute &lt;math&gt;P(x(k)\ |\ y(1), \dots, y(t))&lt;/math&gt; for some &lt;math&gt;k &lt; t&lt;/math&gt;.  From the perspective described above, this can be thought of as the probability distribution over hidden states for a point in time ''k'' in the past, relative to time ''t''.

The [[forward-backward algorithm]] is an efficient method for computing the smoothed values for all hidden state variables.

==== Most likely explanation ====
The task, unlike the previous two, asks about the [[joint probability]] of the ''entire'' sequence of hidden states that generated a particular sequence of observations (see illustration on the right).  This task is generally applicable when HMM's are applied to different sorts of problems from those for which the tasks of filtering and smoothing are applicable.  An example is [[part-of-speech tagging]], where the hidden states represent the underlying [[part of speech|parts of speech]] corresponding to an observed sequence of words.  In this case, what is of interest is the entire sequence of parts of speech, rather than simply the part of speech for a single word, as filtering or smoothing would compute.

This task requires finding a maximum over all possible state sequences, and can be solved efficiently by the [[Viterbi algorithm]].

=== Statistical significance ===
For some of the above problems, it may also be interesting to ask about [[statistical significance]].  What is the probability that a sequence drawn from some [[null distribution]] will have an HMM probability (in the case of the forward algorithm) or a maximum state sequence probability (in the case of the Viterbi algorithm) at least as large as that of a particular output sequence?&lt;ref&gt;{{Cite journal |last1=Newberg |first1=L. |doi=10.1186/1471-2105-10-212 |title=Error statistics of hidden Markov model and hidden Boltzmann model results |journal=BMC Bioinformatics |volume=10 |pages=212 |year=2009 |pmid=19589158 |pmc=2722652}} {{open access}}&lt;/ref&gt;  When an HMM is used to evaluate the relevance of a hypothesis for a particular output sequence, the statistical significance indicates the [[false positive rate]] associated with failing to reject the hypothesis for the output sequence.

== A concrete example ==
{{HMM example}}

''A similar example is further elaborated in the [[Viterbi algorithm#Example|Viterbi algorithm]] page.''

== Learning ==

The parameter learning task in HMMs is to find, given an output sequence or a set of such sequences, the best set of state transition and emission probabilities. The task is usually to derive the [[maximum likelihood]] estimate of the parameters of the HMM given the set of output sequences. No tractable algorithm is known for solving this problem exactly, but a local maximum likelihood can be derived efficiently using the [[Baum–Welch algorithm]] or the Baldi–Chauvin algorithm.  The [[Baum–Welch algorithm]] is a special case of the [[expectation-maximization algorithm]]. If the HMMs are used for time series prediction, more sophisticated Bayesian inference methods, like [[Markov chain Monte Carlo]] (MCMC) sampling are proven to be favorable over finding a single maximum likelihood model both in terms of accuracy and stability.&lt;ref&gt;Sipos, I. Róbert. ''Parallel stratified MCMC sampling of AR-HMMs for stochastic time series prediction''. In: Proceedings, 4th Stochastic Modeling Techniques and Data Analysis International Conference with Demographics Workshop (SMTDA2016), pp. 295-306. Valletta, 2016. [http://1drv.ms/b/s!ApL_0Av0YGDLglwEOv1aYAGbmQeL PDF]&lt;/ref&gt; Since MCMC imposes significant computational burden, in cases where computational scalability is also of interest, one may alternatively resort to variational approximations to Bayesian inference, e.g.&lt;ref&gt;{{cite journal |url=http://users.iit.demokritos.gr/~dkosmo/downloads/patrec10/vbb10.pdf |doi=10.1016/j.patcog.2010.09.001 |volume=44 |issue=2 |title=A variational Bayesian methodology for hidden Markov models utilizing Student's-t mixtures |year=2011 |journal=Pattern Recognition |pages=295–306 |last1=Chatzis |first1=Sotirios P. |last2=Kosmopoulos |first2=Dimitrios I. |citeseerx=10.1.1.629.6275}}&lt;/ref&gt; Indeed, approximate variational inference offers computational efficiency comparable to expectation-maximization, while yielding an accuracy profile only slightly inferior to exact MCMC-type Bayesian inference.

== Mathematical description ==

=== General description ===
A basic hidden Markov model can be described as follows:

{| style="margin-left: 1em"
| &lt;math&gt;N&lt;/math&gt;||&lt;math&gt;=&lt;/math&gt;||number of states
|-
| &lt;math&gt;T&lt;/math&gt;||&lt;math&gt;=&lt;/math&gt;||number of observations
|-
| &lt;math&gt;\theta_{i=1 \dots N}&lt;/math&gt;||&lt;math&gt;=&lt;/math&gt;||emission parameter for an observation associated with state &lt;math&gt;i&lt;/math&gt;
|-
| style="padding-right: 0.7em" | &lt;math&gt;\phi_{i=1 \dots N, j=1 \dots N}&lt;/math&gt;|| style="padding-right: 0.7em" | &lt;math&gt;=&lt;/math&gt;||probability of transition from state &lt;math&gt;i&lt;/math&gt; to state &lt;math&gt;j&lt;/math&gt;
|-
| &lt;math&gt;\boldsymbol\phi_{i=1 \dots N}&lt;/math&gt;||&lt;math&gt;=&lt;/math&gt;||&lt;math&gt;N&lt;/math&gt;-dimensional vector, composed of &lt;math&gt;\phi_{i,j=1 \dots N}&lt;/math&gt;; the &lt;math&gt;i&lt;/math&gt;-th row of the matrix &lt;math&gt;\phi_{i=1 \dots N, j=1 \dots N}&lt;/math&gt; (sum of it is &lt;math&gt;1&lt;/math&gt;)
|-
| &lt;math&gt;x_{t=1 \dots T}&lt;/math&gt;||&lt;math&gt;=&lt;/math&gt;||(hidden) state at time &lt;math&gt;t&lt;/math&gt;
|-
| &lt;math&gt;y_{t=1 \dots T}&lt;/math&gt;||&lt;math&gt;=&lt;/math&gt;||observation at time &lt;math&gt;t&lt;/math&gt;
|-
| &lt;math&gt;F(y|\theta)&lt;/math&gt;||&lt;math&gt;=&lt;/math&gt;||probability distribution of an observation, parametrized on &lt;math&gt;\theta&lt;/math&gt;
|-
| &lt;math&gt;x_{t=2 \dots T}&lt;/math&gt;||&lt;math&gt;\sim&lt;/math&gt;||&lt;math&gt;\operatorname{Categorical}(\boldsymbol\phi_{x_{t-1}})&lt;/math&gt;
|-
| &lt;math&gt;y_{t=1 \dots T}&lt;/math&gt;||&lt;math&gt;\sim&lt;/math&gt;||&lt;math&gt;F(\theta_{x_t})&lt;/math&gt;
|}

Note that, in the above model (and also the one below), the prior distribution of the initial state &lt;math&gt;x_1&lt;/math&gt; is not specified.  Typical learning models correspond to assuming a discrete uniform distribution over possible states (i.e. no particular prior distribution is assumed).

In a Bayesian setting, all parameters are associated with random variables, as follows:

{| style="margin-left: 1em"
|-
| &lt;math&gt;N,T&lt;/math&gt;||&lt;math&gt;=&lt;/math&gt;||as above
|-
| style="padding-right: 0.7em" | &lt;math&gt;\theta_{i=1 \dots N}, \phi_{i=1 \dots N, j=1 \dots N}, \boldsymbol\phi_{i=1 \dots N}&lt;/math&gt;|| style="padding-right: 0.7em" | &lt;math&gt;=&lt;/math&gt;|| as above
|-
| &lt;math&gt;x_{t=1 \dots T}, y_{t=1 \dots T}, F(y|\theta)&lt;/math&gt;||&lt;math&gt;=&lt;/math&gt;||as above
|-
| &lt;math&gt;\alpha&lt;/math&gt;||&lt;math&gt;=&lt;/math&gt;||shared hyperparameter for emission parameters
|-
| &lt;math&gt;\beta&lt;/math&gt;||&lt;math&gt;=&lt;/math&gt;||shared hyperparameter for transition parameters
|-
| &lt;math&gt;H(\theta|\alpha)&lt;/math&gt;||&lt;math&gt;=&lt;/math&gt;||prior probability distribution of emission parameters, parametrized on &lt;math&gt;\alpha&lt;/math&gt;
|-
| &lt;math&gt;\theta_{i=1 \dots N}&lt;/math&gt;||&lt;math&gt;\sim&lt;/math&gt;||&lt;math&gt;H(\alpha)&lt;/math&gt;
|-
| &lt;math&gt;\boldsymbol\phi_{i=1 \dots N}&lt;/math&gt;||&lt;math&gt;\sim&lt;/math&gt;||&lt;math&gt;\operatorname{Symmetric-Dirichlet}_N(\beta)&lt;/math&gt;
|-
| &lt;math&gt;x_{t=2 \dots T}&lt;/math&gt;||&lt;math&gt;\sim&lt;/math&gt;||&lt;math&gt;\operatorname{Categorical}(\boldsymbol\phi_{x_{t-1}})&lt;/math&gt;
|-
| &lt;math&gt;y_{t=1 \dots T}&lt;/math&gt;||&lt;math&gt;\sim&lt;/math&gt;||&lt;math&gt;F(\theta_{x_t})&lt;/math&gt;
|}

These characterizations use &lt;math&gt;F&lt;/math&gt; and &lt;math&gt;H&lt;/math&gt; to describe arbitrary distributions over observations and parameters, respectively.  Typically &lt;math&gt;H&lt;/math&gt; will be the [[conjugate prior]] of &lt;math&gt;F&lt;/math&gt;.  The two most common choices of &lt;math&gt;F&lt;/math&gt; are [[Gaussian distribution|Gaussian]] and [[categorical distribution|categorical]]; see below.

=== Compared with a simple mixture model ===
As mentioned above, the distribution of each observation in a hidden Markov model is a [[mixture density]], with the states of the corresponding to mixture components.  It is useful to compare the above characterizations for an HMM with the corresponding characterizations, of a [[mixture model]], using the same notation.

A non-Bayesian mixture model:

{|
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;N&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;=&lt;/math&gt;||&amp;nbsp;||number of mixture components
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;T&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;=&lt;/math&gt;||&amp;nbsp;||number of observations
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;\theta_{i=1 \dots N}&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;=&lt;/math&gt;||&amp;nbsp;||parameter of distribution of observation associated with component &lt;math&gt;i&lt;/math&gt;
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;\phi_{i=1 \dots N}&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;=&lt;/math&gt;||&amp;nbsp;||mixture weight, i.e. prior probability of component &lt;math&gt;i&lt;/math&gt;
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;\boldsymbol\phi&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;=&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;N&lt;/math&gt;-dimensional vector, composed of &lt;math&gt;\phi_{1 \dots N}&lt;/math&gt;; must sum to &lt;math&gt;1&lt;/math&gt;
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;x_{t=1 \dots T}&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;=&lt;/math&gt;||&amp;nbsp;||component of observation &lt;math&gt;t&lt;/math&gt;
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;y_{t=1 \dots T}&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;=&lt;/math&gt;||&amp;nbsp;||observation &lt;math&gt;t&lt;/math&gt;
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;F(y|\theta)&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;=&lt;/math&gt;||&amp;nbsp;||probability distribution of an observation, parametrized on &lt;math&gt;\theta&lt;/math&gt;
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;x_{t=1 \dots T}&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;\sim&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;\operatorname{Categorical}(\boldsymbol\phi)&lt;/math&gt;
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;y_{t=1 \dots T}&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;\sim&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;F(\theta_{x_t})&lt;/math&gt;
|}

A Bayesian mixture model:

{|
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;N,T&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;=&lt;/math&gt;||&amp;nbsp;||as above
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;\theta_{i=1 \dots N}, \phi_{i=1 \dots N}, \boldsymbol\phi&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;=&lt;/math&gt;||&amp;nbsp;||as above
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;x_{t=1 \dots T}, y_{t=1 \dots T}, F(y|\theta)&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;=&lt;/math&gt;||&amp;nbsp;||as above
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;\alpha&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;=&lt;/math&gt;||&amp;nbsp;||shared hyperparameter for component parameters
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;\beta&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;=&lt;/math&gt;||&amp;nbsp;||shared hyperparameter for mixture weights
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;H(\theta|\alpha)&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;=&lt;/math&gt;||&amp;nbsp;||prior probability distribution of component parameters, parametrized on &lt;math&gt;\alpha&lt;/math&gt;
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;\theta_{i=1 \dots N}&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;\sim&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;H(\alpha)&lt;/math&gt;
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;\boldsymbol\phi&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;\sim&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;\operatorname{Symmetric-Dirichlet}_N(\beta)&lt;/math&gt;
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;x_{t=1 \dots T}&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;\sim&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;\operatorname{Categorical}(\boldsymbol\phi)&lt;/math&gt;
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;y_{t=1 \dots T}&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;\sim&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;F(\theta_{x_t})&lt;/math&gt;
|}

=== Examples ===
The following mathematical descriptions are fully written out and explained, for ease of implementation.

A typical non-Bayesian HMM with Gaussian observations looks like this:

{|
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;N&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;=&lt;/math&gt;||&amp;nbsp;||number of states
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;T&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;=&lt;/math&gt;||&amp;nbsp;||number of observations
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;\phi_{i=1 \dots N, j=1 \dots N}&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;=&lt;/math&gt;||&amp;nbsp;||probability of transition from state &lt;math&gt;i&lt;/math&gt; to state &lt;math&gt;j&lt;/math&gt;
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;\boldsymbol\phi_{i=1 \dots N}&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;=&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;N&lt;/math&gt;-dimensional vector, composed of &lt;math&gt;\phi_{i,1 \dots N}&lt;/math&gt;; must sum to &lt;math&gt;1&lt;/math&gt;
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;\mu_{i=1 \dots N}&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;=&lt;/math&gt;||&amp;nbsp;||mean of observations associated with state &lt;math&gt;i&lt;/math&gt;
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;\sigma^2_{i=1 \dots N}&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;=&lt;/math&gt;||&amp;nbsp;||variance of observations associated with state &lt;math&gt;i&lt;/math&gt;
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;x_{t=1 \dots T}&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;=&lt;/math&gt;||&amp;nbsp;||state of observation at time &lt;math&gt;t&lt;/math&gt;
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;y_{t=1 \dots T}&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;=&lt;/math&gt;||&amp;nbsp;||observation at time &lt;math&gt;t&lt;/math&gt;
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;x_{t=2 \dots T}&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;\sim&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;\operatorname{Categorical}(\boldsymbol\phi_{x_{t-1}})&lt;/math&gt;
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;y_{t=1 \dots T}&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;\sim&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;\mathcal{N}(\mu_{x_t}, \sigma_{x_t}^2)&lt;/math&gt;
|}

A typical Bayesian HMM with Gaussian observations looks like this:

{|
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;N&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;=&lt;/math&gt;||&amp;nbsp;||number of states
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;T&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;=&lt;/math&gt;||&amp;nbsp;||number of observations
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;\phi_{i=1 \dots N, j=1 \dots N}&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;=&lt;/math&gt;||&amp;nbsp;||probability of transition from state &lt;math&gt;i&lt;/math&gt; to state &lt;math&gt;j&lt;/math&gt;
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;\boldsymbol\phi_{i=1 \dots N}&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;=&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;N&lt;/math&gt;-dimensional vector, composed of &lt;math&gt;\phi_{i,1 \dots N}&lt;/math&gt;; must sum to &lt;math&gt;1&lt;/math&gt;
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;\mu_{i=1 \dots N}&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;=&lt;/math&gt;||&amp;nbsp;||mean of observations associated with state &lt;math&gt;i&lt;/math&gt;
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;\sigma^2_{i=1 \dots N}&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;=&lt;/math&gt;||&amp;nbsp;||variance of observations associated with state &lt;math&gt;i&lt;/math&gt;
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;x_{t=1 \dots T}&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;=&lt;/math&gt;||&amp;nbsp;||state of observation at time &lt;math&gt;t&lt;/math&gt;
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;y_{t=1 \dots T}&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;=&lt;/math&gt;||&amp;nbsp;||observation at time &lt;math&gt;t&lt;/math&gt;
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;\beta&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;=&lt;/math&gt;||&amp;nbsp;||concentration hyperparameter controlling the density of the transition matrix
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;\mu_0, \lambda&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;=&lt;/math&gt;||&amp;nbsp;||shared hyperparameters of the means for each state
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;\nu, \sigma_0^2&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;=&lt;/math&gt;||&amp;nbsp;||shared hyperparameters of the variances for each state
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;\boldsymbol\phi_{i=1 \dots N}&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;\sim&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;\operatorname{Symmetric-Dirichlet}_N(\beta)&lt;/math&gt;
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;x_{t=2 \dots T}&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;\sim&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;\operatorname{Categorical}(\boldsymbol\phi_{x_{t-1}})&lt;/math&gt;
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;\mu_{i=1 \dots N}&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;\sim&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;\mathcal{N}(\mu_0, \lambda\sigma_i^2)&lt;/math&gt;
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;\sigma_{i=1 \dots N}^2&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;\sim&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;\operatorname{Inverse-Gamma}(\nu, \sigma_0^2)&lt;/math&gt;
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;y_{t=1  \dots T}&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;\sim&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;\mathcal{N}(\mu_{x_t}, \sigma_{x_t}^2)&lt;/math&gt;
|}

A typical non-Bayesian HMM with categorical observations looks like this:

{|
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;N&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;=&lt;/math&gt;||&amp;nbsp;||number of states
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;T&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;=&lt;/math&gt;||&amp;nbsp;||number of observations
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;\phi_{i=1 \dots N, j=1 \dots N}&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;=&lt;/math&gt;||&amp;nbsp;||probability of transition from state &lt;math&gt;i&lt;/math&gt; to state &lt;math&gt;j&lt;/math&gt;
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;\boldsymbol\phi_{i=1 \dots N}&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;=&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;N&lt;/math&gt;-dimensional vector, composed of &lt;math&gt;\phi_{i,1 \dots N}&lt;/math&gt;; must sum to &lt;math&gt;1&lt;/math&gt;
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;V&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;=&lt;/math&gt;||&amp;nbsp;||dimension of categorical observations, e.g. size of word vocabulary
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;\theta_{i=1 \dots N, j=1 \dots V}&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;=&lt;/math&gt;||&amp;nbsp;||probability for state &lt;math&gt;i&lt;/math&gt; of observing the &lt;math&gt;j&lt;/math&gt;th item
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;\boldsymbol\theta_{i=1 \dots N}&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;=&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;V&lt;/math&gt;-dimensional vector, composed of &lt;math&gt;\theta_{i,1 \dots V}&lt;/math&gt;; must sum to &lt;math&gt;1&lt;/math&gt;
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;x_{t=1 \dots T}&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;=&lt;/math&gt;||&amp;nbsp;||state of observation at time &lt;math&gt;t&lt;/math&gt;
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;y_{t=1 \dots T}&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;=&lt;/math&gt;||&amp;nbsp;||observation at time &lt;math&gt;t&lt;/math&gt;
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;x_{t=2 \dots T}&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;\sim&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;\operatorname{Categorical}(\boldsymbol\phi_{x_{t-1}})&lt;/math&gt;
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;y_{t=1 \dots T}&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;\sim&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;\text{Categorical}(\boldsymbol\theta_{x_t})&lt;/math&gt;
|}

A typical Bayesian HMM with categorical observations looks like this:

{|
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;N&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;=&lt;/math&gt;||&amp;nbsp;||number of states
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;T&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;=&lt;/math&gt;||&amp;nbsp;||number of observations
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;\phi_{i=1 \dots N, j=1 \dots N}&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;=&lt;/math&gt;||&amp;nbsp;||probability of transition from state &lt;math&gt;i&lt;/math&gt; to state &lt;math&gt;j&lt;/math&gt;
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;\boldsymbol\phi_{i=1 \dots N}&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;=&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;N&lt;/math&gt;-dimensional vector, composed of &lt;math&gt;\phi_{i,1 \dots N}&lt;/math&gt;; must sum to &lt;math&gt;1&lt;/math&gt;
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;V&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;=&lt;/math&gt;||&amp;nbsp;||dimension of categorical observations, e.g. size of word vocabulary
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;\theta_{i=1 \dots N, j=1 \dots V}&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;=&lt;/math&gt;||&amp;nbsp;||probability for state &lt;math&gt;i&lt;/math&gt; of observing the &lt;math&gt;j&lt;/math&gt;th item
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;\boldsymbol\theta_{i=1 \dots N}&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;=&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;V&lt;/math&gt;-dimensional vector, composed of &lt;math&gt;\theta_{i,1 \dots V}&lt;/math&gt;; must sum to &lt;math&gt;1&lt;/math&gt;
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;x_{t=1 \dots T}&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;=&lt;/math&gt;||&amp;nbsp;||state of observation at time &lt;math&gt;t&lt;/math&gt;
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;y_{t=1 \dots T}&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;=&lt;/math&gt;||&amp;nbsp;||observation at time &lt;math&gt;t&lt;/math&gt;
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;\alpha&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;=&lt;/math&gt;||&amp;nbsp;||shared concentration hyperparameter of &lt;math&gt;\boldsymbol\theta&lt;/math&gt; for each state
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;\beta&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;=&lt;/math&gt;||&amp;nbsp;||concentration hyperparameter controlling the density of the transition matrix
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;\boldsymbol\phi_{i=1 \dots N}&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;\sim&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;\operatorname{Symmetric-Dirichlet}_N(\beta)&lt;/math&gt;
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;\boldsymbol\theta_{1 \dots V}&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;\sim&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;\operatorname{Symmetric-Dirichlet}_V(\alpha)&lt;/math&gt;
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;x_{t=2 \dots T}&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;\sim&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;\operatorname{Categorical}(\boldsymbol\phi_{x_{t-1}})&lt;/math&gt;
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;y_{t=1 \dots T}&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;\sim&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;\operatorname{Categorical}(\boldsymbol\theta_{x_t})&lt;/math&gt;
|}

Note that in the above Bayesian characterizations, &lt;math&gt;\beta&lt;/math&gt; (a [[concentration parameter]]) controls the density of the transition matrix.  That is, with a high value of &lt;math&gt;\beta&lt;/math&gt; (significantly above 1), the probabilities controlling the transition out of a particular state will all be similar, meaning there will be a significant probability of transitioning to any of the other states.  In other words, the path followed by the Markov chain of hidden states will be highly random.  With a low value of &lt;math&gt;\beta&lt;/math&gt; (significantly below 1), only a small number of the possible transitions out of a given state will have significant probability, meaning that the path followed by the hidden states will be somewhat predictable.

=== A two-level Bayesian HMM ===
An alternative for the above two Bayesian examples would be to add another level of prior parameters for the transition matrix.  That is, replace the lines

{|
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;\beta&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;=&lt;/math&gt;||&amp;nbsp;||concentration hyperparameter controlling the density of the transition matrix
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;\boldsymbol\phi_{i=1 \dots N}&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;\sim&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;\operatorname{Symmetric-Dirichlet}_N(\beta)&lt;/math&gt;
|}

with the following:

{|
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;\gamma&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;=&lt;/math&gt;||&amp;nbsp;||concentration hyperparameter controlling how many states are intrinsically likely
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;\beta&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;=&lt;/math&gt;||&amp;nbsp;||concentration hyperparameter controlling the density of the transition matrix
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;\boldsymbol\eta&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;=&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;N&lt;/math&gt;-dimensional vector of probabilities, specifying the intrinsic probability of a given state
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;\boldsymbol\eta&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;\sim&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;\operatorname{Symmetric-Dirichlet}_N(\gamma)&lt;/math&gt;
|-
|&amp;nbsp;||&amp;nbsp;||&lt;math&gt;\boldsymbol\phi_{i=1 \dots N}&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;\sim&lt;/math&gt;||&amp;nbsp;||&lt;math&gt;\operatorname{Dirichlet}_N(\beta N \boldsymbol\eta)&lt;/math&gt;
|}

What this means is the following:
# &lt;math&gt;\boldsymbol\eta&lt;/math&gt; is a [[probability distribution]] over states, specifying which states are inherently likely.  The greater the probability of a given state in this vector, the more likely is a transition to that state (regardless of the starting state).
# &lt;math&gt;\gamma&lt;/math&gt; controls the density of &lt;math&gt;\boldsymbol\eta&lt;/math&gt;.  Values significantly above 1 cause a dense vector where all states will have similar [[prior probability|prior probabilities]].  Values significantly below 1 cause a sparse vector where only a few states are inherently likely (have prior probabilities significantly above 0).
# &lt;math&gt;\beta&lt;/math&gt; controls the density of the transition matrix, or more specifically, the density of the ''N'' different probability vectors &lt;math&gt;\boldsymbol\phi_{i=1 \dots N}&lt;/math&gt; specifying the probability of transitions out of state ''i'' to any other state.

Imagine that the value of &lt;math&gt;\beta&lt;/math&gt; is significantly above 1.  Then the different &lt;math&gt;\boldsymbol\phi&lt;/math&gt; vectors will be dense, i.e. the probability mass will be spread out fairly evenly over all states.  However, to the extent that this mass is unevenly spread, &lt;math&gt;\boldsymbol\eta&lt;/math&gt; controls which states are likely to get more mass than others.

Now, imagine instead that &lt;math&gt;\beta&lt;/math&gt; is significantly below 1.  This will make the &lt;math&gt;\boldsymbol\phi&lt;/math&gt; vectors sparse, i.e. almost all the probability mass is distributed over a small number of states, and for the rest, a transition to that state will be very unlikely.  Notice that there are different &lt;math&gt;\boldsymbol\phi&lt;/math&gt; vectors for each starting state, and so even if all the vectors are sparse, different vectors may distribute the mass to different ending states.  However, for all of the vectors, &lt;math&gt;\boldsymbol\eta&lt;/math&gt; controls which ending states are likely to get mass assigned to them.  For example, if &lt;math&gt;\beta&lt;/math&gt; is 0.1, then each &lt;math&gt;\boldsymbol\phi&lt;/math&gt; will be sparse and, for any given starting state ''i'', the set of states &lt;math&gt;\mathbf{J}_i&lt;/math&gt; to which transitions are likely to occur will be very small, typically having only one or two members.  Now, if the probabilities in &lt;math&gt;\boldsymbol\eta&lt;/math&gt; are all the same (or equivalently, one of the above models without &lt;math&gt;\boldsymbol\eta&lt;/math&gt; is used), then for different ''i'', there will be different states in the corresponding &lt;math&gt;\mathbf{J}_i&lt;/math&gt;, so that all states are equally likely to occur in any given &lt;math&gt;\mathbf{J}_i&lt;/math&gt;.  On the other hand, if the values in &lt;math&gt;\boldsymbol\eta&lt;/math&gt; are unbalanced, so that one state has a much higher probability than others, almost all &lt;math&gt;\mathbf{J}_i&lt;/math&gt; will contain this state; hence, regardless of the starting state, transitions will nearly always occur to this given state.

Hence, a two-level model such as just described allows independent control over (1) the overall density of the transition matrix, and (2) the density of states to which transitions are likely (i.e. the density of the prior distribution of states in any particular hidden variable &lt;math&gt;x_i&lt;/math&gt;).  In both cases this is done while still assuming ignorance over which particular states are more likely than others.  If it is desired to inject this information into the model, the probability vector &lt;math&gt;\boldsymbol\eta&lt;/math&gt; can be directly specified; or, if there is less certainty about these relative probabilities, a non-symmetric [[Dirichlet distribution]] can be used as the prior distribution over &lt;math&gt;\boldsymbol\eta&lt;/math&gt;.  That is, instead of using a symmetric Dirichlet distribution with the single parameter &lt;math&gt;\gamma&lt;/math&gt; (or equivalently, a general Dirichlet with a vector all of whose values are equal to &lt;math&gt;\gamma&lt;/math&gt;), use a general Dirichlet with values that are variously greater or less than &lt;math&gt;\gamma&lt;/math&gt;, according to which state is more or less preferred.

=== Poisson hidden Markov model ===
''Poisson hidden Markov models (PHMM)'' are special cases of hidden Markov models where a [[Poisson process]] has a rate which varies in association with changes between the different states of a Markov model.&lt;ref&gt;R. Paroli. et al., [http://actuaries.org/ASTIN/Colloquia/Porto_Cervo/Paroli_Redaelli_Spezia.pdf ''Poisson hidden Markov models for time series of overdispersed insurance counts'']&lt;/ref&gt;  PHMMs are not necessarily [[Markovian process]]es themselves because the underlying [[Markov chain]] or [[Markov process]] cannot be observed and only the Poisson signal is observed.

== Applications ==
HMMs can be applied in many fields where the goal is to recover a data sequence that is not immediately observable (but other data that depend on the sequence are). Applications include:
* [[Computational finance]]&lt;ref&gt;{{cite journal |doi=10.1007/s10614-016-9579-y |volume=49 |issue=4 |title=Parallel Optimization of Sparse Portfolios with AR-HMMs |year=2016 |journal=Computational Economics |pages=563–578 |last1=Sipos |first1=I. Róbert |last2=Ceffer |first2=Attila |last3=Levendovszky |first3=János}}&lt;/ref&gt;&lt;ref&gt;{{cite journal |url=http://www.sciencedirect.com/science/article/pii/S0957417416000257 |doi=10.1016/j.eswa.2016.01.015 |volume=53 |title=A novel corporate credit rating system based on Student's-t hidden Markov models |year=2016 |journal=Expert Systems with Applications |pages=87–105 |last1=Petropoulos |first1=Anastasios |last2=Chatzis |first2=Sotirios P. |last3=Xanthopoulos |first3=Stylianos}}&lt;/ref&gt;
* [[Single-molecule experiment|Single-molecule kinetic analysis]]&lt;ref&gt;{{cite journal |doi=10.1142/S1793048013300053 |title=SOLVING ION CHANNEL KINETICS WITH THE QuB SOFTWARE |journal=Biophysical Reviews and Letters |date=2013 |volume=8 |issue=3n04 |pages=191–211 |first=CHRISTOPHER |last=NICOLAI}}&lt;/ref&gt;
* [[Cryptanalysis]]
* [[Speech recognition]], including [[Siri]]&lt;ref&gt;{{cite book|last1=Domingos|first1=Pedro|title=The Master Algorithm: How the Quest for the Ultimate Learning Machine Will Remake Our World|date=2015|publisher=Basic Books|isbn=9780465061921|page=37|language=en}}&lt;/ref&gt;
* [[Speech synthesis]]
* [[Part-of-speech tagging]]
* Document separation in scanning solutions
* [[Machine translation]]
* [[Partial discharge]]
* [[Gene prediction]]
* [[Handwriting recognition]]
* [[sequence alignment|Alignment of bio-sequences]]
* [[Time series|Time series analysis]]
* [[Activity recognition]]
* [[Protein folding]]&lt;ref&gt;{{Cite journal |last1=Stigler |first1=J. |last2=Ziegler |first2=F. |last3=Gieseke |first3=A. |last4=Gebhardt |first4=J. C. M. |last5=Rief |first5=M. |title=The Complex Folding Network of Single Calmodulin Molecules |doi=10.1126/science.1207598 |journal=[[Science (journal)|Science]] |volume=334 |issue=6055 |pages=512–516 |year=2011 |pmid=22034433 |pmc=|bibcode=2011Sci...334..512S }}&lt;/ref&gt;
* Sequence classification&lt;ref&gt;{{Cite journal |last1=Blasiak |first1=S. |last2=Rangwala |first2=H. |doi= |title=A Hidden Markov Model Variant for Sequence Classification |journal=IJCAI Proceedings-International Joint Conference on Artificial Intelligence |volume=22 |issue= |pages=1192 |year=2011 |pmid= |pmc=}}&lt;/ref&gt;
* [[Metamorphic virus detection]]&lt;ref&gt;{{Cite journal |last1=Wong |first1=W. |last2=Stamp |first2=M. |doi=10.1007/s11416-006-0028-7 |title=Hunting for metamorphic engines |journal=Journal in Computer Virology |volume=2 |issue=3 |pages=211–229 |year=2006 |pmid= |pmc=}}&lt;/ref&gt;
* [[sequence motif|DNA motif discovery]]&lt;ref&gt;{{Cite journal |last1=Wong |first1=K. -C. |last2=Chan |first2=T. -M. |last3=Peng |first3=C. |last4=Li |first4=Y. |last5=Zhang |first5=Z. |title=DNA motif elucidation using belief propagation |doi=10.1093/nar/gkt574 |journal=Nucleic Acids Research |volume=41 |issue=16 |pages=e153 |year=2013 |pmid=23814189 |pmc=3763557}}&lt;/ref&gt;
*[[Chromatin]] state discovery&lt;ref&gt;{{Cite web|url=http://compbio.mit.edu/ChromHMM/|title=ChromHMM: Chromatin state discovery and characterization|website=compbio.mit.edu|access-date=2018-08-01}}&lt;/ref&gt;
*[[Transportation forecasting]]&lt;ref&gt;{{Cite arxiv|title=Modeling and Forecasting the Evolution of Preferences over Time: A Hidden Markov Model of Travel Behavior|last=El Zarwi|first=Feraz|date=May 2011|eprint = 1707.09133|class = stat.AP}}&lt;/ref&gt;
*Solar irradiance variability &lt;ref&gt;{{Cite journal|url=https://www.sciencedirect.com/science/article/pii/S0038092X98000048|title=The stochastic two-state solar irradiance model (STSIM)|last=Morf|first1=H.|journal=Solar Energy|volume=62|issue=2|pages=101–112|date=Feb 1998|archive-url=|archive-date=|dead-url=|access-date=|bibcode=1998SoEn...62..101M|doi=10.1016/S0038-092X(98)00004-8}}&lt;/ref&gt;&lt;ref&gt;{{Cite journal|url=https://www.sciencedirect.com/science/article/pii/S0038092X18304882|title=A Markov-chain probability distribution mixture approach to the clear-sky index|last1=Munkhammar|first1=J.|last2=Widén|first2=J.|journal = Solar Energy|date=Aug 2018|volume=170|pages=174–183|archive-url=|archive-date=|dead-url=|access-date=|bibcode=2018SoEn..170..174M|doi=10.1016/j.solener.2018.05.055}}&lt;/ref&gt;&lt;ref&gt;{{Cite journal|url=https://www.sciencedirect.com/science/article/pii/S0038092X18307205|title=An N-state Markov-chain mixture distribution model of the clear-sky index|last1=Munkhammar|first1=J.|last2=Widén|first2=J.|journal=Solar Energy|volume=173|pages=487–495|date=Oct 2018|archive-url=|archive-date=|dead-url=|access-date=|bibcode=2018SoEn..173..487M|doi=10.1016/j.solener.2018.07.056}}&lt;/ref&gt;

== History ==
The forward and backward recursions used in HMM as well as computations of marginal smoothing probabilities were first described by [[Ruslan L. Stratonovich]] in 1960&lt;ref name="Stratonovich1960" /&gt; (pages 160—162) and in the late 1950s in his papers in Russian.
The Hidden Markov Models were later described in a series of statistical papers by [[Leonard E. Baum]] and other authors in the second half of the 1960s. One of the first applications of HMMs was [[speech recognition]], starting in the mid-1970s.&lt;ref&gt;{{Cite journal |last1=Baker |first1=J. |authorlink1=James K. Baker |doi=10.1109/TASSP.1975.1162650 |title=The DRAGON system—An overview |journal=IEEE Transactions on Acoustics, Speech, and Signal Processing |volume=23 |pages=24–29 |year=1975 |pmid= |pmc=}}&lt;/ref&gt;&lt;ref&gt;{{Cite journal |last1=Jelinek |first1=F. |last2=Bahl |first2=L. |last3=Mercer |first3=R. |doi=10.1109/TIT.1975.1055384 |title=Design of a linguistic statistical decoder for the recognition of continuous speech |journal=[[IEEE Transactions on Information Theory]] |volume=21 |issue=3 |pages=250 |year=1975 |pmid= |pmc=}}&lt;/ref&gt;&lt;ref&gt;{{cite book |title=Hidden Markov Models for Speech Recognition |publisher=Edinburgh University Press |year=1990 |isbn=978-0-7486-0162-2 |author1=Xuedong Huang |author2=M. Jack |author3=Y. Ariki |authorlink1=Xuedong Huang}}&lt;/ref&gt;&lt;ref&gt;{{cite book |title=Spoken Language Processing |publisher=Prentice Hall |year=2001 |isbn=978-0-13-022616-7 |author1=Xuedong Huang |author2=Alex Acero |author3=Hsiao-Wuen Hon |authorlink1=Xuedong Huang}}&lt;/ref&gt;

In the second half of the 1980s, HMMs began to be applied to the analysis of biological sequences,&lt;ref&gt;{{cite journal |doi=10.1016/0022-2836(86)90289-5 |author=M. Bishop and E. Thompson |title=Maximum Likelihood Alignment of DNA Sequences |journal=[[Journal of Molecular Biology]] |volume=190 |issue=2 |pages=159–165 |year=1986 |pmid=3641921}} {{subscription required}} {{closed access}}&lt;/ref&gt; in particular [[DNA]]. Since then, they have become ubiquitous in the field of [[bioinformatics]].&lt;ref name=durbin&gt;{{Durbin 1998}}&lt;/ref&gt;

== Types ==
Hidden Markov models can model complex [[Markov]] processes where the states emit the observations according to some probability distribution. One such example is the [[Gaussian]] distribution; in such a Hidden Markov Model the states output are represented by a [[Gaussian]] distribution.

Moreover, it could represent even more complex behavior when the output of the states is represented as mixture of two or more Gaussians, in which case the [[probability]] of generating an observation is the product of the probability of first selecting one of the Gaussians and the probability of generating that observation from that Gaussian. In cases of modeled data exhibiting artifacts such as outliers and skewness, one may resort to finite mixtures of heavier-tailed elliptical distributions, such as the multivariate Student's-t distribution, or appropriate non-elliptical distributions, such as the multivariate Normal Inverse-Gaussian.&lt;ref&gt;Sotirios P. Chatzis, "Hidden Markov Models with Nonelliptically Contoured State Densities," IEEE Transactions on Pattern Analysis and Machine Intelligence, vol. 32, no. 12, pp. 2297-2304, Dec. 2010. [http://ieeexplore.ieee.org/abstract/document/5551154/]&lt;/ref&gt;

== Extensions ==
In the hidden Markov models considered above, the state space of the hidden variables is discrete, while the observations themselves can either be discrete (typically generated from a [[categorical distribution]]) or continuous (typically from a [[Gaussian distribution]]). Hidden Markov models can also be generalized to allow continuous state spaces. Examples of such models are those where the Markov process over hidden variables is a [[linear dynamical system]], with a linear relationship among related variables and where all hidden and observed variables follow a [[Gaussian distribution]]. In simple cases, such as the linear dynamical system just mentioned, exact inference is tractable (in this case, using the [[Kalman filter]]); however, in general, exact inference in HMMs with continuous latent variables is infeasible, and approximate methods must be used, such as the [[extended Kalman filter]] or the [[particle filter]].

Hidden Markov models are [[generative model]]s, in which the [[joint distribution]] of observations and hidden states, or equivalently both the [[prior distribution]] of hidden states (the ''transition probabilities'') and [[conditional distribution]] of observations given states (the ''emission probabilities''), is modeled.  The above algorithms implicitly assume a [[Uniform distribution (continuous)|uniform]] prior distribution over the transition probabilities. However, it is also possible to create hidden Markov models with other types of prior distributions. An obvious candidate, given the categorical distribution of the transition probabilities, is the [[Dirichlet distribution]], which is the [[conjugate prior]] distribution of the categorical distribution.  Typically, a symmetric Dirichlet distribution is chosen, reflecting ignorance about which states are inherently more likely than others.  The single parameter of this distribution (termed the ''concentration parameter'') controls the relative density or sparseness of the resulting transition matrix.  A choice of 1 yields a uniform distribution.  Values greater than 1 produce a dense matrix, in which the transition probabilities between pairs of states are likely to be nearly equal.  Values less than 1 result in a sparse matrix in which, for each given source state, only a small number of destination states have non-negligible transition probabilities.  It is also possible to use a two-level prior Dirichlet distribution, in which one Dirichlet distribution (the upper distribution) governs the parameters of another Dirichlet distribution (the lower distribution), which in turn governs the transition probabilities.  The upper distribution governs the overall distribution of states, determining how likely each state is to occur; its concentration parameter determines the density or sparseness of states.  Such a two-level prior distribution, where both concentration parameters are set to produce sparse distributions, might be useful for example in [[unsupervised learning|unsupervised]] [[part-of-speech tagging]], where some parts of speech occur much more commonly than others; learning algorithms that assume a uniform prior distribution generally perform poorly on this task.  The parameters of models of this sort, with non-uniform prior distributions, can be learned using [[Gibbs sampling]] or extended versions of the [[expectation-maximization algorithm]].

An extension of the previously described hidden Markov models with [[Dirichlet distribution|Dirichlet]] priors uses a [[Dirichlet process]] in place of a Dirichlet distribution.  This type of model allows for an unknown and potentially infinite number of states.  It is common to use a two-level Dirichlet process, similar to the previously described model with two levels of Dirichlet distributions.  Such a model is called a ''hierarchical Dirichlet process hidden Markov model'', or ''HDP-HMM'' for short. It was originally described under the name "Infinite Hidden Markov Model"{{ref|Beal, Matthew J., Zoubin Ghahramani, and Carl Edward Rasmussen. "The infinite hidden Markov model." Advances in neural information processing systems 14 (2002): 577-584.}} and was further formalized in{{ref|Teh, Yee Whye, et al. "Hierarchical dirichlet processes." Journal of the American Statistical Association 101.476 (2006).}}.

A different type of extension uses a [[discriminative model]] in place of the [[generative model]] of standard HMMs.  This type of model directly models the conditional distribution of the hidden states given the observations, rather than modeling the joint distribution.  An example of this model is the so-called ''[[maximum entropy Markov model]]'' (MEMM), which models the conditional distribution of the states using [[logistic regression]] (also known as a "[[Maximum entropy probability distribution|maximum entropy]] model").  The advantage of this type of model is that arbitrary features (i.e. functions) of the observations can be modeled, allowing domain-specific knowledge of the problem at hand to be injected into the model.  Models of this sort are not limited to modeling direct dependencies between a hidden state and its associated observation; rather, features of nearby observations, of combinations of the associated observation and nearby observations, or in fact of arbitrary observations at any distance from a given hidden state can be included in the process used to determine the value of a hidden state.  Furthermore, there is no need for these features to be [[statistically independent]] of each other, as would be the case if such features were used in a generative model.  Finally, arbitrary features over pairs of adjacent hidden states can be used rather than simple transition probabilities.  The disadvantages of such models are: (1) The types of prior distributions that can be placed on hidden states are severely limited; (2) It is not possible to predict the probability of seeing an arbitrary observation.  This second limitation is often not an issue in practice, since many common usages of HMM's do not require such predictive probabilities.

A variant of the previously described discriminative model is the linear-chain [[conditional random field]].  This uses an undirected graphical model (aka [[Markov random field]]) rather than the directed graphical models of MEMM's and similar models.  The advantage of this type of model is that it does not suffer from the so-called ''label bias'' problem of MEMM's, and thus may make more accurate predictions.  The disadvantage is that training can be slower than for MEMM's.

Yet another variant is the ''factorial hidden Markov model'', which allows for a single observation to be conditioned on the corresponding hidden variables of a set of &lt;math&gt;K&lt;/math&gt; independent Markov chains, rather than a single Markov chain. It is equivalent to a single HMM, with &lt;math&gt;N^K&lt;/math&gt; states (assuming there are &lt;math&gt;N&lt;/math&gt; states for each chain), and therefore, learning in such a model is difficult: for a sequence of length &lt;math&gt;T&lt;/math&gt;, a straightforward Viterbi algorithm has complexity &lt;math&gt;O(N^{2K} \, T)&lt;/math&gt;. To find an exact solution, a junction tree algorithm could be used, but it results in an &lt;math&gt;O(N^{K+1} \, K \, T)&lt;/math&gt; complexity. In practice, approximate techniques, such as variational approaches, could be used.&lt;ref&gt;{{cite journal |last=Ghahramani |first=Zoubin |authorlink1=Zoubin Ghahramani |last2=Jordan |first2=Michael I. |authorlink2=Michael I. Jordan |title=Factorial Hidden Markov Models |journal=[[Machine Learning (journal)|Machine Learning]] |year=1997 |volume=29 |issue=2/3 |pages=245–273 |doi=10.1023/A:1007425814087}}&lt;/ref&gt;

All of the above models can be extended to allow for more distant dependencies among hidden states, e.g. allowing for a given state to be dependent on the previous two or three states rather than a single previous state; i.e. the transition probabilities are extended to encompass sets of three or four adjacent states (or in general &lt;math&gt;K&lt;/math&gt; adjacent states).  The disadvantage of such models is that dynamic-programming algorithms for training them have an &lt;math&gt;O(N^K \, T)&lt;/math&gt; running time, for &lt;math&gt;K&lt;/math&gt; adjacent states and &lt;math&gt;T&lt;/math&gt; total observations (i.e. a length-&lt;math&gt;T&lt;/math&gt; Markov chain).

Another recent extension is the ''triplet Markov model'',&lt;ref name="TMM"&gt;{{cite journal |url=http://www.sciencedirect.com/science/article/pii/S1631073X02024627 |doi=10.1016/S1631-073X(02)02462-7 |volume=335 |issue=3 |title=Chaı̂nes de Markov Triplet |year=2002 |journal=Comptes Rendus Mathématique |pages=275–278 |last1=Pieczynski |first1=Wojciech}}&lt;/ref&gt; in which an auxiliary underlying process is added to model some data specificities. Many variants of this model have been proposed. One should also mention the interesting link that has been established between the ''theory of evidence'' and the ''triplet Markov models''&lt;ref name="TMMEV" /&gt; and which allows to fuse data in Markovian context&lt;ref name="JASP" /&gt; and to model nonstationary data.&lt;ref name="TSP" /&gt;&lt;ref name="SPL" /&gt; Note that alternative multi-stream data fusion strategies have also been proposed in the recent literature, e.g.&lt;ref&gt;Sotirios P. Chatzis, Dimitrios Kosmopoulos, "Visual Workflow Recognition Using a Variational Bayesian Treatment of Multistream Fused Hidden Markov Models," IEEE Transactions on Circuits and Systems for Video Technology, vol. 22, no. 7, pp. 1076-1086, July 2012. [http://ieeexplore.ieee.org/document/6164251/]&lt;/ref&gt;

Finally, a different rationale towards addressing the problem of modeling nonstationary data by means of hidden Markov models was suggested in 2012.&lt;ref name="Reservoir-HMM"&gt;{{cite journal |last1=Chatzis |first1=Sotirios P. |last2=Demiris |first2=Yiannis |year=2012 |title=A Reservoir-Driven Non-Stationary Hidden Markov Model |url=http://www.sciencedirect.com/science/article/pii/S0031320312001987 |journal=Pattern Recognition |volume=45 |issue=11 |pages=3985–3996 |doi=10.1016/j.patcog.2012.04.018|hdl=10044/1/12611 }}&lt;/ref&gt; It consists in employing a small recurrent neural network (RNN), specifically a reservoir network,&lt;ref&gt;M. Lukosevicius, H. Jaeger (2009) Reservoir computing approaches to recurrent neural network training, Computer Science Review '''3''': 127–149.&lt;/ref&gt; to capture the evolution of the temporal dynamics in the observed data. This information, encoded in the form of a high-dimensional vector, is used as a conditioning variable of the HMM state transition probabilities. Under such a setup, we eventually obtain a nonstationary HMM the transition probabilities of which evolve over time in a manner that is inferred from the data itself, as opposed to some unrealistic ad-hoc model of temporal evolution.

The model suitable in the context of longitudinal data is named latent Markov model.&lt;ref&gt;{{Cite book|title=Panel Analysis: Latent Probability Models for Attitude and Behaviour Processes|last=Wiggins|first=L. M.|publisher=Elsevier|year=1973|isbn=|location=Amsterdam|pages=}}&lt;/ref&gt; The basic version of this model has been extended to include individual covariates, random effects and to model more complex data structures such as multilevel data. A complete overview of the latent Markov models, with special attention to the model assumptions and  to their practical use is provided in&lt;ref&gt;{{Cite book|url=https://sites.google.com/site/latentmarkovbook/home|title=Latent Markov models for longitudinal data|last=Bartolucci|first=F.|last2=Farcomeni|first2=A.|last3=Pennoni|first3=F.|publisher=Chapman and Hall/CRC|year=2013|isbn=978-14-3981-708-7|location=Boca Raton|pages=}}&lt;/ref&gt;

== See also ==
{{Div col|colwidth=22em}}
* [[Andrey Markov]]
* [[Baum–Welch algorithm]]
* [[Bayesian inference]]
* [[Bayesian programming]]
* [[Conditional random field]]
* [[Estimation theory]]
* [[HHpred / HHsearch]] free server and software for protein sequence searching
* [[HMMER]], a free hidden Markov model program for protein sequence analysis
* [[Hidden Bernoulli model]]
* [[Hidden semi-Markov model]]
* [[Hierarchical hidden Markov model]]
* [[Layered hidden Markov model]]
* [[Sequential dynamical system]]
* [[Stochastic context-free grammar]]
*  [[Time Series]] Analysis
* [[Variable-order Markov model]]
* [[Viterbi algorithm]]
{{div col end}}

== References ==
{{Reflist|30em}}

== External links ==
{{Commons category|Hidden Markov Model}}

=== Concepts ===
* {{cite journal |last1=Teif |first1=V. B. |last2=Rippe |first2=K. |year=2010 |title=Statistical–mechanical lattice models for protein–DNA binding in chromatin |journal=J. Phys.: Condens. Matter |volume=22 |issue=41 |page=414105 |doi=10.1088/0953-8984/22/41/414105 |pmid=21386588 |arxiv=1004.5514|bibcode=2010JPCM...22O4105T }}
* [http://www.cs.sjsu.edu/~stamp/RUA/HMM.pdf A Revealing Introduction to Hidden Markov Models] by Mark Stamp, San Jose State University.
* [https://web.archive.org/web/20120415032315/http://www.ee.washington.edu/research/guptalab/publications/EMbookChenGupta2010.pdf Fitting HMM's with expectation-maximization – complete derivation]
* [http://www.comp.leeds.ac.uk/roger/HiddenMarkovModels/html_dev/main.html A step-by-step tutorial on HMMs] ''(University of Leeds)''
* [http://www.cs.brown.edu/research/ai/dynamics/tutorial/Documents/HiddenMarkovModels.html Hidden Markov Models] ''(an exposition using basic mathematics)''
* [http://jedlik.phy.bme.hu/~gerjanos/HMM/node2.html Hidden Markov Models] ''(by Narada Warakagoda)''
* Hidden Markov Models: Fundamentals and Applications [http://www.eecis.udel.edu/~lliao/cis841s06/hmmtutorialpart1.pdf Part 1], [http://www.eecis.udel.edu/~lliao/cis841s06/hmmtutorialpart2.pdf Part 2] ''(by V. Petrushin)''
* Lecture on a Spreadsheet by Jason Eisner, [http://videolectures.net/hltss2010_eisner_plm/video/2/ Video] and [http://www.cs.jhu.edu/~jason/papers/eisner.hmm.xls interactive spreadsheet]

=== Software ===
* [http://www.cs.ubc.ca/~murphyk/Software/HMM/hmm.html Hidden Markov Model (HMM) Toolbox for Matlab] ''(by Kevin Murphy)''
* [http://htk.eng.cam.ac.uk/ Hidden Markov Model Toolkit (HTK)] ''(a portable toolkit for building and manipulating hidden Markov models)''
* [https://cran.r-project.org/web/packages/HMM/index.html Hidden Markov Model R-Package] to set up, apply and make inference with discrete time and discrete space Hidden Markov Models
* [http://birc.au.dk/software/zipHMM zipHMMlib] ''(a library for general (discrete) hidden Markov models, exploiting repetitions in the input sequence to greatly speed up the forward algorithm. Implementation of the posterior decoding algorithm and the Viterbi algorithm are also provided.)''
* [http://www.ghmm.org/ GHMM Library] ''(home page of the GHMM Library project)''
* [https://github.com/KommuSoft/jahmm Jahmm Java Library] ''(general-purpose Java library)''
* [http://www.kanungo.com/software/software.html HMM and other statistical programs] ''(Implementation in C by Tapas Kanungo)''
* [http://hackage.haskell.org/cgi-bin/hackage-scripts/package/hmm The hmm package] A [http://www.haskell.org/ Haskell] library for working with Hidden Markov Models.
* [http://gt2k.cc.gatech.edu/ GT2K] Georgia Tech Gesture Toolkit (referred to as GT2K)
* [http://www.lwebzem.com/cgi-bin/courses/hidden_markov_model_online.cgi Hidden Markov Models -online calculator for HMM – Viterbi path and probabilities. Examples with perl source code.]
* [http://sourceforge.net/projects/cvhmm/ A discrete Hidden Markov Model class, based on OpenCV.]
* [https://cran.r-project.org/web/packages/depmixS4/index.html depmixS4]  R-Package (Hidden Markov Models of GLMs and Other Distributions in S4 )
* [[mlpack]] contains a C++ implementation of HMMs
* [https://adrianulbona.github.io/hmm Hidden Markov Models Java Library] contains basic HMMs abstractions in Java 8
* [http://tuvalu.santafe.edu/~simon/styled-8/ SFIHMM] high-speed C code for the estimation of Hidden Markov Models, Viterbi Path Reconstruction, and the generation of simulated data from HMMs.
*[https://cran.r-project.org/web/packages/LMest/index.html LMest] An R Package for Latent Markov Models for Longitudinal Categorical Data to estimate Markov and latent Markov models and to apply the decoding algorithm and the Viterbi algorithm.
{{Stochastic processes}}

{{Authority control}}

[[Category:Bioinformatics]]
[[Category:Hidden Markov models| ]]
[[Category:Markov models]]
[[Category:Articles with example Python code]]</text>
      <sha1>s5yqwycjl4i5l082z5b2e3p172bhixo</sha1>
    </revision>
  </page>
  <page>
    <title>Index of biophysics articles</title>
    <ns>0</ns>
    <id>35843160</id>
    <revision>
      <id>863867465</id>
      <parentid>809380241</parentid>
      <timestamp>2018-10-13T16:15:12Z</timestamp>
      <contributor>
        <username>RockMagnetist</username>
        <id>12961884</id>
      </contributor>
      <comment>Adding [[Wikipedia:Short description|short description]]: "Index of articles on biophysics" ([[User:Galobtter/Shortdesc helper|Shortdesc helper]])</comment>
      <model>wikitext</model>
      <format>text/x-wiki</format>
      <text xml:space="preserve" bytes="15943">{{short description|Index of articles on biophysics}}
This is a list of articles on [[biophysics]].
{{compact ToC|side=yes|top=yes|num=yes}}

==0&amp;ndash;9==
*[[5-HT3 receptor]]

==A==
*[[ACCN1]]
*[[ANO1]]
*[[AP2 adaptor complex]]
*[[Aaron Klug]]
*[[Acid-sensing ion channel]]
*[[Activating function]]
*[[Active transport]]
*[[Adolf Eugen Fick]]
*[[Afterdepolarization]]
*[[Aggregate modulus]]
*[[Aharon Katzir]]
*[[Alan Lloyd Hodgkin]]
*[[Alexander Rich]]
*[[Alexander van Oudenaarden]]
*[[Allan McLeod Cormack]]
*[[Alpha-3 beta-4 nicotinic receptor]]
*[[Alpha-4 beta-2 nicotinic receptor]]
*[[Alpha-7 nicotinic receptor]]
*[[Alpha helix]]
*[[Alwyn Jones (biophysicist)]]
*[[Amoeboid movement]]
*[[Andreas Mershin]]
*[[Andrew Huxley]]
*[[Animal locomotion]]
*[[Animal locomotion on the water surface]]
*[[Anita Goel]]
*[[Antiporter]]
*[[Aquaporin 2]]
*[[Aquaporin 3]]
*[[Aquaporin 4]]
*[[Archibald Hill]]
*[[Ariel Fernandez]]
*[[Arthropod exoskeleton]]
*[[Arthropod leg]]
*[[Avery Gilbert]]

==B==
*[[BEST2]]
*[[BK channel]]
*[[Bacterial outer membrane]]
*[[Balance (ability)]]
*[[Bat]]
*[[Bat wing development]]
*[[Bert Sakmann]]
*[[Bestrophin 1]]
*[[Biased random walk (biochemistry)]]
*[[Bioelectrochemical reactor]]
*[[Bioelectrochemistry]]
*[[Biofilm]]
*[[Biological material (disambiguation)|Biological material]]
*[[Biological membrane]]
*[[Biomechanics]]
*[[Biomechanics of sprint running]]
*[[Biophysical Society]]
*[[Biophysics]]
*[[Bird flight]]
*[[Bird migration]]
*[[Bisindolylmaleimide]]
*[[Bleb (cell biology)]]
*[[Boris Pavlovich Belousov]]
*[[Brian Matthews (biochemist)]]
*[[Britton Chance]]
*[[Brush border]]
*[[Bulk movement]]

==C==
*[[CACNA1G]]
*[[CACNA1H]]
*[[CACNA1I]]
*[[CACNA2D1]]
*[[CACNA2D2]]
*[[CACNB1]]
*[[CACNB2]]
*[[CACNB3]]
*[[CACNB4]]
*[[CACNG1]]
*[[CACNG2]]
*[[CACNG3]]
*[[CACNG4]]
*[[CD22]]
*[[CD33]]
*[[CHRNA10]]
*[[CHRNA2]]
*[[CHRNA3]]
*[[CHRNA4]]
*[[CHRNA5]]
*[[CHRNA6]]
*[[CHRNA7]]
*[[CHRNA9]]
*[[CHRNB1]]
*[[CHRNB2]]
*[[CHRNB3]]
*[[CHRNB4]]
*[[CHRND]]
*[[CHRNE]]
*[[CHRNG]]
*[[CLCA1]]
*[[CLCA2]]
*[[CLCA3]]
*[[CLCA4]]
*[[CLCC1]]
*[[CLCN1]]
*[[CLCN2]]
*[[CLCN3]]
*[[CLCN4]]
*[[CLCN5]]
*[[CLCN6]]
*[[CLCN7]]
*[[CLCNKA]]
*[[CLCNKB]]
*[[CLIC1]]
*[[CLIC2]]
*[[CLIC3]]
*[[CLIC4]]
*[[CLIC5]]
*[[CLIC6]]
*[[CLNS1A]]
*[[CLNS1B]]
*[[CNGB1]]
*[[Calcium-activated potassium channel]]
*[[Calcium-activated potassium channel subunit alpha-1]]
*[[Calcium 2-aminoethylphosphate]]
*[[Calcium channel]]
*[[Canadian Society for Biomechanics]]
*[[Cardiolipin]]
*[[Carlos Chagas Filho]]
*[[Carrier protein]]
*[[CatSper1]]
*[[CatSper2]]
*[[CatSper3]]
*[[CatSper4]]
*[[Cation channels of sperm]]
*[[Cav1.1]]
*[[Cav1.2]]
*[[Cav1.3]]
*[[Cav1.4]]
*[[Cav2.1]]
*[[Cell adhesion molecule]]
*[[Cell membrane]]
*[[Cellular component]]
*[[Channelome]]
*[[Channelomics]]
*[[Channelrhodopsin]]
*[[Charles Tanford]]
*[[Chemorepulsion]]
*[[Chloride channel]]
*[[Chloroplast membrane]]
*[[Cholesterol depletion]]
*[[Cholinergic receptor, nicotinic, alpha 1]]
*[[Chorioallantoic membrane]]
*[[Christian B. Anfinsen]]
*[[Cilium]]
*[[Climbing]]
*[[Cometabolism]]
*[[Comparative foot morphology]]
*[[Connexon]]
*[[Core (anatomy)]]
*[[Countercurrent multiplication]]
*[[Crenation]]
*[[Crista]]
*[[Cyclic nucleotide-gated channel alpha 1]]
*[[Cyclic nucleotide-gated channel alpha 2]]
*[[Cyclic nucleotide-gated channel alpha 3]]
*[[Cyclic nucleotide-gated channel alpha 4]]
*[[Cyclic nucleotide-gated ion channel]]
*[[Cyclic nucleotide gated channel beta 3]]
*[[Cys-loop receptors]]
*[[Cytolysis]]

==D==
*[[David Callaway]]
*[[David Cohen (physicist)]]
*[[David E. Goldman]]
*[[David J. Brenner]]
*[[David Keynes Hill]]
*[[David Mervyn Blow]]
*[[David S. Cafiso]]
*[[David States]]
*[[Davydov soliton]]
*[[Dendrosome]]
*[[Denny's paradox]]
*[[Depolarization]]
*[[Detlev Bronk]]
*[[Dopamine transporter]]
*[[Douglas Warrick]]
*[[Dušan Ristanović]]
*[[Dynamic similarity (Reynolds and Womersley numbers)]]

==E==
*[[Ecomechanics]]
*[[Efflux (microbiology)]]
*[[Egg white]]
*[[Elasticity of cell membranes]]
*[[Electrochemical gradient]]
*[[Electromethanogenesis]]
*[[Electrophysiology]]
*[[Electrotonic potential]]
*[[Elizabeth Rhoades]]
*[[Ena/Vasp homology proteins]]
*[[Endocytosis]]
*[[Endomembrane system]]
*[[Endoskeleton]]
*[[Enid MacRobbie]]
*[[Enzymatic biofuel cell]]
*[[Enzyme kinetics]]
*[[Ephraim Katzir]]
*[[Eric Kandel]]
*[[Erich Sackmann]]
*[[Erwin Neher]]
*[[Escheriosome]]
*[[Eva Nogales]]
*[[Excitatory amino-acid transporter]]
*[[Exoskeleton]]
*[[Extracellular field potential]]
*[[Extracellular polymeric substance]]

==F==
*[[F15845]]
*[[Filamentous haemagglutinin adhesin]]
*[[Filopodia]]
*[[Flagellum]]
*[[Flapping counter-torque]]
*[[Flight feather]]
*[[Flying and gliding animals]]
*[[Focal adhesion]]
*[[Footspeed]]
*[[Force platform]]
*[[Francis Crick]]
*[[Frederic M. Richards]]
*[[Fritz-Albert Popp]]
*[[Frog battery]]
*[[Functional movement]]
*[[Functional spinal unit]]

==G==
*[[G. N. Ramachandran]]
*[[G12/G13 alpha subunits]]
*[[GABAA receptor]]
*[[GABRA2]]
*[[GABRA3]]
*[[GABRA4]]
*[[GABRA5]]
*[[GABRA6]]
*[[GABRB1]]
*[[GABRB2]]
*[[GABRB3]]
*[[GABRD]]
*[[GABRE]]
*[[GABRG1]]
*[[GABRG2]]
*[[GABRG3]]
*[[GABRP]]
*[[GABRQ]]
*[[GABRR1]]
*[[GABRR2]]
*[[GABRR3]]
*[[GHK flux equation]]
*[[GLRA2]]
*[[GLRA3]]
*[[GLRA4]]
*[[GLRB]]
*[[GLUT1]]
*[[GLUT8]]
*[[GPCR oligomer]]
*[[GRIA1]]
*[[GRIA2]]
*[[GRIA3]]
*[[GRIA4]]
*[[GRIK1]]
*[[GRIK2]]
*[[GRIK3]]
*[[GRIK4]]
*[[GRIK5]]
*[[GRIN1]]
*[[GRIN2A]]
*[[GRIN2B]]
*[[GRIN2C]]
*[[GRIN2D]]
*[[GRIN3A]]
*[[GRIN3B]]
*[[GRINL1A]]
*[[GRINL1B]]
*[[G protein]]
*[[G protein-coupled inwardly-rectifying potassium channel]]
*[[G protein-coupled receptor]]
*[[G protein-gated ion channel]]
*[[Gamma-aminobutyric acid receptor subunit alpha-1]]
*[[Ganglion type nicotinic receptor]]
*[[Gating (electrophysiology)]]
*[[Geoffrey West]]
*[[Georg von Békésy]]
*[[George Karreman]]
*[[George V. Lauder]]
*[[Gilbert Stead]]
*[[Gliding motility]]
*[[Glycerophospholipid]]
*[[Glycine receptor, alpha 1]]
*[[Glycophosphatidylinositol]]
*[[Godfrey Hounsfield]]
*[[Gopinath Kartha]]
*[[Gq alpha subunit]]
*[[Gray's paradox]]
*[[Ground reaction force]]
*[[Gs alpha subunit]]
*[[Gunther O. Hofmann]]

==H==
*[[HCN1]]
*[[HCN2]]
*[[HCN3]]
*[[HCN4]]
*[[HCN channel]]
*[[HERG]]
*[[HTR3A]]
*[[HTR3B]]
*[[HTR3C]]
*[[HTR3D]]
*[[HTR3E]]
*[[HVCN1]]
*[[Hal Anger]]
*[[Hans Frauenfelder]]
*[[Haptotaxis]]
*[[Harold J. Morowitz]]
*[[Harry F. Noller]]
*[[Henri Atlan]]
*[[Hermann Joseph Muller]]
*[[Hermann von Helmholtz]]
*[[Heterotrimeric G protein]]
*[[Hill's muscle model]]
*[[Hille equation]]
*[[Hodgkin cycle]]
*[[Hodgkin–Huxley model]]
*[[Homeoviscous adaptation]]
*[[Homologous desensitization]]
*[[Hopanoids]]
*[[Howard Berg]]
*[[Hugh Herr]]
*[[Human leg]]
*[[Human skeletal changes due to bipedalism]]
*[[Hydrophobic mismatch]]
*[[Hydrostatic skeleton]]
*[[Hyperpolarization (biology)]]

==I==
*[[ITPR1]]
*[[ITPR2]]
*[[ITPR3]]
*[[Iatrogenic hypocholesterolemia]]
*[[Ichiji Tasaki]]
*[[IgSF CAM]]
*[[Inner nuclear membrane|Inner membrane]]
*[[Inner mitochondrial membrane]]
*[[Insect wing]]
*[[Integral membrane protein]]
*[[Interbilayer forces in membrane fusion]]
*[[International Foot and Ankle Biomechanics Community (i-FAB)]]
*[[Intracellular membranes]]
*[[Invadopodia]]
*[[Inward-rectifier potassium ion channel]]
*[[Ion channel]]
*[[Ionotropic effect]]

==J==
*[[J. Murdoch Ritchie]]
*[[Jacques-Arsène d'Arsonval]]
*[[James D. Watson]]
*[[Jane S. Richardson]]
*[[Jeffry B. Skiba]]
*[[Jeremy C. Smith (scientist)]]
*[[Jerome Wolken]]
*[[Johan Paulsson]]
*[[John C. Taschner]]
*[[John Desmond Bernal]]
*[[John Heuser]]
*[[John Hopfield]]
*[[John Kendrew]]
*[[Journal of Applied Biomechanics]]
*[[Julia Goodfellow]]

==K==
*[[KCNA10]]
*[[KCNA2]]
*[[KCNA3]]
*[[KCNA4]]
*[[KCNA5]]
*[[KCNA6]]
*[[KCNA7]]
*[[KCNAB1]]
*[[KCNAB2]]
*[[KCNAB3]]
*[[KCNB1]]
*[[KCNB2]]
*[[KCNC1]]
*[[KCNC2]]
*[[KCNC3]]
*[[KCNC4]]
*[[KCND1]]
*[[KCNE1L]]
*[[KCNE2]]
*[[KCNE4]]
*[[KCNF1]]
*[[KCNG1]]
*[[KCNG2]]
*[[KCNG3]]
*[[KCNG4]]
*[[KCNH3]]
*[[KCNH4]]
*[[KCNH6]]
*[[KCNH7]]
*[[KCNH8]]
*[[KCNIP1]]
*[[KCNIP4]]
*[[KCNJ10]]
*[[KCNJ12]]
*[[KCNJ13]]
*[[KCNJ14]]
*[[KCNJ15]]
*[[KCNJ16]]
*[[KCNJ3]]
*[[KCNJ4]]
*[[KCNJ5]]
*[[KCNJ6]]
*[[KCNJ8]]
*[[KCNJ9]]
*[[KCNK1]]
*[[KCNK10]]
*[[KCNK12]]
*[[KCNK13]]
*[[KCNK15]]
*[[KCNK16]]
*[[KCNK17]]
*[[KCNK18]]
*[[KCNK2]]
*[[KCNK3]]
*[[KCNK4]]
*[[KCNK5]]
*[[KCNK6]]
*[[KCNK7]]
*[[KCNK9]]
*[[KCNMB1]]
*[[KCNMB2]]
*[[KCNMB3]]
*[[KCNMB4]]
*[[KCNN1]]
*[[KCNN2]]
*[[KCNN4]]
*[[KCNQ4]]
*[[KCNQ5]]
*[[KCNS1]]
*[[KCNS2]]
*[[KCNS3]]
*[[KCNT1]]
*[[KCNT2]]
*[[KCNV1]]
*[[KCNV2]]
*[[Kenneth Stewart Cole]]
*[[Kim Sung-Hou]]
*[[Kir2.1]]
*[[Kir2.6]]
*[[Kir6.2]]
*[[Kv1.1]]
*[[KvLQT1]]
*[[KvLQT2]]
*[[KvLQT3]]

==L==
*[[L-type calcium channel]]
*[[Lamellar structure]]
*[[Lamellipodium]]
*[[Lead (leg)]]
*[[Lecithin]]
*[[Lee Spetner]]
*[[Leslie Barnett]]
*[[Ligand-gated ion channel]]
*[[Light-gated ion channel]]
*[[Lignocellulosic biomass]]
*[[Limitations of animal running speed]]
*[[Linus Pauling]]
*[[Lipid-anchored protein]]
*[[Lipid bilayer]]
*[[Lipid bilayer characterization]]
*[[Lipid bilayer fusion]]
*[[Lipid bilayer mechanics]]
*[[Lipid bilayer phase behavior]]
*[[Lipid raft]]
*[[Liposome]]
*[[Liquid ordered phase]]
*[[List of biophysicists]]
*[[List of birds by flight speed]]
*[[List of jumping activities]]
*[[LocDB]]
*[[Locomotor activity]]
*[[Locomotor effects of shoes]]
*[[Luca Turin]]
*[[Lymphocyte homing receptor]]

==M==
*[[M1 protein]]
*[[M2 proton channel]]
*[[MHC class I]]
*[[Magnesium transporter]]
*[[Magnetoception]]
*[[Magnetosome]]
*[[Magnetospirillum]]
*[[Magnetotactic bacteria]]
*[[Magnetotaxis]]
*[[Manfred Eigen]]
*[[Marcelo Osvaldo Magnasco]]
*[[Marche a petit pas]]
*[[Mario Ageno]]
*[[Martin Gruebele]]
*[[Maurice Wilkins]]
*[[Max Delbrück]]
*[[Max Perutz]]
*[[Mechanics of human sexuality]]
*[[Mechanome]]
*[[Mechanosensitive channels]]
*[[Mechanotaxis]]
*[[Membrane biology]]
*[[Membrane channel]]
*[[Membrane contact site]]
*[[Membrane curvature]]
*[[Membrane fluidity]]
*[[Membrane lipids]]
*[[Membrane nanotube]]
*[[Membrane potential]]
*[[Membrane protein]]
*[[Membrane topology]]
*[[Membrane transport]]
*[[Membranome]]
*[[Mesaxon]]
*[[Mesosome]]
*[[Metachronal rhythm]]
*[[Methylhopane]]
*[[Microbial ecology]]
*[[Microbial fuel cell]]
*[[Microsome]]
*[[Model lipid bilayer]]
*[[Moens–Korteweg equation]]
*[[Mohammad-Nabi Sarbolouki]]
*[[Molecular motor]]
*[[Monoamine transporter]]
*[[Motility]]
*[[Motor protein]]
*[[Mucous membrane]]
*[[Mucous membrane of the soft palate]]
*[[Muscular hydrostat]]
*[[Muscular layer]]
*[[Muscularis mucosae]]
*[[Myelin-associated glycoprotein]]
*[[Myelin sheath gap]]
*[[Myofilament]]
*[[Mária Telkes]]

==N==
*[[N-Acetylgalactosamine]]
*[[N-Acetylglucosamine]]
*[[N-Acetylmuramic acid]]
*[[N-type calcium channel]]
*[[NMDA receptor]]
*[[Nanobiomechanics]]
*[[Nanodisc]]
*[[Nav1.1]]
*[[Nav1.2]]
*[[Nav1.4]]
*[[Nav1.5]]
*[[Nectin]]
*[[Neurophysins]]
*[[Nicolas Rashevsky]]
*[[Nicotinic acetylcholine receptor]]
*[[Niosome]]
*[[Norepinephrine transporter]]
*[[Nuclear pore]]

==O==
*[[Optical tweezers]]
*[[Oreste Piro]]
*[[Origin of avian flight]]
*[[Osmoregulation]]
*[[Osmotic pressure]]
*[[Outer mitochondrial membrane]]
*[[Outline of biophysics]]
*[[Overhead throwing motion]]

==P==
*[[P-type ATPase]]
*[[P-type calcium channel]]
*[[P2RX1]]
*[[P2RX2]]
*[[P2RX3]]
*[[P2RX4]]
*[[P2RX5]]
*[[P2RX6]]
*[[P2RX7]]
*[[P2X purinoreceptor]]
*[[P300-CBP coactivator family]]
*[[PF-4840154]]
*[[PKD1]]
*[[PSORT]]
*[[PSORTdb]]
*[[PTS1R]]
*[[Parkinsonian gait]]
*[[Passive transport]]
*[[Paul Lauterbur]]
*[[Paulien Hogeweg]]
*[[Peptide transporter 1]]
*[[Peptidoglycan]]
*[[Peroxisomal targeting signal]]
*[[Perylene]]
*[[Peter Mansfield]]
*[[Petr Paucek]]
*[[Phosphatidylethanolamine]]
*[[Phosphatidylglycerol]]
*[[Phosphatidylinositol]]
*[[Phosphatidylserine]]
*[[Physics of skiing]]
*[[Pink algae]]
*[[Plasma membrane monoamine transporter]]
*[[Plasmolysis]]
*[[Platelet-derived growth factor receptor]]
*[[Pleuroperitoneal]]
*[[Podosome]]
*[[Polar membrane]]
*[[Porosome]]
*[[Potassium channel]]
*[[Prenylation]]
*[[Preprohormone]]
*[[Pressure-volume curves]]
*[[Primary active transport]]
*[[Protein Analysis Subcellular Localization Prediction]]
*[[Protein targeting]]
*[[Protein–lipid interaction]]
*[[Protomer]]
*[[Protoplast]]
*[[Pseudopeptidoglycan]]
*[[Pseudopodia]]
*[[Pterygium]]

==Q==
*[[Q-type calcium channel]]

==R==
*[[R-type calcium channel]]
*[[ROMK]]
*[[RYR1]]
*[[RYR3]]
*[[Radial spoke]]
*[[Receptor (biochemistry)]]
*[[Reinhart Heinrich]]
*[[Reversal potential]]
*[[Richard Ernest Kronauer]]
*[[Robert Corey]]
*[[Robert G. Shulman]]
*[[Robert Haynes]]
*[[Robley C. Williams]]
*[[Roger Wartell]]
*[[Roland Benz]]
*[[Role of skin in locomotion]]
*[[Rosalind Franklin]]
*[[Rosalyn Sussman Yalow]]
*[[Rotating locomotion in living systems]]
*[[Rudolf Podgornik]]
*[[Ryanodine receptor 2]]

==S==
*[[S-layer]]
*[[SCN10A]]
*[[SCN1B]]
*[[SCN2B]]
*[[SCN3A]]
*[[SCN3B]]
*[[SCN4B]]
*[[SCN7A]]
*[[SCN8A]]
*[[SCNN1A]]
*[[SCNN1B]]
*[[SCNN1D]]
*[[SCNN1G]]
*[[SIGLEC]]
*[[SK3]]
*[[SK channel]]
*[[Saffman–Delbrück model]]
*[[Sammy Lee (scientist)]]
*[[Sarcolemma]]
*[[Sarcomere]]
*[[SecY protein]]
*[[Secondary active transport]]
*[[Secretory pathway]]
*[[Semipermeable membrane]]
*[[Sergei Kovalev]]
*[[Serotonin transporter]]
*[[Serous membrane]]
*[[Sessility (zoology)]]
*[[Shaker gene]]
*[[Sialoadhesin]]
*[[Sidney Altman]]
*[[Signal patch]]
*[[Signal peptide]]
*[[Signal peptide peptidase]]
*[[Signal recognition particle receptor]]
*[[Silent synapse]]
*[[Simon Shnoll]]
*[[Simtk-opensim]]
*[[SkQ]]
*[[Small-conductance mechanosensitive channel]]
*[[Sodium channel]]
*[[Soft tissue]]
*[[Soluble cell adhesion molecules]]
*[[Solute pumping]]
*[[Sorting and assembly machinery]]
*[[Sphingomyelin]]
*[[Spinal locomotion]]
*[[Sports biomechanics]]
*[[Steady state (biochemistry)]]
*[[Stephen D. Levene]]
*[[Stretch-activated ion channel]]
*[[Stroma (fluid)]]
*[[Structural biology]]
*[[Structural genomics]]
*[[Structure validation]]
*[[Stuart Kauffman]]
*[[Submucosa]]
*[[Subserosa]]
*[[Synthetic ion channels]]

==T==
*[[T-tubule]]
*[[T-type calcium channel]]
*[[TPCN1]]
*[[TPCN2]]
*[[TRPA (channel)]]
*[[TRPC]]
*[[TRPC1]]
*[[TRPC2]]
*[[TRPC3]]
*[[TRPC4AP]]
*[[TRPC5]]
*[[TRPC6]]
*[[TRPC7]]
*[[TRPM]]
*[[TRPM1]]
*[[TRPM2]]
*[[TRPM3]]
*[[TRPM4]]
*[[TRPM5]]
*[[TRPM6]]
*[[TRPM7]]
*[[TRPM8]]
*[[TRPML]]
*[[TRPN]]
*[[TRPP]]
*[[TRPP3]]
*[[TRPV]]
*[[TRPV1]]
*[[TRPV2]]
*[[TRPV3]]
*[[TRPV4]]
*[[TRPV5]]
*[[TRPV6]]
*[[Talin protein]]
*[[Tandem pore domain potassium channel]]
*[[Tatyana Sapunova]]
*[[Tetraspanin]]
*[[Theories of general anaesthetic action]]
*[[Thomas A. Steitz]]
*[[Thomas Gold]]
*[[Thylakoid]]
*[[Total internal reflection fluorescence microscope]]
*[[Tradeoffs for locomotion in air and water]]
*[[Transepithelial potential difference]]
*[[Transient receptor potential cation channel, member A1]]
*[[Transient receptor potential channel]]
*[[Transient receptor potential channel-interacting protein database]]
*[[Translocon]]
*[[Transmembrane channels]]
*[[Treadmilling]]
*[[Turgor pressure]]
*[[Twin-arginine translocation pathway]]
*[[Two-pore channel]]

==U==
*[[Undulatory locomotion]]
*[[Undulipodium]]

==V==
*[[VCAM-1]]
*[[VDAC1]]
*[[VDAC2]]
*[[VDAC3]]
*[[V formation]]
*[[Venkatraman Ramakrishnan]]
*[[Vertical clinging and leaping]]
*[[Vesicle (biology and chemistry)]]
*[[Vestibulo emotional reflex]]
*[[Voltage-dependent anion channel]]
*[[Voltage-dependent calcium channel]]
*[[Voltage-gated ion channel]]
*[[Voltage-gated potassium channel]]
*[[Voltage-gated potassium channel database]]
*[[Voltage-gated proton channel]]

==W==
*[[WALP peptide]]
*[[Walter Kauzmann]]
*[[Wayne Hendrickson]]
*[[WeNMR]]
*[[Whiffling]]
*[[Wing]]
*[[Womersley number]]
*[[Work loop]]

==X==
*[[X-ray crystallography]]
*[[Xiaowei Zhuang]]

==Y==
*[[Yadin Dudai]]

==Z==
*[[Zinc-activated ion channel]]
*[[Zinovii Shulman]]

[[Category:Biophysics|*]]
[[Category:Indexes of science articles|Biophysics]]</text>
      <sha1>pbjpelwau6r1zz1e18y3yi898lk5n65</sha1>
    </revision>
  </page>
  <page>
    <title>Index of logarithm articles</title>
    <ns>0</ns>
    <id>493259</id>
    <revision>
      <id>840913765</id>
      <parentid>795302281</parentid>
      <timestamp>2018-05-12T22:41:58Z</timestamp>
      <contributor>
        <username>Allforrous</username>
        <id>12120664</id>
      </contributor>
      <comment>new key for [[Category:Logarithms]]: "*" using [[WP:HC|HotCat]]</comment>
      <model>wikitext</model>
      <format>text/x-wiki</format>
      <text xml:space="preserve" bytes="2554">This is a '''list of [[logarithm]] topics''', by Wikipedia page. See also the [[list of exponential topics]].
* [[Acoustic power]]
* [[Antilogarithm]]
* [[Apparent magnitude]]
* [[Baker's theorem]]
* [[Bel (unit)|Bel]]
* [[Benford's law]]
* [[Binary logarithm]]
* [[Bode plot]]
* [[Henry Briggs (mathematician)|Henry Briggs]]
* [[Bygrave slide rule]]
* [[Cologarithm]]
* [[Common logarithm]]
* [[Complex logarithm]]
* [[Discrete logarithm]]
** [[Discrete logarithm records]]
* [[e (mathematical constant)|e]]
** [[Representations of e]]
* [[El Gamal discrete log cryptosystem]]
* [[Harmonic series (mathematics)|Harmonic series]]
* [[History of logarithms]]
* [[Hyperbolic sector]]
* [[Iterated logarithm]]
* [[Otis King]]
* [[Law of the iterated logarithm]]
* [[Linear form in logarithms]]
* [[Linearithmic]]
* [[List of integrals of logarithmic functions]]
* [[Logarithmic growth]]
* [[Logarithmic timeline]]
* [[Log-likelihood ratio]]
* [[Log-log|Log-log graph]]
* [[Log-normal distribution]]
* [[Log-periodic antenna]]
* [[Log-Weibull distribution]]
* [[Logarithmic algorithm]]
* [[Logarithmic convolution]]
* [[Logarithmic decrement]]
* [[Logarithmic derivative]]
* [[Logarithmic differential]]
* [[Logarithmic differentiation]]
* [[Logarithmic distribution]]
* [[Logarithmic form]]
* [[Logarithmic graph paper]]
* [[Logarithmic growth]]
* [[Logarithmic identities]]
* [[Logarithmic number system]]
* [[Logarithmic scale]]
* [[Logarithmic spiral]]
* [[Logarithmic timeline]]
* [[Logit]]
* [[LogSumExp]]
* ''[[Mantissa (disambiguation)|Mantissa]]'' is a disambiguation page; see [[common logarithm]] for the traditional concept of ''mantissa''; see [[significand]] for the modern concept used in computing.
* [[Matrix logarithm]]
* [[Mel scale]]
* [[Mercator projection]]
* [[Mercator series]]
* [[Moment magnitude scale]]
* [[John Napier]]
* [[Napierian logarithm]]
* [[Natural logarithm]]
** [[Natural logarithm of 2]]
* [[Neper]]
* [[Offset logarithmic integral]]
* [[pH]]
* [[Pollard's kangaroo algorithm]]
* [[Pollard's rho algorithm for logarithms]]
* [[Polylogarithm]]
* [[Polylogarithmic function]]
* [[Prime number theorem]]
* [[Richter magnitude scale]]
* [[Grégoire de Saint-Vincent]]
* [[Alphonse Antonio de Sarasa]]
* [[Schnorr signature]]
* [[Semi-log graph]]
* [[Significand]]
* [[Slide rule]]
* [[Smearing retransformation]]
* [[Sound intensity level]]
* [[Super-logarithm]]
* [[Table of logarithms]]
* [[Weber-Fechner law]]

[[Category:Exponentials]]
[[Category:Logarithms|*]]
[[Category:Mathematics-related lists|Logarithm topics]]</text>
      <sha1>ds6mnojj4uwtwkxh13vc1jw56r7r01f</sha1>
    </revision>
  </page>
  <page>
    <title>Interactome</title>
    <ns>0</ns>
    <id>1075046</id>
    <revision>
      <id>871218082</id>
      <parentid>868333448</parentid>
      <timestamp>2018-11-29T17:51:33Z</timestamp>
      <contributor>
        <username>CitationCleanerBot</username>
        <id>15270283</id>
      </contributor>
      <minor/>
      <comment>/* top */Various citation &amp; identifier cleanup, plus AWB genfixes (arxiv version pointless when published)</comment>
      <model>wikitext</model>
      <format>text/x-wiki</format>
      <text xml:space="preserve" bytes="61783">In [[molecular biology]], an '''interactome''' is the whole set of molecular interactions in a particular [[Cell (biology)|cell]]. The term specifically refers to physical interactions among molecules (such as those among proteins, also known as [[protein–protein interactions]], PPIs) but can also describe sets of indirect interactions among genes ([[genetic interactions]]). The interactomes based on PPIs should be associated to the [[proteome]] of the corresponding species in order to provide a global view ("omic") of all the possible molecular interactions that a protein can present.&lt;ref&gt;{{Cite journal|vauthors=Alonso-López D, Gutiérrez MA, Lopes KP, Prieto C, Santamaria R, De Las Rivas J |date=2016|title=APID interactomes: providing proteome-based interactomes with controlled quality for multiple species and derived networks|journal=Nucleic Acids Res.|volume=44|issue=W529–35|pages=W529–35|doi=10.1093/nar/gkw363|pmid=27131791|pmc=4987915}}&lt;/ref&gt;[[File:Network of how 100 of the 528 genes identified with significant differential expression relate to DISC1 and its core interactors.png|400px|right|thumb|Part of the [[DISC1]] interactome with genes represented by text in boxes and interactions noted by lines between the genes. From Hennah and Porteous, 2009.&lt;ref name="pmid19300510"&gt;{{cite journal |author=Hennah W, Porteous D |title=The DISC1 pathway modulates expression of neurodevelopmental, synaptogenic and sensory perception genes |journal=PLoS ONE |volume=4 |issue=3 |pages=e4906 |year=2009 |pmid=19300510 |pmc=2654149 |doi=10.1371/journal.pone.0004906 |url= |editor1-last=Reif |editor1-first=Andreas|bibcode=2009PLoSO...4.4906H }} {{open access}}&lt;/ref&gt;]]
The word "interactome" was originally coined in 1999 by a group of French scientists headed by Bernard Jacq.&lt;ref name="pmid9847149"&gt;{{cite journal |author=Sanchez C |title=Grasping at molecular interactions and genetic networks in Drosophila melanogaster using FlyNets, an Internet database |journal=Nucleic Acids Res. |volume=27 |issue=1 |pages=89–94 |date=January 1999 |pmid=9847149 |pmc=148104 |doi= 10.1093/nar/27.1.89|url=|name-list-format=vanc|author2= Lachaize C |author3= Janody F |display-authors=etal}}&lt;/ref&gt; Mathematically, interactomes are generally displayed as [[Graph (discrete mathematics)|graphs]]. Though interactomes may be described as [[biological network]]s, they should not be confused with other networks such as [[neural network]]s or [[food web]]s.

==Molecular interaction networks==
Molecular interactions can occur between molecules belonging to different biochemical families (proteins, nucleic acids, lipids, carbohydrates, etc.) and also within a given family. Whenever such molecules are connected by physical interactions, they form molecular interaction networks that are generally classified by the nature of the compounds involved. Most commonly, ''interactome'' refers to ''[[protein–protein interaction]]'' (PPI) network (PIN) or subsets thereof. For instance, the Sirt-1 protein interactome and Sirt family second order interactome&lt;ref&gt;{{cite journal|last=Sharma|first=Ankush |author2=Gautam VK |author3=Costantini S |author4=Paladino A |author5=Colonna G|title=Interactomic and pharmacological insights on human Sirt-1|journal=Front. Pharmacol.|date=Feb 2012|doi=10.3389/fphar.2012.00040|pmid=22470339|pmc=3311038|volume=3|pages=40}}&lt;/ref&gt;&lt;ref&gt;{{cite arxiv|last=Sharma|first=Ankush|author2=Costantini S |author3=Colonna G |title=The protein-protein interaction network of human Sirtuin family|date=March 2013|eprint=1302.6423v2|class=q-bio.MN}}&lt;/ref&gt; is the network involving Sirt-1 and its directly interacting proteins where as second order interactome illustrates interactions up to second order of neighbors (Neighbors of neighbors). Another extensively studied type of interactome is the protein–DNA interactome, also called a ''gene-regulatory network'', a network formed by transcription factors, chromatin regulatory proteins, and their target genes. Even ''[[metabolic network]]s'' can be considered as molecular interaction networks: metabolites, i.e. chemical compounds in a cell, are converted into each other by [[enzymes]], which have to bind their substrates physically.

In fact, all interactome types are interconnected. For instance, protein interactomes contain many enzymes which in turn form biochemical networks. Similarly, gene regulatory networks overlap substantially with protein interaction networks and signaling networks.

==Size==
[[File:Yeast interactome size estimate.png|400px|right|thumb|Estimates of the yeast protein interactome. From&lt;ref name="Uetz2005"&gt;Uetz P. &amp; Grigoriev A. (2005) The yeast interactome. In Jorde, L.B., Little, P.F.R., Dunn, M.J. and Subramaniam, S. (Eds), Encyclopedia of Genetics, Genomics, Proteomics and Bioinformatics. John Wiley &amp; Sons Ltd: Chichester, Volume 5, pp. 2033-2051&lt;/ref&gt;]]
It has been suggested that the size of an organism's interactome correlates better than [[genome]] size with the biological complexity of the organism.&lt;ref name="pmid18474861"&gt;{{cite journal |author=Stumpf MP |title=Estimating the size of the human interactome |journal=Proc. Natl. Acad. Sci. U.S.A. |volume=105 |issue=19 |pages=6959–64 |date=May 2008 |pmid=18474861 |pmc=2383957 |doi=10.1073/pnas.0708078105 |url=|name-list-format=vanc|author2= Thorne T |author3= de Silva E |display-authors=etal|bibcode=2008PNAS..105.6959S }}&lt;/ref&gt; Although protein–protein interaction maps containing several thousand binary interactions are now available for several species, none of them is presently complete and the size of interactomes is still a matter of debate.

===Yeast===
The yeast interactome, i.e. all protein–protein interactions among proteins of ''[[Saccharomyces cerevisiae]]'', has been estimated to contain between 10,000 and 30,000 interactions. A reasonable estimate may be on the order of 20,000 interactions. Larger estimates often include indirect or predicted interactions, often from [[affinity purification]]/[[mass spectrometry]] (AP/MS) studies.&lt;ref name=Uetz2005 /&gt;

==Genetic interaction networks==
Genes interact in the sense that they affect each other's function. For instance, a [[mutation]] may be harmless, but when it is combined with another mutation, the combination may turn out to be lethal. Such genes are said to "interact genetically". Genes that are connected in such a way form ''genetic interaction networks''. Some of the goals of these networks are: develop a functional map of a cell's processes, drug target identification, and to predict the function of uncharacterized genes.

In 2010, the most "complete" gene interactome produced to date was compiled from about 5.4 million two-gene comparisons to describe "the interaction profiles for ~75% of all genes in the [[budding yeast]]", with ~170,000 gene interactions. The genes were grouped based on similar function so as to build a functional map of the cell's processes. Using this method the study was able to predict known gene functions better than any other genome-scale data set as well as adding functional information for genes that hadn't been previously described. From this model genetic interactions can be observed at multiple scales which will assist in the study of concepts such as gene conservation. Some of the observations made from this study are that there were twice as many [[Epistasis and functional genomics|negative as positive interactions]], negative interactions were more informative than positive interactions, and genes with more connections were more likely to result in lethality when disrupted.&lt;ref name=yeast&gt;{{cite journal |doi=10.1126/science.1180823 |author=Costanzo M |title=The genetic landscape of a cell |journal=Science |date=2010-01-22 |volume=327 |issue=5964 |pages=425–431 |pmid=20093466|pmc=5600254 |name-list-format=vanc|author2= Baryshnikova A |author3= Bellay J |displayauthors=etal|bibcode=2010Sci...327..425C }}&lt;/ref&gt;

==Interactomics==
'''Interactomics''' is a discipline at the intersection of [[bioinformatics]] and [[biology]] that deals with studying both the interactions and the consequences of those interactions between and among [[protein]]s, and other molecules within a [[cell (biology)|cell]].&lt;ref name="Klemer"&gt;{{cite journal | last =Kiemer | first=L |author2=G Cesareni | year = 2007| title = Comparative interactomics: comparing apples and pears? | journal= Trends in Biotechnology | volume = 25 |pages = 448–454 | doi =10.1016/j.tibtech.2007.08.002 | pmid =17825444 | issue =10}}&lt;/ref&gt; Interactomics thus aims to compare such networks of interactions (i.e., interactomes) between and within species in order to find how the traits of such networks are either preserved or varied.

Interactomics is an example of "top-down" systems biology, which takes an overhead, as well as overall, view of a biosystem or organism. Large sets of genome-wide and proteomic data are collected, and correlations between different molecules are inferred. From the data new hypotheses are formulated about feedbacks between these molecules. These hypotheses can then be tested by new experiments.&lt;ref name="Bruggeman"&gt;{{cite journal | last =Bruggeman | first=F J |author2=H V Westerhoff| year = 2006| title = The nature of systems biology | journal= Trends in Microbiology | volume = 15 |pages = 45–50| doi = 10.1016/j.tim.2006.11.003 |pmid =17113776 | issue =1}}&lt;/ref&gt;

== Experimental methods to map interactomes ==
The study of interactomes is called interactomics. The basic unit of a protein network is the protein–protein interaction (PPI). While there are numerous methods to study PPIs, there are relatively few that have been used on a large scale to map whole interactomes.

The [[Two-hybrid screening|yeast two hybrid]] system (Y2H) is suited to explore the binary interactions among two proteins at a time. Affinity purification and subsequent mass spectrometry is suited to identify a protein complex. Both methods can be used in a high-throughput (HTP) fashion. Yeast two hybrid screens allow false positive interactions between proteins that are never expressed in the same time and place; affinity capture mass spectrometry does not have this drawback, and is the current gold standard. Yeast two-hybrid data better indicates non-specific tendencies towards sticky interactions rather while affinity capture mass spectrometry better indicates functional in vivo protein–protein interactions.&lt;ref&gt;{{cite journal|last=Brettner|first=Leandra M.|author2=Joanna Masel|title=Protein stickiness, rather than number of functional protein-protein interactions, predicts expression noise and plasticity in yeast|journal=BMC Systems Biology|year=2012|volume=6|pages=128|doi=10.1186/1752-0509-6-128|pmid=23017156|pmc=3527306}} {{open access}}&lt;/ref&gt;&lt;ref name="10.3389/fnmol.2014.00058"&gt;{{cite journal |last=Mukherjee |first=K |author2=Slawson |author3=Christmann |author4=Griffith |date=June 2014 |title=Neuron-specific protein interactions of Drosophila CASK-ß are revealed by mass spectrometry |journal=Front. Mol. Neurosci. |volume= 7|issue= |pages= 58| issn = | pmid =25071438|doi = 10.3389/fnmol.2014.00058 | bibcode = | oclc =| id = | language = | laysummary = | laysource = | laydate = | quote = | pmc=4075472}}&lt;/ref&gt;

== Computational methods to study interactomes ==
Once an interactome has been created, there are numerous ways to analyze its properties. However, there are two important goals of such analyses. First, scientists try to elucidate the systems properties of interactomes, e.g. the topology of its interactions. Second, studies may focus on individual proteins and their role in the network. Such analyses are mainly carried out using [[bioinformatics]] methods and include the following, among many others:

=== Validation ===
First, the coverage and quality of an interactome has to be evaluated. Interactomes are never complete, given the limitations of experimental methods. For instance, it has been estimated that typical [[Yeast two-hybrid|Y2H]] screens detect only 25% or so of all interactions in an interactome.&lt;ref name="Chen" /&gt; The coverage of an interactome can be assessed by comparing it to benchmarks of well-known interactions that have been found and validated by independent assays.&lt;ref name="Raja2009"&gt;{{Cite journal | last1 = Rajagopala | first1 = S. V. | last2 = Hughes | first2 = K. T. | last3 = Uetz | first3 = P. | doi = 10.1002/pmic.200900282 | title = Benchmarking yeast two-hybrid systems using the interactions of bacterial motility proteins | journal = Proteomics | volume = 9 | issue = 23 | pages = 5296–5302 | year = 2009 | pmid = 19834901 | pmc =2818629 }}&lt;/ref&gt; Other methods filter out false positives calculating the similarity of known annotations of the proteins involved or define a likelihood of interaction using the subcellular localization of these proteins.&lt;ref&gt;{{Cite journal | author = [[Yanay Ofran]], [[Guy Yachdav]], [[Eyal Mozes]], [[Ta-tsen Soong]], [[Rajesh Nair]] &amp; [[Burkhard Rost]] | title = Create and assess protein networks through molecular characteristics of individual proteins | journal = [[Bioinformatics (journal)|Bioinformatics]] | volume = 22 | issue = 14 | pages = e402–e407 | date = July 2006 | doi = 10.1093/bioinformatics/btl258 | pmid = 16873500 }}&lt;/ref&gt;

===Predicting PPIs===
[[File:Schziophrenia PPI.jpg|400px|right|thumb | Schziophrenia PPI.&lt;ref name="mkgNPJS"/&gt;]]
Using experimental data as a starting point, ''homology transfer'' is one way to predict interactomes. Here, PPIs from one organism are used to predict interactions among homologous proteins in another organism ("''interologs''"). However, this approach has certain limitations, primarily because the source data may not be reliable (e.g. contain false positives and false negatives).&lt;ref&gt;{{cite journal |vauthors=Mika S, Rost B |title=Protein–Protein Interactions More Conserved within Species than across Species|journal=PLoS Computational Biology|volume=2|issue=7|pages=e79|year=2006|pmid=16854211|pmc=1513270|doi=10.1371/journal.pcbi.0020079|bibcode=2006PLSCB...2...79M}}&lt;/ref&gt; In addition, proteins and their interactions change during evolution and thus may have been lost or gained. Nevertheless, numerous interactomes have been predicted, e.g. that of ''[[Bacillus licheniformis]]''.&lt;ref&gt;{{cite journal | last1 = Han | first1 = Y.-C. | display-authors = 1 | last2 = et al | year = 2016| title = Prediction and characterization of protein–protein interaction network in Bacillus licheniformis WX-02 | url = | journal = Sci. Rep. | volume = 6 | issue = | page = 19486 | doi = 10.1038/srep19486 | pmid = 26782814 | pmc = 4726086 | bibcode = 2016NatSR...619486H }}&lt;/ref&gt;

Some algorithms use experimental evidence on structural complexes, the atomic details of binding interfaces and produce detailed atomic models of protein–protein complexes&lt;ref&gt;{{cite journal |doi=10.1093/nar/gkp306 |vauthors=Kittichotirat W, Guerquin M, Bumgarner RE, Samudrala R |title=Protinfo PPC: A web server for atomic level prediction of protein complexes|journal=Nucleic Acids Research|volume=37 |issue=Web Server issue|pages=W519–W525|year=2009 |pmid=19420059 |pmc=2703994}}&lt;/ref&gt;&lt;ref&gt;{{cite journal | pmid = 22261719 | pmc=3296913 | doi=10.1038/embor.2011.261 | volume=13 | issue=3 | title=Large-scale mapping of human protein interactome using structural complexes | date=Mar 2012 | journal=EMBO Rep | pages=266–71| author1=Tyagi | first1=M | last2=Hashimoto | first2=K | last3=Shoemaker | first3=B. A. | last4=Wuchty | first4=S | last5=Panchenko | first5=A. R.}}&lt;/ref&gt; as well as other protein–molecule interactions.&lt;ref&gt;{{cite journal |doi=10.1093/nar/gki401 |vauthors=McDermott J, Guerquin M, Frazier Z, Chang AN, Samudrala R |title=BIOVERSE: Enhancements to the framework for structural, functional, and contextual annotations of proteins and proteomes|journal=Nucleic Acids Research|volume=33 |issue=Web Server issue|pages=W324–W325|year=2005 |pmid=15980482 |pmc=1160162}}&lt;/ref&gt;&lt;ref&gt;{{cite journal | pmid = 22102591 | pmc=3245142 | doi=10.1093/nar/gkr997 | volume=40 | issue=Database issue | title=IBIS (Inferred Biomolecular Interaction Server) reports, predicts and integrates multiple types of conserved interactions for proteins | date=Jan 2012 | journal=Nucleic Acids Res | pages=D834–40| author1=Shoemaker | first1=B. A. | last2=Zhang | first2=D | last3=Tyagi | first3=M | last4=Thangudu | first4=R. R. | last5=Fong | first5=J. H. | last6=Marchler-Bauer | first6=A | last7=Bryant | first7=S. H. | last8=Madej | first8=T | last9=Panchenko | first9=A. R.}} {{cite journal|doi=10.7554/eLife.03430|vauthors=Hopf TA, Schaerfe CP, Rodrigues JP, Green AG, Kohlbacher O, Sander C, Bonvin AM, Marks DS |title=Sequence co-evolution gives 3D contacts and structures of protein complexes|journal=eLife|volume=3|pages=e03430|year=2014|pmid= 25255213 |pmc=4360534}}&lt;/ref&gt; Other algorithms use only sequence information, thereby creating unbiased complete networks of interaction with many mistakes.&lt;ref&gt;{{cite journal|doi=10.1038/nmeth.3178|vauthors=Kotlyar M, Pastrello C, Pivetta F, Lo Sardo A, Cumbaa C, Li H, Naranian T, Niu Y, Ding Z, Vafaee F, Broackes-Carter F, Petschnigg J, Mills GB, Jurisicova A, Stagljar I, Maestro R, Jurisica I |title=In silico prediction of physical protein interactions and characterization of interactome orphans|journal=Nature Methods|volume=12|issue=1|pages=79–84|year=2015|pmid= 25402006 |pmc=}}
{{cite journal|doi=10.1093/bioinformatics/btv077|vauthors=Hamp T, Rost B |title=Evolutionary profiles improve protein-protein interaction prediction from sequence|journal=Bioinformatics|volume=31|issue=12|pages=1945–1950|year=2015|pmid= 25657331 |pmc=}}
{{cite journal|doi=10.1038/srep00239|vauthors=Pitre S, Hooshyar M, Schoenrock A, Samanfar B, Jessulat M, Green JR, Dehne F, Golshani A |title=Short Co-occurring Polypeptide Regions Can Predict Global Protein Interaction Maps|journal=Scientific Reports|volume=2|pages=239|year=2012|pmid= 22355752|pmc=3269044|bibcode=2012NatSR...2E.239P}}
{{cite journal|doi=10.1038/srep00239|vauthors=Pitre S, Hooshyar M, Schoenrock A, Samanfar B, Jessulat M, Green JR, Dehne F, Golshani A |title=Short co-occurring polypeptide regions can predict global protein interaction maps|journal=Scientific Reports|volume=2|pages=239|year=2012|pmid=22355752|pmc=3269044|bibcode=2012NatSR...2E.239P}}
&lt;/ref&gt;

Some methods use machine learning to distinguish how interacting protein pairs differ from non-interacting protein pairs in terms of pairwise features such as cellular colocalization, gene co-expression, how closely located on a DNA are the genes that encode the two proteins, and so on.&lt;ref name="mkgNPJS"&gt;{{cite journal | vauthors = Ganapathiraju MK, Thahir M, Handen A, Sarkar SN, Sweet RA, Nimgaonkar VL, Loscher CE, Bauer EM, Chaparala S| title = Schizophrenia interactome with 504 novel protein–protein interactions | journal = Npj Schizophrenia | volume = 2 | date = April 2016 | doi = 10.1038/npjschz.2016.12 | pmid = 27336055 | pmc = 4898894 | url = http://www.nature.com/articles/npjschz201612 | pages=16012}}&lt;/ref&gt;&lt;ref name="yqProteomics"&gt;{{cite journal | vauthors = Qi Y, Dhiman HK, Bhola N, Budyak I, Kar S, Man D, Dutta A, Tirupula K, Carr BI, Grandis J, Bar-Joseph Z, Klein-Seetharaman J | title = Systematic prediction of human membrane receptor interactions | journal = Proteomics | volume = 9 | issue = 23 | doi = 10.1002/pmic.200900259 | pmid = 19798668 | pmc = 3076061 | pages = 5243–55 | date = December 2009}}&lt;/ref&gt; [[Random Forest]] has been found to be most-effective machine learning method for protein interaction prediction.&lt;ref&gt;{{cite journal | vauthors = Qi Y, Bar-Joseph Z, Klein-Seetharaman J | title = Evaluation of different biological data and computational classification methods for use in protein interaction prediction | journal = Proteins | volume = 63 | issue = 3 | pages = 490–500 | date = May 2006 | doi=10.1002/prot.20865| pmid = 16450363 | pmc = 3250929}}&lt;/ref&gt; Such methods have been applied for discovering protein interactions on human interactome, specifically the interactome of [[Membrane proteins]]&lt;ref name="yqProteomics"/&gt; and the interactome of Schizophrenia-associated proteins.&lt;ref name="mkgNPJS"/&gt;

===Text mining of PPIs===
Some efforts have been made to extract systematically interaction networks directly from the scientific literature. Such approaches range in terms of complexity from simple co-occurrence statistics of entities that are mentioned together in the same context (e.g. sentence) to sophisticated natural language processing and machine learning methods for detecting interaction relationships.&lt;ref&gt;{{Cite journal | pmid = 15886388 | year = 2005 | author1 = Hoffmann | first1 = R | title = Text mining for metabolic pathways, signaling cascades, and protein networks | journal = Science Signaling | volume = 2005 | issue = 283 | pages = pe21 | last2 = Krallinger | first2 = M | last3 = Andres | first3 = E | last4 = Tamames | first4 = J | last5 = Blaschke | first5 = C | last6 = Valencia | first6 = A | doi = 10.1126/stke.2832005pe21 }}&lt;/ref&gt;

===Protein function prediction===
Protein interaction networks have been used to predict the function of proteins of unknown functions.&lt;ref name="Schwikowski2000"&gt;{{Cite journal | last1 = Schwikowski | first1 = B. | last2 = Uetz | first2 = P. | last3 = Fields | first3 = S. | title = A network of protein-protein interactions in yeast | journal = Nature Biotechnology | volume = 18 | issue = 12 | pages = 1257–1261 | year = 2000 | doi = 10.1038/82360 | pmid = 11101803 | pmc = }}&lt;/ref&gt;&lt;ref name="McDermottJ2005"&gt;{{cite journal |doi=10.1093/bioinformatics/bti514 |vauthors=McDermott J, Bumgarner RE, Samudrala R |title=Functional annotation from predicted protein interaction networks|journal=Bioinformatics|volume=21 |issue=15|pages=3217–3226|year=2005|pmid=15919725}}&lt;/ref&gt; This is usually based on the assumption that uncharacterized proteins have similar functions as their interacting proteins (''guilt by association''). For example, YbeB, a protein of unknown function was found to interact with ribosomal proteins and later shown to be involved in [[Prokaryotic translation|translation]].&lt;ref name="YbeB"&gt;{{Cite journal | last1 = Rajagopala | first1 = S. V. | last2 = Sikorski | first2 = P. | last3 = Caufield | first3 = J. H. | last4 = Tovchigrechko | first4 = A. | last5 = Uetz | first5 = P. | title = Studying protein complexes by the yeast two-hybrid system | doi = 10.1016/j.ymeth.2012.07.015 | journal = Methods | volume = 58 | issue = 4 | pages = 392–399 | year = 2012 | pmid = 22841565 | pmc =3517932 }}&lt;/ref&gt; Although such predictions may be based on single interactions, usually several interactions are found. Thus, the whole network of interactions can be used to predict protein functions, given that certain functions are usually enriched among the interactors.&lt;ref name="Schwikowski2000"/&gt;

===Perturbations and disease===
{{main|Network medicine}}
The ''[[topology]]'' of an interactome makes certain predictions how a network reacts to the '''perturbation''' (e.g. removal) of nodes (proteins) or edges (interactions).&lt;ref name="networkbio"&gt;{{Cite journal| first1 = A. -L. | first2 = Z. | title = Network biology: understanding the cell's functional organization | last1 = Barab | journal = Nature Reviews Genetics | volume = 5 | issue = 2 | pages = 101–113 | year = 2004 | pmid = 14735121 | doi = 10.1038/nrg1272 | last2 = Oltvai }}&lt;/ref&gt; Such perturbations can be caused by [[mutations]] of genes, and thus their proteins, and a network reaction can manifest as a [[disease]].&lt;ref name="disnetwork"&gt;{{Cite journal | last1 = Goh | first1 = K. -I. | last2 = Choi | first2 = I. -G. | doi = 10.1093/bfgp/els032 | title = Exploring the human diseasome: The human disease network | journal = Briefings in Functional Genomics | volume = 11 | issue = 6 | pages = 533–542 | year = 2012 | pmid = 23063808 | pmc = }}&lt;/ref&gt; A network analysis can identify [[drug target]]s and [[biomarker]]s of diseases.&lt;ref name="Barabasi"&gt;{{Cite journal | pmid = 21164525 | pmc = 3140052 | year = 2011 | author1 = Barabási | first1 = A. L. | title = Network medicine: A network-based approach to human disease | journal = Nature Reviews Genetics | volume = 12 | issue = 1 | pages = 56–68 | last2 = Gulbahce | first2 = N | last3 = Loscalzo | first3 = J | doi = 10.1038/nrg2918 }}&lt;/ref&gt;

===Network structure and topology===
Interaction networks can be analyzed using the tools of [[graph theory]]. Network properties include the [[Degree (graph theory)|degree]] distribution, [[clustering coefficient]]s, [[betweenness centrality]], and many others. The distribution of properties among the proteins of an interactome has revealed that the interactome networks often have [[Scale-free network|scale-free topology]]&lt;ref&gt;{{Cite journal | author = [[Albert-Laszlo Barabasi]] &amp; [[Zoltan N. Oltvai]] | title = Network biology: understanding the cell's functional organization | journal = [[Nature Reviews. Genetics]] | volume = 5 | issue = 2 | pages = 101–113 | date = February 2004 | doi = 10.1038/nrg1272 | pmid = 14735121 }}&lt;/ref&gt; where '''functional modules''' within a network indicate specialized subnetworks.&lt;ref name="modules"&gt;{{Cite journal | doi = 10.1142/S0219720009004023 | last1 = Gao | first1 = L. | last2 = Sun | first2 = P. G. | last3 = Song | first3 = J. | title = Clustering algorithms for detecting functional modules in protein interaction networks | journal = Journal of Bioinformatics and Computational Biology | volume = 7 | issue = 1 | pages = 217–242 | year = 2009 | pmid = 19226668
}}&lt;/ref&gt; Such modules can be functional, as in a [[signaling pathway]], or structural, as in a protein complex. In fact, it is a formidable task to identify protein complexes in an interactome, given that a network on its own does not directly reveal the presence of a stable complex.

==Studied interactomes==

===Viral interactomes===
Viral protein interactomes consist of interactions among viral or phage proteins. They were among the first interactome projects as their genomes are small and all proteins can be analyzed with limited resources. Viral interactomes are connected to their host interactomes, forming virus-host interaction networks.&lt;ref&gt;{{cite journal |author=Navratil V.|title=VirHostNet: a knowledge base for the management and the analysis of proteome-wide virus-host interaction networks|journal=Nucleic Acids Res.|volume=37 |pages=D661–8|year=2009 |pmid= 18984613 |doi=10.1093/nar/gkn794 |last2=De Chassey |first2=B. |last3=Meyniel |first3=L. |last4=Delmotte |first4=S. |last5=Gautier |first5=C. |last6=Andre |first6=P. |last7=Lotteau |first7=V. |last8=Rabourdin-Combe |first8=C. |issue=Database issue |pmc=2686459|displayauthors=1}}&lt;/ref&gt; Some published virus interactomes include

'''Bacteriophage'''
* ''[[Escherichia coli]]'' [[Lambda phage|bacteriophage lambda]]&lt;ref&gt;{{cite journal |author=Rajagopala SV.|title=The protein interaction map of bacteriophage lambda|journal= BMC Microbiol.|volume=11 |pages=213|year=2011 |pmid= 21943085 |doi=10.1186/1471-2180-11-213 |pmc=3224144 |last2=Casjens |first2=Sherwood |last3=Uetz |first3=Peter|displayauthors=1}} {{open access}}&lt;/ref&gt;
* ''[[Escherichia coli]]'' [[T7 phage|bacteriophage T7]]&lt;ref name="pmid8528255"&gt;{{cite journal |vauthors=Bartel PL, Roecklein JA, SenGupta D, Fields S |title=A protein linkage map of Escherichia coli bacteriophage T7 |journal=Nat. Genet. |volume=12 |issue=1 |pages=72–7 |year=1996 |pmid=8528255 |doi=10.1038/ng0196-72 |url=}}&lt;/ref&gt;
* ''[[Streptococcus pneumoniae]]'' bacteriophage Dp-1&lt;ref&gt;{{cite journal |author=Sabri M.|title=Genome annotation and intraviral interactome for the ''Streptococcus pneumoniae'' virulent phage Dp-1|journal=J. Bacteriol.|volume=193 |pages=551–62|year=2011 |pmid= 21097633 |doi=10.1128/JB.01117-10 |pmc=3019816 |issue=2 |last2=Hauser |first2=R. |last3=Ouellette |first3=M. |last4=Liu |first4=J. |last5=Dehbi |first5=M. |last6=Moeck |first6=G. |last7=Garcia |first7=E. |last8=Titz |first8=B. |last9=Uetz |first9=P.|displayauthors=1}}&lt;/ref&gt;
* ''[[Streptococcus pneumoniae]]'' bacteriophage Cp-1&lt;ref&gt;{{cite journal |author=Häuser R.|title=The proteome and interactome of ''Streptococcus pneumoniae'' phage Cp-1|journal=J. Bacteriol.|volume=193 |pages=3135–8|year=2011 |pmid= 21515781 |doi=10.1128/JB.01481-10 |pmc=3133188 |issue=12 |last2=Sabri |first2=M. |last3=Moineau |first3=S. |last4=Uetz |first4=P.|displayauthors=1}}&lt;/ref&gt;

The lambda and VZV interactomes are not only relevant for the biology of these viruses but also for technical reasons: they were the first interactomes that were mapped with multiple [[Y2H]] vectors, proving an improved strategy to investigate interactomes more completely than previous attempts have shown.

'''Human (mammalian) viruses'''
* Human [[varicella zoster virus]] (VZV)&lt;ref&gt;{{cite journal|last=Stellberger|first=T.|display-authors=etal|title=Improving the yeast two-hybrid system with permutated fusions proteins: the Varicella Zoster Virus interactome|journal=Proteome Sci.|year=2010|pmid=20205919|doi=10.1186/1477-5956-8-8|pmc=2832230|volume=8|pages=8}}&lt;/ref&gt;
* [[Chandipura virus]]&lt;ref name="Chandipura"&gt;{{Citejournal | last1 = Kumar | first1 = K. | last2 = Rana | first2 = J. | last3 = Sreejith | first3 = R. | last4 = Gabrani | first4 = R. | last5 = Sharma | first5 = S. K. | last6 = Gupta | first6 = A. | last7 = Chaudhary | first7 = V. K. | last8 = Gupta | first8 = S. | doi = 10.1007/s00705-012-1389-5 | title = Intraviral protein interactions of Chandipura virus | journal = Archives of Virology | volume = 157 | issue = 10 | pages = 1949–1957 | year = 2012 | pmid = 22763614 | pmc = }}&lt;/ref&gt;
* [[Epstein-Barr virus]] (EBV)&lt;ref name="Fossum 2009 e1000570" /&gt;
* [[Hepatitis C virus]] (HPC),&lt;ref name="Hagen2014"&gt;{{Cite journal | pmid = 24797426 | year = 2014 | author1 = Hagen | first1 = N | title = The intra viral protein interaction network of hepatitis C virus | journal = Molecular &amp; Cellular Proteomics | last2 = Bayer | first2 = K | last3 = Roesch | first3 = K | last4 = Schindler | first4 = M | doi = 10.1074/mcp.M113.036301 | volume=13 | issue=7 | pages=1676–89 | pmc = 4083108 }}&lt;/ref&gt; Human-HCV interactions&lt;ref&gt;{{cite journal | last1 = Han | first1 = Y | last2 = Niu | first2 = J | last3 = Wang | first3 = D | last4 = Li | first4 = Y | year = 2016 | title = Hepatitis C Virus Protein Interaction Network Analysis Based on Hepatocellular Carcinoma | url = | journal = PLoS ONE | volume = 11 | issue = 4| page = e0153882 | doi = 10.1371/journal.pone.0153882| pmid = 27115606 | pmc = 4846009 | bibcode = 2016PLoSO..1153882H }}&lt;/ref&gt;
* [[Hepatitis E virus]] (HEV)&lt;ref name="pmid26463011"&gt;{{cite journal |vauthors=Osterman A, Stellberger T, Gebhardt A, Kurz M, Friedel CC, Uetz P, Nitschko H, Baiker A, Vizoso-Pinto MG |title=The Hepatitis E virus intraviral interactome |journal=Sci Rep |volume=5 |issue= |pages=13872 |year=2015 |pmid=26463011 |pmc=4604457 |doi=10.1038/srep13872 |url=|bibcode=2015NatSR...513872O }}&lt;/ref&gt;
* [[Herpes simplex virus 1]] (HSV-1)&lt;ref name="Fossum 2009 e1000570" /&gt;
* [[Kaposi's sarcoma-associated herpesvirus]] (KSHV)&lt;ref name="Fossum 2009 e1000570"&gt;{{cite journal|last=Fossum|first=E|display-authors=etal|title=Evolutionarily conserved herpesviral protein interaction networks|journal=PLoS Pathog |year=2009|pmid=19730696|doi=10.1371/journal.ppat.1000570|pmc=2731838|volume=5|issue=9|pages=e1000570|editor1-last=Sun|editor1-first=Ren}} {{open access}}&lt;/ref&gt;
* Murine [[cytomegalovirus]] (mCMV)&lt;ref name="Fossum 2009 e1000570" /&gt;

===Bacterial interactomes===
Relatively few bacteria have been comprehensively studied for their protein–protein interactions. However, none of these interactomes are complete in the sense that they captured all interactions. In fact, it has been estimated that none of them covers more than 20% or 30% of all interactions, primarily because most of these studies have only employed a single method, all of which discover only a subset of interactions.&lt;ref name="Chen"&gt;{{Cite journal
| last1 = Chen | first1 = Y. C.
| last2 = Rajagopala | first2 = S. V.
| last3 = Stellberger | first3 = T.
| last4 = Uetz | first4 = P.
| title = Exhaustive benchmarking of the yeast two-hybrid system
| doi = 10.1038/nmeth0910-667
| journal = Nature Methods
| volume = 7
| issue = 9
| pages = 667–668; author 668 668
| year = 2010
| pmid = 20805792
| pmc =
}}&lt;/ref&gt; Among the published bacterial interactomes (including partial ones) are

{| class="wikitable sortable"
| align="center" style="background:#f0f0f0;"|'''Species'''
| align="center" style="background:#f0f0f0;"|'''proteins total'''
| align="center" style="background:#f0f0f0;"|'''interactions'''
| align="center" style="background:#f0f0f0;"|'''type'''
| align="center" style="background:#f0f0f0;"|'''reference'''
|-
| ''[[Helicobacter pylori]]'' ||1,553||~3,004||Y2H||&lt;ref name="Rain"&gt;{{Citejournal | last1 = Rain | first1 = J. C. | last2 = Selig | first2 = L. | last3 = De Reuse | first3 = H. | last4 = Battaglia | first4 = V. R. | last5 = Reverdy | first5 = C. L. | last6 = Simon | first6 = S. P. | last7 = Lenzen | first7 = G. | last8 = Petel | first8 = F. | last9 = Wojcik | first9 = J. R. M. | last10 = Schächter | first10 = V. | last11 = Chemama | first11 = Y. | last12 = Labigne | first12 = A. S. | last13 = Legrain | first13 = P. | title = The protein-protein interaction map of Helicobacter pylori | journal = Nature | volume = 409 | issue = 6817 | pages = 211–215 | doi = 10.1038/35051615 | year = 2001 | pmid = 11196647 | pmc =
}}&lt;/ref&gt;&lt;ref name="Häuser2014"&gt;{{Cite journal | pmid = 24627523 | year = 2014 | author1 = Häuser | first1 = R | title = A Second-generation Protein-Protein Interaction Network of Helicobacter pylori | journal = Molecular &amp; Cellular Proteomics | last2 = Ceol | first2 = A | last3 = Rajagopala | first3 = S. V. | last4 = Mosca | first4 = R | last5 = Siszler | first5 = G | last6 = Wermke | first6 = N | last7 = Sikorski | first7 = P | last8 = Schwarz | first8 = F | last9 = Schick | first9 = M | last10 = Wuchty | first10 = S | last11 = Aloy | first11 = P | last12 = Uetz | first12 = P | doi = 10.1074/mcp.O113.033571 | volume=13 | issue=5 | pages=1318–29 | pmc = 4014287 }}&lt;/ref&gt;
|-
| ''[[Campylobacter jejuni]]''||1,623||11,687||Y2H||&lt;ref&gt;{{cite journal|last=Parrish|first=JR|display-authors=etal|title=A proteome-wide protein interaction map for Campylobacter jejuni|journal=Genome Biol|year=2007|pmid=17615063|doi=10.1186/gb-2007-8-7-r130|pmc=2323224|volume=8|issue=7|pages=R130}}&lt;/ref&gt;
|-
| ''[[Treponema pallidum]]'' ||1,040||3,649||Y2H||&lt;ref name="Titz2008"&gt;{{Cite journal | last1 = Rajagopala | first1 = S. V. | last2 = Titz | first2 = B. R. | last3 = Goll | first3 = J. | last4 = Häuser | first4 = R. | last5 = McKevitt | first5 = M. T. | last6 = Palzkill | first6 = T. | last7 = Uetz | first7 = P. | editor1-last = Hall | editor1-first = Neil | title = The Binary Protein Interactome of Treponema pallidum – the Syphilis Spirochete | doi = 10.1371/journal.pone.0002292 | journal = PLoS ONE | volume = 3 | issue = 5 | pages = e2292 | year = 2008 | pmid = 18509523 | pmc =2386257 | bibcode = 2008PLoSO...3.2292T }}&lt;/ref&gt;
|-
| ''[[Escherichia coli]]'' ||4,288||(5,993)||AP/MS||&lt;ref&gt;{{cite journal|last=Hu|first=P|display-authors=etal|title=Global functional atlas of Escherichia coli encompassing previously uncharacterized proteins|journal=PLoS Biol |year=2009|pmid=19402753|doi=10.1371/journal.pbio.1000096|pmc=2672614|volume=7|issue=4|pages=e96|editor1-last=Levchenko|editor1-first=Andre}} {{open access}}&lt;/ref&gt;
|-
| ''[[Escherichia coli]]'' || 4,288 ||2,234||Y2H||&lt;ref name="Rajagopala2014"&gt;{{Cite journal | pmid = 24561554 | year = 2014 | author1 = Rajagopala | first1 = S. V. | title = The binary protein-protein interaction landscape of Escherichia coli | journal = Nature Biotechnology | last2 = Sikorski | first2 = P | last3 = Kumar | first3 = A | last4 = Mosca | first4 = R | last5 = Vlasblom | first5 = J | last6 = Arnold | first6 = R | last7 = Franca-Koh | first7 = J | last8 = Pakala | first8 = S. B. | last9 = Phanse | first9 = S | last10 = Ceol | first10 = A | last11 = Häuser | first11 = R | last12 = Siszler | first12 = G | last13 = Wuchty | first13 = S | last14 = Emili | first14 = A | last15 = Babu | first15 = M | last16 = Aloy | first16 = P | last17 = Pieper | first17 = R | last18 = Uetz | first18 = P | doi = 10.1038/nbt.2831 | volume=32 | issue=3 | pages=285–90 | pmc=4123855 }}&lt;/ref&gt;
|-
| ''[[Mesorhizobium loti]]'' ||6,752||3,121||Y2H||&lt;ref name="Mloti"&gt;{{Cite journal | last1 = Shimoda | first1 = Y. | last2 = Shinpo | first2 = S. | last3 = Kohara | first3 = M. | last4 = Nakamura | first4 = Y. | last5 = Tabata | first5 = S. | last6 = Sato | first6 = S. | doi = 10.1093/dnares/dsm028 | title = A Large Scale Analysis of Protein-Protein Interactions in the Nitrogen-fixing Bacterium Mesorhizobium loti | journal = DNA Research | volume = 15 | issue = 1 | pages = 13–23 | year = 2008 | pmid = 18192278 | pmc =2650630 }}&lt;/ref&gt;
|-
| ''[[Mycobacterium tuberculosis]]'' ||3,959||&gt;8000||B2H||&lt;ref name="Mtub"&gt;{{Citejournal | last1 = Wang | first1 = Y. | last2 = Cui | first2 = T. | last3 = Zhang | first3 = C. | last4 = Yang | first4 = M. | last5 = Huang | first5 = Y. | last6 = Li | first6 = W. | last7 = Zhang | first7 = L. | last8 = Gao | first8 = C. | last9 = He | first9 = Y. | last10 = Li | doi = 10.1021/pr100808n | first10 = Y. | last11 = Huang | first11 = F. | last12 = Zeng | first12 = J. | last13 = Huang | first13 = C. | last14 = Yang | first14 = Q. | last15 = Tian | first15 = Y. | last16 = Zhao | first16 = C. | last17 = Chen | first17 = H. | last18 = Zhang | first18 = H. | last19 = He | first19 = Z. G. | title = Global Protein−Protein Interaction Network in the Human PathogenMycobacterium tuberculosisH37Rv | journal = Journal of Proteome Research | volume = 9 | issue = 12 | pages = 6665–6677 | year = 2010 | pmid = 20973567 | pmc = }}&lt;/ref&gt;
|-
| ''[[Mycoplasma genitalium]]'' ||482||||AP/MS||&lt;ref name="Myco"&gt;{{Cite journal | last1 = Kuhner | first1 = S. | last2 = Van Noort | first2 = V. | last3 = Betts | first3 = M. J. | last4 = Leo-Macias | first4 = A. | last5 = Batisse | first5 = C. | last6 = Rode | first6 = M. | last7 = Yamada | first7 = T. | last8 = Maier | first8 = T. | last9 = Bader | first9 = S. | doi = 10.1126/science.1176343 | last10 = Beltran-Alvarez | first10 = P. | last11 = Castaño-Diez | first11 = D. | last12 = Chen | first12 = W. -H. | last13 = Devos | first13 = D. | last14 = Güell | first14 = M. | last15 = Norambuena | first15 = T. | last16 = Racke | first16 = I. | last17 = Rybin | first17 = V. | last18 = Schmidt | first18 = A. | last19 = Yus | first19 = E. | last20 = Aebersold | first20 = R. | last21 = Herrmann | first21 = R. | last22 = Böttcher | first22 = B. | last23 = Frangakis | first23 = A. S. | last24 = Russell | first24 = R. B. | last25 = Serrano | first25 = L. | last26 = Bork | first26 = P. | last27 = Gavin | first27 = A. -C. | title = Proteome Organization in a Genome-Reduced Bacterium | journal = Science | volume = 326 | issue = 5957 | pages = 1235–1240 | year = 2009 | pmid = 19965468 | pmc = | bibcode = 2009Sci...326.1235K }}&lt;/ref&gt;
|-
| ''[[Synechocystis]]'' sp. PCC6803 ||3,264||3,236||Y2H||&lt;ref name="Sato"&gt;{{Cite journal | last1 = Sato | first1 = S. | last2 = Shimoda | first2 = Y. | last3 = Muraki | first3 = A. | last4 = Kohara | first4 = M. | last5 = Nakamura | first5 = Y. | last6 = Tabata | first6 = S. | doi = 10.1093/dnares/dsm021 | title = A Large-scale Protein protein Interaction Analysis in Synechocystis sp. PCC6803 | journal = DNA Research | volume = 14 | issue = 5 | pages = 207–216 | year = 2007 | pmid = 18000013 | pmc =2779905 }}&lt;/ref&gt;
|-
| ''[[Staphylococcus aureus]]'' (MRSA) ||2,656||13,219||AP/MS||&lt;ref name="Cherkasov"&gt;{{Cite journal | pmid = 21166474 | year = 2011 | author1 = Cherkasov | first1 = A | title = Mapping the protein interaction network in methicillin-resistant Staphylococcus aureus | journal = Journal of Proteome Research | volume = 10 | issue = 3 | pages = 1139–50 | last2 = Hsing | first2 = M | last3 = Zoraghi | first3 = R | last4 = Foster | first4 = L. J. | last5 = See | first5 = R. H. | last6 = Stoynov | first6 = N | last7 = Jiang | first7 = J | last8 = Kaur | first8 = S | last9 = Lian | first9 = T | last10 = Jackson | first10 = L | last11 = Gong | first11 = H | last12 = Swayze | first12 = R | last13 = Amandoron | first13 = E | last14 = Hormozdiari | first14 = F | last15 = Dao | first15 = P | last16 = Sahinalp | first16 = C | last17 = Santos-Filho | first17 = O | last18 = Axerio-Cilies | first18 = P | last19 = Byler | first19 = K | last20 = McMaster | first20 = W. R. | last21 = Brunham | first21 = R. C. | last22 = Finlay | first22 = B. B. | last23 = Reiner | first23 = N. E. | doi = 10.1021/pr100918u }}&lt;/ref&gt;
|}

The ''E. coli'' and ''Mycoplasma'' interactomes have been analyzed using large-scale protein complex affinity purification and mass spectrometry (AP/MS), hence it is not easily possible to infer direct interactions. The others have used extensive [[yeast two-hybrid]] (Y2H) screens. The ''Mycobacterium tuberculosis'' interactome has been analyzed using a [[bacterial two-hybrid screen]] (B2H).

Note that numerous additional interactomes have been predicted using computational methods (see section above).

===Eukaryotic interactomes===
There have been several efforts to map eukaryotic interactomes through HTP methods. While no biological interactomes have been fully characterized, over 90% of proteins in ''Saccharomyces cerevisiae'' have been screened and their interactions characterized, making it the best-characterized interactome.&lt;ref name="Schwikowski2000"/&gt;&lt;ref name="Uetz2000"&gt;{{Cite journal | last1 = Uetz | first1 = P. | last2 = Giot | first2 = L. | last3 = Cagney | first3 = G. | last4 = Mansfield | first4 = T. A. | last5 = Judson | first5 = R. S. | last6 = Knight | first6 = J. R. | last7 = Lockshon | first7 = D. | last8 = Narayan | first8 = V. | title = A comprehensive analysis of protein-protein interactions in Saccharomyces cerevisiae | journal = Nature | volume = 403 | issue = 6770 | pages = 623–627 | doi = 10.1038/35001009 | year = 2000 | pmid = 10688190 | pmc = }}&lt;/ref&gt;&lt;ref&gt;{{cite journal |last =Krogan |first= NJ |display-authors=etal | year=2006|title = Global landscape of protein complexes in the yeast ''Saccharomyeses Cerivisiae ''| journal = Nature| volume= 440 |pages = 637–643|doi = 10.1038/nature04670 |pmid =16554755|issue =7084|bibcode=2006Natur.440..637K}}&lt;/ref&gt; Species whose interactomes have been studied in some detail include 
* ''[[Schizosaccharomyces pombe]]''&lt;ref name="pmid22540037"&gt;{{cite journal |vauthors=Pancaldi V, Saraç OS, Rallis C, McLean JR, Převorovský M, Gould K, Beyer A, Bähler J |title=Predicting the fission yeast protein interaction network |journal=G3: Genes, Genomes, Genetics |volume=2 |issue=4 |pages=453–67 |year=2012 |pmid=22540037 |pmc=3337474 |doi=10.1534/g3.111.001560 |url=}}&lt;/ref&gt;&lt;ref&gt;{{cite journal | last1 = Vo | first1 = T.V. | display-authors = etal |year = 2016 | title = A Proteome-wide Fission Yeast Interactome Reveals Network Evolution Principles from Yeasts to Human | url = http://www.sciencedirect.com/science/article/pii/S0092867415015561 | journal = Cell | volume = 164 | issue = 1–2| pages = 310–323 | doi = 10.1016/j.cell.2015.11.037 | pmid = 26771498 | pmc = 4715267}}&lt;/ref&gt;
* ''[[Caenorhabditis elegans]]''
* ''[[Drosophila melanogaster]]''
* ''Homo sapiens''
Recently, the pathogen-host interactomes of Hepatitis C Virus/Human (2008),&lt;ref name="hcv"&gt;{{cite journal |author=de Chassey B |title=Hepatitis C virus infection protein network |journal=Molecular Systems Biology |date=2008-11-04 |volume=4 |issue= 4 |page=230 |pmid=18985028 |pmc=2600670 |doi=10.1038/msb.2008.66|name-list-format=vanc|author2= Navratil V |author3= Tafforeau L |display-authors=etal}}&lt;/ref&gt; Epstein Barr virus/Human (2008), Influenza virus/Human (2009) were delineated through HTP to identify essential molecular components for pathogens and for their host's immune system.&lt;ref name="vin"&gt;{{cite journal |author=Navratil V |title=Systems-level comparison of protein–protein interactions between viruses and the human type I interferon system network|journal=Journal of Proteome Research |volume=9 |issue=7 |pages=3527–36 |date=2010-11-05|pmid=20459142 |doi=10.1021/pr100326j|name-list-format=vanc|author2= de Chassey B|display-authors=etal}}&lt;/ref&gt;

=== Predicted interactomes ===
As described above, PPIs and thus whole interactomes can be predicted. While the reliability of these predictions is debatable, they are providing hypotheses that can be tested experimentally. Interactomes have been predicted for a number of species, e.g.
* Human (''[[Homo sapiens]]'')&lt;ref name="pmid15657099"&gt;{{cite journal |vauthors=Brown KR, Jurisica I |title=Online predicted human interaction database |journal=Bioinformatics |volume=21 |issue=9 |pages=2076–82 |year=2005 |pmid=15657099 |doi=10.1093/bioinformatics/bti273 |url=}}&lt;/ref&gt;
* Rice (''[[Oryza sativa]]'')&lt;ref name="pmid21575196"&gt;{{cite journal |vauthors=Gu H, Zhu P, Jiao Y, Meng Y, Chen M |title=PRIN: a predicted rice interactome network |journal=BMC Bioinformatics |volume=12 |issue= |pages=161 |year=2011 |pmid=21575196 |pmc=3118165 |doi=10.1186/1471-2105-12-161 |url=}}&lt;/ref&gt;
* ''[[Xanthomonas oryzae]]''&lt;ref name="pmid24113387"&gt;{{cite journal |vauthors=Guo J, Li H, Chang JW, Lei Y, Li S, Chen LL |title=Prediction and characterization of protein-protein interaction network in Xanthomonas oryzae pv. oryzae PXO99 A |journal=Res. Microbiol. |volume=164 |issue=10 |pages=1035–44 |year=2013 |pmid=24113387 |doi=10.1016/j.resmic.2013.09.001 |url=}}&lt;/ref&gt;
* ''[[Arabidopsis thaliana]]''&lt;ref name="pmid17675552"&gt;{{cite journal |vauthors=Geisler-Lee J, O'Toole N, Ammar R, Provart NJ, Millar AH, Geisler M |title=A predicted interactome for Arabidopsis |journal=Plant Physiol. |volume=145 |issue=2 |pages=317–29 |year=2007 |pmid=17675552 |pmc=2048726 |doi=10.1104/pp.107.103465 |url=}}&lt;/ref&gt;
* [[Tomato]]&lt;ref&gt;{{Cite journal|last=Yue|first=Junyang|last2=Xu|first2=Wei|last3=Ban|first3=Rongjun|last4=Huang|first4=Shengxiong|last5=Miao|first5=Min|last6=Tang|first6=Xiaofeng|last7=Liu|first7=Guoqing|last8=Liu|first8=Yongsheng|date=2016-01-01|title=PTIR: Predicted Tomato Interactome Resource|journal=Scientific Reports|volume=6|pages=25047|doi=10.1038/srep25047|issn=2045-2322|pmid=27121261|pmc=4848565|bibcode=2016NatSR...625047Y}}&lt;/ref&gt;
* ''[[Brassica rapa]]''&lt;ref&gt;{{Cite journal|last=Yang|first=Jianhua|last2=Osman|first2=Kim|last3=Iqbal|first3=Mudassar|last4=Stekel|first4=Dov J.|last5=Luo|first5=Zewei|last6=Armstrong|first6=Susan J.|last7=Franklin|first7=F. Chris H.|date=2012-01-01|title=Inferring the Brassica rapa Interactome Using Protein-Protein Interaction Data from Arabidopsis thaliana|journal=Frontiers in Plant Science|volume=3|pages=297|doi=10.3389/fpls.2012.00297|issn=1664-462X|pmc=3537189|pmid=23293649}}&lt;/ref&gt; 
* ''Maize, corn ([[Maize|Zea mays]])''&lt;ref&gt;{{Cite journal|last=Zhu|first=Guanghui|last2=Wu|first2=Aibo|last3=Xu|first3=Xin-Jian|last4=Xiao|first4=Pei-Pei|last5=Lu|first5=Le|last6=Liu|first6=Jingdong|last7=Cao|first7=Yongwei|last8=Chen|first8=Luonan|last9=Wu|first9=Jun|date=2016-02-01|title=PPIM: A Protein-Protein Interaction Database for Maize|journal=Plant Physiology|volume=170|issue=2|pages=618–626|doi=10.1104/pp.15.01821|issn=1532-2548|pmc=4734591|pmid=26620522}}&lt;/ref&gt;
* ''[[Populus trichocarpa]]''&lt;ref&gt;{{Cite journal|last=Rodgers-Melnick|first=Eli|last2=Culp|first2=Mark|last3=DiFazio|first3=Stephen P.|date=2013-01-01|title=Predicting whole genome protein interaction networks from primary sequence data in model and non-model organisms using ENTS|journal=BMC Genomics|volume=14|pages=608|doi=10.1186/1471-2164-14-608|issn=1471-2164|pmc=3848842|pmid=24015873}}&lt;/ref&gt;

== Network properties ==
Protein interaction networks can be analyzed with the same tool as other networks. In fact, they share many properties with biological or [[social networks]]. Some of the main characteristics are as follows.

[[File:The protein interaction network of Treponema pallidum.png|300px|right|thumb|The ''[[Treponema pallidum]]'' protein interactome.&lt;ref name="Titz2008"/&gt;]]

===Degree distribution===
The degree distribution describes the number of proteins that have a certain number of connections. Most protein interaction networks show a [[Scale-free network|scale-free]] ([[power law]]) degree distribution where the connectivity distribution P(k) ~ k&lt;sup&gt;−γ&lt;/sup&gt; with k being the degree. This relationship can also be seen as a straight line on a [[log-log plot]] since, the above equation is equal to log(P(k)) ~ —y•log(k). One characteristic of such distributions is that there are many proteins with few interactions and few proteins that have many interactions, the latter being called "hubs".

===Hubs===
Highly connected nodes (proteins) are called hubs. Han et al.&lt;ref name="Han2004"&gt;{{Cite journal | pmid = 15190252 | year = 2004 | author1 = Han | first1 = J. D. | title = Evidence for dynamically organized modularity in the yeast protein-protein interaction network | journal = Nature | volume = 430 | issue = 6995 | pages = 88–93 | last2 = Bertin | first2 = N | last3 = Hao | first3 = T | last4 = Goldberg | first4 = D. S. | last5 = Berriz | first5 = G. F. | last6 = Zhang | first6 = L. V. | last7 = Dupuy | first7 = D | last8 = Walhout | first8 = A. J. | last9 = Cusick | first9 = M. E. | last10 = Roth | first10 = F. P. | last11 = Vidal | first11 = M | doi = 10.1038/nature02555 | bibcode = 2004Natur.430...88H }}&lt;/ref&gt; have coined the term "'''party hub'''" for hubs whose expression is correlated with its interaction partners. Party hubs also connect proteins within functional modules such as protein complexes. In contrast, "'''date hubs'''" do not exhibit such a correlation and appear to connect different functional modules. Party hubs are found predominantly in AP/MS data sets, whereas date hubs are found predominantly in binary interactome network maps.&lt;ref name="Yu2008"&gt;{{Cite journal | pmid = 18719252 | year = 2008 | author1 = Yu | first1 = H | title = High-quality binary protein interaction map of the yeast interactome network | journal = Science | volume = 322 | issue = 5898 | pages = 104–10 | last2 = Braun | first2 = P | last3 = Yildirim | first3 = M. A. | last4 = Lemmens | first4 = I | last5 = Venkatesan | first5 = K | last6 = Sahalie | first6 = J | last7 = Hirozane-Kishikawa | first7 = T | last8 = Gebreab | first8 = F | last9 = Li | first9 = N | last10 = Simonis | first10 = N | last11 = Hao | first11 = T | last12 = Rual | first12 = J. F. | last13 = Dricot | first13 = A | last14 = Vazquez | first14 = A | last15 = Murray | first15 = R. R. | last16 = Simon | first16 = C | last17 = Tardivo | first17 = L | last18 = Tam | first18 = S | last19 = Svrzikapa | first19 = N | last20 = Fan | first20 = C | last21 = De Smet | first21 = A. S. | last22 = Motyl | first22 = A | last23 = Hudson | first23 = M. E. | last24 = Park | first24 = J | last25 = Xin | first25 = X | last26 = Cusick | first26 = M. E. | last27 = Moore | first27 = T | last28 = Boone | first28 = C | last29 = Snyder | first29 = M | last30 = Roth | first30 = F. P. | doi = 10.1126/science.1158684 | pmc = 2746753 | bibcode = 2008Sci...322..104Y }}&lt;/ref&gt; Note that the validity of the date hub/party hub distinction was disputed.&lt;ref name="Batada2006"&gt;{{Cite journal | pmid = 16984220 | year = 2006 | author1 = Batada | first1 = N. N. | title = Stratus not altocumulus: A new view of the yeast protein interaction network | journal = PLoS Biology | volume = 4 | issue = 10 | pages = e317 | last2 = Reguly | first2 = T | last3 = Breitkreutz | first3 = A | last4 = Boucher | first4 = L | last5 = Breitkreutz | first5 = B. J. | last6 = Hurst | first6 = L. D. | last7 = Tyers | first7 = M | doi = 10.1371/journal.pbio.0040317 | pmc = 1569888 }}&lt;/ref&gt;&lt;ref name="Bertin2007"&gt;{{Cite journal | pmid = 17564493 | year = 2007 | author1 = Bertin | first1 = N | title = Confirmation of organized modularity in the yeast interactome | journal = PLoS Biology | volume = 5 | issue = 6 | pages = e153 | last2 = Simonis | first2 = N | last3 = Dupuy | first3 = D | last4 = Cusick | first4 = M. E. | last5 = Han | first5 = J. D. | last6 = Fraser | first6 = H. B. | last7 = Roth | first7 = F. P. | last8 = Vidal | first8 = M | doi = 10.1371/journal.pbio.0050153 | pmc = 1892830 }}&lt;/ref&gt; Party hubs generally consist of multi-interface proteins whereas date hubs are more frequently single-interaction interface proteins.&lt;ref name="Kim2006"&gt;{{Cite journal | pmid = 17185604 | year = 2006 | author1 = Kim | first1 = P. M. | title = Relating three-dimensional structures to protein networks provides evolutionary insights | journal = Science | volume = 314 | issue = 5807 | pages = 1938–41 | last2 = Lu | first2 = L. J. | last3 = Xia | first3 = Y | last4 = Gerstein | first4 = M. B. | doi = 10.1126/science.1136174
| bibcode = 2006Sci...314.1938K }}&lt;/ref&gt; Consistent with a role for date-hubs in connecting different processes, in yeast the number of binary interactions of a given protein is correlated to the number of phenotypes observed for the corresponding mutant gene in different physiological conditions.&lt;ref name="Yu2008" /&gt;

===Modules===
Nodes involved in the same biochemical process are highly interconnected.&lt;ref name="Barabasi"/&gt;

==Evolution==
The evolution of interactome complexity is delineated in a study published in ''Nature''.&lt;ref name="ArielFernandez2011"&gt;{{cite journal | last =Fernandez | first=A |author2=M Lynch| year = 2011| title = Non-adaptive origins of interactome complexity | journal= Nature | volume = 474 |pages = 502–505| doi = 10.1038/nature09992 |pmid =21593762 | issue=7352 | pmc=3121905}}&lt;/ref&gt; In this study it is first noted that the boundaries between [[prokaryotes]], unicellular [[eukaryotes]] and multicellular eukaryotes are accompanied by orders-of-magnitude reductions in effective population size, with concurrent amplifications of the effects of [[random genetic drift]]. The resultant decline in the efficiency of selection seems to be sufficient to influence a wide range of attributes at the genomic level in a nonadaptive manner. The Nature study shows that the variation in the power of random genetic drift is also capable of influencing phylogenetic diversity at the subcellular and cellular levels. Thus, population size would have to be considered as a potential determinant of the mechanistic pathways underlying long-term phenotypic evolution. In the study it is further shown that a phylogenetically broad inverse relation exists between the power of drift and the structural integrity of protein subunits. Thus, the accumulation of mildly deleterious mutations in populations of small size induces secondary selection for [[protein–protein interactions]] that stabilize key gene functions, mitigating the structural degradation promoted by inefficient selection. By this means, the complex protein architectures and interactions essential to the genesis of phenotypic diversity may initially emerge by non-adaptive mechanisms.

== Criticisms, challenges, and responses ==
{{Original research|section|date=August 2015}}
Kiemer and Cesareni&lt;ref name="Klemer"/&gt; raise the following concerns with the state (circa 2007) of the field especially with the comparative interactomic: The experimental procedures associated with the field are error prone leading to "noisy results". This leads to 30% of all reported interactions being artifacts. In fact, two groups using the same techniques on the same organism found less than 30% interactions in common. However, some authors have argued that such non-reproducibility results from the extraordinary sensitivity of various methods to small experimental variation. For instance, identical conditions in Y2H assays result in very different interactions when different Y2H vectors are used.&lt;ref name="Chen" /&gt;

Techniques may be biased, i.e. the technique determines which interactions are found. In fact, any method has built in biases, especially protein methods. Because every protein is different no method can capture the properties of each protein. For instance, most analytical methods that work fine with soluble proteins deal poorly with membrane proteins. This is also true for Y2H and AP/MS technologies.

Interactomes are not nearly complete with perhaps the exception of ''S. cerevisiae.'' This is not really a criticism as any scientific area is "incomplete" initially until the methodologies have been improved. Interactomics in 2015 is where genome sequencing was in the late 1990s, given that only a few interactome datasets are available (see table above).

While genomes are stable, interactomes may vary between tissues, cell types, and developmental stages. Again, this is not a criticism, but rather a description of the challenges in the field.

It is difficult to match evolutionarily related proteins in distantly related species. While homologous DNA sequences can be found relatively easily, it is much more difficult to predict homologous interactions ("interologs") because the homologs of two interacting proteins do not need to interact. For instance, even within a proteome two proteins may interact but their paralogs may not.

Each protein–protein interactome may represent only a partial sample of potential interactions, even when a supposedly definitive version is published in a scientific journal. Additional factors may have roles in protein interactions that have yet to be incorporated in interactomes. The binding strength of the various protein interactors, microenvironmental factors, sensitivity to various procedures, and the physiological state of the cell all impact protein–protein interactions, yet are usually not accounted for in interactome studies.&lt;ref&gt;{{cite journal|last1=Welch|first1=G. Rickey|title=The 'fuzzy' interactome|journal=Trends in Biochemical Sciences|date=January 2009|volume=34|issue=1|pages=1–2|doi=10.1016/j.tibs.2008.10.007|pmid=19028099}}&lt;/ref&gt;

==See also==
* [[Bioinformatics]], [[Omics]], [[Proteomics]], [[Genomics]]
* [[Biological network]]s
* [[Network medicine]]
* [[Glossary of graph theory]]
* [[Human interactome]]
* [[Interaction network]]
* [[Protein-protein interactions]]
* [[Metabolic network]]
* [[Metabolic network modelling]]
* [[Metabolic pathway]]
* [[Mathematical biology]]
* [[Systems biology]]
* [[Connectome]]
* [[List of omics topics in biology]]
* [[BioPlex]]

==References==
{{Reflist|30em}}

==Further reading==
* {{cite journal | pmid = 20589078 | pmc = 2891586 | doi=10.1371/journal.pcbi.1000807 | volume=6 | issue=6 | journal = PLOS Computational Biology |date=June 2010 | title = Protein–Protein Interactions Essentials: Key Concepts to Building and Analyzing Interactome Networks |pages=e1000807 | author=De Las Rivas J, Fontanillo C | editor1-last = Lewitter | editor1-first = Fran| bibcode=2010PLSCB...6E0807D }} {{open access}}.
* {{cite journal | doi = 10.1006/jmbi.2001.4526 |vauthors=Park J, Lappe M, Teichmann SA |date=Mar 2001 | title = Mapping protein family interactions: intramolecular and intermolecular protein family interaction repertoires in the PDB and yeast | url = | journal = J Mol Biol | volume = 307 | issue = 3| pages = 929–38 | pmid = 11273711}}

==External links==

===Interactome web servers===
* [https://web.archive.org/web/20111004173202/http://protinfo.compbio.washington.edu/ppc/ Protinfo PPC] predicts the atomic 3D structure of protein protein complexes.{{cite journal |vauthors=Kittichotirat W, Guerquin M, Bumgarner R, Samudrala R |title=Protinfo PPC: A web server for atomic level prediction of protein complexes|journal=Nucleic Acids Research|volume=37|pages=W519–W525|year=2009|doi=10.1093/nar/gkp306|pmid=19420059|pmc=2703994 |issue=Web Server issue}}
* [[IBIS (server)]] reports, predicts and integrates multiple types of conserved interactions for proteins.

=== Interactome visualization tools ===
* [http://gpsprot.org GPS-Prot] Web-based data visualization for protein interactions
* PINV - [http://biosual.cbio.uct.ac.za/pinv.html Protein Interaction Network Visualizer]

===Interactome databases===
* [http://www.thebiogrid.org/ BioGRID] database
* [https://archive.is/20121228183041/http://bioverse.compbio.washington.edu/ Bioverse] database
* [http://mentha.uniroma2.it mentha] the interactome browser {{cite journal | last1 = Calderone | display-authors = 1 | last2 = et al | year = 2013 | title = mentha: a resource for browsing integrated protein-interaction networks | url = http://www.nature.com/nmeth/journal/v10/n8/full/nmeth.2561.html | journal = Nature Methods | volume = 10 | issue = 8| pages = 690–691 | doi = 10.1038/nmeth.2561 | pmid =  23900247}}
* [http://www.ebi.ac.uk/intact IntAct: The Molecular Interaction Database]
* [http://interactome.org Interactome.org] — a dedicated interactome web site.
* [http://apid.dep.usal.es APID] Agile Protein Interactomes Dataserver&lt;ref&gt;{{Cite journal|last=Alonso-López|first=Diego|last2=Gutiérrez|first2=Miguel A.|last3=Lopes|first3=Katia P.|last4=Prieto|first4=Carlos|last5=Santamaría|first5=Rodrigo|last6=De Las Rivas|first6=Javier|date=2016-04-30|title=APID interactomes: providing proteome-based interactomes with controlled quality for multiple species and derived networks|url=http://nar.oxfordjournals.org/content/early/2016/04/30/nar.gkw363|journal=Nucleic Acids Research|volume=44|issue=W1|language=en|pages=W529–35|doi=10.1093/nar/gkw363|issn=0305-1048|pmid=27131791|pmc=4987915}}&lt;/ref&gt;

[[Category:Bioinformatics]]
[[Category:Molecular biology]]
[[Category:Systems biology]]</text>
      <sha1>23kokcery6ae2ya99pu753nzdvkmu07</sha1>
    </revision>
  </page>
  <page>
    <title>Johann Gottlieb Georgi</title>
    <ns>0</ns>
    <id>737905</id>
    <revision>
      <id>823999207</id>
      <parentid>807671733</parentid>
      <timestamp>2018-02-04T18:50:12Z</timestamp>
      <contributor>
        <username>Trey314159</username>
        <id>1818005</id>
      </contributor>
      <minor/>
      <comment>fix homoglyphs: convert Cyrillic characters in Fal[с]k to Latin</comment>
      <model>wikitext</model>
      <format>text/x-wiki</format>
      <text xml:space="preserve" bytes="3285">[[Image:Georgi Johann Gottlied 1729–1802.jpg|thumb|180px|right|Johann Gottlieb Georgi.]]
'''Johann Gottlieb Georgi''' (31 December 1729 – 27 October 1802) was a [[Germany|German]] [[botanist]], [[naturalist]] and [[geographer]].

A native of [[Province of Pomerania (1653–1815)|Pomerania]], Georgi accompanied both [[Johan Peter Falk]] and [[Peter Simon Pallas]] on their respective journeys through [[Siberia]]. During 1770-1774 he travelled on its behalf to [[Astrakhan]], the [[Urals]], [[Bashkortostan|Bashkir]], the [[Barabinsk]] [[steppe]], the Kolyvanskoe silver mines (to assess the ore content), [[Altai Mountains|Altai]], [[Tomsk]], [[Irkutsk]], [[Lake Baikal|Baikal]], and Dauren. In 1783 he became an academician of the [[Russian Academy of Sciences]] in [[St Petersburg]].&lt;ref name=kukersite&gt;
{{Cite journal
 | last1 = Aaloe | first1 = Aasa
 | last2 = Bauert | first2 = Heikki
 | last3 = Soesoo | first3 = Alvar
 | title = Kukersite oil shale
 | publisher = MTÜ GEOGuide Baltoscandia
 | year = 2007
 | location = Tallinn
 | isbn = 978-9985-9834-2-3
 | page = 29
 | url= http://www.gi.ee/geoturism/KukerOilShale_ENG_062011_100dpiS.pdf
 | format = PDF
 | accessdate =2013-03-16}}
&lt;/ref&gt;

Georgi was particularly interested in the Baikal region.  Based on collections from far eastern Russia, in his 1775 publication ''Bemerkungen einer Reise im Russischen Reich im Jahre 1772'', Georgi provided the first botanical descriptions of many of the region's flowering plants, among them the ''Baikal Scullcap'' (S. baicalensis.) Many of these plants and herbs were later collected by European botanists in [[China]], and thereafter became rare specimens in European botanical gardens.&lt;ref&gt;Foster, S., C. X. Yue; Herbal Emissaries: Bringing Chinese Herbs to the West, Rochester, Vt: Healing Arts Press, 1992.&lt;/ref&gt;

After his fellow botanist and travelling companion Falk took his own life in 1774, Georgi edited his notes which were published in Germany in 1785 as ''Beyträge zur topgraphischen Kentniss des russischen Reichs I.III''.

In 1790, Georgi's German work of the description and urban plans of the city of [[St. Petersburg]] was published. It appeared in a second edition in [[Riga]] in 1793, and was finally translated into Russian a year later. His ''Geographisch-physikalische und Naturhistor. Beschreibung des Russ. Reiches'', a nine volume edition of the geography and natural history of the [[Russian Empire]], was published in [[Königsberg]], Germany during 1797 - 1802.

{{botanist|Georgi}}

==Literature==
* Vera Shirokova, Alexey Sobisevich, 'Illustrations from Academic Expeditions in Russia: The works of Falck and Georgi', iLINNAEUS | iMagazine | iStories (December 2015) https://www.ikfoundation.org/ilinnaeus/istories/verashirokova.php

== References ==
{{reflist}}

{{Authority control}}

{{DEFAULTSORT:Georgi, Johann Gottlieb}}
[[Category:1729 births]]
[[Category:1802 deaths]]
[[Category:German chemists]]
[[Category:German geographers]]
[[Category:Imperial Russian geographers]]
[[Category:Imperial Russian explorers]]
[[Category:German ornithologists]]
[[Category:Full Members of the St Petersburg Academy of Sciences]]
[[Category:People from the Province of Pomerania]]


{{Germany-chemist-stub}}
{{geoscience-bio-stub}}
{{Geographer-stub}}</text>
      <sha1>addgns59a3krfgozqb52al5ie5nivlu</sha1>
    </revision>
  </page>
  <page>
    <title>Juan José Giambiagi</title>
    <ns>0</ns>
    <id>8648100</id>
    <revision>
      <id>710052319</id>
      <parentid>704129734</parentid>
      <timestamp>2016-03-14T17:54:16Z</timestamp>
      <contributor>
        <username>KasparBot</username>
        <id>24420788</id>
      </contributor>
      <comment>migrating [[Wikipedia:Persondata|Persondata]] to Wikidata, [[toollabs:kasparbot/persondata/|please help]], see [[toollabs:kasparbot/persondata/challenge.php/article/Juan José Giambiagi|challenges for this article]]</comment>
      <model>wikitext</model>
      <format>text/x-wiki</format>
      <text xml:space="preserve" bytes="892">{{Infobox person
|image =
|image_size = 300px
|birth_date = {{Birth date|1924|6|18|df=y}}
|birth_place = 
|death_date= {{death date and age|df=yes|1996|1|8|1924|6|18}}
|death_place= 
|nationality = Argentine
|known_for = 
|alma_mater = 
|spouse = 
|children = 
|parents = 
|awards = [[Premio México de Ciencia y Tecnología]] (1990)
|footnotes =
}}
'''Juan José Giambiagi''' (18 June 1924 &amp;ndash; 8 January 1996) was an [[Argentina|Argentinian]] [[physicist]] and co-discoverer of the [[dimensional regularization]].

==References==
*[http://portal.ictp.it/icts/facilities/lecture_rooms/AGH/giambiagi/giambiagi_biography Biography of Juan José Giambiagi]

{{Authority control}}
{{DEFAULTSORT:Giambiagi, Juan Jose}}
[[Category:Recipients of the National Order of Scientific Merit (Brazil)]]
[[Category:1924 births]]
[[Category:1996 deaths]]


{{argentina-scientist-stub}}
{{physicist-stub}}</text>
      <sha1>sf2xj8czdjj9um8mymjixbh7eklwbry</sha1>
    </revision>
  </page>
  <page>
    <title>Karl Grobben</title>
    <ns>0</ns>
    <id>3697442</id>
    <revision>
      <id>813854352</id>
      <parentid>748087597</parentid>
      <timestamp>2017-12-05T16:08:20Z</timestamp>
      <contributor>
        <username>InternetArchiveBot</username>
        <id>27015025</id>
      </contributor>
      <comment>Rescuing 1 sources and tagging 0 as dead. #IABot (v1.6.1) ([[User:Balon Greyjoy|Balon Greyjoy]])</comment>
      <model>wikitext</model>
      <format>text/x-wiki</format>
      <text xml:space="preserve" bytes="2660">'''Karl Grobben''' (August 27, 1854, [[Brno]] – April 13, 1945, [[Salzburg]]) was an [[Austria]]n [[biologist]].&lt;ref name="Uschmann"&gt;{{cite book |url=http://daten.digitale-sammlungen.de/bsb00016325/image_117 |chapter=Grobben, Karl |author=Georg Uschmann |page=101 |series=Neue Deutsche Biographie |title=Sibenter Band. Grassauer – Hartmann |year=1966 |publisher=Duncker &amp; Humblot |language=German}}&lt;/ref&gt; He graduated from, and later worked at, the [[University of Vienna]], chiefly on [[Mollusca|molluscs]] and [[crustacean]]s. He was also the editor of a new edition of [[Carl Friedrich Wilhelm Claus]]' ''Lehrbuch der Zoologie'', and the coiner of the terms ''[[protostome]]'' and ''[[deuterostome]]''.&lt;ref name="Uschmann"/&gt;

==Taxonomy==
Taxa named by Grobben include:
*[[Eumalacostraca]] &lt;small&gt;Grobben, 1892&lt;/small&gt;
*[[Sagittidae]] &lt;small&gt;Claus &amp; Grobben, 1905&lt;/small&gt;
*[[Sagittoidea]] &lt;small&gt;Claus &amp; Grobben, 1905&lt;/small&gt;
*[[Protostome|Protostomia]] &lt;small&gt;Grobben, 1908&lt;/small&gt;
*[[Deuterostome|Deuterostomia]] &lt;small&gt;Grobben, 1908&lt;/small&gt;

Taxa named in Grobben's honour include:
*''[[Gerbillus grobbeni]]'' &lt;small&gt;Klaptocz, 1909&lt;/small&gt;&lt;ref&gt;{{cite book |title=The Eponym Dictionary of Mammals |author=Bo Beolens, Michael Watkins &amp; Michael Grayson |year=2009 |publisher=[[Johns Hopkins University Press]] |isbn=978-0-8018-9304-9 |chapter=Grobben |page=169 |url=https://books.google.com/books?id=I-kSmWLc6vYC&amp;pg=PA169}}&lt;/ref&gt;
*''[[Sphaerophthalmus grobbeni]]'' &lt;small&gt;Spandl, 1923&lt;/small&gt;&lt;ref name="BEMON"&gt;{{cite web |url=http://test.b-neat.org/bemon/?page=petymol.g.html |title=Karl Grobben |work=Biographical Etymology of Marine Organism Names |author=Hans G. Hanssen |publisher=Baltic and North East Atlantic Taxa |accessdate=April 4, 2011 |deadurl=yes |archiveurl=https://web.archive.org/web/20110830171345/http://test.b-neat.org/bemon/?page=petymol.g.html |archivedate=August 30, 2011 |df= }}&lt;/ref&gt;
*''[[Limnadia grobbeni]]'' &lt;small&gt;Daday, 1925&lt;/small&gt;&lt;ref name="BEMON"/&gt;
*''[[Actinia grobbeni]]'' &lt;small&gt;Watzl, 1922&lt;/small&gt;&lt;ref name="BEMON"/&gt;
*''[[Paladilhiopsis grobbeni]]'' &lt;small&gt;Kuscer, 1928&lt;/small&gt;&lt;ref name="BEMON"/&gt;
*''[[Raillietina grobbeni]]'' &lt;small&gt;Böhm, 1925&lt;/small&gt;&lt;ref name="BEMON"/&gt;
*''[[Trypanophis grobbeni]]'' &lt;small&gt;(Poche, 1904)&lt;/small&gt;&lt;ref name="BEMON"/&gt;

==References==
{{reflist}}

{{Authority control}}
{{DEFAULTSORT:Grobben, Karl}}
[[Category:1854 births]]
[[Category:1945 deaths]]
[[Category:Austrian carcinologists]]
[[Category:Austrian malacologists]]
[[Category:Austrian biologists]]
[[Category:University of Vienna alumni]]
[[Category:University of Vienna faculty]]

{{zoologist-stub}}
{{Austria-scientist-stub}}</text>
      <sha1>icnvdxbac251oo89lg3ng8os4x9vzwm</sha1>
    </revision>
  </page>
  <page>
    <title>Lajos Abafi</title>
    <ns>0</ns>
    <id>14450665</id>
    <revision>
      <id>867363910</id>
      <parentid>867363884</parentid>
      <timestamp>2018-11-05T06:35:47Z</timestamp>
      <contributor>
        <username>GoodDay</username>
        <id>589223</id>
      </contributor>
      <model>wikitext</model>
      <format>text/x-wiki</format>
      <text xml:space="preserve" bytes="4117">{{Infobox scientist
| honorific_prefix  = 
| name              = Lajos Abafi
| honorific_suffix  = 
| native_name       = 
| native_name_lang  = 
| image             = Abafi Aigner Lajos.jpg|
| image_size        = 
| image_upright     = 
| alt               = 
| caption           = 
| birth_name        = Ludwig Abafi-Aigner
| birth_date        = {{birth date |1840|02|11}}
| birth_place       = Nagyjécsa, [[Kingdom of Hungary]], [[Austrian Empire]]
| death_date        = {{death date and age |1909|06|19 |1840|02|11}}
| death_place       = Budapest, [[Austria-Hungary]]
| death_cause       = 
| resting_place     = 
| resting_place_coordinates = &lt;!--{{coord|LAT|LONG|type:landmark|display=inline,title}}--&gt;
| other_names       = 
| pronounce         =
| residence         = 
| citizenship       = Hungarian
| nationality       = 
| fields            = Lepidoptera
| workplaces        = 
| patrons           = 
| education         = 
| alma_mater        = 
| thesis_title      = &lt;!--(or  | thesis1_title =  and  | thesis2_title = )--&gt;
| thesis_url        = &lt;!--(or  | thesis1_url  =   and  | thesis2_url  =  )--&gt;
| thesis_year       = &lt;!--(or  | thesis1_year =   and  | thesis2_year =  )--&gt;
| doctoral_advisor  = &lt;!--(or  | doctoral_advisors = )--&gt;
| academic_advisors = 
| doctoral_students = 
| notable_students  = 
| known_for         = 
| influences        = 
| influenced        = 
| awards            = 
| author_abbrev_bot = 
| author_abbrev_zoo = 
| spouse            = &lt;!--(or | spouses = )--&gt;
| partner           = &lt;!--(or | partners = )--&gt;
| children          = 
| signature         = &lt;!--(filename only)--&gt;
| signature_alt     = 
| website           = &lt;!--{{URL|www.example.com}}--&gt;
| footnotes         = 
}}

'''Lajos Abafi''' or '''Ludwig Abafi-Aigner''' (11 February 1840 in [[Nagyjécsa]], [[Kingdom of Hungary]], [[Austrian Empire]] – 19 June 1909 in [[Budapest]], [[Austria-Hungary]]) was a [[Hungary|Hungarian]] [[Editing|editor]], a [[library|librarian]] and [[entomologist]].

His family, of [[Germany|German]] origin, moved to [[Bratislava|Pozsony]] (today [[Bratislava]]) in 1858. There, he learned the [[Hungarian language]]. His family then moved to [[Pest, Hungary|Pest]] in 1863. Ludwig part completed his studies in [[Cologne]] and part in [[Stuttgart]]. He was especially interested in [[Lepidoptera]] and he founded a popular library. In 1870, he became a [[freemason]]. He worked for twelve years on a history of freemasonry. He changed his first name Ludwig to its Hungarian form, Lajos, and he assumed his "nom de plume" Abafi. His enterprise declined during the years 1880 to 1890, when he closed it. From 1890, he was entirely devoted to [[entomology]]. He published his observations in the revue of the Budapest museum ''Természetrajzi Füzetek'' and  participated as editor and author in the  ''Fauna Regni Hungariae''. His book, ''Magyarország lepkéi'' (butterflies of Hungary) of 1907, was extremely popular and influenced many generations of entomologists of his country.

== Partial list of publications ==
*''A magyar népdalról'' (Pest, 1872)
*''Mikes Kelemen'' (Pest, 1872)
*''Feszler Ignác Aurél'' (1878)
*''Geschichte der Freimaurerei in Österreich-Ungarn,'' 5 vols. (Budapest, 1890–1899)
*''A szabadkőművesség története Magyarországon'' (Budapest, 1900)
*''Az olaszországi magyar légió történetéhez''
*''Magyarország lepkéi'' (Budapest, 1907)

== Sources ==
* {{Cite encyclopedia|author=Hangay, George |year=2004|title=Abafi-Aigner, Lajos (Ludwig Aigner)|encyclopedia=Encyclopedia of Entomology|volume=1|editor=Capinera, John L.|publisher=Kluwer Academic Publishers|location=Dordrecht|page=1 |isbn=0-7923-8670-1|url=https://link.springer.com/static-content/lookinside/768/prt%253A978-1-4020-6359-6%252F1/000.png|display-editors=etal}}{{dead link|date=September 2016|bot=medic}}{{cbignore|bot=medic}}

{{Authority control}}

{{DEFAULTSORT:Abafi, Lajos}}
[[Category:1840 births]]
[[Category:1909 deaths]]
[[Category:Hungarian entomologists]]
[[Category:Lepidopterists]]
[[Category:Freemasons]]


{{hungary-scientist-stub}}
{{Entomologist-stub}}</text>
      <sha1>myyu6x08tydfqmnrip7a9tkj3vcjntz</sha1>
    </revision>
  </page>
  <page>
    <title>Lev Rukhin</title>
    <ns>0</ns>
    <id>32617710</id>
    <revision>
      <id>869892167</id>
      <parentid>837281886</parentid>
      <timestamp>2018-11-21T01:47:10Z</timestamp>
      <contributor>
        <username>GoodDay</username>
        <id>589223</id>
      </contributor>
      <comment>Intro</comment>
      <model>wikitext</model>
      <format>text/x-wiki</format>
      <text xml:space="preserve" bytes="2178">{{Orphan|date=February 2017}}
{{Infobox scientist
| name = Lev Rukhin
| birth_date =  16 October 1912
| death_date = 8 September 1959
| death_place       = [[Leningrad]]
| residence         = [[Russia]]
| citizenship       = 
| nationality       = [[Soviet Union|Soviet]]
| ethnicity         = 
| field             = [[Geology]]
| work_institutions =  
| alma_mater        = 
| doctoral_advisor  = 
| doctoral_students = 
| known_for         = 
| author_abbrev_bot = 
| author_abbrev_zoo = 
| influences        = 
| influenced        = 
| prizes            = 
| religion          = 
| footnotes         = 
| signature         =
}}
'''Lev Rukhin''' ({{lang-ru|Рухин Лев Борисович;}} 16 October 1912 in [[Moscow]] – 8 September 1959 in [[Leningrad]]) was a Russian geologist.

==biography==
He was born in [[Moscow]]. He graduated from [[Saint Petersburg State University|Leningrad State University]] (1933).
Major works are devoted to the [[lithology]] and [[paleogeography]]. He was one of the first to use statistical methods in studying sedimentary rocks.&lt;ref name="lit"&gt;{{Cite book  |last1= Вассоевич |first1=Н. Б. |last2= |first2=|last3= |first3= |script-title=ru:''Памяти профессора Л. Б. Рухина'', «Уч. записки ЛГУ. Сер. геологических наук» |year= 1962 |publisher= |location= |isbn= | pages=|language=ru}}&lt;/ref&gt;
He was awarded the "Badge of Honor" and medals.&lt;ref&gt;[http://slovari.yandex.ru/~%D0%BA%D0%BD%D0%B8%D0%B3%D0%B8/%D0%91%D0%A1%D0%AD/%D0%A0%D1%83%D1%85%D0%B8%D0%BD%20%D0%9B%D0%B5%D0%B2%20%D0%91%D0%BE%D1%80%D0%B8%D1%81%D0%BE%D0%B2%D0%B8%D1%87/ Great Soviet Encyclopedia] {{ru icon}}&lt;/ref&gt;

== Works ==
* {{ru icon}} Основы общей палеогеографии, Л., 1959.

==References== 
{{Reflist}}

==External links==
* {{ru icon}} [http://bse.sci-lib.com/article098355.html Lev Rukhin Great Soviet Encyclopedia]
* {{ru icon}} [http://oval.ru/enc/62316.html geologist Lev Rukhin]

{{Authority control}}

{{DEFAULTSORT:Rukhin, Lev}}
[[Category:Russian geologists]]
[[Category:Soviet geologists]]
[[Category:1912 births]]
[[Category:1959 deaths]]


{{geologist-stub}}</text>
      <sha1>ap3vi80awhym6prlmow5m52nz92s07j</sha1>
    </revision>
  </page>
  <page>
    <title>List of GRC Software</title>
    <ns>0</ns>
    <id>52583141</id>
    <revision>
      <id>869884236</id>
      <parentid>869884101</parentid>
      <timestamp>2018-11-21T00:29:29Z</timestamp>
      <contributor>
        <ip>2607:FEA8:A2E0:E6D:9DAC:DD37:66B7:4606</ip>
      </contributor>
      <model>wikitext</model>
      <format>text/x-wiki</format>
      <text xml:space="preserve" bytes="1298">{{unreferenced|date=December 2016}}
'''List of GRC Software'''

This is a list of [[Governance, risk management, and compliance]] (GRC) software. GRC software is used across a wide variety of mid to large enterprise corporations. Professionals responsible for the acquisition, development and maintenance of GRC software are generally the [[Chief risk officer|CRO]] (Chief Risk Officer), [[Chief information officer|CIO]] and risk officers.
&lt;!--
################# READ THIS

Please do not add web links or products which do not have Wikipedia articles

--&gt;
*[https://Fixnix.co FixNix]
*[https://www.readinow.com/ ReadiNow]
*[[LockPath]]
* [https://www.vosesoftware.com/products/pelican/ Pelican]
* [[ACL (software company)|ACL GRC]]
* [[Active Risk]]
* [[GRC Envelop]] ([[free and open-source software]] through the [[MIT License]])
* [[InfoZoom]]
* [[MetricStream]]
* [[OpenPages]]
* [[ServiceNow]]
* [[TraceSecurity]]
* [[SAI Global]] 
* [[Pentana Audit]]

== References ==
&lt;!--- See [[Wikipedia:Footnotes]] on how to create references using &lt;ref&gt;&lt;/ref&gt; tags which will then appear here automatically --&gt;
{{Reflist}}

&lt;!--- Categories ---&gt;
[[Category:Articles created via the Article Wizard]]
[[Category:Lists of software|ERP software]]
[[Category:Risk management software]]
[[Category:Auditing]]</text>
      <sha1>a85bqqeqvx1wuddy17ege6g4j0phajg</sha1>
    </revision>
  </page>
  <page>
    <title>List of Game Boy colors and styles</title>
    <ns>0</ns>
    <id>2366759</id>
    <revision>
      <id>858046206</id>
      <parentid>856073574</parentid>
      <timestamp>2018-09-04T18:41:50Z</timestamp>
      <contributor>
        <username>Ost316</username>
        <id>6289403</id>
      </contributor>
      <comment>link [[bezel (screen)|bezel]] using [[:en:User:Edward/Find link|Find link]] | Cleaned up using [[WP:AutoEd|AutoEd]]; c/e</comment>
      <model>wikitext</model>
      <format>text/x-wiki</format>
      <text xml:space="preserve" bytes="13453">{{Refimprove|date=August 2013}}

This is a list of case colors and styles that have been produced for the [[Game Boy]] line of handheld systems since 1989.

==Game Boy==
[[File:Game-Boy-Original.jpg|thumb|150px|right|Game Boy - Off-white]]

{| class="wikitable"
!Basic colours
|-
|Off-white (1989)
|-
!Play It Loud series
|-
|Deep Black (1995)
|-
|Gorgeous Green (1995)
|-
|Radiant Red (1995)
|-
|Vibrant Yellow (1995)
|-
|High Tech Transparent (1995) (US)
|-
|Traditional White (1995) (JP)
|-
|Cool Blue (1995) (EU)
|}

===Special Edition Variants===
* Red with [[Manchester United F.C.|Manchester United]] logo (UK)
* Red with [[EB Games|EB]] logo on it (UK EB Games - Sold with [[Killer Instinct]], limited to 350 systems)
* Black with [[Wario]] logo (UK - Contest Prize on Ghost Train show 1989 - 1991)
* Black with [[Fiat]] in the bottom-left (Won in contest)
* Hot pink with [[Kirby (character)|Kirby]] logo (UK - Nintendo magazine contest - 1994)
* Pink with heart logo (Won in a gameshow)
* Off-white with [[Toyota]] logo (JP - Toyota car purchase - 1992)
* Off-white with [[Hyundai]] logo (Korea)
* Off-white with Altus Newing logo
* Off-white with [[Milka]] cow logo
* Off-white with [[Planet Hollywood]] logo
* Off-white with Santa Clara Division logo
* Off-white with Vivitar PMA Atlanta '93 in the bottom-left
* Off-white with [[Kirin Company|Kirin Beverage]] in the bottom-left
* Off white with Iveco Truck Ford with Commercial Motor in the bottom-left (Won in contest - 1991)
* Off-white with Bee Ind logo
* Off-white with [[Japan Airlines|JAL]] logo
* Off-white with [[Soyuz TM-17]] logo (Sold in the [[Memorial Museum of Cosmonautics]])

==Game Boy Pocket==
[[File:Game-Boy-Pocket-FL.jpg|thumb|150px|right|Game Boy Pocket - Silver]]
[[File:Game-Boy-Pocket-Black.jpg|thumb|150px|right|Game Boy Pocket - Black]]

===Serial numbers for basic colors 1996===
(no indicator models)
* Serial M******** Japan release: Made in Japan
* Serial MH******** Japan release: Made in China
* Serial MH******* Pal release: Made in China
* Serial MG******* North American release: Made in China

===Basic colors===
* Silver (1996)
* Black (1996)
* Green (1996)
* Blue (1996)
* Red (1996)
* Yellow (1996)
* Clear (1996)
* Pink (Japan, 1996)
* Clear Purple (Japan, 1996)

===Limited Edition colors===
* Ice Blue (1997) (Some boxes were packed with Zelda)
* Extreme Green (1997)
* Emerald Green (1998) (Toys 'R' Us JP)
* Clear (Ice) blue (1996) (Toys 'R' Us JP)
* Silver w/ grey border (US, 1996)
* Silver w/ black border (US, 1997)
* Gold (Packaged w/[[Donkey Kong Land]]) (EU) (AUS)
* Blue/Yellow (1997) blue front/yellow back. 'Swedish Limited Edition' with certificate, 3000ex made
* Off-white (In the style of the original Game Boy with Purple buttons)&lt;ref&gt;{{Cite web|url=http://nintendoagemedia.com/users/2957/photobucket/FC113202-FBAE-489B-5548EC39A840EC5A.jpeg|title=FC113202-FBAE-489B-5548EC39A840EC5A.jpeg|last=|first=|date=|website=|archive-url=|archive-date=|dead-url=|access-date=September 4, 2018}}&lt;/ref&gt;

===Special Edition variants===
* Nintendo Power 100th Issue Edition - gold w/ logo | This was available for purchase by the Nintendo Power adverts or by winning their 100th issue contest (1997)
* [[File:Gameboy Pocket Model F Famitsu edition 1997.jpg|thumb|Game Boy Pocket Model F Famitsu edition 1997 The mirror like [[bezel (screen)|bezel]] is exclusive to this rare version, "GAME BOY pocket FAMITSU 1997 [MODEL F] can be read. ]]Famitsu Limited Edition - clear (Japan, 1997)
* [[All Nippon Airways|ANA]] - clear blue w/ logo (Japan, 1997)
* [[Atlus]] - white w/ light blue border (Japan, 1997)
* [[Seibu Lions]] - blue w/ logo (Japan, 1997)
* [[Hello Kitty]]/Uranai Party - pink w/ artwork (Japan, 1997)
* [[Tamagotchi]] - Pink (Japan, 11/7/1997)
* Thomas &amp; Betts - blue w/ logo (Belgium)
* [[Toyota]] - clear w/ logo {{when|date=December 2010}}
* V Drink - green w/ logo (Australia)
* Imagineer Glow-In-Dark - light green glowing in dark - Prize in Imagineers Multi Racing Championship [N64] Contest - 2000pcs made (Japan, 1996)

==Game Boy Light (Japan Only)==
[[File:Game-Boy-Light-FL.jpg|thumb|150px|right|Game Boy Light - Silver]]

===Basic colors===
* Gold (1998)
* Silver (1998)

===Limited Edition colors===
* [[Toys 'R' Us]] - Clear Yellow (1998)

===Special Edition variants===
* [[Astro Boy]] - clear w/ artwork (1998)
* [[Osamu Tezuka]] - red w/ artwork (1998)
* Famitsu F02 Event Version - clear blue w/ white border (1998)
* Famitsu F02 Mail Order Version - clear blue w/ white border (1998)
* [[Pokémon Center]] Tokyo - yellow w/ logo &amp; artwork (1998)

==Game Boy Color==
[[File:Game-Boy-Color-Purple.png|thumb|150px|upright|Game Boy Color - Atomic Purple]]
[[File:Game-Boy-Color-Yellow.jpg|thumb|150px|upright|Game Boy Color - Dandelion]]
[[File:Game-Boy-Color-Mirinda.jpg|thumb|150px|upright|Game Boy Color - Mirinda]]

===Basic colors===
* Grape - purple (1998)
* Teal (1998, 1999 NA)
* Kiwi - neon green (1998, 1999 NA)
* Berry - fuchsia (1998, 1999 NA)
* Dandelion - yellow (1998, 1999 NA)
* Atomic Purple - clear purple (1998)
* Neotones Ice - clear (Japan only)

===Limited Edition colors===
* Clear Black (2000, Japan)
* Clear Green (Toys 'R' Us, Japan, 2000)
* Midnight Blue (Toys 'R' Us, Japan, 1999)
* Ice Blue (Toys 'R' Us, Japan)
* Clear Orange (Daiei, Japan, 1999)
* Clear Blue (ANA)
* Solid Black (Toys R' Us, New York City, 2000)

===Special Edition variants===
* Mirinda - clear orange w/ logo (Mexico, Czech Republic, Hungary 2000)
* Yedigun - clear orange w/ logo (Turkey, 2000)
* Neotones - clear green and yellow w/ Aussie flag &amp; yellow buttons (Australia)
* [[Tommy Hilfiger]] - yellow w/ logo (US, 1999)
* Tsutaya - water blue w/ orange buttons (Japan, 2000)
* [[Sakura Taisen]] - clear pink (2000)
* Hello Kitty Special Box - light pink w/ logo (Japan, 1999)
* Hello Kitty Special Box 2 - light pink w/ logo (Japan, 2000)
* Lawson - Aqua Blue &amp; Milky White (1999)
* Takarazuka - atomic gold w/ aquatic life artwork (Japan, 1999)
* Jusco - clear purple w/ Mario artwork (1999)
* Jusco - clear w/ Mario artwork (1999)
* [[Cardcaptor Sakura]] - white &amp; pink w/ artwork (Japan, 1999)
* [[Ferrero SpA]] competition - yellow w/ [[Happy Hippo]] Logo &amp; Happy Hippo Character "Max Mutig" (came bundled with the game "Das Geheimnis der Happy Hippo Insel")(limited to 111 units) (Germany,2001)
* Hookups- lime green with Hookups logo. Asr 2001 (100 made)
* V-drink (Clear w/ logo)

===Pokémon===
* [[Pokémon]] - Special [[Pikachu]] edition yellow &amp; blue w/ logo, artwork &amp; colored buttons (bundled w/ ''[[Pokémon Yellow]]'')
* Pokémon - silver &amp; gold iridescent w/artwork around screen (U.S., Toys 'R' Us exclusive)
* Pokémon - clear blue &amp; white w/ artwork (Hong Kong)
* Pokémon - clear green &amp; white w/ artwork (Taiwan)
* Pokémon - yellow &amp; blue w/ logo, artwork &amp; colored buttons (Australia)
* Pokémon Center - silver w/ artwork &amp; logo (1999)
* Pokémon Center - orange &amp; blue w/ artwork &amp; logo (1999)

==Game Boy Advance==
[[File:Nintendo-Game-Boy-Advance-Milky-Blue-FL.jpg|thumb|250px|right|Game Boy Advance - Glacier]]
[[File:Nintendo-Game-Boy-Advance-Purple-FL.jpg|thumb|250px|right|Game Boy Advance - Indigo]]
[[File:Nintendo-Game-Boy-Advance-White-FL.jpg|thumb|250px|right|Game Boy Advance - Arctic]]

===Basic colors===
* Indigo - purple (2001)
* Arctic - white (2001)
* Glacier - clear blue (2001)
* Fuchsia (2001)
* Spice - orange (Japan, 2001)
* Black (2001)

===Limited Edition colors===
* Platinum/Silver (2002)
* Gold (Japan, 2002)
* Daiei - clear orange front &amp; clear black back (Daiei, Japan, 2001)
* Jet - black (Toys 'R' Us, U.S., 2003)
* Red (Zellers, Canada)

===Special Edition variants===
* [[Target Corporation|Target]] - Grape w/ logo (US, 2001)
* [[Target Corporation|Target]] - Red w/ logo (US, 2002)
* [[Chobits]] - clear blue w/ logo (Japan, 2002)
* [[King of Fighters]] - clear black w/ logo (Japan, 2002)
* Toys 'R' Us - Solid Midnight Blue w/ logo (US, 2002)
* Toys 'R' Us - Transparent Midnight Blue (Japan, 2001)
* [[Mega Man (character)|Rockman]] Custom - blue (Japan, 2001)
* Jusco - Glacier w/ Mario artwork (2001)
* Hello Kitty - pink w/ logo (Japan, 2001)
* [[Yomiuri Giants]] - clear purple w/ artwork (2001)

===Pokémon===
* Pokémon Center ([[Latios]] &amp; [[Latias]]) - blue w/ red buttons (2002)
* Pokémon Center - [[Celebi (Pokémon)|Celebi]] green w/ artwork (2001)
* Pokémon Center - [[Suicune]] blue w/ artwork (2001)
* Pokémon Center NY - gold w/ artwork (US, 2001)
* Pokémon Center NY - gold w/ artwork (JP, 2001)

==Game Boy Advance SP==
[[File:Game-Boy-Advance-SP-Mk1-Blue.jpg|thumb|250px|right|Game Boy Advance SP - Cobalt]]
[[File:Gameboy-Advance-SP-Mk2.jpg|thumb|250px|right|Game Boy Advance SP - Pearl Blue (backlit)]]

===Basic colors===
* Cobalt - frontlit (2003)
* Platinum - frontlit (2003)
* Onyx - frontlit (2003)
* Flame Red - frontlit (2003)
* Pearl Blue - backlit (2005)
* Graphite - backlit (2005)
* Pearl Pink - backlit (2006)

===Limited Edition colors===
* All Blacks (NZ)
* Banana Yellow Donkey Kong Edition (JP, 10/2004, Limited to 1,000)
* Black "Who are you?" Edition (Walmart, US, 2004)
* Blue Marble (JP, EU, 2004)
* Bokura no Taiyou (JP, 2004)
* Camo Gray (JP)
* Camo Green (JP)
* China Dragon (China, 11/2004)
* Classic NES (US, 2004)
* Disney Channel Promo Cobalt Blue (North America, 2003 or 2004, AGS-001, TV contest)
* Toon Disney Channel (North America)
* Toon Disney/Jetix (North America, 2008, AGS-101, 200 made for TV contest)
* Disney Channel Graphite (North America, 2005 or 2006, AGS-101)
* Dual Platinum/Onyx (US, 2004)
* Famicom "The 20th Anniversary Edition" (JP, 10-2003, limited to 1,000)
* Famicom 2 (JP)
* Final Fantasy Tactics (JP)
* IBokura no Taiyou : "Jango Red &amp; Black" (JP, 07-2003)
* Indigo (AUS, 2004)
* Kingdom Hearts Deep Silver (All, 2004)
* Lime/Orange limited edition (US, 2004)
* Mario vs Donkey Kong (UK, 2004)
* Naruto Orange (JP 07-2004)
* Pearl White (US, JP, 2004)
* Pikachu "Toys 'R' Us"(US, 2004)
* ''Pokémon Emerald'' Bundle, Dark Green (AUS)
* Rockman EXE 4 Tournament Red Sun (JP, 12/2003)
* Rip Curl (AUS, 2004)
* Samus Satin (JP)
* SD Gundam G Generation "Char Aznable Custom" (JP, 12/2003)
* Seiken Densetsu: "Mana Blue Edition" (JP, 08-2003)
* Surfblue (US, 2004)
* Swarovski (US)
* Swiss Gamer (Switzerland)
* Target Branded Lime (US, 2003)
* Toys 'R' Us Gold (US, 11/2003)&lt;ref&gt;{{Cite news|url=http://www.ign.com/boards/threads/tru-exclusive-gold-gba-sp-super-mario-advance-4-bundle-for-sale.48495179/|title=TRU Exclusive Gold GBA SP/Super Mario Advance 4  Bundle for Sale|work=IGN Boards|access-date=2018-09-04|language=en-US}}&lt;/ref&gt;
* Toys 'R' US Japan Limited Edition "Star Light Gold" (JP)
* Toys 'R' US SpongeBob SquarePants (2004)
* Toys 'R' Us Pearl Green (US, 2004)
* Tribal (All, 2004)
* White (All)
* Zelda: Gold with Triforce and Hylian crest (EU, 2004)

===Pokémon===
* [[Pikachu]] - Yellow (Toys R Us 2005, Pokémon Center Japan)
* Pokémon Center Limited Edition "[[Charizard]] Edition" (JP, 02/2004) - Fire Red
* Pokémon Center Limited Edition "[[Groudon]] Edition" (US, JP, 12/2003) - Ruby (Red)
* Pokémon Center Limited Edition "[[Kyogre]] Edition" (JP, 12/2003) - Sapphire (Blue)
* Pokémon Center Limited Edition "[[Rayquaza]] Edition" (JP, 09/2004) - Emerald (Green)
* Pokémon Center Limited Edition "[[Torchic]]" (US, JP, 03/2003) - Orange
* Pokémon Center Limited Edition "[[Venusaur]] Edition" (JP, 02/2004) - Leaf Green

==Game Boy Micro==
[[File:Game-Boy-Micro.png|thumb|250px|right|Game Boy Micro - Silver]]
[[File:Game boy micro all black.JPG|thumb|250px|right|Game Boy Micro - Black]]

===Basic colors===
* Silver (Worldwide 2005)
* Black (Japan and Australia [US with silver [[faceplate (housing)|faceplate]]] 2005)
* Purple (Japan and Australia, 2005)
* Pearl Blue (Japan, 2005)
* Pink (Europe, 2005)
* Green (Europe and Asia, 2005)
* Blue (Europe and Australia, 2005)
* Red (Asia and Australia, 2005)

===Special Edition variants===
* 20th Anniversary Edition - red w/ gold faceplate (USA, 2005)
* Famicom - red w/ gold faceplate (Japan, 2005)
* ''Pokémon'' - red w/ black faceplate &amp; Pikachu silhouette (Japan, 2005)
* ''[[Final Fantasy IV]]'' - blue unit with b&amp;w [[Yoshitaka Amano|Amano]] artwork (Japan, 2005)
* ''[[Mother 3]]'' - red w/ red, worn faceplate (Japan, 2006)
* [[Toonami]] - black w/ logo &amp; graphics (Giveaway, USA, 2006)

===List of [[Faceplate (housing)|Faceplates]]===
* Super Robo Taisen - Black faceplate with logo by Nintendo (Club Nintendo Japan)
* Famicom controller II - Like the famicom version but with a II logo and volume slider (Club Nintendo Japan)
* 10th Anniversary Tower Records - red w/ yellow faceplate (Japan)

Some others: [[Cup of noodles|Cup of Noodles]], [[Fujifilm]], the [[Hanshin Tigers]] baseball team, Parco, [[Shiseido]] and a movie called ''[[Custom Made 10.30|Custom Made]]''

==See also==
{{Portal|1990s|2000s}}

*[[List of Nintendo DS colors and styles]]
*[[List of Nintendo 3DS colors and styles]]
*[[Comparison of Nintendo portable consoles]]

==References==
{{reflist}}

==External links==
* [http://gameboy.about.com/ About.com Guide to Game Boy] - All things Game Boy: News, reviews, history, culture and development. Updated several times a week.
* [http://www.imgcab.com/gameboy/gameboy0.html GAMEBOY GALLERIA] - A pictorial encyclopedia of the various Game Boy models.

{{DEFAULTSORT:Colors And Styles}}
[[Category:Game Boy consoles]]
[[Category:Lists of colors|Game Boy]]</text>
      <sha1>2ncao81ubsxwksnupufnc0mga9j3ijo</sha1>
    </revision>
  </page>
  <page>
    <title>List of cosmological computation software</title>
    <ns>0</ns>
    <id>42017954</id>
    <revision>
      <id>865599233</id>
      <parentid>859917588</parentid>
      <timestamp>2018-10-24T22:51:07Z</timestamp>
      <contributor>
        <username>Citation bot</username>
        <id>7903804</id>
      </contributor>
      <minor/>
      <comment>Add: type, url. You can [[WP:UCB|use this bot]] yourself. [[WP:DBUG|Report bugs here]]. | [[User:Josve05a|Josve05a]]</comment>
      <model>wikitext</model>
      <format>text/x-wiki</format>
      <text xml:space="preserve" bytes="12781">{{Software_for_Cosmologists}}

The [[cosmic microwave background]] (CMB) is the thermal radiation assumed to be left over from the "[[Big Bang]]" of [[Physical cosmology|cosmology]].  The CMB is a snapshot of the oldest light in our universe, imprinted on the sky when the universe was just 380,000 years old. It shows tiny temperature fluctuations that correspond to regions of slightly different densities, representing the seeds of all future structure: the stars and galaxies of today. Therefore, analysis of the small anisotropies in the CMB helps us to understand the origin and the fate of our universe. In past few decades, there has been a lot of improvement in the observations and several experiments, performed to understand the basic structure of the universe. For analyzing data of different cosmological experiments and for understanding the theoretical nature of the universe many advanced methods and computing software are developed in and used by Cosmologists for years. These software are widely used by the cosmologists across the globe.

The computational software, used in cosmology can be classified into the following major classes.

* '''Map generation and processing software:''' These software are used for preparing the CMB sky maps from the crude observational data. The software HEALPIX&lt;ref&gt;{{cite arXiv|last=Gorski|first=Krzysztof M.|author2=Benjamin D. Wandelt |author3=Frode K. Hansen |author4=Eric Hivon |author5=Anthony J. Banday |title=The HEALPix Primer |date=23 May 1999|eprint=astro-ph/9905275}}&lt;/ref&gt;&lt;ref&gt;{{cite web|title=HEALPIX|url=http://healpix.jpl.nasa.gov/|work=software|publisher=NASA}}&lt;/ref&gt;&lt;ref&gt;{{cite journal|last=Gorski|first=K. M.|author2=E. Hivon |author3=A. J. Banday |author4=B. D. Wandelt |author5=F. K. Hansen |author6=M. Reinecke |author7=M. Bartelman |title=HEALPix -- a Framework for High Resolution Discretization, and Fast Analysis of Data Distributed on the Sphere|journal=Astrophysical Journal|date=2005|volume=622|issue=2|pages=759–771|doi=10.1086/427976  |bibcode=2005ApJ...622..759G|arxiv = astro-ph/0409513 }}&lt;/ref&gt;  is used for map generation and processing.
* '''Cosmological Boltzmann codes:''' These codes are used for calculating the theoretical power spectrum given the cosmological parameters. These codes are capable of calculating the power spectrum from the standard LCDM model or its derivatives.  Some of the most used CMB Boltzmann codes are CMBFAST,&lt;ref&gt;{{cite journal|last=Seljak|first=Uros|author2=Zaldarriaga, Matias |title=A Line of Sight Approach to Cosmic Microwave Background Anisotropies|journal=Astrophysical Journal|date=1996|volume=469|pages=437–444|doi=10.1086/177793 |bibcode=1996ApJ...469..437S|arxiv = astro-ph/9603033 }}&lt;/ref&gt;&lt;ref&gt;{{cite journal|last=Zaldarriaga|first=Matias|author2=Uros Seljak |author3=Edmund Bertschinger |title=Integral Solution for the Microwave Background Anisotropies in Non-flat Universes|journal=Astrophysical Journal|date=1998|volume=494|issue=2|pages=491–502|doi=10.1086/305223|bibcode=1998ApJ...494..491Z|arxiv = astro-ph/9704265 }}&lt;/ref&gt;&lt;ref&gt;{{cite web|last=Seljak|first=U., &amp; Zaldarriaga, M.|title=CMBFAST|url=http://lambda.gsfc.nasa.gov/toolbox/tb_cmbfast_ov.cfm}}&lt;/ref&gt; CAMB,&lt;ref&gt;{{cite journal|last=Lewis|first=Antony|author2=Challinor, Anthony |title=CAMB: Code for Anisotropies in the Microwave Background|journal=Astrophysics Source Code Library |page=ascl:1102.026 |bibcode=2011ascl.soft02026L|arxiv =&lt;!-- --&gt; |year=2011}}&lt;/ref&gt; CMBEASY,&lt;ref&gt;{{cite web|last=Doran|first=Michael|title=CMBEASY|url=http://www.thphys.uni-heidelberg.de/~robbers/cmbeasy/}}&lt;/ref&gt;&lt;ref&gt;{{cite journal|last=Doran|first=Michael|title=CMBEASY:: an Object Oriented Code for the Cosmic Microwave Background|journal=Journal of Cosmology and Astroparticle Physics|date=27 Apr 2006|volume=0510|issue=10|pages=011|doi=10.1088/1475-7516/2005/10/011 |arxiv = astro-ph/0302138 |bibcode = 2005JCAP...10..011D |url=http://cds.cern.ch/record/604587|type=Submitted manuscript}}&lt;/ref&gt; CLASS,&lt;ref&gt;{{cite journal|last=Blas|first=D.|author2=J. Lesgourgues |author3=T. Tram |title=CLASS II: Approximation schemes|journal=Journal of Cosmology and Astroparticle Physics|date=2011|volume=1107|issue=7|pages=034|doi=10.1088/1475-7516/2011/07/034|arxiv=1104.2933|bibcode=2011JCAP...07..034B}}&lt;/ref&gt;&lt;ref&gt;{{cite arxiv|last=Lesgourgues|first=J|title=CLASS I: Overview|eprint=1104.2932|class=astro-ph.IM|year=2011}}&lt;/ref&gt;&lt;ref&gt;{{cite web|last=Lesgourgues|first=J.|title=CLASS|url=http://class-code.net/}}&lt;/ref&gt; CMBAns etc.
* '''Cosmological parameter estimator:'''   The parameter estimation codes are used for calculating the best-fit parameters from the observation data. The ready to use codes available for this purpose are CosmoMC,&lt;ref&gt;{{cite journal|last=Lewis|first=Antony|author2=Sarah Bridle |title=Cosmological parameters from CMB and other data: a Monte-Carlo approach|journal=Physical Review D |page=103511|date=2002|doi=10.1103/PhysRevD.66.103511|arxiv = astro-ph/0205436 |bibcode = 2002PhRvD..66j3511L|volume=66|issue=10}}&lt;/ref&gt;&lt;ref&gt;{{cite journal|last=Lewis|first=Antony|title=Efficient sampling of fast and slow cosmological parameters|journal=Physical Review D|date=2013|volume=87|issue=10|pages=103529|doi=10.1103/PhysRevD.87.103529|arxiv = 1304.4473 |bibcode = 2013PhRvD..87j3529L }}&lt;/ref&gt; AnalyzeThis,&lt;ref&gt;{{cite journal|last=Doran|first=Michael|author2=Christian M. Mueller |title=Analyze This! A Cosmological Constraint Package for CMBEASY|journal=Journal of Cosmology and Astroparticle Physics|date=2004|volume=0409|issue=3|pages=003|doi=10.1088/1475-7516/2004/09/003 |arxiv = astro-ph/0311311 |bibcode = 2004JCAP...09..003D }}&lt;/ref&gt; SCoPE&lt;ref&gt;{{cite journal|last=Das|first=Santanu|author2=Tarun Souradeep |title=SCoPE: An efficient method of Cosmological Parameter Estimation|journal=Journal of Cosmology and Astroparticle Physics|date=2014|volume=1407|issue=18|pages=018|doi=10.1088/1475-7516/2014/07/018 |arxiv = 1403.1271 |bibcode = 2014JCAP...07..018D }}&lt;/ref&gt; etc.

== Map generation and processing software ==

=== HEALPix ===

[[HEALPix]] (sometimes written as Healpix), an acronym for Hierarchical Equal Area isoLatitude Pixelisation of a 2-sphere, can refer to either an algorithm for pixelization of the 2-sphere, an associated software package, or an associated class of map projections.  Healpix is widely used for cosmological random map generation. The original motivation for devising HEALPix was one of necessity. [[NASA]]'s [[WMAP]] and the [[European Space Agency]]’s mission [[Planck (spacecraft)|Planck]] - produce multi-frequency data sets sufficient for the construction of full-sky maps of the microwave sky at an angular resolution of a few arc minutes. The principal requirements in the development of HEALPix were to create a mathematical structure that supports a suitable discretization of functions on a sphere at sufficiently high resolution, and to facilitate fast and accurate statistical and astrophysical analysis of massive full-sky data sets.  The HEALPix maps are used in almost all the data processing research in cosmology.

== Cosmological Boltzmann codes ==

=== CMBFAST ===

[[CMBFAST]] is a computer code, developed by [[Uroš Seljak]] and [[Matias Zaldarriaga]] (based on a Boltzmann code written by Edmund Bertschinger, [[Chung-Pei Ma]] and Paul Bode) for computing the power spectrum of the cosmic microwave background anisotropy. It is the first efficient program to do so, reducing the time taken to compute the anisotropy from several days to a few minutes by using a novel semi-analytic line-of-sight approach.

=== CAMB ===

Code for Anisotropies in the Microwave Background by Antony Lewis and Anthony Challinor. The code was originally based on CMBFAST. Later several developments are made to make it a faster and more accurate and compatible with the present research. The code is written in an object oriented manner to make it more user friendly.

=== CMBEASY ===

CMBEASY is a software package written by Michael Doran, Georg Robbers and Christian M. Müller. The code is based on the CMBFAST package. CMBEASY is fully object oriented C++. This considerably simplifies manipulations and extensions of the CMBFAST code. In addition, a powerful Spline class can be used to easily store and visualize data. Many features of the CMBEASY package are also accessible via a graphical user interface. This may be helpful for gaining intuition, as well as for instruction purposes.

=== CLASS ===

CLASS is a new Boltzmann code developed in this line. The purpose of CLASS is to simulate the evolution of linear perturbations in the universe and to compute CMB and large scale structure observables. Its name also comes from the fact that it is written in object-oriented style mimicking the notion of class. Classes are a programming feature available, e.g., in C++ and python, but these languages are known to be less vectorizable/parallelizable than plain C (or Fortran), and hence potentially slower. CLASS is written in plain C for high performances, while organizing the code in a few modules that reproduce the architecture and philosophy of C++ classes, for optimal readability and modularity.

== Parameter estimation packages ==

[[File:Snapshot3-2-.png|thumbnail|right|A snapshot of AnalyzeThis (CMBEASY) GUI package. The plot shows the marginalize probability distribution from a MCMC chain.]]

=== AnalizeThis ===

AnalizeThis is a parameter estimation package used by cosmologists. It comes with the CMBEASY package. The code is written in C++ and uses the global metropolis Algorithm for estimation of cosmological parameters. The code was developed by Michael Doran, for parameter estimation using WMAP-5 likelihood. However, the code was not updated after 2008 for the new CMB experiments. Hence this package is currently not in use by the CMB research community. The package comes up with a nice GUI.

=== CosmoMC ===

CosmoMC is a Fortran 2003 [[Markov chain Monte Carlo]] (MCMC) engine for exploring cosmological parameter space. The code does brute force (but accurate) theoretical [[matter power spectrum]] and [[Cosmic microwave background|Cl]] calculations using CAMB. CosmoMC uses a simple local Metropolis algorithm along with an optimized fast-slow sampling method. This fast-slow sampling method provides faster convergence for the cases with many nuisance parameters like Planck. CosmoMC package also provides subroutines for post processing and plotting of the data.

CosmoMC was written by Antony Lewis in 2002 and later several versions are developed to keep the code up-to date with different cosmological experiments. It is presently the most used cosmological parameter estimation code.

=== SCoPE ===

SCoPE/Slick Cosmological Parameter Estimator is a newly developed cosmological MCMC package written by Santanu Das in C language. Apart of standard global metropolis algorithm the code uses three unique technique named as 'delayed rejection' that increases the acceptance rate of a chain, 'pre-fetching' that helps an individual chain to run on parallel CPUs and 'inter-chain covariance update' that prevents clustering of the chains allowing faster and better mixing of the chains. The code is capable of faster computation of cosmological parameters from WMAP and Planck data.

== Other packages ==
* [http://cds.cern.ch/record/408710/files/9911389.pdf MADCAP] - Microwave Anisotropy Data Computational Analysis Package developed by Borrill et al.
* [https://www.cfa.harvard.edu/~sasselov/rec/ RECFAST] - Software was developed by Seager, Sasselov, and Scott and used to calculate the recombination history of the universe. The package is used by cosmological boltzmann codes (CMBFast, CAMB etc.)

=== Likelihood software packages ===

Different cosmology experiments, in particular the CMB experiments like [[WMAP]] and [[Planck (spacecraft)|Planck]] measures the temperature fluctuations in the CMB sky and then measure the CMB power spectrum from the observed skymap. But for parameter estimation the χ² is required. Therefore, all these CMB experiments comes up with its own likelihood software.
* [http://lambda.gsfc.nasa.gov/product/map/current/likelihood_get.cfm WMAP Likelihood Package]
* [http://irsa.ipac.caltech.edu/data/Planck/release_1/software/ Planck Likelihood Software]

==See also==
{{Portal|Cosmology}}
* [[Illustris project]]
* [[Lambda-CDM model]]
* [[Physical cosmology]]
* [[Planck (spacecraft)]]
* [[Observational cosmology]]
* [[Wilkinson Microwave Anisotropy Probe]]
* [[Cosmological perturbation theory]]

== Notes ==
{{Reflist|30em}}

[[Category:Physical cosmology]]
[[Category:Cosmic background radiation]]
[[Category:Lists of software|Cosmological computation software]]
[[Category:Scientific modeling]]
[[Category:Scientific simulation software]]</text>
      <sha1>e2wajkvd3dfwk6ladnkjdm0fc8uf4z0</sha1>
    </revision>
  </page>
  <page>
    <title>List of photochemists</title>
    <ns>0</ns>
    <id>40789532</id>
    <revision>
      <id>727082501</id>
      <parentid>665995059</parentid>
      <timestamp>2016-06-26T14:58:51Z</timestamp>
      <contributor>
        <username>Dirac66</username>
        <id>2038644</id>
      </contributor>
      <comment>/* Photochemists */ Added Kasha. Placed Eichengrun in alphabetical order.</comment>
      <model>wikitext</model>
      <format>text/x-wiki</format>
      <text xml:space="preserve" bytes="733">This is a '''list of notable photochemists'''. [[Photochemistry]], a sub-discipline of [[chemistry]], is the study of [[chemical reaction]]s that proceed with the absorption of light by atoms or molecules.

==Photochemists==
{{expand list|date=October 2013}}
* [[Nicola Armaroli]]
* [[Vincenzo Balzani]]
* [[E. J. Bowen]]
* [[John William Draper]]
* [[Arthur Eichengrün]]
* [[Theodor Grotthuss]]
* [[Selig Hecht]]
* [[Michael Kasha]]
* [[Walter Sidney Metcalf]]
* [[David Phillips (chemist)|David Phillips]]
* [[James Pitts (chemist)|James Pitts]] 
* [[Fritz Weigert]]

==See also==
* [[Photochemistry]]
* [[Lists of people by occupation]]

{{DEFAULTSORT:Photochemists}}
[[Category:Photochemists|*]]
[[Category:Lists of scientists]]</text>
      <sha1>63zioosz9sdg3esupk1dry2eex47ge2</sha1>
    </revision>
  </page>
  <page>
    <title>List of therapeutic monoclonal antibodies</title>
    <ns>0</ns>
    <id>8599665</id>
    <revision>
      <id>871773230</id>
      <parentid>871768778</parentid>
      <timestamp>2018-12-03T09:45:28Z</timestamp>
      <contributor>
        <ip>77.245.36.66</ip>
      </contributor>
      <model>wikitext</model>
      <format>text/x-wiki</format>
      <text xml:space="preserve" bytes="81083">{{Dynamic list}}
This is a '''list of therapeutic, diagnostic and preventive [[monoclonal antibodies]]''', antibodies that are clones of a single parent cell. When used as drugs, the [[International Nonproprietary Name]]s (INNs) end in -mab. The remaining syllables of the INNs, as well as the column ''Source'', are explained in ''[[Nomenclature of monoclonal antibodies]]''.

[[File:Engineered monoclonal antibodies.svg|thumb|400px|Types of monoclonal antibodies with other structures than naturally occurring antibodies.]]
The abbreviations in the column ''Type'' are as follows:
* mab: whole monoclonal antibody
* Fab: [[Fragment antigen-binding|fragment, antigen-binding]] (one arm)
** F(ab')&lt;sub&gt;2&lt;/sub&gt;: fragment, antigen-binding, including hinge region (both arms)
** Fab': fragment, antigen-binding, including hinge region (one arm)
* [[Variable fragment]]s:
** scFv: [[single-chain variable fragment]]
** di-scFv: dimeric single-chain variable fragment
** sdAb: [[single-domain antibody]]
* [[Bispecific monoclonal antibodies]]:
** 3funct: [[trifunctional antibody]] 
** BiTE: [[bi-specific T-cell engager]]

This list of over 500 monoclonal antibodies includes [[approved drug|approved]] and [[investigational drug]]s as well as drugs that have been withdrawn from market; consequently, the column ''Use'' does not necessarily indicate clinical usage. See the list of FDA approved therapeutic monoclonal antibodies in the [[Monoclonal antibody therapy]] page.

{| class="sortable wikitable"
 ! Name !! Trade name !! Type !! Source !! Target 
!Approved!! Use
 |-
 | [[3F8]] || || mab || mouse || [[GM2 (ganglioside)|GD2 ganglioside]] 
||| [[neuroblastoma]]
 |-
 | [[8H9]]&lt;ref name=Ch1418 /&gt; || || mab ||  mouse || [[B7-H3]] 
||| neuroblastoma, sarcoma, metastatic brain cancers
 |-
 | [[Abagovomab]]&lt;ref name=WHOList95 /&gt; || || mab || mouse || [[CA-125]] (imitation) 
||| [[ovarian cancer]]
 |-
 | [[Abciximab]] || ReoPro || Fab || chimeric || [[CD41]] (integrin alpha-IIb) 
|Y|| [[platelet aggregation inhibitor]]
 |-
 | [[Abituzumab]]&lt;ref name=WHOList109 /&gt; || || mab || humanized || [[CD51]] 
||| cancer
 |-
 | [[Abrezekimab]]&lt;ref name=WHOList118 /&gt; || || Fab || humanized || interleukin 13
||| ?
 |-
 | [[Abrilumab]] || || mab || human || integrin α4β7 
||| [[inflammatory bowel disease]], [[ulcerative colitis]], [[Crohn's disease]]
 |-
 | [[Actoxumab]] || || mab || human || ''[[Clostridium difficile (bacteria)|Clostridium difficile]]'' 
||| [[Clostridium difficile colitis|''Clostridium difficile'' colitis]]
 |-
 | [[Adalimumab]] || Humira || mab || human || [[TNF-α]] 
|Y|| [[Rheumatoid arthritis]], [[Crohn's disease]], Plaque [[Psoriasis]], [[Psoriatic Arthritis]], [[Ankylosing Spondylitis]], [[Juvenile Idiopathic Arthritis]], [[Hemolytic disease of the newborn]]
 |-
 | [[Adecatumumab]]&lt;ref name=WHOList90 /&gt; || || mab || human || [[EpCAM]] 
||| [[prostate cancer|prostate]] and [[breast cancer]]
 |-
 | [[Atidortoxumab]]&lt;ref name=WHOList117 /&gt; || || mab || human || ''[[Staphylococcus aureus]]'' alpha toxin
||| ?
 |-
 | [[Aducanumab]] || || mab || human || [[beta-amyloid]] 
||| Alzheimer's disease
 |-
 | Afasevikumab&lt;ref name=WHOList113 /&gt; || || mab || human || [[IL17A]] and [[IL17F]] 
||| multiple sclerosis
 |-
 | [[Afelimomab]] || || F(ab')&lt;sub&gt;2&lt;/sub&gt; || mouse || [[TNF-α]] 
||| [[sepsis]]
 |-
 | [[Alacizumab pegol]]&lt;ref name=WHOList98 /&gt; || || F(ab')&lt;sub&gt;2&lt;/sub&gt; || humanized || [[VEGFR2]] 
||| [[cancer]]
 |-
 | [[Alemtuzumab]]&lt;ref name=WHOList83 /&gt; || Lemtrada, Campath || mab || humanized || [[CD52]] 
|Y|| [[Multiple sclerosis]]
 |-
 | [[Alirocumab]] ||Praluent|| mab || human || [[PCSK9]] 
|Y|| [[hypercholesterolemia]]
 |-
 | [[Indium (111In) altumomab pentetate|Altumomab pentetate]] || Hybri-ceaker || mab || mouse || [[Carcinoembryonic antigen|CEA]] 
||| colorectal cancer (diagnosis)
 |-
 | [[Amatuximab]] || || mab || chimeric || [[mesothelin]] 
||| cancer
 |-
 | [[Anatumomab mafenatox]] || || Fab || mouse || [[Tumor-associated glycoprotein 72|TAG-72]] 
||| [[non-small cell lung carcinoma]]
 |-
 | [[Andecaliximab]] || || mab || chimeric || [[gelatinase B]]
||| gastric cancer or gastroesophageal junction adenocarcinoma
 |-
 | [[Anetumab ravtansine]]&lt;ref name=WHOList109 /&gt; || || mab || human || MSLN 
||| cancer
 |-
 | [[Anifrolumab]] || || mab || human || [[interferon receptor|interferon α/β receptor]] 
||| [[systemic lupus erythematosus]]
 |-
 | [[Anrukinzumab]]&lt;ref name=WHOList98 /&gt; (= IMA-638)&lt;ref name="IMA-638" /&gt; || || mab || humanized || [[Interleukin 13|IL-13]] 
||| asthma
 |-
 | [[Apolizumab]]&lt;ref name=WHOList87 /&gt; || || mab || humanized || [[HLA-DR]] ? 
||| [[hematological cancer]]s
 |-
 | [[Aprutumab ixadotin]]&lt;ref name=WHORList77 /&gt; || || mab || human || [[fibroblast growth factor receptor|FGFR2]]
||| ?
 |-
 | [[Arcitumomab]] || CEA-Scan || Fab' || mouse || [[Carcinoembryonic antigen|CEA]] 
||| gastrointestinal cancers (diagnosis)
 |-
 | [[Ascrinvacumab]] || || mab || human || activin receptor-like kinase 1 
||| cancer
 |-
 | [[Aselizumab]]&lt;ref name=WHOList88 /&gt; || || mab || humanized || [[L-selectin]] (CD62L) 
||| severely injured patients
 |-
 | [[Atezolizumab]]&lt;ref name=WHOList112 /&gt; ||Tecentriq|| mab || humanized || [[CD274|PD-L1]] 
|Y|| cancer
 |-
 | Atinumab&lt;ref name=WHOList104 /&gt; || || mab || human || [[RTN4]] 
||| ?
 |-
 | [[Atorolimumab]] || || mab || human || [[Rhesus factor]] 
||| [[hemolytic disease of the newborn]]{{Citation needed|date=November 2009}}
 |-
 | [[Avelumab]]&lt;ref name=WHOList113 /&gt; ||Bavencio|| mab || human || [[CD274|PD-L1]] 
|Y|| cancer
 |-
 | [[Azintuxizumab vedotin]]&lt;ref name=WHOList116 /&gt;  || || mab || chimeric/humanized || [[CD319]]
||| cancer
 |-
 | [[Bapineuzumab]]&lt;ref name=WHOList93 /&gt; || || mab || humanized || [[beta amyloid]] 
||| [[Alzheimer's disease]]
 |-
 | [[Basiliximab]] || Simulect || mab || chimeric || [[CD25]] (α chain of [[interleukin 2|IL-2]] receptor) 
|Y|| prevention of organ [[transplant rejection]]s
 |-
 | [[Bavituximab]]&lt;ref name=WHOList95 /&gt; || || mab || chimeric || [[phosphatidylserine]] 
||| cancer, viral infections
 |-
 | [[BCD-100]] || || ? || human || [[programmed cell death 1|PD-1]] 
||| melanoma
 |-
 | [[Bectumomab]] || LymphoScan || Fab' || mouse || [[CD22]] 
||| [[non-Hodgkin's lymphoma]] (detection)
 |-
 | [[Begelomab]]&lt;ref name=WHOList111 /&gt; || || mab || mouse || [[dipeptidylpeptidase 4|DPP4]] 
||| ?
 |-
 | [[Belantamab mafodotin]]&lt;ref name=WHOList118 /&gt; || || mab || humanized || [[B-cell maturation antigen|BCMA]]
||| cancer
 |-
 | [[Belimumab]] || Benlysta || mab || human || [[B-cell activating factor|BAFF]] 
|Y|| non-Hodgkin lymphoma etc.
 |-
 | Bemarituzumab&lt;ref name=WHOList117 /&gt; || || mab || humanized || [[fibroblast growth factor receptor 2|FGFR2]]
||| gastric cancer or gastroesophageal junction adenocarcinoma
 |-
 | [[Benralizumab]] ||Fasenra|| mab || humanized || [[CD125]] 
|Y|| asthma
 |-
 | [[Berlimatoxumab]]&lt;ref name=WHOList117 /&gt; || || mab ||human || ''Staphylococcus aureus'' bi-component leukocidin
 ||| ?
 |-
 | [[Bermekimab]] || Xilonix || mab || human || [[IL1A]] 
||| colorectal cancer
 |-
 | [[Bersanlimab]]&lt;ref name=WHOList118 /&gt; || || mab || human || ICAM-1
||| ?
 |-
 | [[Bertilimumab]]&lt;ref name=WHOList88 /&gt; || || mab || human || [[CCL11]] (eotaxin-1) 
||| severe allergic disorders
 |-
 | [[Besilesomab]]&lt;ref name=WHOList92 /&gt; || Scintimun || mab || mouse || [[Carcinoembryonic antigen|CEA]]-related antigen 
||| inflammatory lesions and metastases (detection)
 |-
 | [[Bevacizumab]]&lt;ref name=WHOList83 /&gt; || Avastin || mab || humanized || [[Vascular endothelial growth factor A|VEGF-A]] 
|Y|| metastatic cancer, [[retinopathy of prematurity]]
 |-
 | [[Bezlotoxumab]] ||Zinplava|| mab || human || ''[[Clostridium difficile (bacteria)|Clostridium difficile]]'' 
|Y|| [[Clostridium difficile colitis|''Clostridium difficile'' colitis]]
 |-
 | [[Biciromab]] || FibriScint || Fab' || mouse || [[fibrin]] II, beta chain 
||| [[thromboembolism]] (diagnosis)
 |-
 | [[Bimagrumab]]&lt;ref name=WHOList108 /&gt; || || mab || human || [[ACVR2B]] 
||| [[myostatin]] inhibitor
 |-
 | [[Bimekizumab]]&lt;ref name=WHOList110 /&gt; || || mab || humanized || [[interleukin 17a|IL 17A]] and [[interleukin 17f|IL 17F]] 
||| ankylosing spondylitis, psoriasis
 |-
 | Birtamimab || || mab || chimeric || [[serum amyloid A]] protein
||| [[amyloidosis]]
 |-
 | [[Bivatuzumab mertansine]] || || mab || humanized || [[CD44]] v6 
||| [[squamous cell carcinoma]]
 |-
 | [[Bleselumab]]&lt;ref name=WHOList113 /&gt; || || mab || human || [[CD40]] 
||| organ transplant rejection
 |-
 | [[Blinatumomab]] ||Blincyto|| BiTE || mouse || [[CD19]] 
|Y|| pre-B [[Acute lymphoblastic leukemia|ALL]] (CD19+)
 |-
 | Blontuvetmab&lt;ref name=WHOList114 /&gt; || Blontress || mab || veterinary || [[CD20]] 
|||
 |-
 | [[Blosozumab]]&lt;ref name=WHOList105 /&gt; || || mab || humanized || [[SOST]] 
||| osteoporosis
 |-
 | [[Bococizumab]] || || mab || humanized || neural apoptosis-regulated proteinase 1 
||| dyslipidemia
 |-
 | [[Brazikumab]]&lt;ref name=WHOList115 /&gt; || || mab || human || [[interleukin 23|IL23]] 
||| Crohn's disease
 |-
 | [[Brentuximab vedotin]] ||Adcentris|| mab || chimeric || [[CD30]] (TNFRSF8) 
|Y|| [[Hodgkin lymphoma]]
[[Anaplastic large-cell lymphoma]]
 |-
 | [[Briakinumab]] || || mab || human || [[interleukin-12|IL-12]], [[interleukin-23|IL-23]] 
||| [[psoriasis]], [[rheumatoid arthritis]], [[inflammatory bowel disease]]s, [[multiple sclerosis]]
 |-
 | [[Brodalumab]] ||Siliz|| mab || human || [[interleukin-17|IL-17]] 
|Y||[[Plaque psoriasis]]
 |-
 | [[Brolucizumab]]&lt;ref name=WHOList112 /&gt; || || scFv || humanized || [[vascular endothelial growth factor A|VEGFA]] 
||| wet age-related macular degeneration
 |-
 | [[Brontictuzumab]]&lt;ref name=WHOList111 /&gt; || || mab || humanized || Notch 1 
||| cancer
 |-
 | [[Burosumab]]&lt;ref name=WHOList115 /&gt; || Crysvita || mab || human || [[fibroblast growth factor 23|FGF 23]] 
|Y|| [[X-linked hypophosphatemia]]
 |-
 | [[Cabiralizumab]]&lt;ref name=WHOList114 /&gt; || || mab || humanized || [[colony stimulating factor 1 receptor|CSF1R]] 
||| metastatic pancreatic cancer
 |-
 | [[Camidanlumab tesirine]]&lt;ref name=WHOList117 /&gt; || || mab || human || CD25
||| B-cell Hodgkin’s lymphoma, non-Hodgkin lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia
 |-
 | [[Camrelizumab]]&lt;ref name=WHORList77 /&gt; || || mab || humanized || [[programmed cell death 1|PD-1]]
||| [[hepatocellular carcinoma]]
 |-
 | [[Canakinumab]]&lt;ref name=WHOList97 /&gt; || Ilaris || mab || human || [[Interleukin 1|IL-1]] 
|Y|| [[Cryopyrin-associated periodic syndrome]]
 |-
 | [[Cantuzumab mertansine]] || || mab || humanized || [[mucin]] CanAg 
||| colorectal cancer etc.
 |-
 | [[Cantuzumab ravtansine]]&lt;ref name=WHOList105 /&gt; || || mab || humanized || MUC1 
||| cancers
 |-
 | [[Caplacizumab]]&lt;ref name=WHOList106 /&gt; || Cablivi || sdAb || humanized || VWF 
|Y|| [[thrombotic thrombocytopenic purpura]], [[thrombosis]]
 |-
 | [[Capromab pendetide]] || Prostascint || mab || mouse || prostatic carcinoma cells 
|Y|| prostate cancer (detection)
 |-
 | [[Carlumab]] || || mab || human || [[MCP-1]] 
||| oncology/immune indications
 |-
 | [[Carotuximab]]&lt;ref name=WHOList114 /&gt; || || mab || chimeric || [[endoglin]] 
||| [[angiosarcoma]]
 |-
 | [[Catumaxomab]]&lt;ref name=WHOList93 /&gt; || Removab || 3funct || rat/mouse hybrid || [[EpCAM]], [[CD3 (immunology)|CD3]] 
|Y|| ovarian cancer, malignant [[ascites]], gastric cancer
 |-
 | [[cBR96-doxorubicin immunoconjugate]] || || mab || humanized || [[Lewis antigen system|Lewis-Y antigen]] 
||| cancer
 |-
 | [[Cedelizumab]] || || mab || humanized || [[CD4]] 
||| prevention of organ transplant rejections, treatment of autoimmune diseases
 |-
 | [[Cemiplimab]] || Libtayo || mab || human || [[programmed cell death 1|PCDC1]]
|Y|| cutaneous squamous cell carcinoma
 |-
 | Cergutuzumab amunaleukin&lt;ref name=WHOList113 /&gt; || || mab || humanized || [[Interleukin 2|IL2]] 
||| cancer
 |-
 | [[Certolizumab pegol]]&lt;ref name=WHOList90 /&gt; || Cimzia || Fab' || humanized || [[TNF-α]] 
|Y|| [[Crohn's disease]], [[Rheumatoid arthritis]], [[axial spondyloarthritis]], [[psoriasis arthritis]]
 |-
 | [[Cetrelimab]]&lt;ref name=WHOList118 /&gt; || || mab || human || [[programmed cell death 1|PD-1]]
||| cancer
 |-
 | [[Cetuximab]] || Erbitux || mab || chimeric || [[Epidermal growth factor receptor|EGFR]] 
|Y|| metastatic [[colorectal cancer]] and [[head and neck cancer]]
 |-
 | [[Cibisatamab]]&lt;ref name=WHOList118 /&gt; || || mab || humanized || CEACAM5
||| cancer
 |-
 | [[Cirmtuzumab]] || || ? || humanized || [[ROR1]]
||| chronic lymphocytic leukemia
 |-
 | [[Citatuzumab bogatox]]&lt;ref name=WHOList99 /&gt; || || Fab || humanized || [[EpCAM]] 
||| ovarian cancer and other solid tumors
 |-
 | [[Cixutumumab]] || || mab || human || [[Insulin-like growth factor 1 receptor|IGF-1 receptor (CD221)]] 
|Y|| solid tumors
 |-
 | [[Clazakizumab]]&lt;ref name="ALD518" /&gt; || || mab || humanized || IL6
||| rheumatoid arthritis
 |-
 | [[Clenoliximab]] || || mab || chimeric || [[CD4]] 
||| rheumatoid arthritis
 |-
 | [[Clivatuzumab tetraxetan]] || hPAM4-Cide || mab || humanized || [[MUC1]] 
||| [[pancreatic cancer]]
 |-
 | [[Codrituzumab]]&lt;ref name=WHOList109 /&gt; || || mab || humanized || [[glypican 3]] 
||| cancer
 |-
 | [[Cofetuzumab pelidotin]]&lt;ref name=WHOList117 /&gt; || || mab ||humanized || [[protein tyrosine kinase 7|PTK7]]
||| cancer
 |-
 | [[Coltuximab ravtansine]]&lt;ref name=WHOList109 /&gt; || || mab || chimeric || [[CD19]] 
||| cancer
 |-
 | [[Conatumumab]]&lt;ref name=WHOList99 /&gt; || || mab || human || [[TRAIL-R2]] 
||| cancer
 |-
 | [[Concizumab]]&lt;ref name=WHOList108 /&gt; || || mab || humanized || [[tissue factor pathway inhibitor|TFPI]] 
||| [[bleeding]]
 |-
 | [[Cosfroviximab]]&lt;ref name=WHOList116 /&gt;  || ZMapp || mab || chimeric || ebolavirus glycoprotein
||| Ebola virus
 |-
 | [[Crenezumab]] || || mab || humanized || [[1-40-beta-amyloid|1-40-β-amyloid]] 
||| Alzheimer's disease
 |-
 | [[Crizanlizumab]]&lt;ref name=WHORList77 /&gt; || || mab || humanized || [[selectin P]]
||| [[sickle-cell disease]]
 |-
 | [[Crotedumab]]&lt;ref name=WHOList114 /&gt; || || mab || human || [[glucagon receptor|GCGR]] 
||| diabetes
 |-
 | [[CR6261]] || || mab || human || [[Hemagglutinin (influenza)|Influenza A hemagglutinin]] 
||| infectious disease/influenza A
 |-
 | [[Cusatuzumab]]&lt;ref name=WHOList118 /&gt; || || mab || humanized || CD70
||| cancer
 |-
 | [[Dacetuzumab]]&lt;ref name=WHOList98 /&gt; || || mab || humanized || [[CD40]] 
||| hematologic cancers
 |-
 | [[Daclizumab]] || Zenapax || mab || humanized || [[CD25]] (α chain of [[interleukin 2|IL-2]] receptor) 
|Y|| prevention of organ transplant rejections, [[multiple sclerosis]]
 |-
 | [[Dalotuzumab]] || || mab || humanized || [[Insulin-like growth factor 1 receptor|IGF-1 receptor (CD221)]] 
||| cancer etc.
 |-
 | [[Dapirolizumab pegol]]&lt;ref name=WHOList110 /&gt; || || mab || humanized || [[CD154|CD154 (CD40L)]] 
||| ?
 |-
 | [[Daratumumab]]&lt;ref name=WHOList101 /&gt; ||Darzalex|| mab || human || [[CD38]] 
|Y|| Multiple myeloma
 |-
 | [[Dectrekumab]]&lt;ref name=WHOList112 /&gt; || || mab || human || [[interleukin 13|IL-13]] 
||| ?
 |-
 | [[Demcizumab]] || || mab || humanized || DLL4 
||| cancer
 |-
 | [[Denintuzumab mafodotin]]&lt;ref name=WHOList111 /&gt; || || mab || humanized || [[CD19]] 
||| cancer
 |-
 | [[Denosumab]]&lt;ref name=WHOList94 /&gt; || Prolia || mab || human || [[RANKL]] 
|Y|| [[osteoporosis]], bone metastases etc.
 |-
 | [[Depatuxizumab mafodotin]]&lt;ref name=WHOList115 /&gt; || || mab || chimeric/humanized || EGFR 
||| glioblastoma
 |-
 | [[Iodine (131 I) derlotuximab biotin|Derlotuximab biotin]] || || mab || chimeric || histone complex 
||| recurrent [[glioblastoma multiforme]]
 |-
 | [[Detumomab]] || || mab || mouse || B-lymphoma cell 
||| lymphoma
 |-
 | [[Dezamizumab]]&lt;ref name=WHORList77 /&gt; || || mab || humanized || [[serum amyloid P component]]
||| ?
 |-
 | [[Dinutuximab]] || Unituxin || mab || chimeric || [[GD2|GD2 ganglioside]] 
|Y|| [[neuroblastoma]]
 |-
 | [[Diridavumab]] || || mab || human || hemagglutinin 
||| [[influenza A]]
 |-
 | [[Domagrozumab]]&lt;ref name=WHOList114 /&gt; || || mab || humanized || [[growth differentiation factor 8|GDF-8]] 
||| [[Duchenne muscular dystrophy]]
 |-
 | [[Dorlimomab aritox]]&lt;ref name=WHOList66 /&gt; || || F(ab')&lt;sub&gt;2&lt;/sub&gt; || mouse || ? 
||| ?
 |-
 | Dostarlimab&lt;ref name=WHOList119 /&gt; || || mab || humanized || [[programmed cell death protein 1|PCDP1]]
||| cancer 
 |-
 | [[Drozitumab]] || || mab || human || [[TNFRSF10B|DR5]] 
||| cancer etc.
 |-
 | [[DS-8201]] || || ? || humanized || HER2 
||| gastric or [[gastroesophageal junction]] adenocarcinoma
 |-
 | [[Duligotuzumab]]&lt;ref name=WHOList107 /&gt; || || mab || humanized || [[HER3|ERBB3 (HER3)]] 
||| testicular cancer
 |-
 | [[Dupilumab]] || Dupixent || mab || human || [[Interleukin 4|IL4]] 
|Y|| atopic diseases
 |-
 | [[Durvalumab]] ||Imfinzi|| mab || human || [[CD274|PD-L1]] 
|Y|| cancer
 |-
 | [[Dusigitumab]] || || mab || human || [[Insulin-like growth factor II|ILGF2]] 
||| B-cell malignancies
 |-
 | [[Duvortuxizumab]]&lt;ref name=WHOList116 /&gt;  || || scFv || chimeric/humanized || [[CD19]], [[CD3 epsilon|CD3E]]
||| cancer
 |-
 | [[Ecromeximab]]&lt;ref name=WHOList87 /&gt; || || mab || chimeric || GD3 [[ganglioside]] 
||| malignant melanoma
 |-
 | [[Eculizumab]]&lt;ref name=WHOList87 /&gt; || Soliris || mab || humanized || [[Complement component 5|C5]] 
|Y|| [[paroxysmal nocturnal hemoglobinuria]], atypical HUS
 |-
 | [[Edobacomab]] || || mab || mouse || [[endotoxin]] 
||| sepsis caused by [[Gram-negative]] bacteria
 |-
 | [[Edrecolomab]] || Panorex || mab || mouse || [[EpCAM]] 
||| colorectal carcinoma
 |-
 | [[Efalizumab]]&lt;ref name=WHOList85 /&gt; || Raptiva || mab || humanized || [[LFA-1]] ([[CD11a]]) 
||| [[psoriasis]] (blocks [[T-cell]] migration)
 |-
 | [[Efungumab]]&lt;ref name=WHOList95 /&gt; || Mycograb || scFv || human || [[Hsp90]] 
||| invasive [[Candidiasis|''Candida'' infection]]
 |-
 | [[Eldelumab]] || || mab || human || [[interferon]] gamma-induced protein 
||| [[Crohn's disease]], [[ulcerative colitis]]
 |-
 | Elezanumab&lt;ref name=WHORList77 /&gt; || || mab || human || [[repulsive guidance molecule A|RGMA]]
||| [[spinal cord injury]] and multiple sclerosis
 |-
 | [[Elgemtumab]]&lt;ref name=WHOList112 /&gt; || || mab || human || [[ERBB3]] (HER3) 
||| cancer
 |-
 | [[Elotuzumab]] || Empliciti || mab || humanized || [[SLAMF7]] 
|Y|| [[multiple myeloma]]
 |-
 | [[Elsilimomab]] || || mab || mouse || [[Interleukin 6|IL-6]] 
||| ?
 |-
 | [[Emactuzumab]]&lt;ref name=WHOList111 /&gt; || || mab || humanized || [[colony stimulating factor 1 receptor|CSF1R]] 
||| cancer
 |-
 | [[Emapalumab]] || Gamifant || mab || human || [[interferon gamma]]
|Y|| [[hemophagocytic lymphohistiocytosis]]
 |-
 | [[Emibetuzumab]] || || mab || humanized || [[HHGFR]] 
||| cancer
 |-
 | [[Emicizumab]]&lt;ref name=WHOList113 /&gt; || Hemlibra || mab || humanized || activated [[coagulation factor IX|F9]], [[coagulation factor X|F10]] 
|Y|| [[haemophilia A]]
 |-
 | [[Enapotamab vedotin]]&lt;ref name=WHOList118 /&gt; || || mab || human || AXL
||| cancer
 |-
 | [[Enavatuzumab]] || || mab || humanized || [[TWEAK receptor]] 
||| cancer etc.
 |-
 | [[Enfortumab vedotin]] || || mab || human || nectin-4
||| [[urothelial cancer]]
 |-
 | [[Enlimomab pegol]]&lt;ref name=WHOList77 /&gt; || || mab || mouse || [[ICAM-1]] (CD54) 
||| ?
 |-
 | [[Enoblituzumab]] || || mab || humanized || [[CD276]] 
||| cancer
 |-
 | [[Enokizumab]] || || mab || humanized || [[Interleukin 9|IL9]] 
||| asthma
 |-
 | [[Enoticumab]]&lt;ref name=WHOList107 /&gt; || || mab || human || [[DLL4]] 
||| ?
 |-
 | [[Ensituximab]] || ||  mab || chimeric || [[5AC]] 
||| cancer
 |-
 | [[Epitumomab cituxetan]]&lt;ref name=WHOList51 /&gt; || || mab || mouse || episialin 
||| ?
 |-
 | [[Epratuzumab]] || || mab || humanized || [[CD22]] 
||| cancer, [[systemic lupus erythematosus|SLE]]
 |-
 | [[Eptinezumab]] || || mab || humanized || calcitonin gene-related peptide
||| migraine
 |-
 | [[Erenumab]]&lt;ref name=WHOList115 /&gt; || Aimovig || mab || human || [[calcitonin gene-related peptide receptor|CGRP]] 
|Y|| migraine
 |-
 | [[Erlizumab]]&lt;ref name=WHOList84 /&gt; || || F(ab')&lt;sub&gt;2&lt;/sub&gt; || humanized || [[ITGB2]] (CD18) 
||| [[heart attack]], [[stroke]], [[traumatic shock]]
 |-
 | [[Ertumaxomab]]&lt;ref name=WHOList93/&gt; || Rexomun || 3funct || rat/mouse hybrid || [[HER2/neu]], [[CD3 (immunology)|CD3]] 
|Y|| breast cancer etc.
 |-
 | [[Etaracizumab]] || Abegrin || mab || humanized || [[integrin]] [[alpha-v beta-3|α&lt;sub&gt;v&lt;/sub&gt;β&lt;sub&gt;3&lt;/sub&gt;]] 
|Y|| melanoma, [[prostate cancer]], [[ovarian cancer]] etc.
 |-
 | [[Etigilimab]]&lt;ref name=WHOList118 /&gt; || || mab || humanized || TIGIT
||| ?
 |-
 | [[Etrolizumab]] || || mab || humanized || [[integrin]] [[beta-7|β&lt;sub&gt;7&lt;/sub&gt;]] 
||| [[inflammatory bowel disease]]
 |-
 | [[Evinacumab]] || || mab || human || angiopoietin 3 
||| [[dyslipidemia]]
 |-
 | [[Evolocumab]]&lt;ref name=WHOList108 /&gt; ||Repatha|| mab || human || [[PCSK9]] 
|Y|| [[hypercholesterolemia]]
 |-
 | [[Exbivirumab]]&lt;ref name=WHOList91 /&gt; || || mab || human || [[hepatitis B]] surface antigen 
||| hepatitis B
 |-
 | [[Technetium (99mTc) fanolesomab|Fanolesomab]]&lt;ref name=WHOList86/&gt; || NeutroSpec || mab || mouse || [[CD15]] 
||| [[appendicitis]] (diagnosis)
 |-
 | [[Faralimomab]] || || mab || mouse || [[interferon receptor]] 
||| ?
 |-
 | [[Faricimab]]&lt;ref name=WHOList118 /&gt; || || mab || humanized || VEGF-A and Ang-2
||| angiogenesis, ocular vascular diseases
 |-
 | [[Farletuzumab]] || || mab || humanized || [[folate receptor 1]] 
||| ovarian cancer
 |-
 | [[Fasinumab]] || || mab || human || [[Nerve growth factor|HNGF]] 
||| acute sciatic pain
 |-
 | [[FBTA05]]&lt;ref&gt;{{cite journal | last1=Buhmann| first1=R | title=Immunotherapy of recurrent B–cell malignancies after allo SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion| journal=Bone Marrow Transplantation | volume=43 | issue=5| pages=383–397 | year=2008 | url=http://www.nature.com/bmt/journal/v43/n5/full/bmt2008323a.html | pmid=18850012 | last2=Simoes  | first2=B | last3=Stanglmaier | first3=M | last4=Yang | first4=T | last5=Faltin | first5=M | last6=Bund | first6=D | last7=Lindhofer | first7=H | last8=Kolb | first8=HJ | doi=10.1038/bmt.2008.323|display-authors=etal}}&lt;/ref&gt;&lt;ref&gt;{{cite journal | last1=Boehrer| first1=S | title=Cytotoxic effects of the trifunctional bispecific antibody FBTA05 in ex-vivo cells of chronic lymphocytic leukaemia depend on immune-mediated mechanisms | journal=Anti-Cancer Drugs |volume=12 | issue=10| pages=3085–3091 | year=2011 | doi=10.1097/CAD.0b013e328344887f | pmid=21637160 | last2=Schroeder | first2=Petra | last3=Mueller | first3=Tina | last4=Atz | first4=Judith | last5=Chow | first5=Kai Uwe|display-authors=etal}}&lt;/ref&gt; || Lymphomun || 3funct || rat/mouse hybrid || [[CD20]] 
||| [[chronic lymphocytic leukaemia]]
 |-
 | [[Felvizumab]] || || mab || humanized || [[respiratory syncytial virus]] 
||| respiratory syncytial virus infection
 |-
 | [[Fezakinumab]]&lt;ref name=NCT00883896 /&gt;&lt;ref name=NCT00563524 /&gt; || || mab || human || [[Interleukin 22|IL-22]] 
||| rheumatoid arthritis, [[psoriasis]]
 |-
 | [[Fibatuzumab]]&lt;ref name=WHOList113 /&gt; || || mab || humanized || [[EPHA3|ephrin receptor A3]] 
||| ?
 |-
 | [[Ficlatuzumab]] || || mab || humanized || [[Hepatocyte growth factor|HGF]] 
||| cancer etc.
 |-
 | [[Figitumumab]] || || mab || human || [[Insulin-like growth factor 1 receptor|IGF-1 receptor (CD221)]] 
||| [[adrenocortical carcinoma]], [[non-small cell lung carcinoma]] etc.
 |-
 | [[Firivumab]]&lt;ref name=WHOList111 /&gt; || || mab || human || influenza A virus hemagglutinin 
||| ?
 |-
 | [[Flanvotumab]] || || mab || human || [[TYRP1]] (glycoprotein 75) 
||| melanoma
 |-
 | [[Fletikumab]] || || mab || human || [[interleukin 20|IL 20]] 
||| rheumatoid arthritis
 |-
 | [[Flotetuzumab]]&lt;ref name=WHOList118 /&gt; || || di-scFv || humanized || IL 3 receptor
||| hematological malignancies
 |-
 | [[Fontolizumab]]&lt;ref name=WHOList87 /&gt; || HuZAF || mab || humanized || [[IFN-γ]] 
||| Crohn's disease etc.
 |-
 | [[Foralumab]]&lt;ref name=WHOList103 /&gt; || || mab || human || [[CD3 epsilon]] 
||| ?
 |-
 | [[Foravirumab]]&lt;ref name=WHOList99 /&gt; || || mab || human || [[rabies]] virus glycoprotein 
||| rabies (prophylaxis)
 |-
 | [[Fremanezumab]]&lt;ref name=WHORList77 /&gt; || Ajovy || mab || humanized || calcitonin gene-related peptide alpha
|Y|| migraine and [[cluster headache]]
 |-
 | [[Fresolimumab]] || || mab || human || [[TGF-β]] 
||| [[idiopathic pulmonary fibrosis]], [[focal segmental glomerulosclerosis]], cancer
 |-
 | Frovocimab&lt;ref name=WHOList119 /&gt; || || mab || humanized || [[PCSK9]]
||| hypercholesterolemia
 |-
 | Frunevetmab&lt;ref name=WHOList116 /&gt;  || || mab || veterinary || [[nerve growth factor|NGF]] 
||| ?
 |-
 | [[Fulranumab]] || || mab || human || [[Nerve growth factor|NGF]] 
||| pain
 |-
 | [[Futuximab]]&lt;ref name=WHOList107 /&gt; || || mab || chimeric || [[Epidermal growth factor receptor|EGFR]] 
||| cancer
 |-
 | [[Galcanezumab]]&lt;ref name=WHOList114 /&gt; || Emgality || mab || humanized || [[calcitonin]] 
|Y|| [[migraine]]
 |-
 | [[Galiximab]] || || mab || chimeric || [[CD80]] 
||| [[B-cell lymphoma]]
 |-
 | Gancotamab || || scFv || human || HER2/neu
||| cancer
 |-
 | [[Ganitumab]] || || mab || human || [[Insulin-like growth factor 1 receptor|IGF-1 receptor (CD221)]] 
||| cancer
 |-
 | [[Gantenerumab]]&lt;ref name=WHOList97 /&gt; || || mab || human || [[beta amyloid]] 
||| Alzheimer's disease
 |-
 | [[Gatipotuzumab]]&lt;ref name=WHOList116 /&gt;  || || mab || humanized || [[mucin 1|MUC1]]
||| cancer
 |-
 | [[Gavilimomab]]&lt;ref name=WHOList84 /&gt; || || mab || mouse || [[CD147]] (basigin) 
||| [[graft versus host disease]]
 |-
 | [[Gedivumab]]&lt;ref name=WHOList116 /&gt; || || mab || human || [[hemagglutinin HA]]
||| ?
 |-
 | [[Gemtuzumab ozogamicin]] || Mylotarg || mab || humanized || [[CD33]] 
|Y|| [[acute myelogenous leukemia]]
 |-
 | [[Gevokizumab]] || || mab || humanized || [[IL-1β]] 
||| [[diabetes]] etc.
 |-
 | Gilvetmab&lt;ref name=WHOList116 /&gt;  || || mab || veterinary || [[programmed cell death 1|PCDC1]]
||| ?
 |-
 | Gimsilumab&lt;ref name=WHOList117 /&gt; || || mab || human || [[colony stimulating factor 2|CSF2]]
||| rheumatoid arthritis
 |-
 | [[Girentuximab]]&lt;ref name=WHOList101 /&gt; || Rencarex || mab || chimeric || [[carbonic anhydrase 9]] (CA-IX)
|Y|| clear cell [[renal cell carcinoma]]&lt;ref&gt;http://www.prnewswire.com/news-releases/prometheus-obtains-exclusive-us-commercialization-rights-for-rencarex-121075044.html&lt;/ref&gt;
 |-
 | [[Glembatumumab vedotin]]&lt;ref name=WHOList102 /&gt;&lt;ref name="Glembatumumab" /&gt; || || mab || human || [[GPNMB]] 
||| melanoma, breast cancer
 |-
 | [[Golimumab]]&lt;ref name=WHOList91 /&gt; || Simponi || mab || human || [[TNF-α]] 
|Y|| rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis
 |-
 | [[Gomiliximab]] || || mab || chimeric || [[CD23]] ([[IgE receptor]]) 
||| [[allergic asthma]]
 |-
 | Gosuranemab || || mab || humanized || [[tau protein]]
||| [[progressive supranuclear palsy]]
 |-
 | [[Guselkumab]] || Tremfya || mab || human || [[Interleukin 23|IL23]] 
|Y|| [[psoriasis]]
 |-
 | [[Ianalumab]]&lt;ref name=WHOList117 /&gt; || || mab || human || [[BAFF-R]]
 ||| autoimmune hepatitis
|-
 | [[Ibalizumab]]&lt;ref name=WHOList97 /&gt; || Trogarzo || mab || humanized || [[CD4]] 
|Y|| [[HIV infection]]
 |-
 | [[IBI308]] || || ? || human || [[programmed cell death 1|PD-1]]
||| squamous cell [[non-small cell lung carcinoma|non-small cell lung cancer]]
 |-
 | [[Ibritumomab tiuxetan]] || Zevalin || mab || mouse || [[CD20]] 
|Y|| non-Hodgkin's lymphoma
 |-
 | [[Icrucumab]] || || mab || human || [[VEGFR-1]] 
||| cancer etc.
 |-
 | [[Idarucizumab]]&lt;ref name=WHOList109 /&gt; ||Praxbind|| mab || humanized || [[dabigatran]] 
|Y|| reversal of anticoagulant effects of dabigatran
 |-
 | [[Ifabotuzumab]]&lt;ref name=WHORList77 /&gt; || || mab || humanized || [[ephrin receptor A3|EPHA3]]
||| ?
 |-
 | [[Igovomab]] || Indimacis-125 || F(ab')&lt;sub&gt;2&lt;/sub&gt; || mouse || [[CA-125]] 
||| ovarian cancer (diagnosis)
 |-
 | [[Iladatuzumab vedotin]]&lt;ref name=WHOList117 /&gt; ||  ||  mab || humanized || [[CD97B]]
||| cancer
 |-
 | [[IMAB362]] ||  || mab || human || [[CLDN18]].2 
||| gastrointestinal adenocarcinomas and pancreatic tumor
 |-
 | [[Imalumab]]&lt;ref name=WHOList111 /&gt; || || mab || human || [[macrophage migration inhibitory factor|MIF]] 
||| cancer
 |-
 | [[Imaprelimab]]&lt;ref name=WHOList118 /&gt; || || mab || humanized || [[melanoma cell adhesion molecule|MCAM]]
||| ?
 |-
 | [[Imciromab]] || Myoscint || mab || mouse || [[cardiac]] [[myosin]] 
|Y|| [[cardiac]] imaging
 |-
 | [[Imgatuzumab]]&lt;ref name=WHOList107 /&gt; || || mab || humanized || [[Epidermal growth factor receptor|EGFR]] 
||| cancer
 |-
 | [[Inclacumab]]&lt;ref name=WHOList106 /&gt; || || mab || human || selectin P 
||| cardiovascular disease
 |-
 | [[Indatuximab ravtansine]]&lt;ref name=WHOList105 /&gt; || || mab || chimeric || [[SDC1]] 
||| cancer
 |-
 | [[Indusatumab vedotin]]&lt;ref name=WHOList112 /&gt; || || mab || human || [[guanylate cyclase 2C|GUCY2C]] 
||| cancer
 |-
 | [[Inebilizumab]]&lt;ref name=WHOList113 /&gt; || || mab || humanized || [[CD19]] 
||| cancer, [[systemic sclerosis]], [[multiple sclerosis]]
 |-
 | [[Infliximab]] || Remicade || mab || chimeric || [[TNF-α]] 
|Y|| rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, Crohn's disease, ulcerative colitis
 |-
 | [[Intetumumab]]&lt;ref name=NCT00537381 /&gt;&lt;ref name=NCT00246012 /&gt; || || mab || human || [[CD51]] 
||| solid tumors (prostate cancer, melanoma)
 |-
 | [[Inolimomab]] || || mab || mouse || [[CD25]] (α chain of [[Interleukin 2|IL-2]] receptor) 
||| graft versus host disease
 |-
 | [[Inotuzumab ozogamicin]]&lt;ref name=WHOList92 /&gt; || Besponsa || mab || humanized || [[CD22]] 
|Y|| [[Acute lymphoblastic leukemia|ALL]]
 |-
 | [[Ipilimumab]]&lt;ref name=WHOList94 /&gt; || Yervoy || mab || human || [[CD152]] 
|Y|| [[melanoma]]
 |-
 | [[Iomab-B]] || || ? || mouse || [[CD45]]
||| ablation of bone marrow
 |-
 | [[Iratumumab]]&lt;ref name=WHOList94 /&gt; || || mab || human || [[CD30]] (TNFRSF8) 
||| [[Hodgkin's lymphoma]]
 |-
 | [[Isatuximab]] || || mab || chimeric || [[CD38]] 
||| multiple myeloma
 |-
 | [[Iscalimab]]&lt;ref name=WHOList118 /&gt; || || mab || human || CD40
||| ?
 |-
 | [[Istiratumab]]&lt;ref name=WHOList117 /&gt; || || mab || human || [[insulin-like growth factor 1 receptor|IGF1R]], [[CD221]]
||| advanced solid tumors
 |-
 | [[Itolizumab]]&lt;ref name=WHOList103 /&gt; || Alzumab || mab || humanized || [[CD6]] 
|Y|| psoriasis
 |-
 | [[Ixekizumab]] ||Taltz|| mab || humanized || [[interleukin 17a|IL 17A]] 
|Y|| autoimmune diseases
 |-
 | [[Keliximab]] || || mab || chimeric || [[CD4]] 
||| chronic asthma
 |-
 | [[Labetuzumab]]&lt;ref name=WHOList85 /&gt; || CEA-Cide || mab || humanized || [[Carcinoembryonic antigen|CEA]] 
||| [[colorectal cancer]]
 |-
 | [[Lacnotuzumab]]&lt;ref name=WHOList116 /&gt; || || mab || humanized || [[colony stimulating factor 1|CSF1]], [[macrophage colony stimulating factor|MCSF]]
||| cancer
 |-
 | [[Ladiratuzumab vedotin]]&lt;ref name=WHOList117 /&gt; || || mab || humanized || [[LIV-1]]
||| cancer
 |-
 | [[Lampalizumab]]&lt;ref name=WHOList107 /&gt; || || Fab || humanized || [[Complement factor D|CFD]] 
||| geographic atrophy secondary to age-related macular degeneration
 |-
 | [[Lanadelumab]]&lt;ref name=WHOList114 /&gt; || Takhzyro || mab || human || [[kallikrein]] 
|Y|| [[angioedema]]
 |-
 | [[Landogrozumab]]&lt;ref name=WHOList113 /&gt; || || mab || humanized || [[growth differentiation factor 8|GDF-8]] 
||| muscle wasting disorders
 |-
 | [[Laprituximab emtansine]]&lt;ref name=WHOList114 /&gt; || || mab || chimeric || [[epidermal growth factor receptor|EGFR]] 
||| ?
 |-
 | [[Larcaviximab]]&lt;ref name=WHOList116 /&gt; || || mab || chimeric || ebolavirus glycoprotein
||| Ebola virus
 |-
 | [[Lebrikizumab]] || || mab || humanized || [[Interleukin 13|IL-13]] 
||| [[asthma]]
 |-
 | [[Lemalesomab]]&lt;ref name=WHOList84 /&gt; || || mab || mouse || NCA-90 (granulocyte antigen) 
||| diagnostic agent
 |-
 | [[Lendalizumab]]&lt;ref name=WHOList114 /&gt; || || mab || humanized || C5
||| ?
 |-
 | [[Lenvervimab]]&lt;ref name=WHOList118 /&gt; || || mab || humanized || hepatitis B surfage antigen
||| hepatitis B
 |-
 | [[Lenzilumab]]&lt;ref name=WHOList111 /&gt; || || mab || human || [[colony stimulating factor 2|CSF2]] 
||| [[chronic myelomonocytic leukemia]] and [[juvenile myelomonocytic leukemia]]
 |-
 | [[Lerdelimumab]]&lt;ref name=WHOList83 /&gt; || || mab || human || [[TGF beta 2]] 
||| reduction of scarring after [[glaucoma surgery]]
 |-
 | [[Leronlimab]]&lt;ref name=WHOList118 /&gt; || || mab || humanized || CCR5
||| ?
 |-
 | [[Lesofavumab]]&lt;ref name=WHOList116 /&gt; || || mab || human || hemagglutinin HA
||| ?
 |-
 | [[Letolizumab]]&lt;ref name=WHOList116 /&gt; || || scFv || humanized || [[tumor necrosis factor related activation protein|TRAP]]
||| inflammatory diseases
 |-
 | [[Lexatumumab]]&lt;ref name=WHOList95 /&gt; || || mab || human || [[TRAIL-R2]] 
||| cancer
 |-
 | [[Libivirumab]]&lt;ref name=WHOList91 /&gt; || || mab || human || [[hepatitis B]] surface antigen 
||| hepatitis B
 |-
 | [[Lifastuzumab vedotin]] || || mab || humanized || phosphate-sodium co-transporter 
||| cancer
 |-
 | [[Ligelizumab]]&lt;ref name=WHOList107 /&gt; || || mab || humanized || [[IGHE]] 
||| severe asthma and [[chronic spontaneous urticaria]]
 |-
 | [[Loncastuximab tesirine]]&lt;ref name=WHOList117 /&gt; || || mab || chimeric || [[CD19]]
||| cancer
 |-
 | [[Losatuxizumab vedotin]]&lt;ref name=WHOList116 /&gt; || || mab || chimeric/humanized || [[epidermal growth receptor factor|EGRF]], [[ERBB1]] [[HER1]]
||| cancer
 |-
 | [[Lutetium (177 Lu) lilotomab satetraxetan|Lilotomab satetraxetan]]&lt;ref name=WHOList112 /&gt; || || mab || mouse || [[CD37]] 
||| cancer
 |-
 | [[Lintuzumab]] || || mab || humanized || [[CD33]] 
||| cancer
 |-
 | [[Lirilumab]]&lt;ref name=WHOList107 /&gt; || || mab || human || [[KIR2D]] 
||| solid and hematological cancers
 |-
 | [[Lodelcizumab]]&lt;ref name=WHOList108 /&gt; || || mab || humanized || [[PCSK9]] 
||| [[hypercholesterolemia]]
 |-
 | [[Lokivetmab]]&lt;ref name=WHOList112 /&gt; || Cytopoint&lt;ref name="Guthrie 2017"&gt;{{cite news |last=Guthrie|first=Arlo|title=Zoetis launches breakthrough treatment for canine atopic dermatitis |url=https://www.vetnurse.co.uk/b/veterinary-nursing-news/archive/2017/06/27/zoetis-launches-breakthrough-treatment-for-canine-atopic-dermatitis.aspx |accessdate=2018-07-06 |work=VetNurse News |date=27 June 2017}}&lt;/ref&gt; || mab || veterinary || ''[[Canis lupus familiaris]]'' [[interleukin 31|IL31]] 
|Y|| clinical signs of atopic dermatitis in dogs&lt;ref name="Guthrie 2017" /&gt;
 |-
 | [[Lorvotuzumab mertansine]] || || mab || humanized || [[CD56]] 
||| cancer
 |-
 | [[Lucatumumab]]&lt;ref name=WHOList98 /&gt; || || mab || human || [[CD40]] 
||| [[multiple myeloma]], [[non-Hodgkin's lymphoma]], [[Hodgkin's lymphoma]]
 |-
 | [[Lulizumab pegol]] || || mab || humanized || [[CD28]] 
||| autoimmune diseases
 |-
 | [[Lumiliximab]]&lt;ref name=WHOList90 /&gt; || || mab || chimeric || [[CD23]] ([[IgE receptor]]) 
||| [[chronic lymphocytic leukemia]]
 |-
 | [[Lumretuzumab]]&lt;ref name=WHOList111 /&gt; || || mab || humanized || [[ERBB3]] (HER3) 
||| cancer
 |-
 | [[Lupartumab amadotin]]&lt;ref name=WHORList77 /&gt; || || mab || human || LYPD3
||| ?
 |-
 | [[Lutikizumab]]&lt;ref name=WHORList77 /&gt; || || mab || humanized || interleukin 1 alpha
||| ?
 |- 
 | [[Mapatumumab]]&lt;ref name=WHOList93 /&gt; || || mab || human || [[TRAIL]]-R1 
||| cancer
 |-
 | [[Margetuximab]] || || mab || humanized || HER2
||| breast cancer
 |-
 | Marstacimab || || mab || human || [[tissue factor pathway inhibitor|TFPI]]
||| bleeding with [[hemophilia]]
 |-
 | [[Maslimomab]] || || ? || mouse || T-cell receptor 
|||
 |-
 | [[Mavrilimumab]] || || mab || human || [[GMCSF receptor alpha-chain|GMCSF receptor α-chain]] 
||| [[rheumatoid arthritis]]
 |-
 | [[Matuzumab]]&lt;ref name=WHOList88 /&gt; || || mab || humanized || [[Epidermal growth factor receptor|EGFR]] 
||| colorectal, lung and stomach cancer
 |-
 | [[Mepolizumab]] || Bosatria || mab || humanized || [[Interleukin 5|IL-5]] 
|Y|| asthma and white blood cell diseases
 |-
 | [[Metelimumab]]&lt;ref name=WHOList86 /&gt; || || mab || human || [[TGF beta 1]] 
||| [[systemic scleroderma]]
 |-
 | [[Milatuzumab]]&lt;ref name=WHOList98 /&gt; || || mab || humanized || [[CD74]] 
||| multiple myeloma and other hematological malignancies
 |-
 | [[Minretumomab]] || || mab || mouse || [[Tumor-associated glycoprotein 72|TAG-72]] 
||| tumor detection (and therapy?)
 |-
 | [[Mirikizumab]]&lt;ref name=WHOList117 /&gt; || || mab || humanized || [[interleukin 23 alpha|IL23A]]
||| psoriasis
 |-
 | [[Mirvetuximab soravtansine]] || || mab || chimeric || [[folate receptor alpha]] 
||| ovarian cancer
 |-
 | [[Mitumomab]] || || mab || mouse || GD3 [[ganglioside]] 
||| [[small cell lung carcinoma]]
 |-
 | [[Modotuximab]] || || mab || chimeric || EGFR extracellular domain III
||| cancer
 |-
 | [[Mogamulizumab]] || Poteligeo || mab || humanized || [[CCR4]] 
|Y|| [[adult T-cell leukemia/lymphoma]]
 |-
 | [[Monalizumab]]&lt;ref name=WHOList113 /&gt; || || mab || humanized || [[NKG2|NKG2A]] 
||| rheumatoid arthritis, gynecologic malignancies, and other cancers
 |-
 | [[Morolimumab]] || || mab || human || [[Rhesus factor]] 
|||
 |-
 | [[Mosunetuzumab]]&lt;ref name=WHOList117 /&gt; || || mab || humanized || [[CD3 epsilon|CD3E]], [[MS4A1]], [[CD20]]
||| cancer
 |-
 | [[Motavizumab]]&lt;ref name=WHOList95 /&gt; || Numax || mab || humanized || [[respiratory syncytial virus]] 
||| respiratory syncytial virus (prevention)
 |-
 | [[Moxetumomab pasudotox]] || Lumoxiti || mab || mouse || [[CD22]] 
|Y|| [[hairy cell leukemia]]
 |-
 | [[Muromonab-CD3]] || Orthoclone OKT3 || mab || mouse || [[CD3 (immunology)|CD3]] 
||| prevention of organ transplant rejections
 |-
 | [[Nacolomab tafenatox]] || || Fab || mouse || C242 antigen 
||| colorectal cancer
 |-
 | [[Namilumab]]&lt;ref name=WHOList104 /&gt; || || mab || human || [[CSF2]] 
|||
 |-
 | [[Naptumomab estafenatox]]&lt;ref name=WHOList96 /&gt; || || Fab || mouse || [[5T4]] 
||| non-small cell lung carcinoma, [[renal cell carcinoma]]
 |-
 | [[Naratuximab emtansine]]&lt;ref name=WHOList114 /&gt; || || mab || chimeric || [[CD37]] 
|||
 |-
 | [[Narnatumab]] || || mab || human || [[MST1R]] (aka RON)
||| cancer
 |-
 | [[Natalizumab]] || Tysabri || mab || humanized || [[integrin]] α&lt;sub&gt;4&lt;/sub&gt; 
|Y|| [[multiple sclerosis]], Crohn's disease
 |-
 | [[Navicixizumab]]&lt;ref name=WHOList114 /&gt; || || mab || chimeric/humanized || [[DLL4]] and [[VEGFA]]
||| cancer
 |-
 | [[Navivumab]]&lt;ref name=WHOList113 /&gt; || || mab || human || [[influenza A virus]] [[hemagglutinin HA]] 
|||
 |-
 | [[Naxitamab]] || || ? || humanized || c-Met
||| high-risk neuroblastoma and refractory osteomedullary disease
 |-
 | [[Nebacumab]] || || mab || human || [[endotoxin]] 
||| sepsis
 |-
 | [[Necitumumab]]&lt;ref name=WHOList100 /&gt; ||Portrazza|| mab || human || [[Epidermal growth factor receptor|EGFR]] 
|Y|| non-small cell lung carcinoma
 |-
 | [[Nemolizumab]]&lt;ref name=WHOList112 /&gt; || || mab || humanized || [[IL31RA]] 
||| [[eczema]]&lt;ref&gt;http://www.nejm.org/doi/full/10.1056/NEJMoa1606490&lt;/ref&gt;
 |-
 | [[NEOD001]] || || ? || humanized || amyloid
||| [[primary systemic amyloidosis]]
 |-
 | [[Nerelimomab]] || || mab || mouse || [[TNF-α]] 
||| ?
 |-
 | [[Nesvacumab]] || || mab || human || [[angiopoietin 2]] 
||| cancer
 |-
 | [[Netakimab]]&lt;ref name=WHOList118 /&gt; || || mab || chimeric || interleukin 17A
||| ?
 |-
 | [[Nimotuzumab]]&lt;ref name=WHOList94 /&gt;&lt;ref name=WHOList56 /&gt; || Theracim, Theraloc || mab || humanized || [[epidermal growth factor receptor|EGFR]] 
|Y|| squamous cell carcinoma, head and neck cancer, [[nasopharyngeal cancer]], [[glioma]]
 |-
 | Nirsevimab || || mab || human || [[respiratory syncytial virus fusion protein|RSVFR]]
||| [[respiratory syncytial virus]]
 |-
 | [[Nivolumab]] || Opdivo || mab || human || [[programmed cell death 1|PD-1]] 
|Y|| cancer
 |-
 | [[Technetium (99mTc) nofetumomab merpentan|Nofetumomab merpentan]] || Verluma || Fab || mouse || ? 
||| cancer (diagnosis)
 |-
 | [[Obiltoxaximab]] || Anthim || mab || chimeric || ''[[Bacillus anthracis]]'' anthrax 
|Y|| ''Bacillus anthracis'' spores
 |-
 | [[Obinutuzumab]] ||Gazyva || mab || humanized || [[CD20]] 
|Y||[[Chronic lymphatic leukemia]]
 |-
 | [[Ocaratuzumab]] || || mab || humanized || [[CD20]] 
||| cancer
 |-
 | [[Ocrelizumab]]&lt;ref name=WHOList94 /&gt; ||Ocrevus|| mab || humanized || [[CD20]] 
|Y|| rheumatoid arthritis, lupus erythematosus etc.
 |-
 | [[Odulimomab]] || || mab || mouse || [[LFA-1]] ([[CD11a]]) 
||| prevention of organ transplant rejections, immunological diseases
 |-
 | [[Ofatumumab]]&lt;ref name=WHOList93 /&gt; || Arzerra || mab || human || [[CD20]] 
|Y|| chronic lymphocytic leukemia etc.
 |-
 | [[Olaratumab]] ||Lartruvo|| mab || human || [[Platelet-derived growth factor receptor alpha|PDGF-R α]] 
|Y|| cancer
 |-
 | [[Oleclumab]]&lt;ref name=WHOList116 /&gt; || || mab || human || [[5'-nucleotidase]]
||| [[pancreatic cancer|pancreatic]] and [[colorectal cancer]]
 |-
 | [[Olendalizumab]] || || mab || humanized || complement C5a
||| systemic lupus erythematosus, [[lupus nephritis]], acute [[graft-versus-hose disease]]
 |-
 | [[Olokizumab]]&lt;ref name=WHOList103 /&gt; || || mab || humanized || [[Interleukin 6|IL6]] 
||| rheumatoid arthritis
 |-
 | [[Omalizumab]]&lt;ref name=WHOList84 /&gt; || Xolair || mab || humanized || [[IgE]] [[Fc region]] 
|Y|| allergic asthma
 |-
 | Omburtamab&lt;ref name=WHOList119 /&gt; || || mab || mouse || CD276
||| cancer
 |-
 | [[OMS721]] || || ? || human || MASP-2
||| atypical hemolytic uremic syndrome
 |-
 | [[Onartuzumab]] || || Fab || humanized || human scatter factor receptor kinase 
||| cancer
 |-
 | [[Ontuxizumab]] || || mab || chimeric/humanized || [[tumor endothelial marker 1|TEM1]] 
||| cancer
 |-
 | [[Onvatilimab]]&lt;ref name=WHOList118 /&gt; || || mab || human || [[VISTA_(protein)|VSIR]]
||| ?
 |-
 | [[Opicinumab]] || || mab || human || LINGO-1 
||| [[multiple sclerosis]]
 |-
 | [[Oportuzumab monatox]]&lt;ref name=WHOList100 /&gt; || Vicinium || scFv || humanized || [[EpCAM]] 
||| [[bladder cancer]]
 |-
 | [[Oregovomab]]&lt;ref name=WHOList86 /&gt; || OvaRex || mab || mouse || [[CA-125]] 
||| ovarian cancer
 |-
 | [[Orticumab]]&lt;ref name=WHOList107 /&gt; || || mab || human || [[oxidized low-density lipoprotein|oxLDL]] 
|||
 |-
 | [[Otelixizumab]]&lt;ref name=WHOList98 /&gt; || || mab || chimeric/humanized || [[CD3 (immunology)|CD3]] 
||| diabetes mellitus type 1
 |-
 | Otilimab || || mab || human || GMCSF
||| osteoarthritis, rheumatoid arthritis
 |-
 | [[Otlertuzumab]] || || mab || humanized || [[CD37]] 
||| cancer
 |-
 | [[Oxelumab]] || || mab || human || [[OX-40]] 
||| asthma
 |-
 | [[Ozanezumab]] || || mab || humanized || NOGO-A 
||| ALS and [[multiple sclerosis]]
 |-
 | [[Ozoralizumab]] || || mab || humanized || ''[[TNF-α]]'' 
||| inflammation
 |-
 | [[Pagibaximab]]&lt;ref name=WHOList93 /&gt; || || mab || chimeric || [[lipoteichoic acid]] 
||| sepsis (''[[Staphylococcus]]'')
 |-
 | [[Palivizumab]] || Synagis, Abbosynagis || mab || humanized || F protein of [[respiratory syncytial virus]] 
|Y|| respiratory syncytial virus (prevention)
 |-
 | [[Pamrevlumab]]&lt;ref name=WHOList113 /&gt; || || mab || human || [[connective tissue growth factor|CTGF]] 
||| idiopathic pulmonary fibrosis (IPF), pancreatic cancer
 |-
 | [[Panitumumab]]&lt;ref name=WHOList91 /&gt; || Vectibix || mab || human || [[epidermal growth factor receptor|EGFR]] 
|Y|| colorectal cancer
 |-
 | [[Pankomab]] || || mab || humanized || tumor specific glycosylation of [[MUC1]] 
||| ovarian cancer
 |-
 | [[Panobacumab]]&lt;ref name=WHOList100 /&gt; || || mab || human || ''[[Pseudomonas aeruginosa]]'' 
||| ''Pseudomonas aeruginosa'' infection
 |-
 | [[Parsatuzumab]]&lt;ref name=WHOList107 /&gt; || || mab || human || [[EGFL7]] 
||| cancer
 |-
 | [[Pascolizumab]]&lt;ref name=WHOList87 /&gt; || || mab || humanized || [[Interleukin 4|IL-4]] 
||| asthma
 |-
 | [[Pasotuxizumab]]&lt;ref name=WHOList111 /&gt; || || mab || chimeric/humanized || [[folate hydrolase]] 
||| cancer
 |-
 | [[Pateclizumab]]&lt;ref name=WHOList105 /&gt; || || mab || humanized || [[lymphotoxin alpha|LTA]] 
||| [[TNF]]
 |-
 | [[Patritumab]]&lt;ref name=WHOList106 /&gt; || || mab || human || ERBB3 ([[HER3]]) 
||| cancer
 |-
 | [[PDR001]] || || ? || humanized || [[programmed cell death 1|PD-1]]
||| melanoma
 |-
 | [[Pembrolizumab]] ||Keytruda|| mab || humanized || [[programmed cell death 1|PD-1]] 
|Y|| [[melanoma]] and other cancers
 |-
 | [[Pemtumomab]] || Theragyn || ? || mouse || [[MUC1]] 
||| cancer
 |-
 | [[Perakizumab]]&lt;ref name=WHOList107 /&gt; || || mab || humanized || [[interleukin 17a|IL 17A]] 
||| [[arthritis]]
 |-
 | [[Pertuzumab]] || Omnitarg || mab || humanized || [[HER2/neu]] 
|Y|| cancer
 |-
 | [[Pexelizumab]]&lt;ref name=WHOList85 /&gt; ||  || scFv || humanized || C5
||| reduction of side effects of [[cardiac surgery]]
 |-
 | [[Pidilizumab]] || || mab || humanized || [[programmed cell death 1|PD-1]] 
||| cancer and infectious diseases
 |-
 | [[Pinatuzumab vedotin]]&lt;ref name=WHOList108 /&gt; || || mab || humanized || [[CD22]] 
||| cancer
 |-
 | [[Pintumomab]] || || mab || mouse || [[adenocarcinoma]] antigen 
||| [[adenocarcinoma]] (imaging)
 |-
 | [[Placulumab]] || || mab || human || human TNF 
||| pain and inflammatory diseases
 |-
 | [[Plozalizumab]]&lt;ref name=WHOList113 /&gt; || || mab || humanized || [[chemokine receptor 2|CCR2]] 
||| [[diabetic nephropathy]] and [[arteriovenous graft patency]]
 |-
 | [[Pogalizumab]]&lt;ref name=WHOList114 /&gt; || || mab || humanized || [[tumor necrosis factor receptor|TNFR]] superfamily member 4 
||| ?
 |-
 | [[Polatuzumab vedotin]]&lt;ref name=WHOList108 /&gt; || || mab || humanized || [[CD79B]] 
||| [[diffuse large B-cell lymphoma]]
 |-
 | [[Ponezumab]] || || mab || humanized ||human [[beta-amyloid]] 
||| Alzheimer's disease
 |-
 | [[Porgaviximab]]&lt;ref name=WHOList116 /&gt; || || mab || chimeric || Zaire ebolavirus glycoprotein 
||| Ebola virus disease
 |-
 | [[Prasinezumab]]&lt;ref name=WHOList117 /&gt; || || mab || humanized || [[sodium cyclopentadienide|NACP]]
||| [[Parkinson's disease]]
 |-
 | [[Prezalizumab]]&lt;ref name=WHOList114 /&gt; || || mab || humanized || [[inducible T-cell co-stimulatory ligand|ICOSL]] 
||| ?
 |-
 | [[Priliximab]] || || mab || chimeric || [[CD4]] 
||| Crohn's disease, multiple sclerosis
 |-
 | [[Pritoxaximab]]&lt;ref name=WHOList108 /&gt; || || mab || chimeric || ''[[Escherichia coli|E. coli]]'' [[shiga toxin]] type-1 
||| ?
 |-
 | [[Pritumumab]] || || mab || human || [[vimentin]] 
||| [[brain cancer]]
 |-
 | [[PRO 140]] || || ? || humanized || [[CCR5]] 
||| HIV infection
 |-
 | [[Quilizumab]]&lt;ref name=WHOList106 /&gt; || || mab || humanized || IGHE 
||| asthma
 |-
 | [[Racotumomab]]&lt;ref name=WHOList100 /&gt; || Vaxira || mab || mouse || NGNA ganglioside
|Y|| non-small cell lung cancer
 |-
 | [[Radretumab]]&lt;ref name=WHOList104 /&gt; || || mab || human || [[fibronectin]] extra domain-B 
||| cancer
 |-
 | [[Rafivirumab]]&lt;ref name=WHOList99 /&gt; || || mab || human || [[rabies]] virus glycoprotein 
||| rabies (prophylaxis)
 |-
 | [[Ralpancizumab]] || || mab || humanized || neural apoptosis-regulated proteinase 1 
||| [[dyslipidemia]]
 |-
 | [[Ramucirumab]] || Cyramza || mab || human || [[VEGFR2]] 
|Y|| solid tumors
 |-
 | Ranevetmab || || mab || veterinary || NGF
||| osteoarthritis in [[dog]]s
 |-
 | [[Ranibizumab]]&lt;ref name=WHOList90 /&gt; || Lucentis || Fab || humanized || [[VEGF-A]] 
|Y|| [[macular degeneration]] (wet form)
 |-
 | [[Raxibacumab]]&lt;ref name=WHOList92 /&gt; || || mab || human || [[anthrax]] toxin, protective antigen 
|Y|| anthrax (prophylaxis and treatment)
 |-
 | [[Ravagalimab]]&lt;ref name=WHOList118 /&gt; || || mab || humanized || CD40
||| Crohn's disease
 |-
 | [[Ravulizumab]]&lt;ref name=WHOList117 /&gt; || || mab || humanized || C5
||| [[paroxysmal nocturnal hemaglobinuria]], [[atypical hemolytic uremic syndrome]]
 |-
 | [[Refanezumab]] || || mab || humanized || myelin-associated glycoprotein 
||| recovery of motor function after stroke
 |-
 | [[Regavirumab]] || || mab || human || [[cytomegalovirus]] glycoprotein B 
||| cytomegalovirus infection
 |-
 | [[Relatlimab]] || || mab || human || [[LAG3]]
||| melanoma
 |-
 | [[Remtolumab]]&lt;ref name=WHORList77 /&gt; || || mab || human || interleukin 17 alpha, TNF
||| ?
 |-
 | [[Reslizumab]]&lt;ref name=WHOList85 /&gt; || Cinqair || mab || humanized || [[Interleukin 5|IL-5]] 
|Y|| [[inflammation]]s of the airways, skin and gastrointestinal tract
 |-
 | [[Rilotumumab]] || || mab || human || [[hepatocyte growth factor|HGF]] 
||| solid tumors
 |-
 | [[Rinucumab]] || || mab || human || platelet-derived growth factor receptor beta 
||| neovascular age-related macular degeneration
 |-
 | [[Risankizumab]]&lt;ref name=WHOList113 /&gt; || || mab || humanized || [[IL23A]] 
||| Crohn's disease, psoriasis, psoriatic arthritis, and asthma
 |-
 | [[Rituximab]] || MabThera, Rituxan || mab || chimeric || [[CD20]] 
|Y|| lymphomas, [[leukemia]]s, some autoimmune disorders
 |-
 | [[Rivabazumab pegol]]&lt;ref name=WHOList113 /&gt; || || mab || humanized || ''[[Pseudomonas aeruginosa]]'' type III secretion system 
||| ?
 |-
 | [[Robatumumab]] || || mab || human || [[Insulin-like growth factor 1 receptor|IGF-1 receptor (CD221)]] 
||| cancer
 |-
 | [[Rmab]] || RabiShield || ? || human || rabies virus G glycoprotein
|Y|| [[post-exposure prophylaxis]] of rabies
 |-
 | [[Roledumab]]&lt;ref name=WHOList103 /&gt; || || mab || human || [[RHD (gene)|RHD]] 
||| [[Rh disease]]
 |-
 | [[Romilkimab]]&lt;ref name=WHOList118 /&gt; || || mab || chimeric/humanized || interleukin 13
||| ?
 |-
 | [[Romosozumab]] || Evenity || mab || humanized || [[sclerostin]] 
||| [[osteoporosis]]
 |-
 | [[Rontalizumab]] || || mab || humanized || [[Interferon-alpha|IFN-α]] 
||| [[systemic lupus erythematosus]]
 |-
 | [[Rosmantuzumab]] || || mab || humanized || root plate-specific spondin 3
||| cancer
 |-
 | [[Rovalpituzumab tesirine]]&lt;ref name=WHOList113 /&gt; || || mab || humanized || [[delta-like ligand 3|DLL3]] 
||| small cell lung cancer
 |-
 | [[Rovelizumab]] || LeukArrest || mab || humanized || [[CD11]], [[CD18]] 
|Y|| [[haemorrhagic shock]] etc.
 |-
 | [[Rozanolixizumab]]&lt;ref name=WHORList77 /&gt; || || mab || chimeric/humanized || FCGRT
||| ?
 |-
 | [[Ruplizumab]]&lt;ref name=WHOList83 /&gt; || Antova  || mab || humanized || [[CD154]] (CD40L) 
|Y|| rheumatic diseases
 |-
 | [[SA237]] || || ? || humanized || IL-6R
||| [[neuromyelitis optica]] and neuromyelitis optica spectrum disorders
 |-
 | [[Sacituzumab govitecan]] || || mab || humanized || TROP-2 
||| [[triple-negative breast cancer]]
 |-
 | [[Samalizumab]] || || mab || humanized || [[CD200]] 
||| cancer
 |-
 | [[Samrotamab vedotin]]&lt;ref name=WHOList118 /&gt; || || mab || chimeric/humanized || LRRC15
||| cancer
 |-
 | [[Sarilumab]] || Kevzara || mab || human || [[Interleukin 6|IL6]] 
|Y|| rheumatoid arthritis, [[ankylosing spondylitis]]
 |-
 | [[Satralizumab]] || || mab || humanized || IL6 receptor
||| [[neuromyelitis optica]]
 |-
 | [[Satumomab pendetide]] || || mab || mouse || [[Tumor-associated glycoprotein 72|TAG-72]] 
||| cancer (diagnosis)
 |-
 | [[Secukinumab]] ||Cosentyx|| mab || human || [[interleukin 17a|IL 17A]] 
|Y|| [[uveitis]], rheumatoid arthritis [[psoriasis]]
 |-
 | [[Selicrelumab]]&lt;ref name=WHOList116 /&gt; || || mab || human || [[CD40]]
||| ?
 |-
 | [[Seribantumab]]&lt;ref name=WHOList108 /&gt; || || mab || human || [[ERBB3]] (HER3) 
||| cancer
 |-
 | [[Setoxaximab]]&lt;ref name=WHOList108 /&gt; || || mab || chimeric ||  ''[[Escherichia coli|E. coli]]'' [[shiga toxin]] type-2 
||| ?
 |-
 | [[Setrusumab]]&lt;ref name=WHOList117 /&gt; || || mab || human || [[sclerostin|SOST]]
||| ?
 |-
 | [[Sevirumab]] || || ? || human || [[cytomegalovirus]] 
||| cytomegalovirus infection
 |-
 | [[Sibrotuzumab]] || || mab || humanized || [[FAP (gene)|FAP]] 
||| cancer
 |-
 | [[SGN-CD19A]] || || mab || humanized || [[CD19]] 
||| [[acute lymphoblastic leukemia]] and B-cell non-Hodgkin lymphoma
 |-
 | [[SHP647]] || || ? || human || mucosal addressin cell adhesion molecule
||| Crohn's disease
 |-
 | [[Sifalimumab]] || || mab || humanized || [[Interferon-alpha|IFN-α]] 
||| [[systemic lupus erythematosus|SLE]], [[dermatomyositis]], [[polymyositis]]
 |-
 | [[Siltuximab]] ||Sylvant|| mab || chimeric || [[interleukin-6|IL-6]] 
|Y|| cancer
 |-
 | [[Simtuzumab]]&lt;ref name=WHOList107 /&gt; || || mab || humanized || [[LOXL2]] 
||| [[fibrosis]]
 |-
 | [[Siplizumab]]&lt;ref name=WHOList87 /&gt; || || mab || humanized || [[CD2]] 
||| psoriasis, [[graft-versus-host disease]] (prevention)
 |-
 | [[Sirtratumab vedotin]]&lt;ref name=WHOList117 /&gt; || || mab || human || [[SLITRK6]] 
||| cancer
 |-
 | [[Sirukumab]] || || mab || human || [[Interleukin 6|IL-6]] 
||| rheumatoid arthritis
 |-
 | [[Sofituzumab vedotin]] || || mab || humanized || [[CA-125]] 
||| ovarian cancer
 |-
 | [[Solanezumab]]&lt;ref name=WHOList100 /&gt; || || mab || humanized || [[beta amyloid]] 
||| Alzheimer's disease
 |-
 | [[Solitomab]]&lt;ref name=WHOList106 /&gt; || || BiTE || mouse || [[EpCAM]] 
||| gastrointestinal, lung, and other cancers
 |-
 | [[Sonepcizumab]]&lt;ref&gt;{{Cite journal
| doi = 10.1002/jcp.21588
| title = Blockade of Sphingosine-1-phosphate Reduces Macrophage Influx and Retinal and Choroidal Neovascularization
| year = 2009
| last1 = Xie | first1 = B.
| last2 = Shen | first2 = J.
| last3 = Dong | first3 = A.
| last4 = Rashid | first4 = A.
| last5 = Stoller
| pmc = 2905312 | first5 = G.
| last6 = Campochiaro | first6 = P. A.
| journal = Journal of Cellular Physiology
| volume = 218
| pages = 192–198
| pmid = 18781584
| issue = 1
}}&lt;/ref&gt; || || ? || humanized || [[sphingosine-1-phosphate]] 
||| [[Choroidal neovascularization|choroidal]] and [[retina]]l [[neovascularization]]
 |-
 | [[Sontuzumab]]&lt;ref name=WHOList56 /&gt; || || mab || humanized || episialin 
|||
 |-
 | [[Spartalizumab]]&lt;ref name=WHOList117 /&gt; || || mab || humanized || [[programmed cell death 1|PDCD1]], [[CD279]]
||| melanoma
 |-
 | [[Stamulumab]]&lt;ref name=WHOList94 /&gt;&lt;ref name=WHOList56/&gt; || || mab || human || [[myostatin]] 
|||  muscular dystrophy
 |-
 | [[Sulesomab]] || LeukoScan || Fab' || mouse || NCA-90 (granulocyte antigen) 
||| [[osteomyelitis]] (imaging)
 |-
 | [[Suptavumab]] || || mab || human || RSVFR
||| medically attended [[lower respiratory tract infection|lower respiratory disease]]
 |-
 | [[Sutimlimab]]&lt;ref name=WHOList118 /&gt; || || mab || chimeric/humanized || [[complement component 1s|C1s]]
||| [[cold agglutinin disease]]
 |-
 | [[Suvizumab]]&lt;ref name=WHOList102 /&gt; || || mab || humanized || [[HIV-1]] 
||| viral infections
 |-
 | [[Suvratoxumab]]&lt;ref name=WHOList116 /&gt; || || mab || human || ''Staphylococcus aureus'' alpha toxin
||| [[nosocomial pneumonia]]
 |-
 | [[Tabalumab]] || || mab || human || [[B-cell activating factor|BAFF]] 
||| B-cell cancers
 |-
 | [[Tacatuzumab tetraxetan]] || AFP-Cide || mab || humanized || [[alpha-fetoprotein]] 
||| cancer
 |-
 | [[Tadocizumab]]&lt;ref name=WHOList56 /&gt; || || Fab || humanized || [[integrin]] α&lt;sub&gt;IIb&lt;/sub&gt;β&lt;sub&gt;3&lt;/sub&gt; 
||| [[percutaneous coronary intervention]]
 |-
 | [[Talacotuzumab]]&lt;ref name=WHOList117 /&gt; || || mab || humanized || [[CD123]]
||| ?
 |-
 | [[Talizumab]] || || mab || humanized || [[IgE]] 
||| [[allergic reaction]]
 |-
 | Tamtuvetmab&lt;ref name=WHOList114 /&gt; || Tactress || mab || veterinary || [[CD52]] 
|||
 |-
 | [[Tanezumab]]&lt;ref name=WHOList99 /&gt; || || mab || humanized || [[nerve growth factor|NGF]] 
||| [[pain]]
 |-
 | [[Taplitumomab paptox]]&lt;ref name=WHOList84/&gt; || || mab || mouse || [[CD19]] 
||| cancer{{Citation needed|date=November 2009}}
 |-
 | [[Tarextumab]] || || mab || human || Notch receptor 
||| cancer
 |-
 | Tavolimab || || mab || chimeric/humanized || CD134
||| cancer
 |-
 | [[Tefibazumab]]&lt;ref name=WHOList92 /&gt; || Aurexis || mab || humanized || [[clumping factor A]] 
||| ''[[Staphylococcus aureus]]'' infection
 |-
 | [[Telimomab aritox]] || || Fab || mouse || ?  
|||
 |-
 | [[Telisotuzumab vedotin]] || || mab || humanized || HGFR
||| cancer
 |- 
 | [[Tenatumomab]]&lt;ref name=WHOList98 /&gt; || || mab || mouse || [[tenascin C]] 
||| cancer
 |-
 | [[Teneliximab]]&lt;ref name=WHOList87 /&gt; || || mab || chimeric || [[CD40]] 
||| autoimmune diseases and prevention of [[organ transplant rejection]]
 |-
 | [[Teplizumab]]&lt;ref name=WHOList97 /&gt; || || mab || humanized || [[CD3 (immunology)|CD3]] 
||| [[diabetes mellitus type 1]]
 |-
 | [[Tepoditamab]]&lt;ref name=WHOList118 /&gt; || || mab || human || dendritic cell-associated [[lectin 2]]
||| cancer
 |-
 | [[Teprotumumab]] || || mab || human || [[Insulin-like growth factor 1 receptor|IGF-1 receptor (CD221)]] 
||| [[thyroid eye disease]]
 |-
 | [[Tesidolumab]]&lt;ref name=WHOList112 /&gt; || || mab || human || [[Complement C5|C5]] 
|||
 |-
 | [[Tetulomab]] || || mab || humanized || [[CD37]] 
||| cancer&lt;ref&gt;{{Cite journal |author1=Jostein Dahle |author2=Ada H. V. Repetto-Llamazares |author3=Camilla S. Mollatt |author4=Katrine B. Melhus |author5=Oyvind S. Bruland |author6=Arne Kolstad |author7=Roy H. Larsen | title = Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin's lymphoma | journal = [[Anticancer research]] | volume = 33 | issue = 1 | pages = 85–95 | date= January 2013 | pmid = 23267131}}&lt;/ref&gt;
 |-
 | [[Tezepelumab]]&lt;ref name=WHOList113 /&gt; || || mab || human || [[thymic stromal lymphopoietin|TSLP]] 
||| asthma, [[atopic dermatitis]]
 |-
 | [[TGN1412]] || || ? || humanized || [[CD28]] 
||| chronic lymphocytic leukemia, rheumatoid arthritis
 |-
 | Tibulizumab&lt;ref name=WHOList117 /&gt; || || mab || humanized || [[B-cell activating factor|BAFF]]
||| autoimmune disorders
 |-
 | [[Tildrakizumab]] || Ilumya || mab || humanized || [[Interleukin 23|IL23]] 
|Y|| immunologically mediated inflammatory disorders
 |-
 | [[Tigatuzumab]]&lt;ref name=WHOList98 /&gt; || || mab || humanized || [[TRAIL-R2]] 
||| cancer
 |-
 | [[Timigutuzumab]]&lt;ref name=WHOList116 /&gt; || || mab || humanized || [[HER2]]
||| cancer
 |-
 | [[Timolumab]]&lt;ref name=WHOList114 /&gt; || || mab || human || [[amine oxidase copper containing 3|AOC3]] 
|||
 |-
 | [[Tiragotumab]]&lt;ref name=WHOList117 /&gt; || || mab || human || [[TIGIT]]
||| cancer
 |-
 | [[Tislelizumab]]&lt;ref name=WHOList117 /&gt; || || mab || humanized || [[programmed cell death 1|PCDC1]], [[CD279]]
||| non-small cell lung cancer
 |-
 | [[Tisotumab vedotin]]&lt;ref name=WHOList113 /&gt; || || mab || human || [[coagulation factor III]] 
|||relapsed or refractory [[cervical cancer]]&lt;ref&gt;{{Cite journal|last=Wright|first=Rob|date=13 February 2018|title=Seattle Genetics Legacy Of Partnering|url=https://www.lifescienceleader.com/doc/seattle-genetics-legacy-of-partnering-0001|journal=Life Science Leader|volume=|pages=|at=Beyond The Printed Page|access-date=22 February 2018|via=}}&lt;/ref&gt;
 |-
 | [[TNX-650]] || || ? || humanized || [[interleukin 13|IL-13]] 
||| Hodgkin's lymphoma
 |-
 | [[Tocilizumab]]&lt;ref name=WHOList90 /&gt; || Actemra, RoActemra || mab || humanized || [[IL-6 receptor]] 
|Y|| rheumatoid arthritis
 |-
 | [[Tomuzotuximab]]&lt;ref name=WHOList116 /&gt; || || mab || humanized || [[epidermal growth factor receptor|EGFR]], [[HER1]]
||| cancer
 |-
 | [[Toralizumab]]&lt;ref name=WHOList87 /&gt; || || mab || humanized || [[CD154]] (CD40L) 
||| rheumatoid arthritis, lupus nephritis etc.
 |-
 | [[Tosatoxumab]]&lt;ref name=WHOList109 /&gt; || || mab || human || ''[[Staphylococcus aureus]]'' 
|||
 |-
 | [[Tositumomab]] || Bexxar || ? || mouse || [[CD20]] 
|Y|| [[follicular lymphoma]]
 |-
 | [[Tovetumab]] || || mab || human || [[PDGFRA]] 
||| cancer
 |-
 | [[Tralokinumab]] || || mab || human || [[Interleukin 13|IL-13]] 
||| asthma, atopic dermatitis
 |-
 | [[Trastuzumab]] || Herceptin || mab || humanized || [[HER2/neu]] 
|Y|| [[breast cancer]]
 |-
 | [[Trastuzumab emtansine]] || Kadcyla || mab || humanized || [[HER2/neu]] 
|Y|| [[breast cancer]]
 |-
 | [[TRBS07]]&lt;ref&gt;{{cite journal | last1=Ruf| first1=P | title=Two new trifunctional antibodies for the therapy of human malignant melanoma | url=http://onlinelibrary.wiley.com/doi/10.1002/ijc.11630/full | journal=International Journal of Cancer | volume=108 | pages=725–732 | year=2004 | pmid=14696099 | doi=10.1002/ijc.11630 | last2=Jäger | first2=M | last3=Ellwart | first3=J | last4=Wosch | first4=S | last5=Kusterer | first5=E | last6=Lindhofer | first6=H | issue=5|display-authors=etal}}&lt;/ref&gt; || Ektomab || 3funct || ? || [[GM2 (ganglioside)|GD2 ganglioside]] 
||| melanoma
 |-
 | [[Tregalizumab]]&lt;ref name=WHOList104 /&gt; || || mab || humanized || [[CD4]] 
|||
 |-
 | [[Tremelimumab]] || || mab || human || [[CTLA-4]] 
||| non-small cell lung, head &amp; neck, urothelial cancer
 |-
 | [[Trevogrumab]] || || mab || human || [[growth differentiation factor]] 8 
||| [[muscle atrophy]] due to orthopedic disuse and [[sarcopenia]]
 |-
 | [[Tucotuzumab celmoleukin]]&lt;ref name=WHOList94 /&gt;&lt;ref name=WHOList56 /&gt; || || mab || humanized || [[EpCAM]] 
||| cancer
 |-
 | [[Tuvirumab]] || || ? || human || [[hepatitis B]] virus  
||| chronic hepatitis B
 |-
 | [[Ublituximab]]&lt;ref name=WHOList104 /&gt; || || mab || chimeric || [[MS4A1]] 
||| multiple sclerosis, chronic lymphocytic leukemia
 |-
 | [[Ulocuplumab]] || || mab || human || [[CXCR4|CXCR4 (CD184)]] 
||| hematologic malignancies
 |-
 | [[Urelumab]] || || mab || human || [[CD137|4-1BB]] (CD137) 
||| cancer etc.
 |-
 | [[Urtoxazumab]]&lt;ref name=WHOList90 /&gt; || || mab || humanized || ''[[Escherichia coli]]'' 
||| diarrhoea caused by ''E. coli''
 |-
 | [[Ustekinumab]]&lt;ref name=WHOList99 /&gt; || Stelara || mab || human || [[Interleukin 12|IL-12]], [[Interleukin 23|IL-23]] 
|Y|| multiple sclerosis, psoriasis, psoriatic arthritis
 |-
 | [[Utomilumab]]&lt;ref name=WHOList115 /&gt; || || mab || human || [[CD137|4-1BB]] (CD137) 
||| diffuse large B-cell lymphoma
 |-
 | [[Vadastuximab talirine]]&lt;ref name=WHOList113 /&gt; || || mab || chimeric || [[CD33]] 
||| [[Acute myeloid leukemia]]
 |-
 | [[Vanalimab]]&lt;ref name=WHOList118 /&gt; || || mab || humanized || CD40
||| ?
 |-
 | [[Vandortuzumab vedotin]]&lt;ref name=WHOList112 /&gt; || || mab || humanized || [[STEAP1]] 
||| cancer
 |-
 | [[Vantictumab]] || || mab || human || [[Frizzled|Frizzled receptor]] 
||| cancer
 |-
 | [[Vanucizumab]]&lt;ref name=WHOList111 /&gt; || || mab || humanized || [[angiopoietin 2]] 
||| cancer
 |-
 | [[Vapaliximab]]&lt;ref name=WHOList87 /&gt; || || mab || chimeric || [[AOC3]] (VAP-1) 
|||
 |-
 | [[Varisacumab]]&lt;ref name=WHOList116 /&gt; || || mab || human || [[vascular endothelial growth factor A|VEGF-A]]
||| angiogenesis
 |-
 | [[Varlilumab]] || || mab || human || [[CD27]] 
||| solid tumors and hematologic malignancies
 |-
 | [[Vatelizumab]]&lt;ref name=WHOList105 /&gt; || || mab || humanized || [[ITGA2]] (CD49b) 
|||
 |-
 | [[Vedolizumab]] || Entyvio || mab || humanized || [[integrin]] α&lt;sub&gt;4&lt;/sub&gt;β&lt;sub&gt;7&lt;/sub&gt; 
|Y|| Crohn's disease, [[ulcerative colitis]]
 |-
 | [[Veltuzumab]]&lt;ref name=WHOList98 /&gt; || || mab || humanized || [[CD20]] 
||| non-Hodgkin's lymphoma
 |-
 | [[Vepalimomab]] || || mab || mouse || [[AOC3]] (VAP-1) 
||| inflammation
 |-
 | Vesencumab&lt;ref name=WHOList104 /&gt; || || mab || human || [[neuropilin 1|NRP1]] 
||| solid malignancies
 |-
 | [[Visilizumab]]&lt;ref name=WHOList84 /&gt; || Nuvion || mab || humanized || [[CD3 (immunology)|CD3]] 
||| Crohn's disease, ulcerative colitis
 |-
 | [[Vobarilizumab]]&lt;ref name=WHOList114 /&gt; || || scFv || humanized || [[interleukin 6 receptor|IL6R]] 
||| inflammatory autoimmune diseases
 |-
 | [[Volociximab]]&lt;ref name=WHOList93 /&gt; || || mab || chimeric || [[integrin]] α&lt;sub&gt;5&lt;/sub&gt;β&lt;sub&gt;1&lt;/sub&gt; 
||| solid tumors
 |-
 | [[Vonlerolizumab]] || || mab || humanized || [[CD134]]
||| cancer
 |-
 | [[Vopratelimab]]&lt;ref name=WHOList118 /&gt; || || mab || humanized || [[CD278]], aka ICOS
||| ?
 |-
 | [[Vorsetuzumab mafodotin]] || || mab || humanized || [[CD70]] 
||| cancer
 |-
 | [[Votumumab]] || HumaSPECT || mab || human || [[tumor antigen]] CTAA16.88 
||| colorectal tumors
 |-
 | [[Vunakizumab]]&lt;ref name=WHORList77 /&gt; || || mab || humanized || interleukin 17 alpha
||| ?
 |-
 | [[Xentuzumab]]&lt;ref name=WHOList114 /&gt; || || mab || humanized || [[insulin-like growth factor 1|IGF1]], [[insulin-like growth factor 2|IGF2]]
|||?
 |-
 | [[XMAB-5574]] || || ? || humanized || CD19
||| diffuse large B-cell lymphoma
 |-
 | [[Zalutumumab]]&lt;ref name=WHOList93/&gt; || HuMax-EGFr || mab || human || [[Epidermal growth factor receptor|EGFR]] 
||| [[squamous cell carcinoma of the head and neck]]
 |-
 | [[Zanolimumab]]&lt;ref name=WHOList90 /&gt; || HuMax-CD4 || mab || human || [[CD4]] 
||| rheumatoid arthritis, psoriasis, T-cell lymphoma
 |-
 | [[Zatuximab]]&lt;ref name=WHOList107 /&gt; || || mab || chimeric || [[HER1]] 
||| cancer
 |-
 | [[Zenocutuzumab]]&lt;ref name=WHOList117 /&gt; || || mab || humanized || [[ERBB3]], [[HER3]]
||| cancer
 |-
 | [[Ziralimumab]]&lt;ref name=WHOList84 /&gt; || || mab || human || [[CD147]] (basigin) 
||| ?
 |-
 | [[Zolbetuximab]]&lt;ref name=WHOList117 /&gt; || || mab || chimeric || [[claudin 18|CLDN18]]
||| cancer
 |-
 | [[Zolimomab aritox]] || || mab || mouse || [[CD5 (protein)|CD5]] 
||| systemic lupus erythematosus, graft-versus-host disease
|}

==References==
{{Reflist|2|refs=
&lt;ref name=WHOList51&gt;{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 51 | journal = WHO Drug Information | volume = 18 | issue = 1 | year = 2004 | url = http://whqlibdoc.who.int/druginfo/INN_2004_list51.pdf | format=PDF}}&lt;/ref&gt;
&lt;ref name=WHOList56&gt;{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 56 | journal = WHO Drug Information | volume = 20 | issue = 3 | year = 2006 | url = http://whqlibdoc.who.int/druginfo/INN_2006_list56.pdf | format=PDF}}&lt;/ref&gt;
&lt;ref name=WHOList66&gt;{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 66 | journal = WHO Drug Information | volume = 5 | issue = 4 | year = 1991 | url = http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list66.pdf | format=PDF}}&lt;/ref&gt;
&lt;ref name=WHOList77&gt;{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 77 | journal = WHO Drug Information | volume = 11 | issue = 2 | year = 1997 | url = http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list77.pdf | format=PDF}}&lt;/ref&gt;
&lt;ref name=WHOList83&gt;{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 83 | journal = WHO Drug Information | volume = 14 | issue = 2 | year = 2000 | url = http://whqlibdoc.who.int/druginfo/DRUG_INFO_14_2_2000_INN-83.pdf | format=PDF}}&lt;/ref&gt;
&lt;ref name=WHOList84&gt;{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 84 | journal = WHO Drug Information | volume = 14 | issue = 4 | year = 2000 | url = http://whqlibdoc.who.int/druginfo/DRUG_INFO_14_4_2000_INN-84.pdf | format=PDF}}&lt;/ref&gt;
&lt;ref name=WHOList85&gt;{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 85 | journal = WHO Drug Information | volume = 15 | issue = 2 | year = 2001 | url = http://whqlibdoc.who.int/druginfo/DRUG_INFO_15_2_2001_INN-85.pdf | format=PDF}}&lt;/ref&gt;
&lt;ref name=WHOList86&gt;{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 86 | journal = WHO Drug Information | volume = 16 | issue = 12 | year = 2002 | url = http://whqlibdoc.who.int/druginfo/16_1_2002_INN86.pdf | format=PDF}}&lt;/ref&gt;
&lt;ref name=WHOList87&gt;{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 87 | journal = WHO Drug Information | volume = 16 | issue = 2 | year = 2002 | url = http://whqlibdoc.who.int/druginfo/16_2_2002_INN87.pdf | format=PDF}}&lt;/ref&gt;
&lt;ref name=WHOList88&gt;{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 88 | journal = WHO Drug Information | volume = 17 | issue = 1 | year = 2003 | url = http://whqlibdoc.who.int/druginfo/17_1_2003_INN88.pdf | format=PDF}}&lt;/ref&gt;
&lt;ref name=WHOList90&gt;{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 90 | journal = WHO Drug Information | volume = 18 | issue = 1 | year = 2004 | url = http://whqlibdoc.who.int/druginfo/18_1_2004_INN90.pdf | format=PDF}}&lt;/ref&gt;
&lt;ref name=WHOList91&gt;{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 91 | journal = WHO Drug Information | volume = 18 | issue = 2 | year = 2004 | url = http://whqlibdoc.who.int/druginfo/18_2_2004_INN91.pdf | format=PDF}}&lt;/ref&gt;
&lt;ref name=WHOList92&gt;{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 92 | journal = WHO Drug Information | volume = 18 | issue = 4 | year = 2004 | url = http://whqlibdoc.who.int/druginfo/18_4_2004_INN92.pdf | format=PDF}}&lt;/ref&gt;
&lt;ref name=WHOList93&gt;{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 93 | journal = WHO Drug Information | volume = 19 | issue = 2 | year = 2008 | url = http://whqlibdoc.who.int/druginfo/19_2_2005_INN93.pdf | format=PDF}}&lt;/ref&gt;
&lt;ref name=WHOList94&gt;{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 94 | journal = WHO Drug Information | volume = 19 | issue = 4 | year = 2005 | url = http://whqlibdoc.who.int/druginfo/19_4_2005_INN94.pdf | format=PDF}}&lt;/ref&gt;
&lt;ref name=WHOList95&gt;{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 95 | journal = WHO Drug Information | volume = 20 | issue = 2 | year = 2006 | url = http://whqlibdoc.who.int/druginfo/20_2_2006_INN95.pdf | format=PDF}}&lt;/ref&gt;
&lt;ref name=WHOList96&gt;{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 96 | journal = WHO Drug Information | volume = 20 | issue = 4 | year = 2006 | url = http://whqlibdoc.who.int/druginfo/20_4_2006_INN96.pdf | format=PDF}}&lt;/ref&gt;
&lt;ref name=WHOList97&gt;{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 97 | journal = WHO Drug Information | volume = 21 | issue = 2 | year = 2007 | url = http://whqlibdoc.who.int/druginfo/21_2_2007_INN97.pdf | format=PDF}}&lt;/ref&gt;
&lt;ref name=WHOList98&gt;{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 98 | journal = WHO Drug Information | volume = 21 | issue = 4 | year = 2007 | url = http://www.who.int/medicines/publications/druginformation/innlists/P-List98.pdf | format=PDF}}&lt;/ref&gt;
&lt;ref name=WHOList99&gt;{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 99 | journal = WHO Drug Information | volume = 22 | issue = 2 | year = 2008 | url = http://www.who.int/entity/medicines/publications/druginformation/issues/INN-PList-No99.pdf | format=PDF}}&lt;/ref&gt;
&lt;ref name=WHOList100&gt;{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 100 (prepublication copy) | journal = WHO Drug Information | year = 2008 | url = http://www.who.int/entity/medicines/publications/druginformation/innlists/PL100prepubli.pdf | format=PDF}}&lt;/ref&gt;
&lt;ref name=WHOList101&gt;{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 101 | journal = WHO Drug Information | volume = 23 | issue = 2 | year = 2009 | url = http://whqlibdoc.who.int/druginfo/23_2_2009_INN101.pdf | format=PDF}}&lt;/ref&gt;
&lt;ref name=WHOList102&gt;{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 102 | journal = WHO Drug Information | volume = 23 | issue = 4 | year = 2009 | url = http://www.who.int/medicines/services/inn/FINAL_PL102.pdf | format=PDF}}&lt;/ref&gt;
&lt;ref name=WHOList104&gt;{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 104 | journal = WHO Drug Information | volume = 24 | issue = 4 | year = 2010 | url = http://www.who.int/medicines/publications/druginformation/innlists/Final_PL104.pdf | format=PDF}}&lt;/ref&gt;
&lt;ref name=WHOList105&gt;{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105 | journal = WHO Drug Information | volume = 25 | issue = 2 | year = 2011 | url = http://www.who.int/medicines/publications/druginformation/innlists/Final_PL105.pdf | format=PDF}}&lt;/ref&gt;
&lt;ref name=WHOList103&gt;{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 103 | journal = WHO Drug Information | year = 2011 | url = http://www.who.int/medicines/publications/druginformation/INN_PL103.pdf | format=PDF}}&lt;/ref&gt;
&lt;ref name=WHOList106&gt;{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 106 | journal = WHO Drug Information | volume = 25 | issue = 4 | year = 2011 | url = http://www.who.int/medicines/publications/druginformation/innlists/Final_PL106.pdf | format=PDF}}&lt;/ref&gt;
&lt;ref name=WHOList107&gt;{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107 | journal = WHO Drug Information | volume = 26 | issue = 2 | year = 2012 | url = http://www.who.int/medicines/publications/druginformation/innlists/Final_PL107.pdf | format=PDF}}&lt;/ref&gt;
&lt;ref name=WHOList108&gt;{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 108 | journal = WHO Drug Information | volume = 26 | issue = 4 | year = 2012 | url = http://www.who.int/medicines/publications/druginformation/innlists/PL108_Final.pdf | format=PDF}}&lt;/ref&gt;
&lt;ref name=WHOList109&gt;{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 109 | journal = WHO Drug Information | volume = 27 | issue = 2 | year = 2013 | url = http://www.who.int/medicines/publications/druginformation/innlists/PL109.pdf | format=PDF}}&lt;/ref&gt;
&lt;ref name=WHOList110&gt;{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 110 | journal = WHO Drug Information | volume = 27 | issue = 4 | year = 2013 | url = http://www.who.int/medicines/publications/druginformation/innlists/PL110.pdf | format=PDF}}&lt;/ref&gt;
&lt;ref name=WHOList111&gt;{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111 | journal = WHO Drug Information | volume = 28 | issue = 2 | year = 2014 | url = http://www.who.int/medicines/publications/druginformation/innlists/PL111.pdf | format=PDF}}&lt;/ref&gt;
&lt;ref name=WHOList112&gt;{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 112 | journal = WHO Drug Information | volume = 28 | issue = 4 | year = 2014 | url = http://www.who.int/medicines/publications/druginformation/innlists/PL112.pdf | format=PDF}}&lt;/ref&gt;
&lt;ref name=WHOList113&gt;{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 113 | journal = WHO Drug Information | volume = 29 | issue = 2 | year = 2015 | url = http://www.who.int/medicines/publications/druginformation/innlists/PL113.pdf | format=PDF}}&lt;/ref&gt;
&lt;ref name=WHOList114&gt;{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 114 | journal = WHO Drug Information | volume = 29 | issue = 4 | year = 2015 | url = http://www.who.int/medicines/publications/druginformation/innlists/PL114.pdf | format=PDF}}&lt;/ref&gt;
&lt;ref name=WHOList115&gt;{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115 | journal = WHO Drug Information | volume = 30 | issue = 2 | year = 2016 | url = http://www.who.int/medicines/publications/druginformation/innlists/PL115.pdf | format=PDF}}&lt;/ref&gt;
&lt;ref name=WHOList116&gt;{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 116 | journal = WHO Drug Information | volume = 30 | issue = 4 | year = 2016 | url = http://www.who.int/medicines/publications/druginformation/innlists/PL116.pdf | format=PDF}}&lt;/ref&gt;
&lt;ref name=WHOList117&gt;{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 117 | journal = WHO Drug Information | volume = 31 | issue = 2 | year = 2017 | url = http://www.who.int/medicines/publications/druginformation/innlists/PL117.pdf | format=PDF}}&lt;/ref&gt;
&lt;ref name=WHOList118&gt;{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 118 | journal = WHO Drug Information | volume = 31 | issue = 4 | year = 2017 | url = http://www.who.int/medicines/publications/druginformation/innlists/PL118.pdf | format=PDF}}&lt;/ref&gt;
&lt;ref name=WHOList119&gt;{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 119 | journal = WHO Drug Information | volume = 32 | issue = 2 | year = 2018 | url = http://www.who.int/medicines/publications/druginformation/innlists/PL119.pdf | format=PDF}}&lt;/ref&gt;
&lt;ref name=WHORList77&gt;{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 77 | journal = WHO Drug Information | volume = 31 | issue = 1 | year = 2017 | url = http://www.who.int/medicines/publications/druginformation/innlists/RL77.pdf | format=PDF}}&lt;/ref&gt;

&lt;ref name=NCT00883896&gt;{{ClinicalTrialsGov|NCT00883896|Study to Evaluate the Safety and Efficacy of ILV-094 in Subjects With Rheumatoid Arthritis}}&lt;/ref&gt;
&lt;ref name=NCT00563524&gt;{{ClinicalTrialsGov|NCT00563524|Study Evaluating the Safety and Tolerability of ILV-094 in Subjects With Psoriasis}}&lt;/ref&gt;
&lt;ref name=NCT00537381&gt;{{ClinicalTrialsGov|NCT00537381|A Study of the Safety and Effectiveness of CNTO 95 in Patients With Metastatic Hormone Refractory Prostate Cancer}}&lt;/ref&gt;
&lt;ref name=NCT00246012&gt;{{ClinicalTrialsGov|NCT00246012|A Study of the Safety and Efficacy CNTO 95 in Subjects With Advanced Melanoma}}&lt;/ref&gt;

&lt;ref name="ALD518"&gt;{{cite news|url=http://www.genengnews.com/news/bnitem.aspx?name=68068627&amp;source=genwire|title=BMS Shells Out $85M Up Front for Alder’s Mid-Stage Rheumatoid Arthritis Antibody|date=10 November 2009|publisher=Genetic Engineering &amp; Biotechnology News}}&lt;/ref&gt;
&lt;ref name="IMA-638"&gt;{{cite web|url=http://www.wyeth.com/research/projects |title=Wyeth.com {{!}} Complete Project Listing |year=2008 |publisher=[[Wyeth]] |accessdate=November 19, 2008 |archiveurl=https://web.archive.org/web/20080612044330/http://www.wyeth.com/research/projects |archivedate=June 12, 2008 |deadurl=yes |df= }}&lt;/ref&gt;
&lt;ref name="Glembatumumab"&gt;[[National Cancer Institute|NCI]] Drug Dictionary: [http://www.cancer.gov/drugdictionary/?CdrID=599456 Glemtumumab vedotin]&lt;/ref&gt;
&lt;ref name=Ch1418&gt;{{cite web|url=https://www.sec.gov/Archives/edgar/data/1082554/000104746911001229/a2202121z10-k.htm#da77001_item_1._business|title=United Therapeutics 10-K report|accessdate=5 November 2011}}&lt;/ref&gt;
}}

{{Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems}}
{{Monoclonals for immune system}}
{{Monoclonals for infectious disease and toxins}}
{{Monoclonals for tumors}}
{{Engineered antibodies}}

[[Category:Drug-related lists|Monoclonal Antibodies]]
[[Category:Monoclonal antibodies| ]]
[[Category:Immunology]]</text>
      <sha1>lu83srup5hfsyppq633ksbfxhgyz0hl</sha1>
    </revision>
  </page>
  <page>
    <title>McGill Arctic Research Station</title>
    <ns>0</ns>
    <id>46402668</id>
    <revision>
      <id>823904775</id>
      <parentid>821942938</parentid>
      <timestamp>2018-02-04T03:33:06Z</timestamp>
      <contributor>
        <ip>142.119.5.40</ip>
      </contributor>
      <comment>Added McGill template</comment>
      <model>wikitext</model>
      <format>text/x-wiki</format>
      <text xml:space="preserve" bytes="5437">{{Infobox settlement
|name = McGill Arctic Research Station
|settlement_type = [[Research Station]]
&lt;!-- Location ------------------&gt;
|subdivision_type = Country
|subdivision_name = Canada
|subdivision_type1 = [[Provinces and territories of Canada|Territory]]
|subdivision_name1 = [[Nunavut]]
|subdivision_type2 = Region
|subdivision_name2 = [[Qikiqtaaluk Region]]
|pushpin_map = Canada Nunavut#Canada
|coordinates = {{coord|79|26|00|N|090|46|00|W|type:landmark_region:CA-NU|display=inline,title}}
&lt;!-- Area ---------------------&gt;
|unit_pref =Imperial&lt;!--Enter: Imperial, if Imperial (metric) is desired--&gt;
|area_footnotes =
|area_total_km2 =&lt;!-- ALL fields dealing with a measurements are subject to automatic unit conversion--&gt;
|area_land_km2 =&lt;!--See table @ Template:Infobox Settlement for details on automatic unit conversion--&gt;
&lt;!-- Population -----------------------&gt;
|population = 0 
&lt;!-- General information ---------------&gt;
|timezone = [[Central Time Zone]]
|utc_offset = -6
|timezone_DST = CDT
|utc_offset_DST = -5
|elevation_footnotes =&lt;ref&gt;[http://daleandersen.seti.org/Dale_Andersen/M.A.R.S..html McGill Arctic Research Station]&lt;/ref&gt;
|elevation_m =176
|website=https://www.mcgill.ca/mars/mars-mcgill-arctic-research-station
}}
''' McGill Arctic Research Station (Expedition Fiord)''' (MARS) is a small research station operated by [[McGill University]] located near the centre of [[Axel Heiberg Island]], [[Nunavut]]. It is located approximately {{convert|115|km|abbr=on}} southwest of [[Eureka, Nunavut|Eureka]], a weather and research station. It was first established in 1959 after scientists explored South Fiord (Expedition Fiord). The station contains a small hut, a cook house and two temporary structures. It can support 8-12 people and gives them access to the research activities. The current activities are glaciology, [[climate change]], [[permafrost]], [[hydrology]], [[geology]], [[geomorphology]], [[limnology]], planetary analogues, and [[microbiology]].&lt;ref&gt;McGill Arctic Research Station|McGill Arctic Research Station (M.A.R.S.). ''Dale T. Anderson, Centre for the study of life in the universe.'' Retrieved April 11, 2015&lt;/ref&gt; Today, the station is only used in the summer months so there would be enough power generated from the [[solar panel]]s.&lt;ref&gt;{{cite web|last1=Gonçalves|first1=Mário|title=Axel Heiberg|url=http://ultima0thule.blogspot.ca/2014/07/axel-heiberg-arctic-as-arctic-can-be.html|website=Ultima Thule|accessdate=13 April 2015}}&lt;/ref&gt;

The director of the research station is Wayne Pollard (from McGill University). He has many experiences with drilling and geophysical tools. His goals are to identify niche environments in permafrost capable of harbouring microbial life at or near the limit of its habitability.&lt;ref&gt;{{cite web|last1=White|first1=Lyle|title=Wayne Pollard|url=http://create-astrobiology.mcgill.ca/pollard.html|website=NSERC CREATE  Canadian Astrobiology Training Program|accessdate=13 April 2015}}&lt;/ref&gt;

==Geography==
McGill Arctic Research Station is located near the terminus of three glaciers: Baby Glacier, White Glacier and Thompson Glacier. It is also beside the Expedition River and Colour Lake. The glaciers have been monitored from 1960 to 1999 with gaps in between them. The closest community is [[Grise Fiord]], {{convert|360|km|abbr=on}} away. However, all flights to and from the station all go through [[Resolute Bay Airport]], which is more than {{convert|500|km|abbr=on}} away.&lt;ref&gt;[http://cnnro.ca/mcgill-arctic-research-station/ McGill Arctic Research Station] at the Canadian Network of Northern Research Operators&lt;/ref&gt;  The area surrounding it are rolling hills and tall mountains.

==Climate==
The average temperature at the research station is {{convert|-15|C}}. Because of the cold temperatures, they can test how [[Microorganism|microbe]]s can survive on the other colder planets in our [[Solar System]].&lt;ref&gt;[http://www.nunatsiaqonline.ca/stories/article/65674scientists_detect_cold-loving_microbe_in_nunavuts_high_arctic/ Scientists detect cold-loving microbe in Nunavut’s High Arctic] at ''[[Nunatsiaq News|Nunatsiaq Online]]''. Retrieved April 12, 2015&lt;/ref&gt; The station receives [[polar night]] from the first week of November until the beginning of February, and the [[midnight sun]] from the beginning of April until the second week of September.&lt;ref&gt;Advanced options and sun angles| Sunrise/Sunset/Sun Angle Calculator. ''National Research Council Canada''. Retrieved April 12, 2015&lt;/ref&gt;

==See also==
{{Portal|Nunavut}}
* [[Baffin, Unorganized]] - the census area to which McGill Arctic Research Station belongs
*[[List of research stations in the Arctic]]

==Notes==
{{reflist}}

==External links==
* [https://www.mcgill.ca/mars/mars-mcgill-arctic-research-station Official site]
* [https://web.archive.org/web/20150923221445/http://www.canadiangeographic.ca/blog/posting.asp?ID=877 Canada's North may hold clues to water (and life!) on Mars]
* [http://www.easternsnow.org/proceedings/2000/ecclestone2.pdf Ice Related Data Series from Expedition Fiord]
* [http://thedryvalleys.com/2010/08/ Monthly Archives: August 2010 MARS]

{{McGill}}
{{Arctic Cordillera}}
{{Subdivisions of Nunavut}}

[[Category:Arctic research]]
[[Category:Research stations]]
[[Category:Research in Canada]]
[[Category:Populated places in Arctic Canada]]
[[Category:Populated places in the Qikiqtaaluk Region]]
[[Category:1959 establishments in Canada]]</text>
      <sha1>jc93wnzpcj7cf61p0327ltjt1183o6j</sha1>
    </revision>
  </page>
  <page>
    <title>Model solid approximation</title>
    <ns>0</ns>
    <id>20324423</id>
    <revision>
      <id>703829645</id>
      <parentid>703819163</parentid>
      <timestamp>2016-02-07T22:36:43Z</timestamp>
      <contributor>
        <username>Yikkayaya</username>
        <id>20514654</id>
      </contributor>
      <minor/>
      <comment>Disambiguated: [[extrema]] → [[Maxima and minima]]</comment>
      <model>wikitext</model>
      <format>text/x-wiki</format>
      <text xml:space="preserve" bytes="1997">{{Orphan|date=February 2009}}
{{electronic structure methods}}

The '''model solid approximation''' is a method used for determining the [[Maxima and minima|extrema]] of [[energy bands]] in [[semiconductors]].  The method was first proposed for [[silicon-germanium]] alloys by [[Chris G. Van de Walle]] and Richard M. Martin in 1986&lt;ref&gt;{{citation
 | last = Van de Walle
 | first = Chris G.
 | last2 = Martin
 | first2 = Richard M.
 | journal = Phys. Rev. B
 | volume = 34
 | issue = 8
 | date = 1986-10-15
 | page = 5621
 | title = Theoretical calculations of heterojunction discontinuities in the Si/Ge system
|bibcode = 1986PhRvB..34.5621V |doi = 10.1103/PhysRevB.34.5621 }}&lt;/ref&gt; and extended to several other semiconductor materials by Van de Walle in 1989.&lt;ref&gt;{{citation
 | last = Van de Walle
 | first = Chris G.
 | journal = Phys. Rev. B
 | volume = 39
 | issue = 3
 | date = 1989-01-15
 | page = 1871
 | title = Band lineups and deformation potentials in the model-solid theory
|bibcode = 1989PhRvB..39.1871V |doi = 10.1103/PhysRevB.39.1871 }}&lt;/ref&gt;  It has been used extensively for modelling semiconductor heterostructure devices such as [[quantum cascade lasers]].&lt;ref&gt;{{citation
 | last = Faist
 | first = Jérôme
 | last2 = Capasso
 | first2 = Federico
 | last3 = Sivco
 | first3 = Deborah L.
 | last4 = Hutchinson
 | first4 = Albert L.
 | last5 = Chu
 | first5 = Sung-Nee G.
 | last6 = Cho
 | first6 = Alfred Y. Cho
 | journal = Appl. Phys. Lett.
 | volume = 72
 | issue = 6
 | date = 1998-02-09
 | page = 680
 | title = Short wavelength (λ~3.4&amp;nbsp;μm) quantum cascade laser based on strained compensated InGaAs/AlInAs
|bibcode = 1998ApPhL..72..680F |doi = 10.1063/1.120843 }}&lt;/ref&gt;

Although the electrostatic potential in a semiconductor crystal fluctuates on an atomic scale, the model solid approximation averages these fluctuations out to obtain a constant energy level for each material.

== References ==
{{reflist}}

[[Category:Semiconductor properties]]


{{CMP-stub}}</text>
      <sha1>ql0offoi4ak98je9tvmdetx4nrdl4u6</sha1>
    </revision>
  </page>
  <page>
    <title>Morphological Catalogue of Galaxies</title>
    <ns>0</ns>
    <id>22320247</id>
    <revision>
      <id>870601231</id>
      <parentid>645467403</parentid>
      <timestamp>2018-11-25T22:01:57Z</timestamp>
      <contributor>
        <username>Albert SN</username>
        <id>12845862</id>
      </contributor>
      <model>wikitext</model>
      <format>text/x-wiki</format>
      <text xml:space="preserve" bytes="1412">{{Infobox astronomical survey}}

The '''Morphological Catalogue of Galaxies''' '''(MCG)'''&lt;ref&gt;
{{cite journal
 |last1=Vorontsov-Velyaminov |first1=B.
 |date=1974
 |title=Morphological Catalogue of Galaxies discriminated against
 |journal=[[The Observatory (journal)|The Observatory]]
 |volume=94 |pages=319
 |bibcode=1974Obs....94..319V
}}&lt;/ref&gt; or '''Morfologiceskij Katalog Galaktik''', is a Russian catalogue of 30,642 [[galaxy|galaxies]] compiled by [[Boris Vorontsov-Velyaminov]] and [[V. P. Arkhipova]]. It is based on scrutiny of prints of the [[Palomar Sky Survey]] plates, and putatively complete to a [[photographic magnitude]] of 15. Including galaxies to magnitude 16 would have resulted in an unmanageably large dataset. The catalog was published in five parts (chapters) between 1962 and 1974,&lt;ref&gt;{{cite book|author=Vorontsov-Velyaminov B.A. |author2=Krasnogorskaya A.A. |author3=Arkhipova V.P.|title=Morphological catalogue of galaxies|date=1962–1974|publisher=Moscow State University|location=Moscow|oclc=010670926}}&lt;/ref&gt; the final chapter including a certain number of galaxies with a photographic magnitude above 15.&lt;ref&gt;[http://heasarc.gsfc.nasa.gov/W3Browse/galaxy-catalog/mcg.html MCG - Morphological Galaxy Catalog]. HEASARC&lt;/ref&gt;

==References==
{{reflist}}

[[Category:MCG objects| ]]
[[Category:Astronomical catalogues of galaxies]]


{{astronomical-catalogue-stub}}
{{galaxy-stub}}</text>
      <sha1>rbo329sqvq427cie7ggcxsrs4d0yuta</sha1>
    </revision>
  </page>
  <page>
    <title>Nekton</title>
    <ns>0</ns>
    <id>227214</id>
    <revision>
      <id>871434455</id>
      <parentid>871381632</parentid>
      <timestamp>2018-12-01T01:24:40Z</timestamp>
      <contributor>
        <username>Oshwah</username>
        <id>3174456</id>
      </contributor>
      <comment>Reverted to revision 826975020 by [[Special:Contributions/Mgiganteus1|Mgiganteus1]] ([[User talk:Mgiganteus1|talk]]): Rv possible vandalism. ([[WP:TW|TW]])</comment>
      <model>wikitext</model>
      <format>text/x-wiki</format>
      <text xml:space="preserve" bytes="3926">'''Nekton''' or '''necton''' refers to the aggregate of actively swimming [[aquatic life|aquatic organisms]] in a body of water. The term was proposed by German biologist [[Ernst Haeckel]] to differentiate between the active swimmers in a body of water, and the passive organisms that were carried along by the current, the [[plankton]]. As a guideline, nektonic organisms have a high [[Reynolds number]] (greater than 1000) and planktonic organisms a low one (less than 10). However, some organisms can begin life as plankton and transition to nekton later on in life, sometimes making distinction difficult when attempting to classify certain plankton-to-nekton species as one or the other. For this reason, some biologists choose not to use this term. 

==History==
The term was first proposed and used by the German biologist [[Ernst Haeckel]] in 1891 in his article ''Plankton-Studien'' where he contrasted it with [[plankton]], the aggregate of passively floating, drifting, or somewhat motile organisms present in a body of water, primarily tiny [[algae]] and [[bacteria]], small eggs and larvae of marine organisms, and [[protozoa]] and other minute consumers.  Today it is sometimes considered an obsolete term because it often does not allow for the meaningful quantifiable distinction between these two groups.  Some biologists no longer use it.&lt;ref name="Aleyev1977"&gt;{{cite book|title=Nekton|last1=Aleyev|first1=Yu. G.|year=1977|doi=10.1007/978-94-010-1324-6}}&lt;/ref&gt;&lt;ref&gt;Haeckel, E. 1891. Plankton-Studien. ''Jenaische Zeitschrift für Naturwissenschaft'' 25 / (Neue Folge) 18: 232-336. [https://www.biodiversitylibrary.org/page/11963729 BHL].&lt;/ref&gt;

==Definition==
As a guideline, nekton are larger and tend to swim largely at biologically high [[Reynolds number]]s (&gt;10³ and up beyond 10⁹), where inertial flows are the rule, and eddies (vortices) are easily shed. Plankton, on the other hand, are small and, if they swim at all, do so at biologically low Reynolds numbers (0.001 to 10), where the viscous behavior of water dominates, and reversible flows are the rule. Organisms such as [[jellyfish]] and others are considered plankton when they are very small and swim at low Reynolds numbers, and considered nekton as they grow large enough to swim at high Reynolds numbers.  Many animals considered classic examples of nekton (e.g., ''[[Mola mola]]'', [[squid]], [[marlin]]) start out life as tiny members of the plankton and then, it was argued, gradually transition to nekton as they grow.

== Oceanic nekton ==
Oceanic nekton comprises animals largely from three [[clade]]s:
*[[Vertebrata|Vertebrates]] form the largest contribution; these animals are supported by either [[bone]]s or [[cartilage]].
*[[Mollusca|Mollusks]] are animals such as [[squid]]s and [[scallop]]s.
*[[Crustacea]]ns are animals such as [[lobsters]] and [[crab]]s.

There are organisms whose initial life stage is identified as being planktonic but when they grow and increase in body size they become nektonic. A typical example is the [[Medusa (biology)|medusa]] of the jellyfish.

== See also ==
* [[neuston]] (the organisms, typically microscopic, that float near the surface of the water)
* [[pleuston]] (all organisms that float near the surface of the water)
* [[plankton]] (the organisms that float and drift within the water)
* [[benthos]] (the organisms at the bottom of a body of water)

==References==
{{reflist}}

== External links ==
* Stefan Nehring and Ute Albrecht (1997): „hell und das redundante Benthon: Neologismen in der deutschsprachigen Limnologie“. In: ''Lauterbornia'' H. 31: 17-30, Dinkelscherben, December 1997  [http://www.stefannehring.de/downloads/061_Nehring+Albrecht-1997_Lauterbornia-31_benthon.pdf E-Text (PDF-Datei)]
{{Wiktionary-inline|nekton}}

{{aquatic ecosystem topics}}
{{aquatic organisms}}

{{Authority control}}
[[Category:Aquatic ecology]]
[[Category:Oceanographical terminology]]</text>
      <sha1>e7eeqozfxq3eh4ip6z6hz1bzjbpdy57</sha1>
    </revision>
  </page>
  <page>
    <title>Numerical sign problem</title>
    <ns>0</ns>
    <id>17749634</id>
    <revision>
      <id>854995666</id>
      <parentid>854995436</parentid>
      <timestamp>2018-08-15T05:59:49Z</timestamp>
      <contributor>
        <username>Headbomb</username>
        <id>1461430</id>
      </contributor>
      <minor/>
      <comment>/* Methods for reducing the sign problem */ Pos Lat</comment>
      <model>wikitext</model>
      <format>text/x-wiki</format>
      <text xml:space="preserve" bytes="14302">In [[applied mathematics]], the '''numerical sign problem''' is the problem of numerically evaluating the [[integral]] of a highly [[Oscillation|oscillatory]] [[Function (mathematics)|function]] of a large number of variables. [[Numerical methods]] fail because of the near-cancellation of the positive and negative contributions to the integral. Each has to be integrated to very high [[Accuracy and precision|precision]] in order for their difference to be obtained with useful [[Accuracy and precision|accuracy]].

The sign problem is one of the major unsolved problems in the physics of [[many-particle system]]s. It often arises in calculations of the properties of a [[quantum mechanical]] system with large number of strongly interacting [[fermion]]s, or in field theories involving a non-zero density of strongly interacting fermions.

==Overview&lt;!--'Complex action problem' redirects here--&gt;==

In physics the sign problem is typically (but not exclusively) encountered in calculations of the properties of a quantum mechanical system with large number of strongly interacting fermions, or in field theories involving a non-zero density of strongly interacting fermions. Because the particles are strongly interacting, [[perturbation theory]] is inapplicable, and one is forced to use brute-force numerical methods. Because the particles are fermions, their [[wavefunction]] changes sign when any two fermions are interchanged (due to the anti-symmetry of the wave function, see [[Pauli principle]]). So unless there are cancellations arising from some symmetry of the system, the quantum-mechanical sum over all multi-particle states involves an integral over a function that is highly oscillatory, and hence hard to evaluate numerically, particularly in high dimension. Since the dimension of the integral is given by the number of particles, the sign problem becomes severe in the [[thermodynamic limit]]. The field-theoretic manifestation of the sign problem is discussed below.

The sign problem is one of the major unsolved problems in the physics of many-particle systems, impeding progress in many areas:
* [[Condensed matter physics]] — It prevents the numerical solution of systems with a high density of strongly correlated electrons, such as the [[Hubbard model]].&lt;ref&gt;{{cite journal |doi=10.1103/PhysRevB.41.9301 |bibcode=1990PhRvB..41.9301L |title=Sign problem in the numerical simulation of many-electron systems |journal=Physical Review B |volume=41 |issue=13 |pages=9301–9307 |year=1990 |last1=Loh |first1=E. Y. |last2=Gubernatis |first2=J. E. |last3=Scalettar |first3=R. T. |last4=White |first4=S. R. |last5=Scalapino |first5=D. J. |last6=Sugar |first6=R. L.}}&lt;/ref&gt;
* [[Nuclear physics]] — It prevents the ''[[ab initio]]'' calculation of properties of [[nuclear matter]] and hence limits our understanding of [[atomic nucleus|nuclei]] and [[neutron star]]s.
* [[Quantum field theory]] — It prevents the use of [[lattice QCD]]&lt;ref&gt;{{Cite journal |author=de Forcrand, Philippe |title=Simulating QCD at finite density |journal=Pos Lat |volume=010 |year=2010 |arxiv=1005.0539 |bibcode=2010arXiv1005.0539D}}&lt;/ref&gt; to predict the phases and properties of [[quark matter]].&lt;ref name='Philipsen'&gt;{{cite journal |last=Philipsen |first=O. |year=2008 |title=Lattice calculations at non-zero chemical potential: The QCD phase diagram |url=http://pos.sissa.it//archive/conferences/077/011/Confinement8_011.pdf |journal=Proceedings of Science |volume=77 |pages=011 |doi=10.22323/1.077.0011}}&lt;/ref&gt; (In [[lattice field theory]], the problem is also known as the '''complex action problem'''&lt;!--boldface per WP:R#PLA--&gt;.)&lt;ref&gt;{{cite journal |doi=10.1103/PhysRevD.66.106008 |arxiv=hep-th/0108041 |bibcode=2002PhRvD..66j6008A |title=New approach to the complex-action problem and its application to a nonperturbative study of superstring theory |journal=Physical Review D |volume=66 |issue=10 |year=2002 |last1=Anagnostopoulos |first1=K. N. |last2=Nishimura |first2=J.}}&lt;/ref&gt;

==The sign problem in field theory==
Sources:&lt;ref name='Wiese-cluster'/&gt;&lt;ref name='Kieu'/&gt;

In a field theory approach to multi-particle systems, the fermion density is controlled by the value of the fermion [[chemical potential]] &lt;math&gt;\mu&lt;/math&gt;. One evaluates the [[Partition function (quantum field theory)|partition function]] &lt;math&gt;Z&lt;/math&gt; by summing over all classical field configurations, weighted by &lt;math&gt;\exp(-S)&lt;/math&gt; where &lt;math&gt;S&lt;/math&gt; is the [[Action (physics)|action]] of the configuration. The sum over fermion fields can be performed analytically, and one is left with a sum over the [[boson]]ic fields &lt;math&gt;\sigma&lt;/math&gt; (which may have been originally part of the theory, or have been produced by a [[Hubbard–Stratonovich transformation]] to make the fermion action quadratic)

:&lt;math&gt;Z = \int D \sigma \; \rho[\sigma]&lt;/math&gt;

where &lt;math&gt;D \sigma&lt;/math&gt; represents the measure for the sum over all configurations &lt;math&gt;\sigma(x)&lt;/math&gt; of the bosonic fields, weighted by

:&lt;math&gt;\rho[\sigma]=\det(M(\mu,\sigma))\exp(-S[\sigma])&lt;/math&gt;

where &lt;math&gt;S&lt;/math&gt; is now the action of the bosonic fields, and &lt;math&gt;M(\mu,\sigma)&lt;/math&gt; is a matrix that encodes how the fermions were coupled to the bosons. The expectation value of an observable &lt;math&gt;A[\sigma]&lt;/math&gt; is therefore an average over all configurations weighted by &lt;math&gt;\rho[\sigma]&lt;/math&gt;

:&lt;math&gt;
\langle A \rangle_\rho = \frac{\int D \sigma \; A[\sigma] \; \rho[\sigma]}{\int D \sigma \; \rho[\sigma]} .
&lt;/math&gt;

If &lt;math&gt;\rho[\sigma]&lt;/math&gt; is positive, then it can be interpreted as a probability measure, and &lt;math&gt;\langle A \rangle_\rho&lt;/math&gt; can be calculated by performing the sum over field configurations numerically, using standard techniques such as [[Monte Carlo integration|Monte Carlo importance sampling]].

The sign problem arises when &lt;math&gt;\rho[\sigma]&lt;/math&gt; is non-positive. This typically occurs in theories of fermions when the fermion chemical potential &lt;math&gt;\mu&lt;/math&gt; is nonzero, i.e. when there is a nonzero background density of fermions. If &lt;math&gt;\mu\neq 0&lt;/math&gt; there is no particle-antiparticle symmetry, and &lt;math&gt;\det(M(\mu,\sigma))&lt;/math&gt;, and hence the weight &lt;math&gt;\rho(\sigma)&lt;/math&gt;, is in general a complex number, so Monte Carlo importance sampling cannot be used to evaluate the integral.

=== Reweighting procedure ===

A field theory with a non-positive weight can be transformed to one with a positive weight, by incorporating the non-positive part (sign or complex phase) of the weight into the observable. For example, one could decompose the weighting function into its modulus and phase,
:&lt;math&gt;\rho[\sigma] = p[\sigma]\, \exp(i\theta[\sigma])&lt;/math&gt;
where &lt;math&gt;p[\sigma]&lt;/math&gt; is real and positive, so
:&lt;math&gt; \langle A \rangle_\rho 
= \frac{ \int D\sigma A[\sigma] \exp(i\theta[\sigma])\; p[\sigma]}{\int D\sigma \exp(i\theta[\sigma])\; p[\sigma]}
= \frac{ \langle A[\sigma] \exp(i\theta[\sigma]) \rangle_p}{ \langle \exp(i\theta[\sigma]) \rangle_p} &lt;/math&gt;

Note that the desired expectation value is now a ratio where the numerator and denominator are expectation values that both use a positive weighting function, &lt;math&gt;p[\sigma]&lt;/math&gt;. However, the phase &lt;math&gt;\exp(i\theta[\sigma])&lt;/math&gt; is a highly oscillatory function in the configuration space, so if one uses Monte Carlo methods to evaluate the numerator and denominator, each of them will evaluate to a very small number, whose exact value is swamped by the noise inherent in the Monte Carlo sampling process. The "badness" of the sign problem is measured by the smallness of the denominator &lt;math&gt;\langle \exp(i\theta[\sigma]) \rangle_p&lt;/math&gt;: if it is much less than 1 then the sign problem is severe.
It can be shown (e.g.&lt;ref name='Wiese-cluster'/&gt;) that
:&lt;math&gt;\langle \exp(i\theta[\sigma]) \rangle_p \propto \exp(-f V/T)&lt;/math&gt;
where &lt;math&gt;V&lt;/math&gt; is the volume of the system, &lt;math&gt;T&lt;/math&gt; is the temperature, and &lt;math&gt;f&lt;/math&gt; is an energy density. The number of Monte Carlo sampling points needed to obtain an accurate result therefore rises exponentially as the volume of the system becomes large, and as the temperature goes to zero.

The decomposition of the weighting function into modulus and phase is just one example (although it has been advocated as the optimal choice since it minimizes the variance of the denominator &lt;ref name='Kieu'&gt;{{cite journal |doi=10.1103/PhysRevE.49.3855 |arxiv=hep-lat/9311072 |bibcode=1994PhRvE..49.3855K |title=Monte Carlo simulations with indefinite and complex-valued measures |journal=Physical Review E |volume=49 |issue=5 |pages=3855–3859 |year=1994 |last1=Kieu |first1=T. D. |last2=Griffin |first2=C. J.}}&lt;/ref&gt;). In general one could write
:&lt;math&gt;\rho[\sigma] = p[\sigma] \frac{\rho[\sigma]}{p[\sigma]}&lt;/math&gt;
where &lt;math&gt;p[\sigma]&lt;/math&gt; can be any positive weighting function (for example, the weighting function of the &lt;math&gt;\mu=0&lt;/math&gt; theory.)&lt;ref&gt;{{Cite journal |arxiv=hep-lat/9705042 |last1=Barbour |first1=I. M. |title=Results on Finite Density QCD |journal=Nuclear Physics B - Proceedings Supplements |volume=60 |issue=1998 |pages=220–233 |last2=Morrison |first2=S. E. |last3=Klepfish |first3=E. G. |last4=Kogut |first4=J. B. |last5=Lombardo |first5=M.-P. |doi=10.1016/S0920-5632(97)00484-2 |year=1998|bibcode=1998NuPhS..60..220B }}&lt;/ref&gt; The badness of the sign problem is then measured by
:&lt;math&gt;\left\langle \frac{\rho[\sigma]}{p[\sigma]}\right\rangle_p \propto \exp(-f V/T)&lt;/math&gt;
which again goes to zero exponentially in the large-volume limit.

==Methods for reducing the sign problem==

The sign problem is [[NP-hard]], implying that a full and generic solution of the sign problem would also solve all problems in the complexity class NP in polynomial time.&lt;ref&gt;{{Cite journal |arxiv=cond-mat/0408370 |doi=10.1103/PhysRevLett.94.170201 |pmid=15904269 |bibcode=2005PhRvL..94q0201T |title=Computational Complexity and Fundamental Limitations to Fermionic Quantum Monte Carlo Simulations |journal=Physical Review Letters |volume=94 |issue=17 |pages=170201 |year=2005 |last1=Troyer |first1=Matthias |last2=Wiese |first2=Uwe-Jens }}&lt;/ref&gt; If (as is generally suspected) there are no polynomial-time solutions to NP problems (see [[P versus NP problem]]), then there is no ''generic'' solution to the sign problem. This leaves open the possibility that there may be solutions that work in specific cases, where the oscillations of the integrand have a structure that can be exploited to reduce the numerical errors.

In systems with a moderate sign problem, such as field theories at a sufficiently high temperature or in a sufficiently small volume, the sign problem is not too severe and useful results can be obtained by various methods, such as more carefully tuned reweighting, analytic continuation from imaginary &lt;math&gt;\mu&lt;/math&gt; to real &lt;math&gt;\mu&lt;/math&gt;, or Taylor expansion in powers of &lt;math&gt;\mu&lt;/math&gt;.&lt;ref name='Philipsen'/&gt;&lt;ref&gt;{{Cite journal |arxiv=hep-lat/0610116 |last1=Schmidt |first1=Christian |title=Lattice QCD at Finite Density |journal=Pos Lat |volume=021 |year=2006|bibcode=2006slft.confE..21S }}&lt;/ref&gt;

There are various proposals for solving systems with a severe sign problem:

* Meron-cluster algorithms. These achieve an exponential speed-up by decomposing the fermion world lines into clusters that contribute independently. Cluster algorithms have been developed for certain theories,&lt;ref name='Wiese-cluster'&gt;{{cite journal |doi=10.1103/PhysRevLett.83.3116 |arxiv=cond-mat/9902128 |bibcode=1999PhRvL..83.3116C |title=Meron-Cluster Solution of Fermion Sign Problems |journal=Physical Review Letters |volume=83 |issue=16 |pages=3116–3119 |year=1999 |last1=Chandrasekharan |first1=Shailesh |last2=Wiese |first2=Uwe-Jens}}&lt;/ref&gt; but not for the Hubbard model of electrons, nor for [[Quantum chromodynamics|QCD]], the theory of quarks.
* Stochastic quantization. The sum over configurations is obtained as the equilibrium distribution of states explored by a complex [[Langevin equation]]. So far, the algorithm has been found to evade the sign problem in test models that have a sign problem but do not involve fermions.&lt;ref&gt;{{cite journal |doi=10.1103/PhysRevLett.102.131601 |pmid=19392346 |arxiv=0810.2089 |bibcode=2009PhRvL.102m1601A |title=Can Stochastic Quantization Evade the Sign Problem? The Relativistic Bose Gas at Finite Chemical Potential |journal=Physical Review Letters |volume=102 |issue=13 |pages=131601 |year=2009 |last1=Aarts |first1=Gert}}&lt;/ref&gt;
* Fixed node method. One fixes the location of nodes (zeros) of the multiparticle wavefunction, and uses Monte Carlo methods to obtain an estimate of the energy of the ground state, subject to that constraint.&lt;ref&gt;{{cite journal |doi=10.1103/PhysRevLett.72.2442 |pmid=10055881 |bibcode=1994PhRvL..72.2442V |title=Fixed-Node Quantum Monte Carlo Method for Lattice Fermions |journal=Physical Review Letters |volume=72 |issue=15 |pages=2442–2445 |year=1994 |last1=Van Bemmel |first1=H. J. M. |last2=Ten Haaf |first2=D. F. B. |last3=Van Saarloos |first3=W. |last4=Van Leeuwen |first4=J. M. J. |last5=An |first5=G. |hdl=1887/5478}}&lt;/ref&gt;
* Majorana algorithms. Using Majorana fermion representation to perform Hubbard-Stratenovich transformations can help to solve the fermion sign problem of a class of fermionic many-body models.&lt;ref&gt;{{cite journal |doi=10.1103/PhysRevB.91.241117 |arxiv=1408.2269 |bibcode=2015PhRvB..91x1117L |title=Solving the fermion sign problem in quantum Monte Carlo simulations by Majorana representation |journal=Physical Review B |volume=91 |issue=24 |year=2015 |last1=Li |first1=Zi-Xiang |last2=Jiang |first2=Yi-Fan |last3=Yao |first3=Hong}}&lt;/ref&gt;&lt;ref&gt;{{Cite journal |doi=10.1103/PhysRevLett.117.267002 |pmid=28059531 |arxiv=1601.05780 |bibcode=2016PhRvL.117z7002L |title=Majorana-Time-Reversal Symmetries: A Fundamental Principle for Sign-Problem-Free Quantum Monte Carlo Simulations |journal=Physical Review Letters |volume=117 |issue=26 |pages=267002 |year=2016 |last1=Li |first1=Zi-Xiang |last2=Jiang |first2=Yi-Fan |last3=Yao |first3=Hong}}&lt;/ref&gt;

==See also==
* [[Method of stationary phase]]
* [[Oscillatory integral]]

==References==
&lt;references/&gt;

{{DEFAULTSORT:Numerical Sign Problem}}
[[Category:Statistical mechanics]]
[[Category:Numerical artefacts]]
[[Category:Unsolved problems in physics]]</text>
      <sha1>mp5sr7a2baxavly9gby51lkfu8l3ml0</sha1>
    </revision>
  </page>
  <page>
    <title>Planet Hunters</title>
    <ns>0</ns>
    <id>36379523</id>
    <revision>
      <id>862959367</id>
      <parentid>855748180</parentid>
      <timestamp>2018-10-07T20:30:53Z</timestamp>
      <contributor>
        <username>OlEnglish</username>
        <id>7181920</id>
      </contributor>
      <comment>added [[Category:Exoplanet search projects]] using [[WP:HC|HotCat]]</comment>
      <model>wikitext</model>
      <format>text/x-wiki</format>
      <text xml:space="preserve" bytes="10555">{{Primary sources|date=October 2012}}
[[File:Planethunters.jpg|thumb|right|The Planet Hunters logo.]]
'''Planet Hunters''' is a [[citizen science]] project to find planets using human eyes. It does this by having users analyze data from the NASA [[Kepler Space Mission]].&lt;ref&gt;{{cite web|title=What is Planet Hunters|url=https://www.planethunters.org/#/about|publisher=Planet Hunters website|accessdate=24 May 2017}}&lt;/ref&gt; It was launched by a team led by [[Debra Fischer]] at [[Yale University]],&lt;ref&gt;http://news.yale.edu/2010/12/16/citizen-scientists-join-search-earth-planets&lt;/ref&gt; as part of the [[Zooniverse (citizen science project)|Zooniverse]] project.&lt;ref&gt;{{cite web|title=The Zooniverse|url=https://www.zooniverse.org/|publisher=Zooniverse website|accessdate=9 July 2012}}&lt;/ref&gt;

==Planet hunting==
The Planet Hunters project exploits the fact that humans are better at recognising visual patterns than computers. The website displays an image of data collected by the NASA Kepler Space Mission and asks human users (referred to as "Citizen Scientists") to look at the data and see how the brightness of a star changes over time. This brightness data is represented as a graph and referred to as a star's ''light curve''. Such curves are helpful in discovering [[extrasolar planets]] due to the brightness of a star decreasing when a planet passes in front of it, as seen from Earth.&lt;ref&gt;{{Cite news|url=https://www.nasa.gov/mission_pages/kepler/multimedia/images/transit-light-curve.html|title=Light Curve of a Planet Transiting Its Star|last=Administrator|first=NASA Content|date=2015-04-16|work=NASA|access-date=2017-12-16|language=en}}&lt;/ref&gt; Periods of reduced brightness can thus provide evidence of [[Methods of detecting exoplanets#Transit photometry|planetary transits]], but may also be caused by errors in recording, projection, or other phenomena.&lt;ref&gt;{{cite web|title=Planet Hunting Tutorial|publisher=Planet Hunters website|url=http://www.planethunters.org/site_guide#video|accessdate=9 July 2012|deadurl=yes|archiveurl=https://web.archive.org/web/20120621080836/http://www.planethunters.org/site_guide#video|archivedate=21 June 2012|df=}}&lt;/ref&gt;

===Sorting the light curves===
Users are asked to sort the light curves based on the patterns. The patterns available are "quiet" and "variable". When the light curve is quiet, the graph mostly follows a straight path. When the light curve is variable, there are a number of things that it can do. It can be "regular", "pulsating", or "irregular".&lt;ref&gt;{{cite web|title=Sorting the Light Curves|url=http://www.planethunters.org/site_guide#video|publisher=Planet Hunters website|accessdate=10 July 2012|deadurl=yes|archiveurl=https://web.archive.org/web/20120621080836/http://www.planethunters.org/site_guide#video|archivedate=21 June 2012|df=}}&lt;/ref&gt; A regular light curve means it goes up once and down once, reaching an apex and descending. A pulsating light curve means it goes up and down along the y-axis on a rather steep basis. An irregular light curve has points that go up and down on the y-axis in an unpredictable pattern.

==Special occurrence==

===Eclipsing binary stars===
From time to time, the project will observe eclipsing binary stars. Essentially these are stars that orbit each other. Much as a planet can interrupt the brightness of a star, another star can too. There is a noticeable difference on the light curves. It will appear as a large transit (a large dip) and a smaller transit (a smaller dip).&lt;ref&gt;{{cite web|title=Eclipsing Binary Stars|url=http://www.planethunters.org/site_guide#video|publisher=Planet Hunters website|accessdate=10 July 2012|deadurl=yes|archiveurl=https://web.archive.org/web/20120621080836/http://www.planethunters.org/site_guide#video|archivedate=21 June 2012|df=}}&lt;/ref&gt;&lt;ref&gt;{{Cite web|url=https://imagine.gsfc.nasa.gov/educators/hera_college/binary-model.html|title=Eclipsing Binary Light Curves|website=imagine.gsfc.nasa.gov|access-date=2017-12-16}}&lt;/ref&gt;

===Multiplanet systems===
As of December 2017, there are a total of 621 multiplanetary stars, or stars that contains at least two confirmed planets.&lt;ref&gt;{{Cite web|url=http://exoplanet.eu/catalog/|title=Interactive Extra-solar Planets Catalog|last=Schneider|first=Jean|date=16 December 2017|website=[[The Extrasolar Planets Encyclopedia]]|access-date=2017-12-16}}&lt;/ref&gt; In a multiplanet system plot, there are many different patterns of transit. Due to the different sizes of planets, the transits dip down to different points.&lt;ref&gt;{{cite web|title=Multiplanet Systems|url=http://www.planethunters.org/site_guide#video|publisher=Planet Hunters website|accessdate=10 July 2012|deadurl=yes|archiveurl=https://web.archive.org/web/20120621080836/http://www.planethunters.org/site_guide#video|archivedate=21 June 2012|df=}}&lt;/ref&gt;

===Stellar flares===
Stellar flares are observed when there is an explosion on the surface of a star. This will cause the star's brightness to shoot up considerably, with a steep drop off.&lt;ref&gt;{{cite web|title=Stellar Flares|url=http://www.planethunters.org/site_guide#video|publisher=Planet Hunters website|accessdate=10 July 2012|deadurl=yes|archiveurl=https://web.archive.org/web/20120621080836/http://www.planethunters.org/site_guide#video|archivedate=21 June 2012|df=}}&lt;/ref&gt;

==Discoveries==
So far, over 12 million observations have been analyzed. Out of those, 34 candidate planets had been found as of July 2012.&lt;ref&gt;{{cite web|title=Planetometer|url=http://www.planethunters.org/planetometer|publisher=Planet Hunters website|accessdate=10 July 2012|deadurl=yes|archiveurl=https://web.archive.org/web/20110721124511/http://www.planethunters.org/planetometer|archivedate=21 July 2011|df=}}&lt;/ref&gt; In October 2012 it was announced that two volunteers from the Planet Hunters initiative had discovered a novel [[Neptune]]-like planet which is part of a four star double binary system, orbiting one of the pairs of stars while the other pair of stars orbits at a distance of around 1000 AU. This is the first planet discovered to have a stable orbit in such a complex stellar environment. The system is located just under 5000 light years away, and the new planet has been designated [[PH1]], short for Planet Hunters 1.&lt;ref&gt;{{Cite web|title=Planet with four suns discovered by volunteers|url=https://www.bbc.co.uk/news/science-environment-19950923|publisher=[[BBC]]|accessdate=16 October 2012}}&lt;/ref&gt;&lt;ref&gt;{{Cite journal|bibcode=2013ApJ...768..127S|title=Planet Hunters: A Transiting Circumbinary Planet in a Quadruple Star System|author1=Schwamb|first1=Megan E.|last2=Orosz|first2=Jerome A.|last3=Carter|first3=Joshua A.|last4=Welsh|first4=William F.|last5=Fischer|first5=Debra A.|last6=Torres|first6=Guillermo|last7=Howard|first7=Andrew W.|last8=Crepp|first8=Justin R.|last9=Keel|first9=William C.|last10=Lintott|first10=Chris J.|last11=Kaib|first11=Nathan A.|last12=Terrell|first12=Dirk|last13=Gagliano|first13=Robert|last14=Jek|first14=Kian J.|last15=Parrish|first15=Michael|last16=Smith|first16=Arfon M.|last17=Lynn|first17=Stuart|last18=Simpson|first18=Robert J.|last19=Giguere|first19=Matthew J.|last20=Schawinski|first20=Kevin|volume=1210|date=2012|pages=3612|arxiv=1210.3612|display-authors=9|doi=10.1088/0004-637X/768/2/127}}&lt;/ref&gt;

''Yellow rows indicate a circumbinary planet. Light green rows indicate planet orbiting around one star in a multiple star system.''
{| class="sortable wikitable" style="width: 100%; text-align: center;"
|- 
! [[Planet]]
! [[Mass]]&lt;br /&gt;&lt;small&gt;({{Jupiter mass|link=y}})&lt;/small&gt;
! [[Radius]]&lt;br /&gt;&lt;small&gt;({{Jupiter radius|link=y}})&lt;/small&gt;
! [[Orbital period|Orbital&lt;br /&gt;period]]&lt;br /&gt;&lt;small&gt;([[day|d]])&lt;/small&gt;
! [[Semimajor axis|Semimajor&lt;br /&gt;axis]]&lt;br /&gt;&lt;small&gt;([[Astronomical unit|AU]])&lt;/small&gt;
! [[Eccentricity (orbit)|Orbital&lt;br /&gt;ecc.]]
! [[Inclination|Inclin.]]&lt;br /&gt;&lt;small&gt;([[degree (angle)|°]])&lt;/small&gt;
! [[Star]]
! [[Constellation|Constell.]]&lt;br&gt;
! [[Apparent magnitude|App.&lt;br /&gt;mag.]]
! [[Stellar distance|Distance]]&lt;br /&gt; &lt;small&gt;([[light year|ly]])&lt;/small&gt;
! [[Stellar classification|Spectral&lt;br /&gt;type]]
! Year of confirmation
! Ref
|-
| PH1&lt;br /&gt;([[Kepler-64b]]) || 0.08-0.14 || 0.551 || 138.506 || 0.634 || 0.0539 || 90.022 || [[kepler-64]] || [[Cygnus (constellation)|Cygnus]] || 13.718 || ~5000 || F/M || 2012 || 
|-
| PH2&lt;br /&gt;([[Kepler-86b]]) ||  || 0.85-0.95 || 282.5255 || 0.828 || 0.12-0.49 || 89.83 || [[kepler-86]] || [[Cygnus (constellation)|Cygnus]] ||  || 1206 || ~G4 || 2013 || 
|-
| PH3&lt;br /&gt;([[Kepler-289c]]) ||  ||  ||  ||  ||  ||  || [[Kepler-289]] ||  ||  ||  ||  || 2014 || 
|}

Furthermore, the unusual [[light curve]] of [[KIC 8462852]] (also known as Tabby's Star)&lt;ref&gt;
{{cite journal
 |last1=Boyajian |first=T. S.
 |display-authors=etal
 |date=27 January 2016
 |title=Planet Hunters X: KIC 8462852 – Where’s the flux?
 |journal=[[Monthly Notices of the Royal Astronomical Society]]
 |volume=457 |issue=4 |pages=3988–4004
 |doi=10.1093/mnras/stw218
 |arxiv=1509.03622
|bibcode = 2016MNRAS.457.3988B }}&lt;/ref&gt; has engendered speculation that an alien civilization's [[Dyson sphere]]&lt;ref name="theatlantic"&gt;{{cite web |first=Chris |last=Bodenner |url=https://www.theatlantic.com/notes/all/2015/10/maybe-its-a-dyson-sphere/411121/#note-410974 |title=Maybe It's a Dyson Sphere |publisher=[[The Atlantic]] |work=Notes |date=16 October 2015 |accessdate=15 June 2017}}&lt;/ref&gt;&lt;ref name="theatlantic2"&gt;{{cite web |first=Chris |last=Bodenner |url=https://www.theatlantic.com/notes/all/2015/10/maybe-its-a-dyson-sphere/411121/#note-411124 |title=Maybe It's a Dyson Sphere, Cont'd |publisher=The Atlantic |work=Notes |date=17 October 2015 |accessdate=15 June 2017}}&lt;/ref&gt; is responsible.&lt;ref name="theatlantic3"&gt;{{cite web |first=Ross |last=Andersen |url=https://www.theatlantic.com/science/archive/2015/10/the-most-interesting-star-in-our-galaxy/410023/ |title=The Most Mysterious Star in Our Galaxy |publisher=The Atlantic |date=13 October 2015 |accessdate=15 June 2017}}&lt;/ref&gt;

==See also==
:{{Portal|Astronomy}}
Zooniverse projects:
{{columns-list|colwidth=15em|style=width: 600px; font-style: italic;|
*[[Asteroid Zoo]]
*[[Backyard Worlds]]
*[[Disk Detective]]
*[[Galaxy Zoo]]
*[[Old Weather]]
*[[SETILive]]
*[[The Milky Way Project]]
}}

==References==
{{reflist}}

==External links==
* {{Official website|http://www.planethunters.org/}}

[[Category:Astronomy websites]]
[[Category:Astronomy projects]]
[[Category:Human-based computation]]
[[Category:Citizen science]]
[[Category:Internet properties established in 2010]]
[[Category:Exoplanet search projects]]</text>
      <sha1>0wj6ogy9635itmzrafgzuwdm4xjany4</sha1>
    </revision>
  </page>
  <page>
    <title>Research Moored Array for African-Asian-Australian Monsoon Analysis and Prediction</title>
    <ns>0</ns>
    <id>37798147</id>
    <revision>
      <id>856775201</id>
      <parentid>679033998</parentid>
      <timestamp>2018-08-27T13:12:43Z</timestamp>
      <contributor>
        <username>Pbsouthwood</username>
        <id>10044298</id>
      </contributor>
      <comment>Adding [[Wikipedia:Short description|short description]]: "A system of moored observation buoys in the Indian Ocean that collects meteorological and oceanographic data" ([[User:Galobtter/Shortdesc helper|Shortdesc helper]])</comment>
      <model>wikitext</model>
      <format>text/x-wiki</format>
      <text xml:space="preserve" bytes="5967">{{short description|A system of moored observation buoys in the Indian Ocean that collects meteorological and oceanographic data}}
The '''Research Moored Array for African-Asian-Australian Monsoon Analysis and Prediction''', also known as '''RAMA''', is a system of [[Mooring (oceanography)|moored]] observation [[buoys]] in the [[Indian Ocean]] that collects [[Meteorology|meteorological]] and [[Oceanography|oceanographic]] data. The data collected by RAMA will greatly enhance the ability of scientists to understand climatic events and predict [[monsoon]] events. Climatic and oceanic events in the Indian Ocean affect weather and climate throughout the rest of the world (such as [[El Niño]], hurricanes, and United States weather), so RAMA will support weather forecasting and climate research worldwide. Although widely supported internationally, the system has only been partially implemented ({{As of|2012|lc=y}}) due to [[Piracy in Somalia|pirate activity]] off the coast of [[Somalia]].&lt;ref name="mallik"&gt;{{cite web|author=Y.Mallikarjun|date=2012-01-20|title=Pirates keep ocean researchers at bay|publisher=[[The Hindu]]|url=http://www.thehindu.com/news/national/article2815123.ece
|accessdate=8 February 2013}}&lt;/ref&gt;

==Aims and Objectives==
Although the data coverage for the Indian Ocean has been poor, it has not been non-existent. Satellites have been taking measurements, but those measurements require validation in situ. Some nations, like India and Australia, operate national ocean observing programs. Researchers have mounted observing equipment on ships of opportunity to take measurements. Also, the [[Argo (oceanography)|Argo]] float system has taken data in the Indian Ocean. What RAMA will contribute is large scale, long term data with high temporal resolution. High temporal resolution will allow rapid changes to be captured. With the installation of RAMA, the Indian Ocean will have a basin-wide observing system similar to [[Tropical Atmosphere Ocean project|TAO/TRITON]] in the [[Pacific Ocean]] and [[Prediction and Research Moored Array in the Atlantic|PIRATA]] in the [[Atlantic Ocean|tropical Atlantic]]. RAMA will complete the worldwide network of tropical ocean observing buoys, which will help with modeling and forecasting.&lt;ref name="RAMA2013"&gt;{{cite web|author=Rick Cole|year=25 March 2013|title=RDSEA Reports:RAMA Done, PIRATA Next|publisher=MarineLink.com|accessdate=4 July 2013|url=http://www.marinelink.com/news/reports-pirata-rdsea352870.aspx
}}&lt;/ref&gt;&lt;ref name="McP"/&gt;The data RAMA collects will facilitate the study of "ocean-atmosphere interactions, mixed layer dynamics, and ocean circulation related to the monsoon on intraseasonal to decadal time scales."

==Scale==
When complete RAMA will have 46 moored buoys, each of which is designed to be serviced annually. 38 are to be surface buoys and eight are subsurface ones. 
There are four types of moored buoys: 
* Surface moorings equipped with instruments to measure air temperature, relative humidity, wind velocity, [[downwelling]] [[shortwave radiation]], rainfall, sea surface temperature, conductivity, and pressure. [[Sea surface temperature]] and conductivity can be used together to calculate [[salinity]]. 
* Enhanced surface moorings with extra instruments to "more precisely define surface heat, moisture, and momentum fluxes"&lt;ref name="McP"/&gt; in addition to downwelling [[longwave]] radiation and [[barometric pressure]]. 
* Five subsurface [[Acoustic Doppler Current Profiler]] buoys to measure current velocity between 300–400&amp;nbsp;meters deep and 30–40&amp;nbsp;meters deep. They would provide faulty measurements in waters shallower than 30–40&amp;nbsp;meters because of backscatter from the ocean surface. 
* Three subsurface, deep ocean moorings to measure currents between 1000&amp;nbsp;meters and 4000&amp;nbsp;meters deep.

Data obtained from the buoys is beamed to the [[Global Telecommunications System]] using the [[Argos System|Service Argos]] Satellite Relay System. From there, it is distributed to agencies that require that information, such as weather centers. All of the data is free to access.&lt;ref name="McP"/&gt;

==Progress==

By the end of 2008, 22 of the 46 buoys were in position, and the system was expected to be fully implemented by 2012.&lt;ref name="McP"/&gt; However, pirate activity off the coast of Somalia has jeopardized the completion of the project. Shipping insurers require special insurance to enter the piracy regions, which cover a large portion of the Indian Ocean. As of July 2011, 30 of the 46 moored buoys were established, but "13 of the remaining 16 are in the insurer's exclusion zone".&lt;ref name="jones"/&gt; Some buoys have even been shot at. While satellite data can still give enough information to make monsoon predictions, climate system studies will be affected by the gap in information.&lt;ref name="jones"&gt;{{cite web|author=Nicola Jones|date=2011-07-07|title=Pirates scupper monsoon research|publisher=[[Nature (journal)|Nature]]|url=http://www.nature.com/news/2011/110707/full/news.2011.402.html|accessdate=27 November 2012}}&lt;/ref&gt;

==Data provided==

Despite the system being incomplete, it has already begun providing valuable data. Farmers in Australia were able to use the data provided by RAMA to prepare for a bad growing season in 2008. It has also helped correct improper satellite measurements of surface heat flux.&lt;ref name="McP"&gt;{{cite web|author=M.J McPhaden|year=April 2009|title=Research Moored Array for African-Asian-Australian Monsoon Analysis and Prediction|publisher=[[American Meteorological Society]]|url=http://www.pmel.noaa.gov/tao/rama/RAMA_BAMS.pdf|accessdate=27 November 2012|display-authors=etal}}&lt;/ref&gt;
{{Clear}}

==References==
{{Reflist}}

{{physical oceanography|expanded=other}}
{{Earth-based meteorological observation}}

[[Category:Weather forecasting]]
[[Category:Oceanographic instrumentation]]
[[Category:Physical oceanography]]
[[Category:Research projects]]
[[Category:Buoyage]]</text>
      <sha1>ps0kcgi6n0ihd5vx766iryypkka2xct</sha1>
    </revision>
  </page>
  <page>
    <title>SLAC bag model</title>
    <ns>0</ns>
    <id>42642303</id>
    <revision>
      <id>845695733</id>
      <parentid>659865431</parentid>
      <timestamp>2018-06-13T14:32:23Z</timestamp>
      <contributor>
        <username>Lithopsian</username>
        <id>8390765</id>
      </contributor>
      <comment>stubsort</comment>
      <model>wikitext</model>
      <format>text/x-wiki</format>
      <text xml:space="preserve" bytes="498">The '''SLAC bag model''' is a simple theoretical model for a possible structure for [[hadron]]s. The [[MIT bag model]] is another similar model.&lt;ref&gt;{{Cite book | isbn = 9783718600335 | title = Particle Physics (Contemporary Concepts in Physics) | last1 = Lee | first1 = T. D. | year = 1981 | publisher = Taylor &amp; Francis | page = 573  }}&lt;/ref&gt; The "SLAC" in the name stands for [[Stanford Linear Accelerator Center]].

== References ==
{{reflist}}

[[Category:Particle physics]]


{{nuclear-stub}}</text>
      <sha1>d6izo5ebqzbgjot1wzqlzms423o4uzi</sha1>
    </revision>
  </page>
  <page>
    <title>Science, Numbers, and I</title>
    <ns>0</ns>
    <id>40593828</id>
    <revision>
      <id>742403888</id>
      <parentid>742401503</parentid>
      <timestamp>2016-10-03T14:04:14Z</timestamp>
      <contributor>
        <username>AnomieBOT</username>
        <id>7611264</id>
      </contributor>
      <minor/>
      <comment>Dating maintenance tags: {{Refimprove}}</comment>
      <model>wikitext</model>
      <format>text/x-wiki</format>
      <text xml:space="preserve" bytes="1849">{{refimprove|date=October 2016}}

{{Infobox book 
| name = Science, Numbers, and I
| author = [[Isaac Asimov]]
| image = File:ScienceNumbersAndI.jpg
| caption = First edition
| country = United States
| language = English
| series = [[Science, Technology and Speculation]] essays
| genre = 
| publisher = [[Doubleday (publisher)|Doubleday]]
| release_date = 1968
| media_type = print ([[Hardback]] and [[Paperback]])
| pages = 
| isbn = 0441754570
| preceded_by = [[From Earth to Heaven]]
| followed_by = [[The Solar System and Back]]
}} 
'''''Science, Numbers, and I''''' is a collection of seventeen scientific [[essay]]s by [[Isaac Asimov]]. It was the sixth of a series of books collecting essays from ''[[The Magazine of Fantasy and Science Fiction]]''. It was first published by [[Doubleday &amp; Company]] in 1968.

==Contents==

#Balancing the Books (''F&amp;SF'', July 1966)
#BB or Not BB, That is the Question (August 1966)
#I'm Looking Over a Four-Leaf Clover (September 1966)
#Portrait of the Writer as a Boy (October 1966)
#Old Man River (November 1966)
#The Symbol-Minded Chemist (December 1966)
#Right Beneath Your Feet (January 1967)
#Impossible, That's All (February 1967)
#Crowded! (March 1967)
#A Matter of Scale (April 1967)
#Times of Our Lives (May 1967)
#Non-Time Travel (June 1967)
#Twelve Point Three Six Nine (July 1967)
#Kaleidoscope in the Sky (August 1967)
#The Great Borning (September 1967)
#Music to My Ears (October 1967)
#Knock Plastic! (November 1967)

==External links==
*[http://www.asimovonline.com/oldsite/Essays/f_and_sf_essays.html Asimovonline.com]

[[Category:Scientific essays]]
[[Category:Essay collections by Isaac Asimov]]
[[Category:1968 books]]
[[Category:Works originally published in The Magazine of Fantasy &amp; Science Fiction]]
[[Category:Doubleday (publisher) books]]


{{essay-stub}}
{{science-book-stub}}</text>
      <sha1>qr8daax0tql3pm5nex8bsy4d3hf6wog</sha1>
    </revision>
  </page>
  <page>
    <title>Taylor's salamander</title>
    <ns>0</ns>
    <id>3846723</id>
    <revision>
      <id>860258338</id>
      <parentid>825979484</parentid>
      <timestamp>2018-09-19T12:42:16Z</timestamp>
      <contributor>
        <username>Maias</username>
        <id>1827467</id>
      </contributor>
      <comment>removed [[Category:Animals described in 1982]]; added [[Category:Amphibians described in 1982]] using [[WP:HC|HotCat]]</comment>
      <model>wikitext</model>
      <format>text/x-wiki</format>
      <text xml:space="preserve" bytes="6603">{{Speciesbox
| name = Taylor's salamander
| status = CR
| status_system = IUCN3.1
| status_ref = &lt;ref name=iucn&gt;{{cite journal | author = IUCN SSC Amphibian Specialist Group | title = ''Ambystoma taylori'' | journal = [[IUCN Red List of Threatened Species]] | volume= 2016 | page = e.T59070A53974679 | publisher = [[IUCN]] | year = 2016 | url = https://dx.doi.org/10.2305/IUCN.UK.2015-4.RLTS.T59070A53974679.en | accessdate = 19 January 2016}}&lt;/ref&gt;
| image = Ambystoma taylori.jpeg
| taxon = Ambystoma taylori
| authority = [[Ronald A. Brandon|Brandon]], Maruska, and Rumph, 1982&lt;ref name="Brandon et al. 1982"/&gt;
}}

'''Taylor's salamander''', ''Ambystoma taylori,'' is a species of salamander found only in [[Laguna Alchichica]], a high-altitude ({{convert|2290|m|abbr=on}} [[above sea level]]) crater lake to the southwest of Perote, [[Puebla]], Mexico.&lt;ref name=iucn/&gt;&lt;ref name=Frost/&gt;&lt;ref name="Percino-Daniel et al. 2016"/&gt; It was [[Species description|first described]] in 1982 but had been known to science prior to that.&lt;ref name="Brandon et al. 1982"/&gt;&lt;ref name=Frost/&gt; It is a [[neoteny|neotenic]] salamander, breeding while still in the larval state and not undergoing [[metamorphosis]].&lt;ref name="Brandon et al. 1982"/&gt; The lake in which it lives is becoming increasingly saline and less suitable for the salamander, which is declining in numbers. The [[International Union for Conservation of Nature]] (IUCN) has rated it as being "[[critically endangered]]".&lt;ref name=iucn/&gt;

==Taxonomy==
It was described in 1982 by Brandon, Maruska, and Rumph,&lt;ref name="Brandon et al. 1982"/&gt; and named for [[Edward Harrison Taylor]] (1889–1978), an American herpetologist.&lt;ref name="Brandon et al. 1982"/&gt;&lt;ref name="Beolens et al. 2013"/&gt; However, the species had been known to science long before then. Taylor himself attempted to describe the species as ''Ambystoma subsalsum'' in 1943,&lt;ref name="Taylor 1943"/&gt; but mistakenly used a Mexican or [[plateau tiger salamander]] as the [[holotype]]. This rendered the name invalid, and made it into a synonym for the tiger salamander.&lt;ref name="Brandon et al. 1982"/&gt;&lt;ref name=Frost/&gt; &lt;!-- James Anderson extensively catalogued "''A. subsalsum''" in his 1960's field work, applying the name to actual population that now comprises ''A. taylori.'' Reference???--&gt;

==Ecology==
This salamander is moderately sized, with most individuals measuring {{convert|70|mm|abbr=on}} being mature, while the largest one being {{convert|102|-|113|mm|abbr=on}} in snout–vent length.&lt;ref name="Brandon et al. 1982"/&gt; It is a neotenic species, which means it retains its caudal fin and [[external gills]] into adulthood, never undergoing complete [[metamorphosis]]. It is entirely aquatic, breeding and laying its eggs in the same lake where it lives.&lt;ref name=EDGE/&gt; Taylor's salamanders are pale yellowish in color, with dark spots along their dorsal sides.&lt;ref name="Brandon et al. 1982"/&gt; They have relatively short, thick external gill stalks. Their heads are quite large, and their limbs are underdeveloped, as in most ''Ambystoma'' neotenes. They feed by [[bucca (mythological creature)|bucca]]l suction, and are basically [[omnivore]]s.&lt;ref name=EDGE/&gt;

==Habitat==
The ''A. taylori'' habitat in Lake Alchichica is brackish, with a [[salinity]] of {{convert|9.2|g/L|abbr=on}}.&lt;ref name="Percino-Daniel et al. 2016"/&gt; It is also very [[alkaline]], with a pH of 8.5–10. The lake's water has a temperature range of 18–21&amp;nbsp;°C.&lt;ref name=EDGE/&gt; The salamanders typically hide below the water line, under overhangs in the crater's edge, and into the deep water.&lt;ref name=iucn/&gt;&lt;ref name=EDGE/&gt;

==Status==
Lake Alchichica is becoming more saline as water is extracted for irrigation and drinking. The level of the lake has fallen and if this deterioration in water quality continues, this salamander is likely to become [[Extinction|extinct]]. The [[International Union for Conservation of Nature]] has assessed the salamander's conservation status as being "[[critically endangered]]" and has proposed that a [[captive breeding]] programme be established.&lt;ref name=iucn/&gt;

==References==
{{Reflist|30em|refs=
&lt;ref name="Beolens et al. 2013"&gt;{{cite book |last1 = Beolens | first1 = Bo | last2 = Watkins | first2 = Michael | last3 = Grayson | first3 = Michael |title=The Eponym Dictionary of Amphibians |url=https://books.google.com/books?id=ZZY3BAAAQBAJ&amp;pg=PT332 |date=2013 |publisher=Pelagic Publishing |isbn=978-1-907807-42-8 |pages=331–332}}&lt;/ref&gt;

&lt;ref name="Brandon et al. 1982"&gt;{{cite journal |last1=Brandon |first1=R. A. |last2=Maruska |first2=E. J. |last3=Rumph |first3=W. T. |year=1982 |orig-year=1981 |title=A new species of neotenic ''Ambystoma'' (Amphibia, Caudata) endemic to Laguna Alchichia, Puebla, Mexico |journal=Bulletin of the Southern California Academy of Sciences |volume=80 |pages=112–125 |doi= |url=https://www.biodiversitylibrary.org/part/42445 }}&lt;/ref&gt;

&lt;ref name=EDGE&gt;{{cite web |url=http://www.edgeofexistence.org/amphibians/species_info.php?id=559 |title=Taylor's Salamander (''Ambystoma taylori'') |author= |year= |work=EDGE of Existence programme (Evolutionarily Distinct and Globally Endangered species) |publisher=Zoological Society of London |accessdate=19 March 2017}}&lt;/ref&gt;

&lt;ref name=Frost&gt;{{cite web |url=http://research.amnh.org/vz/herpetology/amphibia/Amphibia/Caudata/Ambystomatidae/Ambystoma/Ambystoma-taylori |title=''Ambystoma taylori'' Brandon, Maruska, and Rumph, 1982 |author=Frost, Darrel R. |year=2017 |work=Amphibian Species of the World: an Online Reference. Version 6.0 |publisher=American Museum of Natural History |accessdate=19 March 2017}}&lt;/ref&gt;

&lt;ref name="Percino-Daniel et al. 2016"&gt;{{cite journal|last1=Percino-Daniel|first1=Ruth|last2=Recuero|first2=Ernesto|last3=Vázquez-Domínguez|first3=Ella|last4=Zamudio|first4=Kelly R.|last5=Parra-Olea|first5=Gabriela|title=All grown-up and nowhere to go: paedomorphosis and local adaptation in ''Ambystoma'' salamanders in the Cuenca Oriental of Mexico |journal=Biological Journal of the Linnean Society |date=2016 |volume=118 |issue=3 |pages=582–597 |doi=10.1111/bij.12750}}&lt;/ref&gt;

&lt;ref name="Taylor 1943"&gt;{{cite journal |last1=Taylor |first1=Edward H. |title=A new ambystomid salamander adapted to brackish water |journal=Copeia |date=1943 |volume=1943 |issue=3 |pages=151–156 |doi=10.2307/1438606}}&lt;/ref&gt;
}}

{{Taxonbar|from=Q2512313}}

[[Category:Mole salamanders]]
[[Category:Amphibians described in 1982]]
[[Category:Endemic fauna of Mexico]]
[[Category:Fauna of Central Mexico]]
[[Category:Amphibians of Mexico]]
[[Category:EDGE species]]</text>
      <sha1>4hrfsml22qvt1112e027hbtrxq23l6v</sha1>
    </revision>
  </page>
  <page>
    <title>The Four Faces of Nuclear Terrorism</title>
    <ns>0</ns>
    <id>19228597</id>
    <revision>
      <id>696244884</id>
      <parentid>614309202</parentid>
      <timestamp>2015-12-21T21:42:54Z</timestamp>
      <contributor>
        <username>Yobot</username>
        <id>7328338</id>
      </contributor>
      <minor/>
      <comment>[[WP:CHECKWIKI]] error fixes / Fix ISBN format, replaced: | isbn             = ISBN → | isbn = using [[Project:AWB|AWB]] (11759)</comment>
      <model>wikitext</model>
      <format>text/x-wiki</format>
      <text xml:space="preserve" bytes="2564">{{Infobox book
| name             = The Four Faces of Nuclear Terrorism
| image            = The Four Faces of Nuclear Terrorism.jpg
| image_size = 175px
| caption    = 
| author           = Charles D Ferguson&lt;br&gt;William C Potter&lt;br&gt;Amy Sands
| title_orig       = 
| translator       = 
| illustrator      = 
| cover_artist     = 
| country          = 
| language         = 
| series           = 
| subject          = [[Nuclear terrorism]]
| genre            = 
| publisher        = 
| pub_date         = 2004
| english_pub_date = 
| media_type       = 
| pages            = 376 pp.
| isbn =  978-0-415-95243-9
| oclc             = 57965807
| dewey            = 
| congress         = 
| preceded_by      = 
| followed_by      = 
}}

'''''The Four Faces of Nuclear Terrorism''''' is a 2004 book by Charles D. Ferguson and [[William C. Potter]] (with Amy Sands, Leonard S. Spector and Fred L. Wehling) which explores the motivations and capabilities of terrorist organizations to carry out significant attacks using stolen [[nuclear weapons]], to construct and detonate crude nuclear weapons, to release radiation by attacking or sabotaging nuclear facilities, and to build and use radiological weapons or "[[dirty bomb]]s." The authors argue that these "four faces" of [[nuclear terrorism]] are real threats which U.S. policy has failed to take into account. The book is the result of a two-year study by the Monterey Institute's Center for Nonproliferation Studies.&lt;ref&gt;[http://www.iebooke.com/Pro-ASP-NET-3-5-Server-Controls-and-AJAX-Components-Mar-2008-eBook-BBL_9.htm The Four Faces of Nuclear Terrorism]&lt;/ref&gt;&lt;ref&gt;[http://www.aps.org/units/fps/newsletters/2005/july/reviews.html The American Physical Society]&lt;/ref&gt;&lt;ref&gt;{{cite web |url=http://bos.sagepub.com/content/61/2/67.full |title=Avoiding the Nuclear Nightmare |author=Bennett Ramberg |date=March 1, 2005 |volume=61 |issue=2 |work=Bulletin of the Atomic Scientists  |pages=67–68 }}&lt;/ref&gt;

==See also==
* [[List of books about nuclear issues]]
* ''[[Nuclear Terrorism: The Ultimate Preventable Catastrophe]]''
* ''[[On Nuclear Terrorism]]''
* ''[[The Seventh Decade: The New Shape of Nuclear Danger]]''

==References==
&lt;references/&gt;

{{DEFAULTSORT:Four Faces of Nuclear Terrorism}}
[[Category:2004 books]]
[[Category:American political books]]
[[Category:Books about politics of the United States]]
[[Category:Books about nuclear issues]]
[[Category:Books about terrorism]]
[[Category:Nuclear history of the United States]]
[[Category:Nuclear terrorism]]


{{poli-book-stub}}
{{nuclear-tech-book-stub}}</text>
      <sha1>k0454zm8phf6vfl2rybadieeq5pc00h</sha1>
    </revision>
  </page>
  <page>
    <title>The Mathematical Experience</title>
    <ns>0</ns>
    <id>13478782</id>
    <revision>
      <id>868700159</id>
      <parentid>868386571</parentid>
      <timestamp>2018-11-13T21:42:24Z</timestamp>
      <contributor>
        <username>GreenC bot</username>
        <id>27823944</id>
      </contributor>
      <comment>update National Book Awards urls</comment>
      <model>wikitext</model>
      <format>text/x-wiki</format>
      <text xml:space="preserve" bytes="4228">{{italic title}}
'''''The Mathematical Experience''''' (1981) is a book by [[Philip J. Davis]] and [[Reuben Hersh]] that discusses the practice of modern [[mathematics]] from a [[history of mathematics|historical]] and [[philosophy of mathematics|philosophical]] perspective. The book discusses the psychology of mathematicians. It gives examples of famous proofs and outstanding problems, such as the [[Riemann hypothesis]]. It goes on to speculate about what a proof really means, in relationship to actual truth. Other topics include mathematics in education and some computer mathematics.

The first paperback edition won a U.S. [[National Book Award]] in Science.&lt;ref name=nba1983&gt;
[https://www.nationalbook.org/awards-prizes/national-book-awards-1983 "National Book Awards – 1983"]. [[National Book Foundation]]. Retrieved 2012-03-07.&lt;/ref&gt;&lt;ref group=lower-alpha&gt;This was the 1983 [[List of winners of the National Book Award#Science|award for paperback Science]]. 
&lt;br&gt;From 1980 to 1983 in [[National Book Award#History|National Book Award history]] there were dual hardcover and paperback awards in most categories, and [[National Book Award for Nonfiction#nonfiction categories|several nonfiction subcategories]] including General Nonfiction. Most of the paperback award-winners were reprints, including this one.&lt;/ref&gt; It is cited by some mathematicians as influential in their decision to continue their studies in [[graduate school]]; and has been hailed as a classic of mathematical literature.&lt;ref&gt;
{{cite web
 |title=MathForge.net--Power Tools for Online Mathematics |url=http://www.mathforge.net/index.jsp?page=seeReplies&amp;messageNum=103
 |archiveurl=https://web.archive.org/web/20061002203307/http://mathforge.net/index.jsp?page=seeReplies&amp;messageNum=103
 |archivedate=2006-10-02 |date=18 September 2002 |author=jkauzlar (perhaps James Joseph Kauzlarich?)
 |quote=One of the classics of mathematical literature, The Mathematical Experience, by Philip J Davis and Rueben Hersh, remains pertinent and fulfills its lofty ambitions even 20 years past its 1981 publication.
}}&lt;/ref&gt;
On the other hand, [[Martin Gardner]] disagreed with some of the authors' philosophical opinions.&lt;ref&gt;{{cite journal |last1= Gardner |first1= Martin |date=August 13, 1981 |title=Is Mathematics for Real? |journal=New York Review of Books |pages=37–40 }}&lt;/ref&gt;

A new edition, published in 1995, includes exercises and problems, making the book more suitable for classrooms. There is also ''The Companion Guide to The Mathematical Experience, Study Edition''. Both were co-authored with [[Elena Marchisotto]].&lt;ref&gt;Reviews of the 1995 edition:
*{{citation|title=none|first1=J. P.|last1=Burgess|first2=P.|last2=Ernest|journal=Philosophia Mathematica|volume=5|issue=2|pages=175–188|date=June 1997|doi=10.1093/philmat/5.2.173}}
*{{citation|first=A.|last=Bultheel|authorlink=Adhemar Bultheel|journal=Bulletin of the Belgian Mathematical Society|volume=4|issue=5|pages=706–707|year=1997|title=Review|url=https://people.cs.kuleuven.be/~adhemar.bultheel/WWW/BMS/r154.php}}
*{{citation|url=https://www.ams.org/journals/notices/199710/comm-millett.pdf|first=Kenneth C.|last=Millett|journal=Notices of the American Mathematical Society|pages=1316–1318|volume=44|issue=10|date=November 1997|title=Review}}
*{{citation|title=Review|journal=MAA Reviews|first=Richard J.|last=Wilders|date=March 2012|url=https://www.maa.org/press/maa-reviews/the-mathematical-experience-study-edition}}
&lt;/ref&gt; Davis and Hersh wrote a follow-up book, ''Descartes' Dream: The World According to Mathematics'' ([[Harcourt (publisher)|Harcourt]], 1986), and each has written other books with related themes, such as ''Mathematics And Common Sense: A Case of Creative Tension'' by Davis and ''What is Mathematics, Really?'' by Hersh.

==Notes==
{{reflist|group=lower-alpha}}

{{reflist}}

== External links ==
{{Wikiversity school}}
*[http://www.ams.org/notices/199710/comm-millett.pdf Book Review] of the 1995 edition, by Kenneth C. Millett at the [[American Mathematical Society]].

{{Areas of mathematics |collapsed}}

{{DEFAULTSORT:Mathematical Experience}}
[[Category:Mathematics books]]
[[Category:National Book Award-winning works]]
[[Category:1981 books]]</text>
      <sha1>9rtshpw90kqr2kp6ptb6on2k1mrhg1h</sha1>
    </revision>
  </page>
  <page>
    <title>The Oprah Effect</title>
    <ns>0</ns>
    <id>48738380</id>
    <revision>
      <id>818353588</id>
      <parentid>802247860</parentid>
      <timestamp>2018-01-03T01:56:27Z</timestamp>
      <contributor>
        <username>Muboshgu</username>
        <id>602857</id>
      </contributor>
      <comment>Added {{[[Template:notability|notability]]}} tag to article ([[WP:TW|TW]])</comment>
      <model>wikitext</model>
      <format>text/x-wiki</format>
      <text xml:space="preserve" bytes="3720">{{notability|date=January 2018}}
'''The Oprah Effect''' is the phenomenon in which consuming [[soft news]] causes the politically unaware to vote more consistently with their own views, articulated by Matthew A. Baum and Angela S. Jamison in their 2006 study, "''The Oprah Effect: How Soft News Helps Inattentive Citizens Vote Consistently''".&lt;ref&gt;{{cite web |url=https://www.hks.harvard.edu/fs/mbaum/documents/OprahEffect_JOP.pdf|author=Matthew Baum and Angels Jamison|title=The ''Oprah'' Effect: How Soft News Helps Inattentive Citizens Vote Consistently|publisher=The Journal of Politics}}&lt;/ref&gt; The findings and conclusions of the study centered around the distinction between hard and soft news as written about by Baum, and the complex interactions both types of news have on people with low and high political awareness. The term was pioneered by [[Oprah Winfrey]].

The increase of soft news content available has led some scholars to question its value in informing the public, and therefore question whether the media is properly fulfilling its duty to inform the citizens.&lt;ref&gt;{{cite journal|last1=Patterson|first1=Thomas|title=The Search for a Standard: Markets and the Media|journal=Political Communication|date=2003|volume=20|pages=139–143}}&lt;/ref&gt;&lt;ref&gt;{{cite journal|last1=Zeller|first1=John|title=A New Standard of News Quality: Burglar Alarms for the Monitorial Citizen|journal=Political Communication|date=2003|volume=20}}&lt;/ref&gt; The Oprah Effect was demonstrated by testing a dependent variable of voting consistently versus an independent variable which measured how often the voter watched daytime talk shows. Voting consistency measures the consistency between a voter's preferences and their vote. For the context of this experiment, the measure of voting consistently was created by applying Lau and Redlawsk's model of "correct" voting to data from the 2000 [[American National Election Studies|National Election Studies]]. Increased consumption of soft news caused low information voters to vote more consistently, but had no significant effect on more aware voters. Exposure to hard news modestly increased the voting consistency of politically aware individuals, but had no significant effect on those with low political awareness.

While Baum and Jamison agree that soft news contains lower quality political information, they conclude from their analysis that soft news fulfills a valuable duty by providing information to apolitical individuals. This is because soft news still exposes those individuals to the political information that they need to cast a vote for the candidate which best reflects their personal interests, even if it doesn't contain highly complex political information. They theorize that exposure to soft news has this effect on low information individuals because most people with little political knowledge have no interest in harder news, making their decision to consume soft news one between  consuming soft news or consuming no news. Even though soft news may not be highly informational, it's still beneficial compared to consuming no news. They also go even further, contending that even if an individual with little political knowledge were to consume hard news, the more complex political information would be difficult for them to comprehend, and they would get relatively little out of it. As a result, they conclude their results should give some pause to critics of the increase soft news content in the media, because it increases the voting consistency of those with little political knowledge.

==References==
{{Reflist}}
{{Oprah Winfrey}}
[[Category:Oprah Winfrey]]
[[Category:News]]
[[Category:Political science]]
{{DEFAULTSORT:Oprah Effect, The}}</text>
      <sha1>eg9lfkijrfe5zdzmxfzqg698c0u8z6l</sha1>
    </revision>
  </page>
  <page>
    <title>Tuberculosis classification</title>
    <ns>0</ns>
    <id>1034511</id>
    <revision>
      <id>849734750</id>
      <parentid>801032176</parentid>
      <timestamp>2018-07-11T00:24:08Z</timestamp>
      <contributor>
        <username>InternetArchiveBot</username>
        <id>27015025</id>
      </contributor>
      <comment>Rescuing 1 sources and tagging 0 as dead. #IABot (v2.0beta)</comment>
      <model>wikitext</model>
      <format>text/x-wiki</format>
      <text xml:space="preserve" bytes="3819">{{main article|Tuberculosis}}

==Tuberculosis classification system==
The current clinical classification system for tuberculosis (TB) is based on the pathogenesis of the disease.&lt;ref&gt;[http://ajrccm.atsjournals.org/cgi/content/full/161/4/1376 Diagnostic Standards and Classification of Tuberculosis in Adults and Children]. Am. J. Respir. Crit. Care Med., Volume 161, Number 4, April 2000, 1376-1395.  This Official Statement of the [[American Thoracic Society]] and the [[Centers for Disease Control and Prevention]] was Adopted by the ATS Board of Directors, July 1999. This Statement was endorsed by the Council of the [[Infectious Disease Society of America]], September 1999.  Class 0-5 are explained on pages 1391-1392.
&lt;/ref&gt;

Health care providers should comply with local laws and regulations requiring the reporting of TB.  All persons with class 3 or class 5 TB should be reported promptly to the local health department. See [[list of notifiable diseases]].

{| class="wikitable"
|+ Classification System for TB
|-
! scope="col" | Class
! scope="col" | Type
! scope="col" | Description
|-
| 0 || No TB exposure&lt;br/&gt;Not infected || No history of exposure&lt;br/&gt;Negative reaction to [[tuberculin]] skin test
|-
| 1 || TB exposure&lt;br/&gt;No evidence of infection|| History of exposure&lt;br/&gt;Negative reaction to tuberculin skin test
|-
| 2 || TB infection &lt;br/&gt;No disease || Positive reaction to tuberculin skin test&lt;br/&gt;Negative bacteriologic studies (if done)&lt;br/&gt;No clinical, bacteriologic, or radiographic evidence of TB
|-
| 3 || TB, clinically active || ''M. tuberculosis'' cultured (if done)&lt;br/&gt; Clinical, bacteriologic, or radiographic evidence of current disease
|-
|4 ||TB &lt;br/&gt; Not clinically active || History of episode(s) of TB &lt;br/&gt; '''or''' &lt;br/&gt;Abnormal but stable radiographic findings &lt;br/&gt;Positive reaction to the tuberculin skin test&lt;br/&gt; Negative bacteriologic studies (if done) &lt;br/&gt; '''and'''&lt;br/&gt; No clinical or radiographic evidence of current disease
|-
|5||TB suspect ||Diagnosis pending&lt;br/&gt;TB disease should be ruled in or out within 3 months
|-
|}

==CDC TB classification for immigrants and refugees==
The [[U.S. Citizenship and Immigration Services]] has an additional TB classification for [[immigrant]]s and [[refugee]]s developed by the [[Centers for Disease Control and Prevention]] (CDC).&lt;ref&gt;CDC Immigration Requirements: [https://www.cdc.gov/immigrantrefugeehealth/pdf/tuberculosis-ti-2009.pdf Technical Instructions for Tuberculosis Screening and Treatment].  October 1, 2009.  Classifications, see pages 21-22.
&lt;/ref&gt;  The ''B notification program'' is an important screening strategy to identify new arrivals who have a high risk for TB.&lt;ref&gt;[http://www.dhs.wisconsin.gov/tb/pdf/Letter%20B1_B2%20FINAL_10_09.pdf Revised CDC TB Classification system for overseas screening of immigrants and Refugees with Class B1/B2 TB Conditions] {{Webarchive|url=https://web.archive.org/web/20110708183810/http://www.dhs.wisconsin.gov/TB/pdf/Letter%20B1_B2%20FINAL_10_09.pdf |date=2011-07-08 }}. State of Wisconsin, Department of Health Services, Division of Public Health, International Health and Respiratory Disease Unit, Bureau of Communicable Diseases and Emergency Response. September 29, 2009.  Accessed 2011-07-27.&lt;/ref&gt;
{| class="wikitable"
|+ United States Immigrant/Refugee TB Classification - revised 2009
! scope="col" | Class 
|-
| No TB Classification (Normal) 
|-
| Class A TB with waiver, infectious
|-
| Class B1 TB, Pulmonary 
|-
| Class B1 TB, Extrapulmonary 
|-
| Class B2 TB Latent TB Infection (LTBI) Evaluation
|-
| Class B3 TB, Contact Evaluation
|}

==See also==
*[[Tuberculosis radiology]] for CXR details
*[[Tuberculosis diagnosis]]

==References==
&lt;references/&gt;

[[Category:Tuberculosis]]
[[Category:Classification systems|Tuberculosis Classification System]]</text>
      <sha1>j6ac9u332qqvqock4nefc1kq5hk2n7j</sha1>
    </revision>
  </page>
  <page>
    <title>Walter Jacobi</title>
    <ns>0</ns>
    <id>30046055</id>
    <revision>
      <id>868212182</id>
      <parentid>859925666</parentid>
      <timestamp>2018-11-10T19:00:53Z</timestamp>
      <contributor>
        <username>Ser Amantio di Nicolao</username>
        <id>753665</id>
      </contributor>
      <minor/>
      <comment>/* References */add category</comment>
      <model>wikitext</model>
      <format>text/x-wiki</format>
      <text xml:space="preserve" bytes="2762">{{Infobox scientist
| name = Walter Jacobi
| image = Walter Jacobi.jpg
| image_size = 
| caption = Jacobi in 2002
| birth_date  =January 13, 1918
| birth_place=[[Saalfeld]],&lt;ref name="choo"&gt;{{cite web |url=http://www.timesfreepress.com/news/2009/aug/20/huntsville-rocket-scientist-jacobi-dies-91/?mobile |title=Huntsville rocket scientist Jacobi dies at 91 |author=Associated Press |date=August 20, 2009 |publisher=Chattanooga Times Free Press |accessdate=December 14, 2010}}&lt;/ref&gt; Germany
| death_date = {{Death date and age|2009|08|19|1918|1|13}}
| death_place=[[Huntsville, Alabama]], United States
| nationality = German,  United States
| field = [[Aeronautics]]
| alma_mater = 
| work_institutions = [[Peenemünde]]&lt;br&gt;[[Fort Bliss]]&lt;br&gt;[[Redstone Arsenal]]&lt;br&gt;[[Marshall Space Flight Center]]
| doctoral_advisor =
| doctoral_students =
| known_for  =
| awards =
}}
'''Walter Jacobi''' (January 13, 1918 &amp;ndash; August 19, 2009)&lt;ref name="obit"&gt;{{cite web |url=http://www.nmspacemuseum.org/halloffame/detail.php?id=47 |title=Original German Rocket Team member Walter Jacobi dies at 91 |author=Shelby G. Spires  |date=August 19, 2009 |work=The Huntsville Times |accessdate=December 14, 2010}}&lt;/ref&gt; was a rocket scientist and member of the "[[Wernher von Braun|von Braun]] rocket group", at [[Peenemünde]] (1939–1945) working on the [[V-2]] rockets in [[World War II]].  He was among the scientists to surrender and travel to the United States to provide rocketry expertise via [[Operation Paperclip]].  He came to the United States on the first boat, November 16, 1945.&lt;ref name="astronautix"&gt;{{cite web |url=http://www.astronautix.com/astros/jacobi.htm |title=Jacobi, Walter |publisher=Astronautix |accessdate=December 14, 2010}}&lt;/ref&gt; with [[Operation Paperclip]] and [[Fort Bliss]], [[Texas]] (1945–1949).  He continued his work with the team when they moved to [[Redstone Arsenal]], and he joined [[Marshall Space Flight Center]] to work for [[NASA]].&lt;ref name="obit"/&gt;  Jacobi worked on rocket "structure and components."&lt;ref name="choo"/&gt;

He continued to support the space program and appear at public events until his death.&lt;ref name="obit"/&gt;

== References ==
{{reflist}}

{{authority control}}

{{DEFAULTSORT:Jacobi, Walter}}
[[Category:German aerospace engineers]]
[[Category:German rocket scientists]]
[[Category:1918 births]]
[[Category:2009 deaths]]
[[Category:American aerospace engineers]]
[[Category:Early spaceflight scientists]]
[[Category:German emigrants to the United States]]
[[Category:German inventors]]
[[Category:V-weapons people]]
[[Category:Marshall Space Flight Center]]
[[Category:NASA people]]
[[Category:Operation Paperclip]]
[[Category:20th-century American engineers]]


{{US-engineer-stub}}
{{germany-engineer-stub}}</text>
      <sha1>kywzyr2ama8tuxvxwh04prvaasvmniz</sha1>
    </revision>
  </page>
</mediawiki>
